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Abstract 
Glioblastoma is the most common high-grade primary brain tumour in adults. 
Current treatments have limited success with average survival comprehensively low. 
Effective drug treatments are hindered predominantly by the complex genetic 
background of glioblastoma heterogeneity, as such there is a compelling need for 
the development of effective therapeutics. An approach is to target abnormal 
metabolic pathways that are universally dysregulated in glioblastoma. The 
identification of potential targets and the development of therapeutic agents is 
crucial for the advancement of treatment. Hexokinase 2 (HK2) has a prominent role 
in glycolysis, acting as the rate-limiting step in the pathway. HK2 is highly expressed 
in many cancers and its role as the rate-limiting step of glycolysis may potentially 
contribute to tumour growth. Overexpression of HK2 has also been associated with 
drug resistant phenotypes, in parallel, its inhibition has improved the effectiveness of 
anticancer agents, suggesting HK2 as a potential therapeutic target. The role of 
methylation and its association with expression levels of HK2 was determined in 
glioblastoma fresh frozen biopsies and patient-derived cultures, through 
pyrosequencing and quantitative PCR. CRISPR knockout was utilised to investigate 
the effect of inhibiting HK2 on proliferation and to determine the role of HK2 in 
chemoresistance. The anti-proliferative effects of HK2 inhibitors 3-bromopyruvic-acid 
(3-BPA) and metformin were investigated via cytotoxic assays and FACS analysis 
was used to determine their mechanism of action. Additionally, downstream 
expression changes were investigated via expression profiler arrays, across 84 key 
genes involved in the regulation and enzymatic pathways of glucose metabolism. 
Hypomethylation was demonstrated in all biopsies (n=100) and cultures (n=15) 
compared to normal brain tissue; with average methylation of 4.6% compared to 
26% respectively (p<0.0001) determined across 15-CpGs. A significant increase 
(p<0.0001) in HK2 expression was discovered, ranging between 6 to >1000- fold 
change in all biopsies and cultures compared to normal brain tissue and a strong 
correlation between hypomethylation and increased level of expression (p<0.0001) 
was established. Furthermore, elevated levels of HK2 revealed notably poorer 
survival outcomes. Sensitivity to 3-BPA in glioblastoma cultures was associated with 
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elevated expression of HK2. Significantly different levels of apoptosis were observed 
with average levels 38% greater in high HK2 expressing cultures (p=0.0014). A 
significant growth rate reduction (p<0.007) was demonstrated in HK2-KO cultures 
compared to parent cultures. Importantly sensitivity to both metformin and TMZ was 
also significantly increased (p<0.0001) in response to HK2-KO, with substantial 
reduction in both ID50 values and cell survival. Notably, HK2-KO cultures yielded 
greater synergistic effects with metformin and TMZ combination treatment. Array 
data revealed significant downstream gene expression alterations (p<0.005) with 
HK2-KO and with the supplementation of both 3-BPA and metformin, where >50% 
genes demonstrated reduced levels of expression compared to the corresponding 
parent/non-treated cultures. This study demonstrates the predominant role of HK2 
within the glycolytic pathway, with overexpression potentially key in driving the 
genetic alterations downstream. This study also verifies a strong correlation between 
increased expression of HK2 and hypomethylation, additionally highlighting the 
impact HK2 has on inferior patient prognosis. HK2-KO revealed considerable 
ubiquitous reductions in downstream gene expression compared to glioblastoma 
biopsy tissue and parent cultures. Additionally, an increase in drug sensitivity was 
depicted with the loss of HK2 signifying the potential of targeting HK2 as a novel 
therapy in a significant subset of glioblastoma. 
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1.1 Cancer 
Cancer is a disease that affects all ages and populations and is one of the leading 
causes of morbidity and mortality in the world (Siegel et al., 2016). Data published 
in 2018 by the World Health Organisation (WHO) International Agency for Research 
on Cancer (IARC) estimated the global cancer burden to have reached 18.1 million 
new cases and 9.6 million deaths in 2018 (IARC, 2018). The total number of people 
worldwide who are alive within 5 years of diagnosis of cancer is estimated to be 43.8 
million (McGuire, 2016). The increasing rates of cancer are due to several factors 
which includes population growth and ageing and the additional changes in 
prevalence in certain cancers linked to social and economic development. The 
increased cancer incidence can also be partly attributed to the advancements of 
cancer detection methods (Christopher et al., 2014; Torre et al., 2015; Philips et al., 
2018). 
1.2 Brain tumours 
Tumours comprising of the brain and the central nervous system (CNS) are some of 
the rarest cancer types. It is estimated that in 2015 these tumour types represented 
1.4% of newly diagnosed cancer cases and were responsible for approximately 2.6% 
of related mortalities in that year (Howlader et al., 2016). A recent review stated 
that there is a continuing substantial increase in the prevalence of glioblastoma 
across a diverse age range, which cannot be accredited to a particular risk factor, 
suggestive of comprehensive environmental and lifestyle aspects (Philips et al., 
2018). Data obtained in 2016 concludes that glioblastoma exceeded leukaemia as 
the leading cause of cancer death in the adult population in the United States 
(Ladomersky et al., 2019). Glioma form a heterogeneous group of tumours of the 
CNS that develop from glial cell origins. They are traditionally classified based on 
histologic type and malignancy grade, where most (diffuse) gliomas show extensive 
infiltration in the CNS parenchyma. Gliomas can be further grouped as astrocytic or 
oligodendroglia (Perry and Wesseling, 2016). Oligodendrogliomas are a rare type of 
brain tumour that develop from glial cells called oligodendrocytes, which function 
normally to provide insulation (myelin) to neurons. Oligodendrogliomas are more 
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prevalent in adults than in children. Astrocytoma develop from glial cells called 
astrocytes, which function normally to transport nutrients and hold neurons in place 
(van den Bent, et al., 2017). Gliomas are characterised based on the severity from 
grade I to IV. Tumours that are categorised in grade I – II are collectively known as 
low grade gliomas, which are distinguished with slower growth rates. High grade 
tumours, grade III- IV, are typified with increased aggressive physiognomies and 
malignancy. Astrocytomas can be any grade, where Grade I are pilocytic 
astrocytomas, the most common grade 2 is a diffuse astrocytoma. Anaplastic 
astrocytoma’s are classified as a grade III, and glioblastoma as grade IV (Eckel-
Passow et al., 2015). 
 
1.2.1 Glioblastoma 
Although glioblastoma is rare tumour with global incidence of less than 10 per 
100,000 people, its poor prognosis with survival rate of 14-15 months after diagnosis 
makes it a crucial public health issue (Hanif et al., 2017). It accounts for 50% of all 
gliomas in all age groups (Rock et al., 2014). It can occur at any age, but the peak 
incidence is between 55 to 60 years (Ohgaki and Kleihues, 2007). The ratio of GBM 
incidence is higher in men as compares to women (Ohgaki and Kleihues, 2007; 
Thakkar et al., 2014). The western world has higher incidence of gliomas then less 
developed countries (Thakkar et al., 2014), which could be due to under reporting of 
gliomas cases, limited access to health care and differences in diagnostic practices 
(Fisher et al., 2007). Glioblastoma is the most common type of brain tumour with 
over 65% of confirmed cases, though compared to other cancer types it is rare, with 
global incidence of less than 10 per 100,000 people (Hanif et al., 2017). Patient 
outcome has an extremely poor prognosis with median survival at approximately 15 
months, with survival greater than 2 years drastically reduced in less than 35% of 
patients (Brodbelt et al., 2015). 
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1.2.2 Glioblastoma classification  
Glioblastoma develops universally with tumour cells exhibiting high morphology and 
have significant genetic heterogeneity, encompassing a broad range of mutations, 
deletions and other genomic and epigenetic aberrations. (Howlader et al., 2016). 
Glioblastoma cell morphology can drastically vary, furthermore the nuclei have 
membrane irregularities with typically oval or elongated shapes and hyperchromatic 
chromatin (Schultz et al., 2005). A key distinguishing feature of glioblastoma cells 
from low grade tumours are large areas of necrosis often focused centrally in the 
tumour area, known as necrotic foci, which is habitually surrounded by 
pseudopalisading cellular areas, noted as a garland like arrangement of hypercellular 
tumour nuclei (Noch et al., 2009). Since 1925, the classification of glial and CNS 
tumours has relied heavily of histological appearance of biopsy material. Modern 
classification of tumours stringently follows WHO guidelines which were updated in 
2016 to include molecular subtyping to characterise different tumour sub-groups 
(Arevalo et al., 2017). Pre-2016 glioblastoma was classified into 2 subgroups 
dependant on primary or secondary tumours. Primary glioblastoma accounted for 
greater than 90% of cases in adults and were defined as having a source of 
origination without any prior tumours, classed as de novo (Ohgaki and Kleihues, 
2007). Secondary glioblastoma occurrence was classified by the development from a 
lower grade astrocytoma. Currently, classification of glioblastoma is based upon 
isocitrate dehydrogenase (IDH) mutation status (Arevalo et al., 2017), determined 
by molecular analysis as shown in Figure 1.1. IDH is an enzyme that catalyses the 
oxidative decarboxylation of isocitrate, producing α-ketoglutarate and CO2. There are 
3 isoforms of IDH, which catalyse the third step of the citric acid cycle, IDH1 and 
IDH2 convert NADP+ to NADH in the mitochondria whilst IDH3 uses NAD+ as a 
cofactor instead. This step in the citric acid cycle is irreversible due to the large 
negative free energy change and is regulated to avoid depletion of isocitrate and the 
accumulation of the ketone alpha-ketoglutarate. Substrate availability (isocitrate, 
NAD+ or NADP+), product inhibition (NADH or NADPH) and competitive feedback 
inhibition (ATP) balance the reaction (Maeting et a., 2000).  
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Isocitrate dehydrogenase (IDH) mutation is a critical genomic alteration occurring in 
lower grade and secondary glioblastoma patients. IDH mutations primarily are seen 
in secondary glioblastoma subtypes and are rarely found in primary tumour tissue 
(Yan et al., 2009). More than 90% of IDH mutation is located at codon R132 of 
IDH1 gene and is responsible for the increased production of 2—hydroxyglutarate. 
This “oncometabolite” induces epigenetic alterations resulting in DNA global 
methylation and histone methylation (Yan et al., 2009; Korshunov et al., 2017). IDH 
mutation has been recognised as an early genomic event which is frequently 
retained during tumour progression from lower grades to high and has become a 
therapeutic target. However, clinical statistics have shown that overall survival in 
patients with IDH-mutations to be 31 months, compared to 15 months with those 
with IDH-wildtype (Kaminska et al., 2019). It has been suggested that the R132H 
mutation in IDH1 mutation reduces the malignant progression of glioma by causing 
a less aggressive phenotype of glioblastoma stem-like cells (GSCs) which are 
involved in the Wnt/β‑catenin signalling, thus reducing proliferation, cell survival and 
invasion (Cui et al., 2016). IDH1 is responsible for the principle source of NADPH in 
the brain protecting it from oxidative stress via the catalysed production of α-
ketoglutarate (KG) from the substrate isocitrate through oxidative decarboxylation 
(Bleeker et al., 2010). Additionally, IDH1 modulates insulin secretion therefore 
determining the cellular response to glucose concentrations (Guay et al., 2013). 
Mutations in IDH1 in secondary glioblastoma was initially identified in the TCGA 
project in 2008, which revealed the frequent occurrence of aberrant IDH1, as well as 
indicating the presence of wild type IDH1 in the primary glioblastoma cohort. The 
role of IDH1 as an early event in tumorigenesis in adult glioma has further been 
support in studies conducted since the TCGA project glioma (Horbinski et al., 2013). 
Recent data suggests IDH1 mutation is a less aggressive phenotype resulting in a 
reduced malignant progression of glioma (Yao et al., 2018). 
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Figure 1.1 WHO classification of adult gliomas Primary stratification based on histological 
separation followed by IDH mutation status for the segregation of glioblastoma. Diffuse glioma are 
segregated based off co-deletion present on chromosome 1p/19q or the mutation of ATRX/TP53. 
GBMs are divided into two categories: IDH-wild-type (wt) GBM and IDH-mutant GBM. IDH-mutant 
GBM progresses from low-grade diffuse astrocytoma or oligodendroglioma. Oligoastrocytomas were 
omitted due to rarity. DDx, Differential diagnosis; IDH, Isocitrate dehydrogenase; ATRX, TP 
dependent helicase ATRX; T P53 Tumour protein p53; NOS, not otherwise specified (Arevalo et al., 
2017). 
 
 
1.3 Treatment of GBM 
The current treatment for glioblastoma is a multimodal approach which involves 
surgical resection of the tumour tissue, fractional radiotherapy treatment at 60Gy 
followed by concomitant chemotherapy with temozolomide (Stupp et al., 2015). The 
foremost therapeutic agent used in the treatment of glioblastoma is the alkylating 
agent temozolomide (TMZ) since a study by Stupp et al. (2005) reported an increase 
in 2 year-survival 10.4% to 26.5% when patients were treated with TMZ in 
combination with radiotherapy. The effectiveness of TMZ treatment in glioblastoma 
is strongly determined by MGMT methylation status. 
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The current treatments have limited success with median survival only 14 months. 
Furthermore, considerable side effects (including nausea, fatigue, headaches and 
loss of appetite) are regularly associated, impacting on patient wellbeing (Goldberg 
et al., 2004; Jordan et al., 2005; Hesketh, 2008). Effective drug treatments are 
hindered predominantly by the complex genetic background of glioblastoma, with 
significant intra- and inter- tumour heterogeneity drastically limiting monotherapies 
(Backes et al., 2015). The blood brain barrier (BBB) is an additional limitation for 
both the development and success of chemotherapeutic agents to be delivered to 
target the tumour, with its principle role to restrict the movement of potentially 
hazardous agents from reaching the brain tumour (Oberoi et al., 2015). The BBB 
consists of several layers, the core of which is made up of specialised capillary 
endothelial cells, which form complex structures built up of transmembrane and 
membrane associated proteins (Feustel et al., 2012). Tight junction structures are 
formed in-between adjacent cells and closely regulate the transport and signalling 
from the capillary (Luissint et al., 2012). Additionally, astrocytes and pericytes 
accompany the endothelial cell complexes, where the astrocytes sheath the BBB, 
contributing and maintaining the endothelial cells and tight junctions (Hong et al., 
2015). Pericytes offer supplementary regulation of endothelial cell expression and 
the polarisation of astrocytes to the BBB (Armulik et al., 2010). The BBB can 
facilitate several transport mechanisms to move required molecules into the brain 
tissue. Studies have shown, however, that glioma tumours can have an antagonistic 
effect upon both the structure and integrity of the BBB (Wong et al., 2013). Glioma 
cells invade the perivascular area around the capillary, which leads to the 
displacement of astrocytic cells, resulting in the degradation of the BBB integrity. 
Consequently, reduction in pericytes ensues impeding regulatory processes and 
increasing permeability of the BBB to molecules by endothelial transcytosis (Watkins 
et al., 2014; Armulik et al., 2010). At the site of the blood brain tumour barrier 
(BBTB), the affected capillaries have an increased permeability in turn allowing for 
potentially easier vascular access to the tumour site (Deeken, 2007). Although 
damage to the BBB essentially increases the effectiveness of chemotherapeutic 
agents, the aggressive nature of glioblastoma cells results in migration and invasion 
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of areas away from the damaged BBTB site, into areas of functional sections of BBB, 
offering protection from drugs (Van Tellingen, 2015).  
 
 
Figure 1.2 Composition and structure of the BBBThe BBB is a multi-layered barrier regulating 
signalling and transport of molecules into brain tissue. Material exchange occurs at the endothelial 
cells in capillaries that are protected by tight junctions. Interspersed among the endothelial cells are 
pericytes that help regulate expression levels of near-by endothelial and astrocytic cells. Astrocyte 
cells wrap the BBB, and both regulate and maintain the BBB (from Yamazaki et al., 2017). 
 
 
It is well documented that cancer cells rely increasingly on the glycolytic pathway as 
the predominant mechanism for energy production, favouring it over the more 
efficient mechanism of oxidative phosphorylation, even with sufficient oxygen 
availability (Marie et al., 2011). The metabolic reprogramming in tumour cells is 
known as the Warburg effect (Poteet et al., 2013) and results in a high demand for 
glucose and large amounts of energy to maintain functional metabolism; however, 
the ability of tumour cells to use aerobic glycolysis confers a significant growth 
advantage (Zhao et al., 2011). The increased dependence on glucose consequently 
leads to over production of lactate (Goodwin et al., 2015), leading to an increase in 
lactic acid concentration and a lower pH in the tumour microenvironment. A higher 
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acidity in the tumour microenvironment subsequently suppress infiltrated immune 
cells by inhibiting T-cell secretion, resulting in a reduction in T-cell response, 
proliferation and cytokine production, contributing to tumour immune evasion 
(Wang, 2017). 
One of the ways in which to modulate therapeutic strategies is through 
immunotherapy models with the aim of reprogramming the patients innate immune 
system to detect and mount an immune response against tumour cells. The 
technique requires patient samples, to which differentiated dendritic cells are 
presented to tumour biopsy cells, the primed dendritic cells are then transplanted 
back into the patient where they induce an aggressive T-cell response (Prins et al., 
2011). The method of priming a patient’s immune cells for the detection of tumour 
cells allows for the potential targeting of numerous cellular targets. Additionally, 
vaccination with specific and non-specific antigens and the immunomodulation via 
pathway inhibition are potential treatments (Reardon et al., 2014). An alternative to 
priming a patient’s immune response is the use of monoclonal antibodies with the 
aim of interrupting receptor signalling through the competitive binding of cell surface 
receptors, resulting in a loss of downstream activation and the downregulation of the 
deregulated signalling pathway (Melstrom and sentovich, 2017). Bevacizumab is an 
example of a monoclonal antibody that is currently being utilized in a range of 
cancers, with the aim to reduce elevated levels of angiogenesis within tumours via 
the targeting and downregulation of the VEGF pathway. Recent data however has 
stated that the addition of Bevacizumab/monoclonal antibody treatment reaps no 
benefits when compared to standard treatment methods (Gilbert et al., 2014), with 
the drawback that VEGF downregulation may induce tumour survival genes with the 
risk of increasing both the chemo-resistance and aggressive invasive behaviour of 
the cells (de Groot et al., 2010).   
 
The inhibition of dysregulated pathways in tumour cells is a key factor in the 
treatment for many cancer types. Advancements in nanotechnology has led to the 
development of small-molecule inhibitors (SMI) designed to block specific pathways 
and/or regulate epigenetic alterations occurring within the tumour. Previous studies 
revealed SMIs that were developed to induce both caspase activity and apoptosis 
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within tumour cells, however due to the relative complexity of development and 
construction cost many SMIs have not been put forward for the clinical trial process 
(Kitambi et al., 2014). Amplification of EGFR and its active mutant EGFRvIII occur 
frequently in glioblastoma, currently 3 generations of tyrosine tyrosine kinase 
inhibitors (TKI) have been developed. Of the first generation, including Gefitinib, 
Erlotinib and Lapatinib it was concluded that they were not very effective in clinical 
trials in glioblastoma. Dacomitinib is a second-generation inhibitor which is 
demonstrating promising results in pre-clinical trial models (Reardon et al., 2013; 
Zahonero et al., 2015; An et al., 2018). The advancement of technologies will 
inevitably lead to the creation of more effective inhibitory treatments (Arkin et al., 
2014).  
An alternative therapeutic idea is the treatment of glioblastoma through the 
utilization of electromagnetic energy fields. The proposed idea is a wearable device 
which generates anti-mitotic electrical fields known as tumour treating fields 
(TTFields); studies have shown the TTFields to have contributed to a reduction in 
glioblastoma cell proliferation (Chaudhry et al., 2015). The development of novel 
therapeutics in the treatment of glioblastoma offer optimism for a potential 
breakthrough from the stark prognosis of current care for afflicted patients. 
1.4 Molecular biology of glioblastoma  
In glioblastoma, genetic aberrations offer functional advantages to the tumour 
including increased chemoresistance, proliferation and survival and invasive traits. 
The identification of key mutations and genetic changes in tumour promoting and 
tumour suppressing genes is crucial to develop multifaceted approach to treatments.  
It has long been understood that cancer is a disease of the genome, with genetic 
aberrations including mutations, deletions, copy number changes, and 
rearrangements (Hanahan and Weinberg, 2011). Multiple sequencing cohorts 
including the International Cancer Genome Consortium (ICGC) have identified a 
multitude of mutations occurring in key genes across more than 50 types of cancer 
(International network of cancer genome projects, 2010). The deregulation of 
several key pathways has been identified including p53, RTK/RAS/PI3K and the 
retinoblastoma protein (RB) (Tomczak et al., 2015). 
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There is also a frequent occurrence of DNA-repair defects in cancer cells, leading to 
an increased mutation rate (Puente et al., 2011). More recently, research has 
highlighted the significance of mechanisms that contribute to gene silencing without 
alterations to the primary DNA sequence (Grasso et al., 2012). These epigenetic 
changes include DNA methylation and post translational histone modifications, which 
are stable and can be inherited and have been shown to contribute to oncogenic 
progression (Baylin and Jones, 2011). The combined effect of genetic and epigenetic 
disruptions results in stable phenotypic changes (You et al., 2012; Timp et al., 2013) 
and mutations in epigenetic regulators have been characterised in a range of cancer 
types including renal cell carcinoma (Varela et al., 2011) , bladder cancer (Gui et al., 
2011), hepatocellular carcinoma (Fujimoto et al., 2012) and adult brain tumours 
(Sturm et al., 2012). Additionally, epigenetic inactivation of DNA repair genes such 
as MGMT and BRCA1 has also been confirmed, resulting in elevated mutation 
incidences and genomic instability (Esteller et al, 2000; Hedenfalk et al., 2001). The 
understanding of the relationship between genetic and epigenetic changes is of 
increasing importance in the progression of cancer research.  
 
Glioblastoma have been shown to possess multiple genetic aberrations, including 
nucleotide substitutions, chromosol abnormalities and divergent epigenetic 
alterations (Cancer Genome Atlas Research Network, 2008). The advancement in 
high-throughput molecular biology techniques over the last few years along with the 
establishment of large scale, multi-dimensional research projects with the aim of 
detailing the genetic variations present within tumour tissue has resulted in some 
improvement in our knowledge of these tumours. The Cancer Genome Atlas (TCGA) 
resource collates and catalogues genetic data across multiple human tumours (Kim 
et al., 2018). The TCGA data for glioblastoma was initially analysed in 2015, 
determining key genetic features (Tomczak et al., 2015). Studies have established 
the deregulation of multiple pathways in glioblastoma including p53 and 
retinoblastoma protein (RB), RTK/RAS/PI3K, the epidermal growth factor receptor 
(EGFR) and isocitrate dehydrogenase (IDH) (Verhaak et al., 2010). Furthermore, the 
multidrug resistance protein-1 (MDR-1), which is part of the ATP-binding cassette 
transporter superfamily has been shown to be upregulated and over-expressed in 
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glioblastoma, allowing the removal of chemotherapeutic agents from the cancer cells 
(Munoz et al., 2014; Alifieris and Trafalis, 2015). Recent advances in genetic high 
throughput screening of glioblastoma tumours have identified distinct subtypes, 
Proneural, Neural, Classical and Mesenchymal. The subtypes present different 
genetic abnormalities, survival length, patient age and treatment response (Meyer et 
al.,2015).   
 
1.4.1 PI3K/Akt pathway alterations 
The tumour suppressor protein phosphatase and tensin homolog (PTEN) regulates 
the P13K/AKT pathway, ultimately controlling cell growth, survival and the 
progression of the cell cycle. Mutations, amplifications and deletions affecting the 
PI3K complex have been shown to occur in glioblastoma (Benitez et al., 2017; Chen 
et al., 2018), with PTEN mutations leading to increased tumorigenicity via 
macrophage recruitment and chemoresistance by histone regulation. The loss of 
PTEN in vitro has been shown to promote cell survival, tumorigenesis and 
chemosresitance in glioblastoma cells (Parsa et al., 2007; Zheng et al., 2008). PTEN 
functions as a feedback regulation mediating the PI3K pathway through the 
dephosphorylation of PIP3 and the consequent inhibition of Akt activation. PTEN 
mutations are present in approximately 25-40% in adult glioblastoma, and loss of 
heterozygosity in 60% to 80% of all cases (Zarghooni et al., 2010; Barrow et al., 
2010; Brennan et al., 2013; Shin et al., 2019). Studies have shown AKT to stimulate 
the expression of glucose transporters which enhances glucose uptake, and directly 
phosphorylates enzymes such as Hexokinases, committing glucose to the glycolytic 
pathway and driving the Warburg effect (Elstrom et al. 2004; Robey and Hay 2009). 
Figure 1.3 details the Akt pathway. 
 
1.4.2 EGFR alterations 
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine 
kinase (RTK) with an extracellular domain which is activated by extracellular ligands 
including growth factors, cytokines and hormones to initiate the activation of intrinsic 
tyrosine kinase activity (Krause and van Etten, 2005). The binding of the ligand 
leads to phosphorylation which consequently activates Ras further inducing the 
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MEK/ERK1/2 and MAP3K pathways as well as the activation of PI3K complex 
resulting in the upregulation of Akt and mTOR (Cancer Genome Atlas Research 
Network, 2008). The signalling cascades ultimately regulate cellular division, 
differentiation and migration (Delgado-Lopez and Corrales-Garcia, 2016). 
Deregulated RTK signalling has been shown (Rusten et al., 2007; Abella et al., 2009) 
to be a fundamental mechanism utilized by tumour cells to avoid regulatory growth 
controls with mutation or overexpression of key genes often contributing to the 
development of various cancers. Gene amplification and/or mutations in EGFR are 
found in approximately 60-85% of glioblastoma (Brennan et al., 2013) and 
overexpressed levels demonstrated in 40% of glioblastoma, responsible for 
increased proliferation levels and resistance to radiotherapy (Monga et al., 2017; Xu 
et al., 2017) The active mutant EGFR variant EGFRvIII occurs frequently in 
glioblastoma, which is usually present in gene amplification, generated by the 
deletions of exons 2-7. The resulting amplification leads to a truncated protein which 
is constitutively phosphorylated playing a critical role in pathogenesis inducing 
increased cell differentiation and proliferation (Pollack et al., 2006; Zadeh et al., 
2013). Current treatments, EGFR-tyrosine kinase inhibitors (TKIs) have shown 
limited efficacy in patients (An et al., 2018). A review of 6 phase III clinical trials 
incorporating 2697 patients was conducted, which concluded that the effect of TKIs 
on patient outcome depended on EGFR status. It was suggested that chemotherapy 
benefited patients with wild type EGFR, and TKIs benefited patients with EGFR 
mutations, concluding that TKIs might be unsuitable for unselected patients (Vale et 
al., 2015). Furthermore, most clinical trials of EGFR TKIs have been restricted to 
patients with tumours demonstrating harbouring common EGFR mutations, 
excluding those with uncommon EGFR mutations (Park et al., 2019). 
 
1.4.3 p53 pathway alterations 
p53 has a key role regulating and suppressing tumour development through its wide 
range of functions which include the detection of DNA damage as well as regulating 
cell division and is the most common mutation to be found in all human cancers 
(Kandoth et al., 2013). The p53 and RB pathways interconnect to regulate cell 
division, predominately in the G1/S phase of the cell cycle arrest (Sherr and 
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McCormick, 2002). p53 is upregulated under cell stress, such as DNA damage by the 
alternative reading frame (ARF) protein, which leads to the inhibition in the cell cycle 
progression and the promotion of apoptosis (Basu and Murphy, 2016). Mutations in 
p53 are more common in IDHmut glioblastoma tumours in approximately 60-70% of 
cases compared to IDHwt glioblastoma tumours where the rate is approximately 25-
30% (England et al., 2013). p53 mutations result in the reduction of mRNA and 
protein expression or its modification leading to deregulated DNA binding. A study 
found that PGC-1α, a known positive regulator of metastasis is bound by mutant 
forms of p53 and was associated with increased metastasis and poor prognosis in 
breast cancer (Basu et al., 2018). Dysfunctional p53 allows for the tumour cells to 
exploit molecular pathways, in the absence of transient or permanent growth arrest, 
increasing the potential invasive and proliferative capabilities as well as increased 
migration, drug resistance, angiogenesis and overall progression of cell cycle survival 
(Nguyen et al., 2014).  
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Figure 1.3. The AKT signalling pathway AKT is activated by PI3K, which itself is activated by 
several upstream signalling pathways such as insulin receptors, RTKs and cytokine receptors, 
including EGFR. AKT targets several downstream molecules changing their activity by phosphorylation 
or complex formation. AKT is involved in cell proliferation, glucose metabolism, cell survival, cell cycle, 
protein synthesis, and in neuronal morphology and plasticity by regulation of several downstream 
molecules shown in this figure. AKT regulates glucose metabolism through regulation of GSK-3, and 
HK2. It also interaction with mTOR signalling affect protein synthesis (Cellsignal, 2019). 
1.5 The role of epigenetics in cancer 
The concept of epigenetics emerged in the 1940s, with initial studies focused on the 
interactions between genes leading to specific phenotypes (Goldberg et al, 2007). 
The significant increase in the understanding of epigenetics has revealed their 
important role in the modification of mechanisms in both healthy and disease states 
(Stephens et al., 2013). Epigenetics broadly refers to the stable and heritable 
phenotypic changes within a cell, whilst the primary DNA sequence is left 
unchanged. DNA methylation, histone modification and non-coding RNAs are the 
primary mediators of epigenetic modifications (Bernstein et al., 2007). Studies have 
shown that the interactions between the epigenetic mechanisms are synchronised 
and regulated, and are essential for the propagation of precise gene expression 
profile patterns for healthy developmental processes (Stephens et al., 2013); 
Furthermore, disruptions in these regulatory mechanisms have been shown to lead 
to aberrant gene expression and signalling pathways as commonly exhibited in 
cancer cells (Sharma et al., 2010). 
 
1.5.1 DNA methylation 
DNA methylation involves the covalent transfer of a methyl group (-CH3) from S-
adenosylmethionine (SAM) to the 5‘carbon on the cytosine (C) moieties within the 
cytosine-guanosinedinucleotides (CpGs) resulting in the formation of 5-
methylcytosine (5mC) (Bernstein et al., 2007). CpG sites are located across the 
entire genome, with some distributed in distinct clustered regions known as CpG 
islands (CGIs). These regions are defined with approximately the GC content at 55% 
across a 500bp area with an expected CpG ratio of 0.65 (Takai and Jones, 2002). 
The CpG islands frequently span the vicinity surrounding gene promotor regions 
covering approximately 60% of human gene promoters. The CpG island are also 
associated with transcription start sites (TSSs) and cover the area of first exons 
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(Sharma et al., 2010). Studies have shown CpG islands to be regularly present often 
in an unmethylated state in both housekeeping and tissue-specific genes 
(Hackenberg et al., 2010). The methylation of DNA is crucial for maintaining 
chromosomal stability through the prevention of potentially harmful regions of the 
genome being transcribed, including areas containing repeat elements and viral 
inserts (Herman and Baylin, 2003). DNA methylation is highly regulated by DNA 
methyltransferases (DNMTs) which add methyl groups or DNA demethylases which 
conversely remove methyl groups (Stephens et al., 2013). The DNA 
methyltransferase family comprises a range of enzymes including DNMT1, DNMT3 
(DNMT3A, DNMT3B) and DNMT3L, where both DNMT3A and DNMT3B can initiate 
methylation of CpG sites independently from replication, on unmethylated and 
hemimethylated DNA (Herman and Baylin, 2003) and have been shown to have a 
significant role in maintaining methylation activity at repeat elements (Liang et al., 
2002; Chen et al., 2003). The maintenance methyltransferase, DNMT1 functions 
during replication and commonly initiates methylation on hemimethylated DNA 
(Bashtrykov et al., 2012). DNMT3L is absent of catalytic ability and its primary 
function is to enhance the methyltransferase activities of the other members of the 
methyltransferase family (Jurkowska et al., 2010; Neri et al., 2013). DNA 
demethylases also influence the activity and function of DNA methylation, consisting 
of activation-induced cytidinedeaminase (AID), apolipoprotein B mRNA-editing 
enzyme 1 (APOBEC1) and ten-eleven translocation (TET) (De Carvalho et al., 2010, 
Ito et al., 2010). The primary function of the DNA demethylases is the oxidation of 
5-methylcytosine to 5-hydroxymethylcytosine, a reaction primarily catalysed by the 
TET family and further augmented by AID and APOBEC1 proteins leading to the 
demination forming cytosine (Pastor et al., 2013). 
Although the mechanism of DNA methylation mediated gene silencing is not fully 
understood, there are two proposed methods. The first determines that the addition 
of the methyl group physically inhibits the direct binding of transcription factors 
(TFs), such as c-Myc/Myn and NFκB, which have recognition sites containing CpG 
sites and have been shown to be inhibited by methylation (Hervouet et al., 2009). 
The other proposed model involves the binding of methyl-CpG-binding proteins 
(MBPs) to CpG sites, competitively blocking the binding of TFs. There are currently 
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three identified families of MBPs, which are responsible for the contribution of 
transcription repression (first group), and the detection of methylated DNA via 
specialised zinc finger domains (second group) (Unoki et al, 2004).  
 
 
 
 
1.5.1.2 DNA methylation in cancer  
Perturbed methylation patterns in tumour cells are a regular occurrence in a range 
of cancer types, frequently manifesting as global hypomethylation, or region-specific 
hypermethylation, dependant on the normal basal methylation level within a specific 
tissue-type (Zhanget al., 2013). DNA methylation patterns in glioblastoma were 
analysed in the TCGA cohort, which revealed a subgroup of gliomas with a specific 
DNA methylation status. The subset of glioblastomas demonstrate concerted 
hypermethylation across a large number of loci, classified as the glioma-CpG island 
methylator phenotype (G-CIMP) (Nagarajan et al., 2014).  
A study determined that the G-CIMP phenotype to be associated with an IDH-
mutant origin, of which two additional clinically relevant subsets of G-CIMP tumours 
exist, G-CIMP-high and G-CIMP-low, dependant on the degree of DNA methylation, 
thus enabling further refinement of glioma classification and improving the 
prediction of patient outcome independent of grade and histology; with the potential 
enhancement of effective therapeutic strategies tailored to each patient. (Malta et 
al., 2018).  
Patient prognosis is inferior with initial diagnosis of G-CIMP-high subtype in primary 
glioma tumours, however in recurrent tumours G-CIMP-low has been shown to have 
a poorer clinical outcome (Ferreira de Souza et al., 2018), and is defined as 
mimicking IDH-wild-type and stem cell-like primary glioblastoma. The occurrence of 
genome-wide DNA hypomethylation in cancer cells as long been established as a 
recurrent epigenetic alteration. The changes in DNA methylation in normal and 
tumour cells is illustrated in Figure 1.4.  
 
 
 18 
 
 
 
 
Figure 1.4. Changes in DNA methylation of tumour suppressor genes in normal and 
tumour cells Outline of the most relevant DNA methylation changes observed in human cancers. 
Includes CpG-island-specific DNA hypermethylation occurring at gene promoters, locking the affected 
gene into an inactive state. Loss of DNA methylation (hypomethylation) occurs genome-wide and is 
often observed at repetitive regions of the genome, leading to overexpression. White circles indicate 
unmethylated CpG sites and red circles show methylated CpG sites. The crossed-out arrow indicates 
the transcription start site and the permanent lack of transcription after DNA methylation. Green 
boxes show exons and the blue rectangle marks the position of a repetitive element (from Pfeifer, 
2018). 
 
 
Studies have shown that the loss in global methylation can lead to adverse effects, 
supporting tumorigenic conditions associated with malignant development in a range 
of cancer types including adult glioblastoma (Cadieux et al., 2006). An example of a 
hypomethylated gene associated with tumour progression is the protease urokinase 
(PLAU/uPA), which has been shown to be both hypomethylated and overexpressed 
in breast cancers (grades 1, 2 and 3) and prostate cancers (Ehrlich, 2009). A recent 
study identified novel hypomethylated genes, cytoplasmic polyadenylation element 
binding protein (CPEB1), PR-domain zinc finger protein 16 (PRDM16) and LIM 
domain only 3 (LMO3) in glioblastoma, all of which showed increased levels of 
expression; however, a cause-and-effect relationship of their molecular mechanisms 
was not established (Li P and Wu M, 2017). Global hypomethylation has been 
associated with the activation of transcriptional proto-oncogenes, such as HRAS in 
melanoma. Hypomethylation has been shown to lead to genomic instability and 
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mitotic recombination, resulting in translocations, deletions, viral oncogenes, and 
growth-related imprinted genes like IGF (Ehrlich, 2009). Additionally, 
hypomethylation has also been associated with the reactivation of various 
transposable elements including long interspersed nuclear elements (LINEs) 
responsible for reverse transcriptase, where hypomethylation of LINE-1 located in 
the MET onco- gene is associated with bladder cancer tumorigenesis (Wolff et al., 
2010). Studies have shown the effects of increased methylation across promotor 
specific DNA has been linked with the inactivation of tumour suppressor genes as a 
prevalent event in tumour development (Jones et al., 2002). Hypermethylation is 
also linked with cancer development through the inactivation of regulatory genes 
involved in a variety of cellular processes including apoptosis, metastasis, cell cycle, 
angiogenesis and metabolism (Herman and Baylin, 2003). Examples of 
hypomethylation include the deregulation of RB in renal cell cancers (Herman et al, 
1994) and the disruption of DNA repair genes such as BRCA1 resulting in a 
decreased capacity for cells to repair genomic errors, contributing to the 
susceptibility of tumour formation (Esteller, 2002). Recent research has focused on 
the identification and classification of hypermethylated genes as a tool for 
stratification of response to therapeutic agents, for example the O6-methylguanine–
DNA methyltransferase (MGMT) status in predicting the response with the use of 
TMZ in the treatment of glioblastoma (Weller et al., 2009).  
 
1.5.1.3 MGMT methylation status 
O6-methylguanine–DNA methyltransferase (MGMT) is a DNA management and 
repair gene The MGMT enzyme removes guanine at the 06 position, impacting the 
effectiveness of alkylating agents such as the commonly used therapeutic agent TMZ 
in glioblastoma (Esteller et al., 2002; Bell et al., 2018). In approximately 45% of 
glioblastoma tumours, the promotor region of MGMT is hypermethylated and these 
patients have a significantly better outcome due to increased effectiveness of 
alkylating agents in the absence of the DNA repair mechanism (Hegi et al., 2005; 
Oliver et al., 2014). A recent study analysed MGMT correlation with survival in a 
well-characterized cohort of 111 IDH wildtype glioblastoma patients, it was 
concluded that MGMT correlated with significantly improved progression-free survival 
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(PFS) and overall survival (OS). Median PFS was 7.2 months in the unmethylated 
group compared to 19.83 months in the highly methylated group and median OS 
was 13.4 months in the unmethylated group compared to 29.93 months in the 
highly methylated group (Radke et al., 2019). MGMT methylation status has become 
a clinical marker determining the effectiveness of the standard glioblastoma 
treatment (Molenaar et al., 2014). 
 
1.5.2 Non-coding RNAs/ Micro RNAs 
Non-coding RNAs are fundamental in the regulation of gene expression (Ling et al., 
2015). Micro RNAs (miRNAs) which are short non-coding regions of RNA up to 
approximately 30 base pairs. miRNA have a significantly important function in post-
transcriptional regulation and the silencing of other RNAs (Santa-Maria et al., 2015). 
Their regulation can modify and influence a range of cellular processes such as 
proliferation, survival, differentiation and motility (Christopher et al., 2016). miRNAs 
are predominantly located intra-cellularly although their regulatory effects can be 
detected extracellularly, recent research has focused on the detection of circulating 
miRNAs in blood plasma as a clinical biomarker for a range of diseases including 
cancer (Pirola et al., 2015). Studies have shown the occurrence of variations in the 
expression profile of miRNA associated with cancer cells (Butkytė et al., 2016). 
miRNA strands are incorporated into a miRNA-induced silencing complex (miRISC) 
(Fabian and Sonenburg, 2012), which has the facility to bind to mRNA sequences 
within the cytoplasm, resulting in the silencing of the mRNA as a consequence of the 
loss of ability for ribosome translation template (Sheu-Gruttadauria et al., 2018). 
miRNA binding to mRNA acts as a post transcriptional method of silencing 
subsequently leading to the degradation of the bound mRNA (Michlewski and 
Cáceres, 2019). 
 
1.5.2.2 miRNA in cancer 
Dysregulation in both mRNA and miRNA is a recurrent event in tumour cells (Lin et 
al., 2015; Hata and Lieberman, 2015). The role of miRNA in tumorigenesis often 
varies dependant on the individual miRNA, which can contribute towards an 
oncogenic or tumour suppressive affect. For example, overexpression of miR-21 is 
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present in most cancer types including glioblastoma (Yang et al., 2013). Its primarily 
targets the FBX011 tumour suppressor gene, resulting in a loss of expression. 
Additionally, in glioblastoma, miR-21 has been strongly associated with impacting 
the p53 and mitochondrial apoptosis pathways (Papagiannakopoulos et al., 2008). 
The significantly increased expression of miR-21 is associated with chemo and radio- 
resistance in glioblastoma (Maachani et al., 2016). TCGA data obtained from the 
glioma cohort revealed the impact of miR-148a and miR-31 in the development of 
glioblastoma, the miRNAs were shown to influence hypoxia-inducible factor 1-alpha 
promoting both tumour growth and increasing angiogenesis. The identification and 
stratification of individual miRNAs role in cancer is challenging, studies have shown 
that specific miRNA can have alternative roles in different cancer types. An example 
is miR-222 where (Fuse et al., 2012) demonstrated it to be detrimental in prostate 
cancer acting as a tumour suppressor, however (Zhang et al., 2010) revealed miR-
222 to positively impact prognosis in glioblastoma via regulation of cellular 
apoptosis.  
 
 
1.6 Cancer as a metabolic disease  
 
1.6.1 The glucose pathway 
The high mutation rate in cancer cells leads to aberrant cellular metabolism and 
alterations of these metabolic pathways significantly contribute in the development 
and growth of many tumours (Cantor and Sabatini, 2012; DeBerardinis and 
Tompson, 2012). It is well documented that cancer cells require increased amounts 
of energy in order to maintain the augmented rates of proliferation and survival 
(vander Heiden et al., 2009; Kami et al, 2013). Normal cells predominately produce 
energy via oxidative phosphorylation (OXPHOS). In contrast, cancer cells undergo a 
metabolic transformation relying increasingly on the glycolytic pathway as the 
predominant mechanism for energy production, favouring it over the more efficient 
OXPHOS even when sufficient oxygen is available (Marie et al., 2011). The switch 
from OXPHOS to glycolysis, along with the associated accumulation of lactate by-
products in the tumour microenvironment, characterises the best known alteration in 
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cancer cell metabolism, the phenomenon known as aerobic glycolysis or the 
“Warburg effect” (Gatenby and Gillies, 2004; Vander Heiden et al. 2009; Goodwin et 
al., 2015). This metabolic switch results in increased acidity from by-products in the 
tumour microenvironment which promotes cancer cell adaptation and aids in the 
development of the tumour niche (Gatenby and Gillies 2004). The prevailing view as 
to the function of the metabolic switch is the production of cellular energy in the 
form of ATP, where glycolysis has been shown to drive ATP production at an 
increased (albeit less efficient) rate in comparison to ATP production via 
mitochondrial OXPHOS, and this is essential to support the increased energy 
demands in cancer cells (Cairns et al., 2011).  Aerobic glycolysis also benefits 
tumour cells allowing the cells to adapt to intermittently hypoxic conditions, a 
common occurrence in poorly vascularised tumours. 
 
Although different cancers develop through abnormalities in different pathways, the 
metabolic requirements for the tumour cells are very similar, involving the pathways 
to support core functions like anabolism, catabolism, and redox balance. Normal 
cells activate PI3K and the downstream pathways AKT and mTOR, promoting an 
anabolic agenda involving increased glycolytic flux and fatty acid synthesis (Yuan 
and Cantley, 2008).Comparatively tumour cells must produce energy in the form of 
ATP in order to produce precursors for macromolecule biosynthesis for the support 
of cell growth development, whilst managing the oxidizing effects as a result from 
their increased metabolism through the reduction of ROS damage (Cairns et al., 
2011). The tumour cells frequently contain mutations associated with the PI3K-AKT-
mTOR pathway resulting in an increased level of signalling activity, whilst often 
bypassing extrinsic stimulation by growth factors (Fruman et al., 2017). Many 
oncogenes and tumour suppressors are involved in the PI3K-AKT-mTOR network, 
and aberrant activation of this pathway is common in a diverse set of cancers 
(DeBerardinis and Tompson, 2012). There is evidence that cancer cells undergo 
continuous metabolic reprogramming to ensure they are utilizing the most effective 
method of producing cellular energy (Phan et al., 2014). Cancers are often 
auxotrophic for specific non-essential amino acids, resulting in abnormalities in 
amino acid biosynthetic pathways. This is advantageous as metabolic reactions 
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involved in the synthesis of non-essential amino-acids are high energy-consuming 
(Zhang and Yang, 2013). An example is serine metabolism which is frequently 
dysregulated in cancers, most commonly melanoma and breast cancers (Locasale et 
al., 2011, Possemato et al., 2011) and in gliomas (Liu et al., 2013). In many cases, 
extracellular serine is sufficient to support cancer cell proliferation, however an 
increase in serine synthesis from glucose even in the presence of abundant 
extracellular serine is present in some cancer cells. A recent study suggested that 
increased serine synthesis may be a resultant requirement to facilitate amino acid 
transport, folate metabolism and nucleotide synthesis (Mattaini et al., 2016). Recent 
therapeutic approaches have been designed to inhibit tumour cell glycolysis, 
including the inhibition of critical steps in the pathway, such as those catalysed by 
lactate dehydrogenase (LDH) and hexokinase 2 (HK2) (Le et al. 2010; Wolf et al. 
2011). 
 
 
1.6.2 Hexokinase 
An overview of the glycolytic pathway is shown in Figure 1.5. Hexokinase (HK) has a 
crucial role catalysing the initial step of the pathway, the ATP-dependent 
phosphorylation of glucose to yield glucose-6-phosphate (G6P). The phosphorylation 
of glucose to G6P promotes a concentration gradient enabling glucose entry into 
cells thus facilitating the major glycolytic pathways. Hexokinases, therefore, 
influence the magnitude and direction of glucose flux within cells (Patra et al., 
2013). There are four major HK isoforms expressed in mammalian tissues, encoded 
by separate genes,  Cairns et al, (2011) comprising HK1, HK2, HK3, and HK4 (also 
known as glucokinase), they share common biochemical properties, but their 
fundamental enzymatic activity and tissue distribution vary (Robey and Hay, 2006). 
HK1, HK2, and HK3 are high-affinity isoforms, whereby HK1 and 2 are inhibited by 
excess of G6P and HK3 by physiological concentrations of glucose (Wilson, 2003). 
HK4 has a low affinity and is predominantly expressed in liver hepatocytes and 
pancreatic β-cells. HK1 and HK2 are associated with mitochondria and are implicated 
in cell survival and proliferation (Gottlob et al., 2001, Majewski et al., 2004). Unlike 
HK1, which is expressed in most mammalian adult tissues, HK2 is only expressed in 
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a select number of adult tissues including adipose, skeletal, and cardiac muscles, 
however it is highly expressed in embryonic tissues (Wilson, 2003). The HK2 gene is 
located on chromosome 2p12 and consists of 60,705 bases, containing 19 exons and 
17 introns, and a promoter region of approximately 4 kb. Studies have shown HK2 to 
be abundantly and selectively overexpressed in a range of cancer types arising in 
tissues that normally express only HK1, including lung and breast (Mathupala et al., 
2001; Wang et al., 2014; Anderson et al., 2016.  There is evidence that HK2 
overexpression in cancer cells promotes tumour invasion as well as enhanced 
resistance to chemotherapy (Wolf et al., 2011). HK2 binds to the outer mitochondrial 
membrane via a mitochondrial binding motif at the N-terminal. HK2 bind to the outer 
mitochondrial membrane protein voltage-dependent anion channel 1 (VDAC1), 
forming a contact site between the outer and inner membranes of the mitochondria 
initiating opening of the channel (Palmieri et al., 2009). The mitochondrially bound 
HK2 enables preferential access of ATP generated by mitochondria, whereby the 
ADP generated by mitochondrial HK2 catalytic activity is transferred back into the 
mitochondria to be re-phosphorylated to further fuel the glycolytic metabolic 
advantage (Roberts et al., 2015). Additionally, the binding to mitochondria 
undergoes feedback inhibition by G-6P. The association of HK2 overexpression 
mediating cell survival may partly be due to the activation of Akt, which stimulates 
expression of both glucose transporters and maintains the HK2-VDAC complex, 
which has been shown to prevent the release of cytochrome C (Cyt C) consequently 
inhibiting apoptotic mechanisms (Okatsu et al., 2012). It has been proposed that 
HK2 competitively competes with pro-apoptotic proteins, suppressing the activation 
of BAX and BAK which are important mediators of mitochondrial membrane 
permeability. This has been shown in glioblastoma and in HeLa cells, where the 
binding of HK2 to mitochondria inhibited the mitochondrial translocation of Bax and 
the release of cytochrome c (Wolf et al, 2010; McCommis et al., 2012). The study 
also showed HK2 ability to interact with the mitochondrial permeability transition 
pore (PTP) in response to Akt pathway activation, thus impacting the regulation of 
the intrinsic apoptotic pathway (McCommis et al., 2012). The association between 
HK2 and mitochondria in inhibiting cell apoptosis is also recognized as a key factor in 
survival of glioma cells (Neary et al, 2013; Zhuo et al., 2015; Vartanian et al., 2016). 
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HK2 also protects against molecular changes such as oxidative stress, whereby its 
kinase activity bound to the mitochondrial membrane contributes to the inhibition of 
mitochondrial death pathways (Roberts et al., 2015). A plausible explanation for the 
selective overexpression of the HK2 isoform in cancer cells may be due to HK2 
possessing two active catalytic domains in its amino- and carboxy- termini, in 
comparison HK1 only possess a single active catalytic domain in its carboxy-
terminus. The two catalytic domains have different kinetic properties more suited for 
the metabolic nature of cancer cells with the advantage of HK2 retaining activity 
under conditions that are inhibitory for the single catalytic domain (Wilson, 2003). 
Recently, selective inhibitors have been developed to target HK2 in order to reduce 
tumour growth and aggression with minimal adverse effects (Lin et al., 2016). 
Currently, there are no effective treatments targeting HK2. Notably the one of the 
most common positron emission tomography (PET) radiolabelled tracer molecules 
used is 18F-fluorodeoxyglucose (18F-FDG), which is a radiolabelled glucose molecule 
which can be utilised to determine sites of abnormal glucose metabolism and to 
characterise and locate many tumours, including gliomas, oesophageal and breast 
(Hui et al., 2018). Overexpression of HK2 in glioblastoma is not fully understood, 
however its selective overexpression in cancer cells and relatively restricted 
distribution in normal adult tissues proposes an attractive potential selective target 
for cancer therapy with nominal side effects to healthy cells. 
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Figure 1.5. The glucose pathway in cancer cell metabolismHK is highlighted, its crucial role 
catalysing the initial step of the glycolytic pathway, the ATP-dependent phosphorylation of glucose to 
yield glucose-6-phosphate (G6P). HK2 overexpression has been established in a range of cancers 
(from Bricker et al., 2012). 
 
1.6.3 The Pentose Phosphate Pathway 
Sufficient levels of NADPH are crucial for rapid cell growth and proliferation and to 
ensure an adequate level is maintained, cells can use an alternative route of glucose 
metabolism called the pentose phosphate pathway (PPP). The PPP is predominantly 
 27 
 
anabolic and is responsible for producing ribose sugars which in turn are utilized in 
nucleotide biosynthesis and NADPH production (Cairns et al., 2011). Glucose-6-
phosphate (G6P) lies at the start of two pathways, glycolysis and the pentose 
phosphate pathway. It may be isomerized to fructose 6-phosphate by 
phosphoglucose isomerase (PGI) when cellular needs are for energy or carbon 
skeletons for synthesis. Alternatively, for increased NADPH production, G6P is 
oxidized by G6P dehydrogenase (G6PDH) in an irreversible reaction as the initial step 
of the pentose phosphate pathway (Patra et al., 2013). The PPP also facilitates the 
generation of nucleotide precursors of DNA for growth and synthesis via G6P being 
dehydrogenated initialising biosynthetic pathways that support anabolic growth 
(Cairns et al., 2011).   
1.6.4 Pyruvate Kinase M2 
The production of biosynthetic precursors via the tricarboxylic acid cycle (TCA) is 
regulated by pyruvate kinase in a rate limiting step in the glycolytic pathway. In 
healthy cells, phosphoenolpyruvate (PEP) to pyruvate is catalysed  by pyruvate 
kinase M1 (PKM1) with the associated phosphorylation of ADP to ATP for energy 
production. Conversely, the embryonic isoform of pyruvate kinase, PKM2 is 
expressed in tumour cells (Christofk et al., 2008; Vander Heiden et al., 2010). PKM2 
is a fundamental driver of aerobic glycolysis and has been associated with increased 
cell proliferation through the promotion of Mammalian target of rapamycin (mTOR) 
pathway (Ye et al., 2012). PKM2 promotes anabolic growth via the interaction with 
hypoxia-inducible factor 1 (HIF1) which promotes the activation of HIF-responsive 
genes (Brocato et al., 2014). PKM2 exists in the catalytically distinct tetrameric and 
dimeric states, its tetrameric form exhibits high catalytic activity and has been linked 
to catabolic metabolism and ATP synthesis. Comparatively PKM2 in its dimeric state 
has a low catalytic activity and a less active state, it has been associated with 
nucleotide synthesis and facilitating the production of glycolytic intermediates to 
enter the glycolysis pathway including the PPP, producing NADPH; which in turn 
suppress ROS production (Dong et al., 2016). Furthermore, in its dimer state PKM2 
has been shown to regulate gene transcription in the nucleus of cancer cells and is 
the major isoform that triggers glycolysis, facilitating and important role in tumour 
cell energy supply, invasion and cell proliferation (Zhang et al., 2019). Due to its low 
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activity, potential effectors can be utilised to promote the formation of tetrameric 
PKM2 could potentially switch glycolysis to mitochondria and inhibit PKM2 entry into 
the nucleus; thus, impairing metabolic demand and growth-supporting signalling in 
tumour cells (Hsu et al., 2018). 
The high rate of expression of PKM2 in cancer cells and its considerable effect on the 
rate of glycolysis and cell growth emphasises its potential as a metabolic biomarker 
in the treatment of cancer (Cairns et al., 2011).  
 
Figure 1.6. Metabolic pathways utilised by cancer cells, showing both the glycolytic and 
PPP pathways Embryonic pyruvate kinase M2 is over expressed in cancer cells driving the Warburg 
effect. PKM2 promotes the conversion of pyruvate to acetyl-CoA and is associated with increased cell 
proliferation through the promotion of mTOR pathway. PKM2 also promotes anabolic growth via the 
interaction with HIF1. Isocitrate (IDH1) enables tumour cells to generate lipids from citrate and 
promotes glioma aggression (from Mayumi et al., 2012). Other metabolic mechanisms: The 
overexpression of phosphoglycerate dehydrogenase (PHGDH) has been associated with glioma cell 
proliferation and invasion (Liu et al., 2013). Overexpression of PHGDH results in the inhibition of 
pyruvate, redirecting metabolites away from the TCA cycle instead to produce serine for the 
biosynthesis of proteins (Locasale et al., 2011). IDH1 wild type has been linked with increased 
aggressive glioblastoma, it allows tumour cells to generate lipids from citrate supporting anabolic 
growth (Sun & Denko, 2014; Miroshnikova et al., 2016). 
 
1.6.5 Hypoxia-Induced Transcription Factors 
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Hypoxia-induced transcription factors characterise secondary mechanisms of 
adaptation in cancer cells which are upregulated by the PI3K/Akt1/mTOR pathway 
(Koizume et al., 2015). Cancer cells induce significant transcriptional effectors, 
predominantly hypoxia-inducible factor 1 and 2 (HIF1 and HIF2) in response to 
hypoxic microenvironmental stress. The reduction in oxygen results in the 
stabilisation of HIF subunits which consequentially initiates hypoxic transcriptional 
response that increases glycolysis and shunts OXPHOS (Sun et al., 2016). HIF-1 can 
be activated via Akt under normoxic conditions (Inoki et al., 2005; Lu et al., 2008), 
or by fumarate hydratase (FH) (Greer et al., 2012). FH cells accumulate fumarate 
which induces HIF1 (Frezza et al., 2011). HIF1 enhances cellular glycolytic potential 
by increasing the transcription of glucose transporters and glycolytic enzymes, and is 
a crucial component facilitating the PI3K pathway to drive the Warburg effect 
(Marbaniang et al., 2018). HIF1 also induces upregulation of phosphoinositide-
dependent kinase-1 (PDK1), a key mediator for the activation of AKT. Up-regulated 
PDK1 restricts the entry of pyruvate into the mitochondrial TCA cycle thus reducing 
oxidative phosphorylation and ROS, further enhancing the up-regulation of glycolysis 
mediated by HIF1 (Kim et al., 2009; Lu et al., 2008). HIF1 upregulation has also 
been shown to have inhibitory effects on a range of factors involved in apoptosis 
and stress responses (Chen et al., 2009; Yang et al., 2012). 
 
 
1.7     Development of new treatments  
1.7.1 Clinical trials and drug development  
TMZ has been a frontline chemotherapeutic agent since it was first licensed for the 
treatment of glioblastoma in 1999, and since 2005 it has become the primary drug 
utilized in a multi-faceted approach, involving surgical resection of the tumour tissue 
and whole brain radiation treatment (Stupp et al., 2005; Hesketh, 2008; Sansom, 
2009). A significant barrier in the development of novel drugs is the time taken to 
conduct rigorous clinical trials to determine safety and efficacy (Piantadosi, 2017). 
The development of a new therapeutic agent from the initial research to the clinical 
trials often takes many years, with the risk that the drug may either not prove 
effective or will not gain approval (Ozdemir-Kaynak et al., 2018). The high-risk 
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investment, often resulting in a low return for a successful marketable drug has led 
to considerable reduction in funding (Pammolli, et al., 2011). The consequential 
outcome is the reduction in the research and development productivity in drug 
discovery, which further compounds the problem of generating novel therapeutic 
agents in the pursuit of enhanced cancer treatments (Schuhmacher et al., 2016). In 
recent years, the development of novel therapeutic agents for the treatment of 
glioblastoma has had many setbacks in a range of drugs, where levels of success 
have fallen short and proven to be less effective than TMZ, examples include 
Mibefradil (Holdhoff et al., 2017), Gliadel  (Alphandéry, 2018) and the EGFR inhibitor 
Afatinib (Reardon et al., 2014).  Recent advances in genetics via accessible high 
throughput next generation sequencing have identified distinctive glioblastoma 
subtypes with unique genetic abnormalities, which has begun to alter the approach 
of treatment. Acknowledging the importance of identifying glioblastoma as 
heterogeneous entities, with genetic abnormalities and relevant biomarkers 
expressed by specific subtypes has become crucial for both the prediction of survival 
length and response, and for the stratification of personalised treatments that target 
unique genetic changes (Verhaak et al., 2010; Meyer et al., 2015; Tefferi et al., 
2015). An alternative approach is to target abnormal metabolic pathways that are 
universally dysregulated in glioblastoma cells and there is growing interest in the 
development of inhibitors to relevant targets of the glycolytic pathway. Treatments 
which modulate metabolism are likely to be effective in a higher percentage of 
patients, whilst sparing normal cells and reducing negative side effects (Wolf et al., 
2010). Studies have also shown an increased efficacy of conventional 
chemotherapeutic drugs in multiple tumour types that have had their metabolism 
altered (Zaal et al., 2018), although the synergistic connection is yet to be fully 
understood. As previously discussed in 1.6.3. HK2 has a crucial role in the 
deregulated glycolytic pathway in cancer cells including glioblastoma (Wolf et al., 
2011). The development of HK inhibitors has gained interest in recent years, 
including 3- bromopyruvic acid (3-BPA), a synthetic derivative of pyruvic acid which 
has an inhibitory effect on HK2 in a range of tumour cells including liver and breast 
cancers (Gandham et al., 2015). 3-BPA will be further discussed in 1.8.1. Another 
HK2 inhibitor, lonidamine (LND) inhibits aerobic glycolysis in cancer cells by targeting 
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condensed mitochondrion and inhibiting mitochondrially bound hexokinases, leading 
to a decrease in glycolysis and cellular ATP (Akins et al., 2018). Another study has 
suggested that LND induces metabolic changes through inhibition of lactate 
transport and its accumulation which leads to intracellular acidification (Nancolas et 
al.,2016).   
 
1.8 HK2 inhibitors  
1.8.1 3- Bromopyruvic acid 
3-BPA is a halogenated analog of pyruvate which demonstrates strong alkylating 
properties toward biomacromolecules (enzymes and proteins). 3-BPA has been 
shown to be an efficient energy blocker through its inhibitory ability targeting several 
key glycolytic enzymes or related metabolic enzymes post glycolysis, including HK2, 
LDH and pyruvate dehydrogenase complex (PDH), making it a potential candidate as 
an antitumor drug (Cardaci et al., 2012; Azevedo-Silva et al., 2016; Lis et al., 2016, 
Fan et al., 2019). 3-BPA has also been shown to inhibit the expression of HK2 
through direct inhibition of the mitochondrial bound HK2 via covalent modification of 
its cysteine residues, resulting in its dissociation from the mitochondrial membrane 
(Ko et al., 2001; Chen et al., 2009). Consequently, 3-BPA induces cell apoptosis, 
from HK2 dissociation which induces the release of mitochondrial apoptosis-inducing 
factor (AIF), to the cytosol resulting in cell death. The release of Cyt-C alongside 
elevated expression of proapoptotic caspase-3 and a decrease of antiapoptotic Bcl-2 
and Mcl-1 has been shown post 3-BPA treatment (Xu et al., 2005; Yadav et al., 
2017). 
3-BPA was first studied as an antitumor molecule in 2001, with cytotoxic effects in 
hepatocellular carcinoma (HCC) cells (Ko et al., 2001). Follow up studies have also 
showed selective inhibition with normal tissue remaining unaffected by 3-BPA 
treatment (Geschwind et al, 2002; Ko et al., 2004). An in vivo mouse model study 
illustrated the significant reduction in both tumour volume and growth rates in 3-
BPA-treated mice when compared to the control mice, and that 3-BPA induced 
apoptosis via HK2 inhibition leading to the activation of apoptotic signals (Kim et al., 
2007). 3-BPA has also been shown to recruit  BAX to mitochondria in cancer cells,  
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resulting in the activation of caspase-3 and the inhibition of antiapoptotic Bcl-2, and 
Mcl-1  (Xu et al., 2005; Icard et al., 2012; Zhang et al., 2012; Xiao et al., 2013; Lee 
et al., 2017). 3-BPA administered at high doses causes necrosis in HL60 human 
myeloid leukaemia cells due to complete depletion of ATP (Calvino et al., 2014). 3-
BPA also has an inhibitory effect on anabolic processes and production through the 
downregulation of the PPP pathway; the inhibition of HK2 may potentially result in 
the reduction of G6P activity and diminished G6PDH, the first substrate/step of the 
PPP pathway, resulting in increased cytotoxic oxidative conditions (Cardaci et al., 
2012; Chiasserini et al., 2017). 
1.8.1.1 Tumour specificity 
Cancer cells overexpress monocarboxylate transporters (MCTs), which export excess 
lactate excreted to avoid intracellular acidification resulting in cell death (Lee et al., 
2016). This leads to an acidic extracellular microenvironment, and cell invasion and 
metastasis. Additionally, this lactate can be taken-up by tumour cells via MCTs to 
resupply cell growth (Halestrap et al., 2012). It is hypothesised that the lactate 
MCTs and 3-BPA are structurally similar, thus allowing 3-BPA to enter the cancer 
cells via this up-take process (Fan et al., 2019). 3-BPA has been shown to be more 
stable in acidic conditions, which may contribute to the reduced toxicity in normal 
tissues, and for its high specific toxicity against tumour tissues because of the 
increased acidity in the extracellular microenvironment (Glick et al., 2014). 
1.8.1.2 Clinical trials, combination treatments and novel chemotherapeutic 
strategies of 3-BPA 
The combination of 3-BPA with chemotherapeutic drugs has potential to reduce 
tumour resistance thereby allowing for lower dosages of chemotherapeutic drugs 
administered to lessen adverse effects. 3-BPA inhibitory effects on both glycolysis 
and mitochondria resulting in the deprivation of ATP in turn may decrease 
chemoresistance due to the inhibition of macromolecule synthesis and DNA repair 
(Ihrlund et al., 2008). 
Studies have shown multidrug resistance (MDR) leukaemia cells (HL60) to 
doxorubicin (DOX) and vincristine remained sensitive to 3-BPA, and when treated in 
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combination the HL60 cells showed increased sensitivity (Xu et al., 2018). 3-BPA also 
increased the sensitivity of pancreatic cancer cells to the heat-shock protein 90 
(HSP90) inhibitor geldanamycin (Cao et al., 2008) in mice xenograft models, with 
significant tumour growth reduction and increased survival rates. Similar results have 
been seen in colorectal cancer cells (Ihrlund et al., 2008). Currently there is no data 
from clinical trials for approved 3-BPA. However, there are reported cases of the 
administration of 3-BrPA to voluntary patients with advanced tumours including 
advanced fibrolamellar hepatocellular carcinoma (Ko et al, 2012), and in a patient 
with stage IV metastatic melanoma, who received the treatment of 3-BPA via 
intravenous infusion (El Sayed et al, 2014).  
The development of a better drug delivery system to administer 3-BPA will 
significantly increase its practical application in a range of cancers whilst 
simultaneously reducing any adverse effects. Studies have shown the use of a 
biodegradable polymer substantially increased survival in animal high-grade glioma 
models whilst showing no neurological or systemic toxicity (Wicks et al., 2015). The 
application of nanotechnology has also been highlighted, where several studies 
utilised stable liposomal nanoparticles for selectively delivery of 3-BPA to tumours 
sites, with the advantage of increased BBB permeability for glioma tumours 
(Gandham et al., 2015; Zhang et al., 2018; Fan et al., 2019).  
 
1.8.2 Lonidamine 
Lonidamine (LND), a derivative of indazole-3-carboxilic acid is an anti-tumour drug 
effective at selectively sensitising tumours to chemotherapy. It inhibits aerobic 
glycolysis and mitochondrial respiration reducing levels of ATP via targeting 
condensed mitochondrion and the interference with membrane bound HK2 (Floridi et 
al., 1981). Subsequent studies have also hypothesised that LND blocks the transport 
of lactic acid across the plasma membrane through the inhibition of 
monocarboxylate transporter (MCT), leading to accumulation and intracellular 
acidification (Nancolas et al.,2016; Akins et al., 2018). Furthermore, it has also been 
suggested that LND is an inhibitor of the mitochondrial pyruvate carrier (MPC) (Nath 
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et al., 2015). A recent study demonstrated the ability of LND to inhibit the MPC, and 
as a result enhances the inhibition of MCT activity by preventing oxidation of the 
accumulated L-lactate through its conversion to pyruvate, consequently, blocking 
entry into the mitochondria and the citric acid cycle (Nancolas et al., 2016). The 
resulting effect would render the cancer cell unable to compensate for the loss in 
glycolytic ATP. LND induces apoptosis in cancer cells and whilst it has limited 
antineoplastic activity as a single therapeutic agent, it offers impressive synergistic 
effects modulating the activities of conventional chemotherapeutic agents such as 
temozolomide (Prabhakara et al., 2008). LND since first being introduced in 1979 as 
an antispermadocidic agent has shown low levels of toxicity to normal tissues when 
administered intravenously, suggesting a high affinity for cancer cells, through the 
selective inhibition of HK2 and other glycolytic components that are overexpressed in 
tumours (Price et al., 1996).  
 
1.9 Ketone bodies: 3-hydroxybuterate  
Another therapeutic approach is targeting the metabolic dysregulation occurring in 
tumour cells via the reduction of the availability of glucose, either pharmacologically 
or through the use of a high-fat, low-carbohydrate ketogenic diet (KD). The KD 
provides increased blood ketones to support the energy needs of normal tissues as 
an alternative substrate to glucose during prolonged starvation, whilst 
simultaneously diminishing the glucose energy source that cancer cells increasingly 
rely upon (Woolf et al., 2016). Their ability to cross the blood–brain barrier reduces 
the reliance of the brain on glucose (Rodrigues et al., 2017). 
Studies have shown that the incorporation of a KD leads to the reduction in tumour 
growth, along with the reduction in angiogenesis, inflammation, migration and 
invasion. Additionally, the KD has also shown to enhance the activity of radiation and 
chemotherapy in glioma mouse models (Marsh et al., 2008; Shelton et al., 2010). 
Strict compliance to the KD is essential to obtain positive results, and this can be 
difficult with the use of prescribed medication such as steroids which often increase 
hunger and raise blood glucose levels, alongside issues of quality of life (Woolf et al., 
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2016). The use of ketone bodies such as 3-hydroxybuterate (3-HB), which is 
synthesised in the liver from acetyl-CoA and secreted into the blood, offer a potential 
therapeutic benefit from which many tissues can up take ketone bodies and 
oxidatively metabolise. 3-HB has a higher calorific value compared to glucose and 
offers an efficient provision of energy per molecule of oxygen compared to glucose, 
however cells need functioning mitochondria as well as sufficient oxygen in order to 
generate energy (Veech et al., 2004). 3-HB is transported into cells via MCTs and is 
degraded via ketolysis into acetyl-CoA, which functions to deliver the acetyl group to 
the TCA to be oxidized for energy production (Newman et al., 2014; Vidali et al., 
2015). In vitro studies have demonstrated 3-HB to elicit ketosis in gliomas, therefore 
possessing antitumor effects (Skinner et al., 2009; Rossi et al., 2015), furthermore 
the supplementation of ketone bodies has shown to augment the effectiveness of 
the KD (Shukla et al., 2014). Studies have shown the effectiveness of 3-HB in 
reducing the proliferation of tumour cells in a range of cancers, including human 
glioblastoma cell lines, even in the presence of high glucose (Woolf et al., 2016). 3-
HB treatment has also demonstrated the ability to increase the sensitivity of cancer 
cells to ionizing radiation, the increased effectiveness allows for the potentiation of 
lower doses (Rossi et al., 2015; Silva-Nichols et al., 2015). Furthermore, 3-HB has 
shown to increase the effectiveness of chemotherapeutic agents when used in 
combination in glioblastoma cells (Scheck et al., 2012), suggesting ketone 
supplementation provides an effective therapeutic approach in addition or without 
the stringent KD approach. Paradoxically a group of studies have shown 3-HB to 
promote growth in cancer cells (Bonuccelli et al, 2010; Martinez-Outschoorn et al., 
2012). It was hypothesised (Rodrigues et al., 2017), that the effect of ketone bodies 
upon the cancer growth was dependant on the energetic phenotype of the tumour, 
for the predominantly glycolytic “Warburg-like phenotype” tumour cells would lack 
the ability to metabolize 3-HB resulting in the inhibition of growth and 
tumorigenesis. Ketone bodies have also demonstrated regulatory roles in epigenetic 
states transcription of gene expression via chromatin modification (Schimazu et al., 
2013). 3-HB is a known inhibitor of histone deacetylases (HDAC), responsible for the 
removal of acetyl epigenetic marks from histones. Deregulation of histone 
acetylation has been shown to result in abnormal expression profiles of genes 
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involved in cell proliferation and differentiation and is associated with malignancy 
(Rodrigues et al., 2017). 
 
 
 
 
 
 
1.10 Metformin  
The development of a new drug through the process of clinical trials often takes 
many years with total costings potentially reaching as high as $2 billion dollars. 
Fastened with the lack of guarantee for clinical approval, investment and generation 
of new therapeutic agents has lessened in recent years (Massey and Robertson, 
2018).  An alternative is the repurposing of existing licenced medication which is 
advantageous in many aspects. Existing drugs are already regarded as safe for 
human use, thus reducing the costs and time of the clinical trial process. The 
repurposing of existing licenced drugs for the treatment of glioblastoma offers a 
potential alternative crucial for faster implementation of new therapeutic treatments 
(Abbruzzese et al., 2017). Recent studies have highlighted several potential 
candidates that could be repurposed for the treatment of glioblastoma, these include 
metformin and disulfiram (Brenneman et al., 2016; Chae et al., 2016). Population 
studies discovered that type II diabetes patients treated with the anti-diabetic drug 
metformin had a reduced incidence of malignant cancers (Evans et al., 2005).  
Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide drug used to treat 
type 2 diabetes. It is an oral drug that prevents the production of glucose in the 
liver, leading to an improvement in the sensitivity towards insulin, resulting in the 
reduction of sugar absorbed by the intestine (Maruthur et al., 2016). Metformin was 
first synthesised in 1929 and has been comprehensively utilized in the treatment of 
diabetes in the United Kingdom from the 1950s (Hadden, 2005). Studies conducted 
in 2005 revealed metformin to potential moderate the risk of cancer, in patients 
being treated with type 2 diabetes (Evans et al., 2005). More recently, clinical trials 
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have assessed metformin and its anti- cancer potential in a range of tumours (Chae 
et al., 2016; Heckman-Stoddard et al., 2017). The repurposing of metformin as a 
potential cancer therapeutic agent is a low risk factor, as stated metformin offers the 
advantage of being orally administered with inconsequential primary side effects 
which can be amended via dose control (Matsuzaki, 2017). Moreover, metformin 
crucially has demonstrated the ability to cross the BBB which is often a major 
obstacle for the formulation of new or existing anti-cancer drugs. Additionally, 
metformin has exhibited a potential to upregulate the functions of the BBB including 
an overall reduction in the permeability via the activation of AMP-activated protein 
Kinase (AMPK) tissue (Łabuzek et al., 2010; Takata et al., 2013). Metformin offers 
the additional advantage with its worldwide availability including less developed 
countries, due to its classification as an essential medication (World Health 
Organization, 2017). 
1.10.2 Metformin clinical trials 
Ongoing clinical trials have assessed metformin and its anti- cancer potential in a 
range of tumours with the resulting success variant. Examples of metformin having a 
positive impact include the phase II trial of ovarian, fallopian tube and primary 
peritoneal cancer (stage II/III/IV), where metformin was utilized in conjunction with 
both adjuvant chemotherapy drugs and surgery (Buckanovich et al., 2017). The 
promising additive effect of metformin in this trial led to the use of metformin in 
phase-III trials. A recent clinical trial for early stage breast cancer (Dowling et al., 
2018) stated the comprehensive constructive effect of the addition of metformin, 
with the significant reduction of cancer biomarkers (Dowling et al., 2018). Other 
clinical trials state the inhibitory effects of metformin on altered gene expression in 
cancer patients (Lord et al., 2016), however numerous clinical trials report 
metformin to have no synergistic impact including a high-risk breast cancer trial (Yee 
et al., 2017) and a phase II late stage pancreatic cancer clinical trial where no 
significant impact was determined (Kordes et al., 2015). The clinical trial data does 
offer an insight into the anti-cancer potential of metformin, particularly in early stage 
cancer whereby it was shown to have the greatest impact as a combination 
treatment (Chae et al., 2016). The mechanism of the anti-tumour activity of 
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metformin is currently not fully understood, studies (Pollak, 2012; He and 
Wondisford, 2015) however state that metformin inhibits respiratory complex I of 
the electron transport chain in mitochondria leading to the activation of AMPK and 
the inhibition of the mTOR pathway. 
1.11 Drug synergy and combination treatments  
The identification of synergistic partners for both new and repurposed inhibitors 
would increase their scope for usage in the treatment of glioblastoma, as part of a 
multi model treatment regime, most notably with the mainstay chemotherapeutic 
agent TMZ. TMZ is the frontline therapeutic agent in glioblastoma treatment 
(Messaoudi et al., 2015), forming part of the STUPP protocol. TMZ is an alkylating 
agent that causes DNA damage resulting in cell death, as with metformin it is orally 
administered and absorbed in gastrointestinal tract (Lee et al., 2018). TMZ is pH 
responsive, in environments greater than pH7 it hydrolyses into methytriazine 
(MTIC) (Di Martino, et al 2017). In vitro studies have shown that TMZ has a 30- 
minute half- life before hydrolysing into MTIC, which has an approximate half- life of 
25 minutes before degrading into the inactive form 4-Amino-5-imidazole-
carboxamide (5-AIC) (Aldea et al., 2014), as shown in Figure 1.7. The effectiveness 
of inhibitors, for example the HK2 inhibitors discussed and metformin, in a 
combination treatment would potentially increase their inhibitory capability (Aldea et 
al., 2014), and the prospective capacity of TMZ. 
Figure 1.7. TMZ structure TMZ must become hydrolysed into its reactive component form of a 
methydiazonium ion and an inactive AIC. The activation of hydrolysis is regulated by a pH greater 
than 7. (Lopes, et al 2013). 
 
1.12 Mechanisms of cell death induced by inhibitors 
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1.12.1 Apoptosis 
Programmed cell death via apoptosis is a crucial cellular mechanism for the 
maintenance of a healthy equilibrium, with the destruction and removal of cells in a 
controlled manner. Apoptosis uses intracellular mechanisms to perform a range of 
functions which include structural development, immune response, chemical-induced 
cell death and hormone dependant atrophy (Elmore, 2007). Apoptosis involves 
multiple cellular pathways leading to the irreversible activation resulting in the 
breakdown of the cell and cellular function. The extrinsic and intrinsic pathways are 
both are operated and regulated through specific caspase proteins (Budihardjo et 
al., 1999), as shown in Figure 1.8. The two pathways are instigated via different 
stimuli; the intrinsic pathway is synchronised to the various functions of the 
mitochondria, including the activation of the caspase pathway and the Apoptotic 
Peptidase Activating Factor 1 (APAF1), which encodes a cytoplasmic protein initiating 
apoptosis by cleaving caspase 9 pre-proprotein (Fulda and Debtain, 2006). 
Conversely, the extrinsic pathway is facilitated by cell surface receptors, which are 
stimulated by death ligands presented by immune-effector cells resulting in the 
formation of the death-inducing signalling complex (DISC). DISC is comprised of the 
death receptor, and caspase 8, which activates the downstream signal cascade of 
caspase pathways resulting in apoptosis (Kischkel et al., 1995). The intrinsic 
pathway is tightly regulated by the mitochondria which control the pathway through 
downstream caspase effectors via the release of cytochrome C (Cyt C), which in turn 
activates the cysteine protease caspase 9 resulting in the activation of caspase 3 and 
7, which are responsible for destroying the cell from within (Hunt, 2002; Boehning et 
al., 2003). The mitochondrial membrane potential (Δψ) is a fundamental factor in 
mitochondrial activity, which drives the tricarboxylic acid cycle (TCA) (Martínez-
Reyes et al., 2016). The combination of apoptogenic factors released by the 
mitochondria with the addition of the depolarisation of the transmembrane potential 
and the loss in oxidative phosphorylation are key factors in eliciting the intrinsic 
apoptotic pathway (Martínez-Reyes et al., 2016). Apoptosis in cancer is frequently 
disrupted, with tumour cells acquiring adaptations in order to prevent and block 
apoptotic pathways. A common occurrence in cancer are the mutations of key pro-
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apoptotic genes leading to the deregulation of apoptosis, including mutation of the 
cell surface receptors CD95 and TNF-related apoptosis-inducing ligand (TRAIL) 
which are responsible for the induction of caspase dependant apoptosis (Fulda and 
Debatin 2006; Song et al., 2008). These key mutations have been revealed as a 
frequent occurrence in head and neck osteosarcoma (Dechant et al., 2004). 
Additionally, the activation of extrinsic pathways can be blocked by an increased 
concentration of anti-apoptotic molecules, which inhibit phosphorylation and 
ubiquitylation of caspase activation and activity, resulting in the loss of receptor 
activation, as often demonstrated in tumours.   
Therapeutic treatments that can restore apoptotic functionality are being 
investigated. However, the activation of the extrinsic pathway through extracellular 
receptors is relatively non-specific and there has been limited progress in the 
development of extrinsic caspase pathway therapies. On-going clinical trials 
targeting TRIAL and CD95 using receptor agonists, such as tumour necrosis factor 
alpha (TNF-α) have so far proved ineffective. However, the development of novel 
agents to reinstate apoptosis potentially offer effective treatment methodologies in a 
range of cancers (Merchant et al., 2012, von Pawel et al., 2014; Ashkenazi, 2015; 
von Karstedt et al., 2017).  
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Figure 1.8 Extrinsic and intrinsic apoptotic pathwaysApoptosis uses a range of signalling 
pathways and comprises of two versions based on the initial signalling trigger. Intrinsic apoptosis has 
multiple triggers relating to metabolism, DNA damage and cellular stress. Extrinsic apoptosis is 
initiated by extra cellular signals, resulting in the generation of DISC (Schleich et al., 2013). 
1.12.2 Cell cycle 
Cell cycle is a crucial mechanism in the maintenance of healthy cell populations and 
the regulation in the generation of new cells. The progression through the various 
stages of the cycle are tightly regulated and controlled with multiple checkpoints in 
order to ensure that faulty cellular processes are constrained and unauthorized to 
progress further in the cycle (Vermeulen et al., 2003). The checkpoints regulate 
fundamental stages of cell division, crucial for the prevention of DNA damage and 
aberrant cell behaviour, in healthy cells the cycle arrests and cellular division is 
prevented with the occurrence of a checkpoint pre- requisite failure (Bertoli et al., 
2014). 
The deregulation of the mechanisms maintaining control is a frequent occurrence in 
tumour development (Evan and Vousden, 2001). The regulatory mechanism 
maintained in cell cycle is controlled predominantly by two main groups of 
molecules, which are cyclins and cyclin-dependent kinases (CDK) (Spoerri et al., 
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2015). The role of CDK is the binding of cyclins resulting in the formation of active 
kinase protein complexes, in the absence of cyclin CDK has little kinase activity. 
Cyclin-CDK complexes phosphorylate substrates appropriate for the specific cell cycle 
phase (Spoerri et al., 2015). Mammalian cells contain at least nine CDKs, four of 
which are associated directly with cell cycle regulation, including CDK1, 2, 3, and 4 
(Crosby, 2007). CDK1 with its partners cyclin A2 and B1 can alone drive cell cycle. 
Cyclin-CDK complexes from earlier phases in the cell cycle instigate later phase 
cyclin-CDK complex activation. Figure 1.9. shows the list of cell cycle checkpoints 
associated with cyclin CDK complexes and the summery of cell cycle developmental. 
3-BPA has been shown to induce cell cycle arrest in cancer cells through a range of 
mechanisms. In breast cancer cells after the treatment of 3-BPA, the G0 and G1 
phases were dramatically decreased. Additionally, expression levels of Bcl-2, c-Myc 
and mutant p53 were significantly reduced all of which are associated with the 
programmed cell death signal transduction pathway (Liu et al, 2009). 3-BPA has also 
shown effective inhibition of cell cycle in colorectal cancer cells, eliciting the 
downregulation of cyclin-dependent kinase CDK4 and CDK2 resulting in a G1 phase 
arrest (Chong et al., 2017). Metformin has also been shown to cause cell cycle arrest 
in a range of cancer cell types via various mechanisms. Metformin was shown to 
induce G1 cell cycle arrest in lung cancer cells through the inhibition of the atypical 
repressor E2F8; overexpression of this transcription factor is associated with poor 
patient prognosis (Jin et al., 2017). In recent studies, metformin was shown to 
induce G2/M cell cycle arrest in glioblastoma cells when treated in combination with 
TMZ (Adeberg et al., 2017), and in breast cancer cells cyclin G2 was upregulated as 
a response to treatment with metformin, which is a key regulator for the G2/M 
checkpoint inhibiting CycB1-Cdc2 complex formation Cdc2 (Zimmermann et al., 
2012, Zimmermann et al., 2016). The crucial regulatory role of CDKs have 
emphasised their potential as a target for anti-cancer treatment, with the 
development of specific inhibitors to target CDK action, interrupting the cell cycle 
regulation.  
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Figure 1.9 Cell cycle developmental progression checkpoints The four main stages to cell 
cycle progression: G1, S, G2 and M phase. Controlling the cells movement through the phases are 
four check points, G1 to S phase transition, S phase checkpoint, G2 phase checkpoint and the spindle 
assembly checkpoint, ensuring that the cell has not suffered damage and that correct prerequisite 
stages have been completed. G1/S, S phase and G2 phase check for DNA damage in order to stop 
any mutations and errors post division. The checkpoints also ensure that the previous step was 
correctly completed, G1/S asses that previous mitosis, S phase checks for duplicated genetic material 
and G2 assess the cell mitotic preparation. The spindle check point assesses establishment of mitotic 
spindle for correct allocation of chromosomes. Each stage is controlled by the creation of a specific 
cyclin Cdk protein complex (Filho et al., 2017). 
 
1.12.3 AMPK and mTOR 
Mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, 
integrates responses from a wide variety of signals including nutrients, hormones, 
growth factors, and cellular stresses in order to regulate several downstream 
processes including protein and lipid synthesis, cell survival, cell motility, autophagy 
and transcription (Hay et al., 2004). mTOR forms two distinct protein signalling 
complexes, mTORC1 and mTORC2 which maintain control of downstream pathways 
(Lipton et al., 2014; Saxton et al., 2017). The rapamycin-sensitive mTORC1 complex 
regulates a range of cellular mechanisms including protein synthesis, cell cycle 
progression, cell growth, and proliferation. Less is known of the functions of the 
mTORC2 complex, however AKT activation has been associated, which is a key 
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influence in cell migration and survival through the inhibition of apoptosis and 
autophagy (Pópulo et al., 2012; Kim et al., 2015).  The activation of AMPK has 
shown to inhibit mTOR acting as a tumour suppressor, however it has also been 
associated as an oncogene through its facilitating role in cell division and metabolic 
reprogramming (Jeon et al., 2012; Liu et al., 2013). In glioblastoma cells AMPK has 
been shown to be actively upregulated (Liu et al., 2013). Figure 1.10 shows the 
mTOR signalling network and pathways.  The effectiveness of 3-BPA at inhibiting 
mTOR is still not fully understood, it has been reported in both lung and liver cancer 
cells that 3-BPA did not add a synergistic effect in combination with rapamycin, 
instead the addition of rapamycin alone blocked the mTOR signalling pathway. 
However, the combination of rapamycin and 3-BPA demonstrated enhanced 
antitumor efficacy with respect to the reduction of glycolytic activity, indicating that 
the dual inhibition of both mTOR signalling and glycolysis offers a potential effective 
therapeutic strategy for cancer treatment (Zhang et al., 2015). It has been 
suggested that metformin has the capability to inhibit the mTOR pathway via several 
pathways, and in pancreatic cancer its mechanism of action has been shown to act 
through the downregulation of transcription factors which result in the downstream 
inhibition of mTOR signalling (Nair et al., 2014).  
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Figure 1.10 Figure showing the mTOR pathwaymTOR forms two separate complexes mTORC1 
and mTORC2 to regulate multiple downstream effectors. mTORC1 affects anabolic and catabolic 
pathways. mTORC2 affects cellular proliferation pathways including cell survival, metabolism and 
cytoskeletal organisation. mTORC1 is primarily inhibited by AMPK phosphorylation of RAPTOR and the 
AKT substrate PRAS40 (Kim et al. al., 2015). 
 
1.12.4 Autophagy 
Autophagy is an alternative method of cell destruction compared to the apoptotic 
programmed cell death. Autophagosomes which comprise of double membrane 
cytosolic vesicles transverse across the cell up taking and absorbing macromolecules 
and organelles, eventually combining with the lysosomes thus becoming 
autolysosomes. The function of the autolysosome complex is to break down the 
absorbed macromolecule content leading to cellular degradation and the recycling of 
molecules (Ramirez et al.,2013; Nakamura et al., 2017). Primary regulation of 
autophagy is through the controlled signalling of Phosphoinositide 3-kinase (P13K) 
and AKT (Heras-Sandoval et al., 2014) as well as the regulation of the mTOR 
pathway, as shown in Figure 1.10. The activation of autophagy in glioblastoma 
offers a therapeutic target (Yan et al. 2016). Autophagy can also be utilized in a 
controlled cellular process, whereby lysosomes deconstruct internal cellular 
structures, in order to maintain balance, including the removal for the of damaged 
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organelles and the regulation of metabolism (Parzych et al., 2014; Kobayashi, 2015). 
The autophagy regulation pathway is shown in Figure 1.11. Additional to inducing 
apoptosis, 3-BPA has also been shown to instigate autophagy under apoptosis-
deficient conditions via the formation of a complex with receptor-interacting 
serine/threonine-protein kinase 3 (RIP3) (Moriwaki et al., 2013). RIP3 is a 
component of the tumour necrosis factor (TNF) receptor-I signalling complex, which 
mediates necroptosis via the activation of autophagy (Yuan and Kroemer, 2010). In 
colorectal cancer cells 3-BPA has been shown to induce cell death by multiple 
mechanisms including autophagy at the same time via the depletion of cellular 
energy stores (Sun et al., 2015). Metformin has also been shown to instigate 
autophagy via the induction of cellular stress and ATP reduction (Lindqvist et al., 
2018), in colorectal cancer cells studies have shown autophagy was induced via p53 
after metformin treatment (Buzzai et al., 2007). Autophagy activation by metformin 
has also been shown in thyroid and endometrial cancer cells (Song et al., 2017; Gu 
et al., 2017). Studies have also found metformin to induce autophagy in 
glioblastoma cells via the activation of AMPK and REDD1, downregulating the mTOR 
pathway (Sesen et al., 2015). 
 
Figure 1.11. Autophagy regulation pathwayThe primary mechanism controlling autophagy is 
mTOR. mTOR downregulation can occur from a range of cellular signalling including cellular stress, 
growth factors and glucose levels. The downregulation results in substrates produced by P13K 
complexes and the ULK complex to move to the phagophore. Further protein complexes are then 
recruited to create the complete autophagosome (Maier and Britton, 2012). 
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1.13 Cell culture models 
Cell culture is an important in vitro tool for the generation of data that cannot be 
attained via in vivo techniques, such as the impact of inhibitory molecules upon 
cellular mechanisms, including proliferation, cell cycle, apoptosis and autophagy. The 
replication of a suitable microenvironment in which to grow cells is essential for such 
work to commence, however tissue culture can result in genetic and phenotypic 
changes (Bara et al., 2014, Nestor et al., 2015). Studies have shown that 
glioblastoma cells in culture significantly loose the amplified levels of expression of 
EGRF present within the tumour tissue (William et al., 2017).  
Additional complications with cell culture models are the heavily relied upon 
immortalized human cancer cell lines, which are abundantly available worldwide, 
advantageous when compared to primary cell material which are extracted from 
small finite biopsy tissue samples. Commonly used glioblastoma cell lines include 
U251MG, U87MG and U373MG (Ponten et al., 1968, Westermark et al., 1973; 
Ponten et al., 1978). In recent years with the advancement of techniques the 
reliability of immortalised cell lines has been scrutinized, studies have shown that the 
cell line U251MG exhibits altered genotypic and phenotypical features compared to 
the progenitor sample. It was shown over time that higher passage U251MG loses 
its original glioblastoma signature with the acquirement of additional genetic 
deletions (Torsvik et al., 2014). A more accurate alternative model is the use of 
patient-derived cultures, which utilizes extracted cells in the same manner. The cell 
line however is set for use only as a short-term low passage culture reducing the 
probability of both genetic and phenotypic deviations from the original sample whilst 
providing a functional cellular system (Roberts et al., 2017). 
 
1.14 Aim and objectives  
Glioblastoma are genetically and phenotypically heterogeneous; current treatment 
options are limited with unpromising outcomes. The development of novel therapies 
targeting aberrant metabolism in glioblastoma could generate potential therapeutic 
advantages.  
This study hypothesises that glycolytic inhibitors can be effective anti-glioblastoma 
agents in vitro. Furthermore, that the combining of therapies to target energy 
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metabolism through several different mechanisms simultaneously will minimise 
development of resistance. The aim of this study was to investigate the efficacy of 
disrupting glucose metabolism in killing glioblastoma cells. The objectives of this 
study were: 
 
 To determine whether hexokinases HK1 and HK2 are differentially 
expressed in glioblastoma compared to normal brain. HK2 has been 
shown to be highly expressed in a range of cancers, a distinguishing 
factor compared to normal tissue. 
 
 To ascertain whether promoter CpG methylation status is involved in 
the regulation of HK1 and HK2 expression in glioblastoma as there is 
evidence that expression of some metabolic enzymes is regulated by 
epigenetic mechanisms. 
 
 To establish the efficacy of HK2 inhibitors in suppressing growth of 
glioblastoma cells in characterised patient-derived cell cultures and to 
determine whether the degree of growth inhibition correlates with 
levels of HK2 expression. 
 
 To investigate whether combining HK2 inhibitors with either metformin 
or temozolomide is more effective than using these drugs in isolation. 
 
 To understand the molecular pathways through which glycolytic 
inhibitors act, including identification of the mechanism of action 
utilised in induction of cell death in glioblastoma cultures via flow 
cytometric assays.  
 
 To determine the effects of physiological conditions on tumour cell 
response to inhibition of HK2, including oxygen and glucose availability 
utilising characterised patient-derived cell cultures. 
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This study was conducted under ethical approval granted by the Life Science Ethics 
Committee, University of Wolverhampton, LSEC/22/0909  
 
2.1 Cell culture  
This study was conducted under ethical approval granted by the Life Science Ethics 
Committee, University of Wolverhampton, Cell biology and genetic investigations of 
primary and metastatic brain tumours (renewal), LSEC/2016/17/TW/11. 
 
2.1.1 Glioblastoma biopsies  
Fresh, frozen glioblastoma biopsy samples were obtained from the REC-approved 
Brain Tumour North West and Walton Research Tissue Banks (Ethics Committee 
approval reference numbers 09/H0304/8 and WRTB 13_02). Written informed 
consent has obtained from all patients prior to their donation of surplus tumour and 
normal brain tissue for research at the primary treatment centre for surgical 
treatment. All tissue samples were fully anonymised prior to their release from the 
tissue banks.  Histological sections of the tumour tissues were examined by 
neuropathologists and were diagnosed according to the WHO classification system 
(Louis et al., 2016). 
 
2.1.2 Glioblastoma cell cultures 
Patient-derived short-term cell cultures were derived from fresh tumour biopsy 
material as described by Lewandowicz et al. (2000) and stored in liquid nitrogen 
until further use. Nineteen glioblastoma patient-derived cell cultures were used in 
this study, which were recovered from liquid nitrogen at low passage (<10) and 
utilized up to passage 20. The established cell lines U251MG and U87MG were 
supplied by Dr Darrell Bigner, Duke University, USA (Bigner et al., 1981) between 
passages 78-86. HEPES-buffered Ham’s F-10 media (Life Technologies Ltd., UK) 
supplemented with 10% foetal calf serum (PAN biotech, UK) were used to culture all 
cells used in this study.  Details of the samples used in this study are shown in Table 
2.1. 
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2.1.3 Control Cells  
Normal human foetal astrocytes (NHA) were used as a non-cancerous control in this 
study as a comparison for the astrocytic origin of the short-term cultures. The NHA 
(Lonza, UK) were utilized to passage 10. Additionally, normal brain tissue was also 
used as a non-cancerous control 
 
2.1.3 Maintenance and cell culture methods 
Cell culture work was completed within a Biomat 2 sterile class II Laminar flow hood 
using Sarstedt tissue culture consumables; sterilised with 70% ethanol (Sigma-
Aldrich, UK) and 1% Trigene (Sigma-Aldrich, UK) solution. Cultured cells in cryovials 
were removed from liquid nitrogen and thawed immediately in a water bath at 37ºC. 
The cells were transferred from the cryovial to a fresh sterile 25ml universal tube, 
3ml of pre-warmed (37ºC) media was then added via dropwise. The tube was then 
centrifuged for 5 minutes at 1000 rpm. The supernatant was aspirated, and the cell 
pellet was gently resuspended in 10 ml of fresh media. The contents were then 
transferred to a T25 (25 cm2) growth flask and placed in a non- carbon dioxide 
incubator (Panasonic MCO-170AIC-PE IncuSafe, Panasonic UK) at 37ºC. Media was 
replaced to growing cultures every 24-48 hours. 
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Table 2.1 Details and characterisations for all Institute of Neurology (IN) patient 
derived cell cultures 
Culture Sex 
Age at 
diagnosis 
Location 
TP53 
deletio
n 
MGMT status 
EGFR over 
representation 
IN859 F 72 R frontal Yes Methylated chr 7p 
IN1265 F 70 R occipital WT Unmethylated chr 7p 
IN1461 F 44 L Parietal WT Unmethylated chr 7p 
IN1472 F 46 Unknown Yes Unmethylated - 
IN1528 M 61 
R temporo-
parietal 
Yes Methylated chr 7p 
IN1612 M 53 
R post-
temporal 
Yes Unmethylated chr 7p 
IN1682 F 48 R parietal WT - chr 7p 
IN1760 F 56 L temporal WT 
Partial 
methylation 
chr 7p 
IN1951 M 30 R parietal WT Unmethylated - 
IN1979 M 46 
L temporo-
parietal 
Yes Unmethylated - 
IN2045 M 25 L frontal WT 
Partial 
methylation 
- 
IN2093 M 55 R frontal WT Unmethylated - 
IN2132 M 57 - WT - - 
U251MG - - - WT 
Partial 
methylation 
chr 7p 
U87MG    WT   
NHA N/A N/A N/A WT Unmethylated  
UWLV22 M 65 - - - - 
UWLV48 M 43 - - - - 
UWLV53 F 48 -    
UWLV152 M 37 - - - - 
UWLV156 F 52 - - - - 
UWLV212 M 69 - - -  
Details and characterisations for all Institute of Neurology (IN) patient derived cell cultures. M = Male, 
F = Female; Age listed in years at diagnosis; L = Left, R = Right; The mutation status of the tumour 
protein gene p-53 characterised through sequencing (Potter et al., 2018); MGMT status identified by 
methylation specific PCR (Licchesi et al, 2009). 
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2.1.5 Growth Media 
All glioblastoma short-term cultures and established cell lines were grown in HAMs F-
10 supplemented with 10% FCS from Pan Biotech FBS GOOD EU range (Pan 
Biotech), without antibiotics or anti-microbial agents. Cultures were grown in non -
vented flasks in a standard incubator under normoxic conditions at 37ºC. The 
cultures were grown in non-CO2 conditions as the F-10 media contains HEPES buffer 
to maintain optimal pH levels. For certain experiments where cells were grown under 
various glucose levels, glucose-free HAMS F-10 (Pan Biotech) was utilized, which 
was supplemented with 10% FCS and 10% HEPES as standard along with glucose 
(Sigma, UK) at the desired concentrations.   
Appendix I includes the F-10 media formulations used for all experiments. Normal 
human foetal astrocytes were grown in ABM Basal Medium and were supplemented 
with AGM SingleQuot Kit and Growth Factors (Lonza, UK). The manufacturer 
standardised cell growth medium contains 4.80% gentamicin sulphate to inhibit 
microbial growth. Cultures were grown in vented flasks with 5% CO2 and incubated 
at 37ºC. Cell cultures were routinely monitored for changes in the growth media and 
cell density, and were regularly fed between 36-48 hours, or when needed due to a 
change in pH of the growth medium. 
Cells were passaged when confluent in order to expand their population and to 
provide enough nutrients and space to divide and grow. Media was aspirated from 
the culture flask and cells were washed with 1x HBSS (Life Technologies) (1ml for 
T25 flasks and 5ml for T75 flasks). Treatment of 1xTrypsin (Sigma-Aldrich, UK) was 
added to the flask (1ml for T25 flasks and 3ml for T75 flasks) and spread evenly in 
order to cover the entire surface. The cells were incubated for 5 minutes at 37ºC to 
detach the adhered cells, and verified using a microscope, ensuring cells were 
detached before inactivating the trypsin via the addition of fresh culture media (3ml 
for T25 flasks and 10ml for T75 flasks). The contents of the flask were then 
transferred to a sterile 25ml universal tube and centrifuged for 1000 rpm for 5 
minutes. After removing the supernatant, the cell pellet was then resuspended in 
fresh media and passaged at a ratio of 1:3 into T75 flasks containing fresh media. 
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Cell pellets were also frozen for long-term storage in liquid nitrogen, 1x10⁶ cells 
were re-suspended in a 1ml volume containing 10% DMSO (Sigma Aldrich, MERCK, 
UK) and 90% FCS. The cell suspension was transferred to labelled cryovials 
(Nalgene Cryoware™ Labware, Roskilde, Denmark) and left for 24 hours at 80ºC in a 
NALGENE® Mr. Frosty (Thermo Scientific, UK). The cryovials were then transferred 
to liquid nitrogen tank (-196ºC) for indefinite storage. All short-term cultures were 
routinely tested for mycoplasma contamination, where approximately 100,000 cells 
were counted and attached to a glass slide using a cytospin centrifuge, fixed in ice-
cold methanol (Sigma-Aldrich, UK) and stained with Hoescht dye (Sigma-Aldrich, UK) 
for visualisation under a fluorescent microscope for the presence of extranuclear 
dots.  
 
2.1.6 Growth proliferation curves  
Growth proliferation curves were conducted to determine the exponential growth 
phase. Cells were seeded in 7 x T25 flasks and measured over a 10-day time period. 
Cells were initially seeded at 1x10⁵ and readings were taken at day 1, 2, 3, 5, 7, 9, 
10 days. At each time point cells were trypsinised, centrifuged and collected before 
being resuspended in growth media and counted on a Countess Cell Counter 
(Thermo Fisher). This method utilizes the staining of live cells with trypan blue, 
using a 1:1 ratio with growth media. Two separate readings were taken for each cell 
count where an average was calculated. Growth curves were repeated three times. 
 
2.2 Growth Inhibition Assays  
2.2.1 Drugs  
3-bromopyruvic acid, metformin, 3-hydroxybuterate, lonidamine, camptothecin and 
temozolomide were purchased from Sigma Aldrich.   
 
2.2.2 Sulforhodamine B (SRB) cell proliferation assay 
The inhibitory effect of the experimental drugs upon cell proliferation was 
determined via SRB colorimetric assay. Cells were seeded in 96 well plates in 
triplicates at 4000 cells per well in 200µl growth media and incubated at 37ºC until 
the determined exponential growth phase was reached. The growth media was then 
 55 
 
aspirated and fresh media (200µl/well) containing an appropriate concentration of 
drug was added. The plate was then incubated for 72 hours. Drug concentrations 
were prepared to required concentrations and serially diluted in growth media in a 
separate 96 well plate before being transferred to the cells. Daily re-treatments of 
fresh drugs were dependant on the half-life of the drug. Control cells were grown in 
media without the presence of the drug. Following the incubation, the media was 
aspirated, and the cells were fixed to the plate using 150μl of 10% (wt/vol) ice-cold 
trichloroacetic acid (TCA) and placed at 40C for 1 hour. The plate was then washed 
three times to remove excess TCA and air dried before being stained with 100 µL of 
0.4% SRB (Sigma-Aldrich, UK) (dissolved in 2% (vol/vol) acetic acid) (Sigma, Merck) 
and incubated for 30-60 minutes at room temperature. SRB colorimetric assay was 
used to assess the viability of the cells, via protein-binding (Vichai et al., 2006). After 
incubation the plate was washed three times to remove excess unbound SRB before 
being dried. 100 µL of 10mM Tris base solution (Sigma Aldrich, Merck) was added to 
the wells and mixed gently for 5 minutes until the SRB dye has been solubilised. The 
optical density absorbance was read at 560 nm wavelength on a GloMax® Multi 
Microplate Reader (Promega). Results were analysed using MS excel and GraphPad 
Prism. Each plate had triplicate repeats of 8 concentrations of drug and 2 negative 
controls. 
 
2.2.4 Calculation of ID50 values                                                                                                                                                           
SRB and MTT data were analysed using MS excel GraphPad PRISM software. ID50 
values were determined using a log (inhibitor) vs. Response or a four-parameter 
logistic curve (4PL) algorithm. This method utilised all O.D absorbance data points 
generated against log molar dosages. The method assumes a non-standard, variable 
slope. This is outlined in Fig 2.1 ID50 values for each drug are calculated from this 
method for each culture tested. Groupings of data were analysed for significant 
difference via the use of an un-paired students t-test. 
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Figure 2.1 Mathematical model used for all analysis on graph pad prism The method allows 
for variable analysis of the drug response yielding more accurate ID50 than seen on a standard curve 
model. 
2.2.5 Experiments utilizing ID50 values 
Experiments that utilised the ID50 values were set-up in the same manner, these 
include all experiments involving flow cytometry. Cells were seeded at the same 
concentration (4000/well) as tested on the 96 well plates. T25 flasks were seeded 
with 5ml at 12,000 cells per ml and T75 flasks were seeded with 15 ml of cells at 
80,000 cells per ml. 
 
2.2.6 Drug Synergy Assays 
Drug synergy assays were conducted to determine the inhibitory effects of paired 
drug combinations. Cultures were treated with either an individual drug or a paired 
combination and the ID50 values were calculated as previously outlined. The 
concentration of the drugs used in combination were ensured to be equimolar, as 
equivalent to the cells treated with a singular drug. The Chou-Talay method of 
determining the combination index (CI) was utilized to calculate the synergy 
between drugs in the combination treatments (Chou et al., 2010); the equation is 
shown in full in Figure 2.2. CI values represent how synergistic (values <1) or 
antagonistic (values >1) the combination treatments are; additionally, values of 1 
are defined as of having an additive effect when used in combination. The greater 
the CI value from 1 is representational of having a stronger effect. Combination 
treatments were run in duplicates per plate, which was repeated three times.    
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Figure 2.2 – Chou Talay synergy equation The equation for working out the CI of each drug 
assessed with the Chou Talay synergy assay (Chou, 2010). Drug A and B solo ID50 values represent 
the sensitivity of the cell to that individual drug. Drug A and B combo represent the ID50 of the drugs 
when used together in an equimolar combination. The equation divides the combination ID50 value by 
its individual treatment counterpart. The CI index is then generated from the values for each drugs 
response. An average contribution to the total CI index of less than 0.5 is determined as achieving a 
synergistic response. A resulting CI index of less than 1 implies the combination of the drug produces 
a response greater than sum of the individual treatments. 
2.3 Extraction and assessment of nucleic acids 
 
2.3.1 Genomic DNA extraction  
Genomic DNA was extracted from both patient- derived short-term glioblastoma 
cultures and frozen biopsy material using DNeasy blood and tissue extraction kit 
(Qiagen, Manchester, UK). Extraction was conducted by the manufacturer’s 
instructions.  DNA extraction from fresh-frozen biopsy tissue required approximately 
25 mg of tissue to be finely sliced, a 180 µl of Buffer ATL was then added and the 
sample was homogenised with the use of a syringe and needle for effective lysis. 50 
µl proteinase K was then added to the homogenised sample, vortexed and left to 
incubate at 56ºC, occasionally vortexed until the tissue was completely lysed. DNA 
extraction from cells required a cell suspension containing 2 to 3 x10⁶ cells, which 
was centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, and the 
pellet was resuspended in 200 µl of PBS and 20 µl of proteinase K. The sample was 
vortexed and left to incubate at 56ºC until completely lysed. Proteinase K was added 
to aid with degradation of proteins. Once the tissue/ cell sample had been fully 
lysed, 4 µl of RNase A (100mg/ml) was added. The lysate was vortexed and 
incubated for 5 minutes at room temperature. After the incubation, RNA-free 
genomic DNA was obtained, to which 200 µl of Buffer AL and incubated for 10 
minutes at 56ºC. 200 µl of 100% ethanol was then added to the isolated DNA 
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sample, mixed and transferred to a DNeasy mini spin column, which was centrifuged 
at 8000 rpm for 1 minute. The DNA bound to the filter membrane inside the spin 
column, was then washed with 500 µl Buffer AW1 and centrifuged for 1 minute at 
10000 rpm. This step was repeated with a second wash with Buffer AW2 and 
centrifuged at 1000 rpm for 3 minutes in order to dry the filter and prevent ethanol 
carry over with the DNA elution step. 20 µl of nuclease-free water (Life 
Technologies, UK) was added to the filter at the centre of the column and incubated 
at room temperature for 1 minute. The columns were then spun at 1000 rpm to 
collect the eluted DNA. The collection tube was stored at -20 ºC until required. 
 
 
 
2.3.2 RNA extraction  
mRNA was extracted from both patient-derived glioblastoma cultures and frozen 
biopsy material using either RNeasy mini kit (Qiagen, Manchester, UK) or miRVANA 
RNA extraction kit (Invitrogen™).  
RNA extraction using the RNeasy mini kit was conducted by the manufacturer’s 
instructions. RNA extraction from fresh-frozen biopsy tissue required approximately 
20-25 mg pf tissue, to be finely sliced. The tissue was then homogenised with the 
addition of 600 µl of Buffer RLT, which contained β-mercaptoethanol (10 µl per 1 ml 
Buffer RLT) and with the use of a syringe and needle and kept on ice. The 
homogenised lysate was then centrifuged at 14000 rpm for 3 minutes and the 
supernatant was transferred to a new nuclease -free microcentrifuge tube.  RNA 
extraction from cells required a cell suspension containing 1 to 2 x10⁶ cells, which 
was centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, and the 
pellet was resuspended in 350 µl of Buffer RLT. Once the tissue/ cell sample had 
been fully lysed it was mixed with 1 volume of 70% ethanol (600 µl for tissue 
samples and 350 µl for cell samples). Ethanol was added to provide optimal binding 
conditions for the RNA. A maximum of 700 µl of sample was then transferred to an 
RNeasy mini spin column which was placed in a 2 ml collection tube and centrifuged 
at 10000 rpm for 15 seconds. The RNA bound to the filter membrane inside the spin 
column was then washed with 700 µl of Buffer RW1 and centrifuged for 10000 rpm 
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for 15 seconds. The washed step was repeated twice with 500 µl of Buffer RPE, 
before an additional centrifugation step for 2 minutes at 10000 rpm to dry the filter 
and prevent ethanol carry over with the RNA elution step. 20 µl of nuclease-free 
water was added to the filter at the centre of the column and centrifuged at 10000 
rpm for 1 minute. The collection tube was stored at -80ºC until required.  
 
RNA extraction using the miRVANA RNA extraction kit was in accordance with the 
manufacturer’s instructions. RNA extraction from cells required a cell suspension 
containing 1 to 2 x10⁶ cells, which was centrifuged at 1000 rpm for 5 minutes. The 
supernatant was removed, and the pellet was resuspended in 450 µl of Lysis/binding 
buffer, which was vortexed until the cells were lysed. 45 µl of Homogenate Additive 
was then added to the lysate mixture, which was incubated on ice for 10 minutes. 
After incubation 450 µl of acid-phenol: chloroform was added to the sample and 
vortexed for 60 seconds to mix. The mixture was immediately centrifuged for 5 
minutes at 13000 rpm. After centrifugation the upper phase aqueous layer was 
transferred to a fresh tube without disrupting the lower phase. To the recovered 
mixture, 1.25 volume of 100 ethanol was added and vortexed before being 
transferred to a filter cartridge. The cartridge was centrifuged for 10000 rpm for 15 
seconds, and to the RNA bound to the filter membrane inside the spin column, 700 
µl of miRNA Wash solution 1 was added and centrifuged for 15 seconds at 1000 
rpm. This step was repeated twice with 500 µl of Wash solution 2/3, before an 
additional centrifugation step for 1 minute 13000 rpm to remove any residual liquid 
and prevent carry over with the RNA elution step. The filter cartridge was 
transferred to a new nuclease -free microcentrifuge tube, and a 100 µl of pre-heated 
90 ºC nuclease-free water was added to the filter at the centre of the column and 
centrifuged at 13000 rpm for 30 seconds. The collection tube was stored at -80 ºC 
until required. 
 
2.3.3 Nucleic acid assessment 
A Nanodrop 2000 (Thermo Scientific, UK) spectrophotometer was utilized to assess 
the quality and quantity of extracted nucleic acids. The calculated concentration of 
nucleic acids was outputted as ng/µl, which was equated using a modified Beer-
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Lambert equation whereby c = (A*ϵ)/b. C is the concentration in ng/µl, A is the 
absorbance in Au (260 nm), ϵ  is the wavelength dependent extinction coefficient 
(50 ng-cm/µL for double stranded DNA and 40 ng-cm/µL for RNA) and b is the pair 
length (cm). The quality of the sample is determined via the ratio of absorbance of 
the genetic material (260nm) and the precipitated proteins (280nm) – (260/280). A 
ratio of 1.8 for DNA and 2.0 for RNA were accepted as pure and deemed 
functional for experiments. The ratio of wavelengths between genetic material 
(260nm) and organic compounds/chaotropic salts (230nm) was also additionally 
used to assess quality of each sample. If the 260/230 ratios were greater than the 
respective 260/280 ratios the samples were deemed to be extremely pure. Nanodrop 
quantification ensured that all DNA/RNA samples were equalised to the same 
concentration for the respective experiments. 
 
2.4 DNA amplification: Polymerase chain reaction (PCR)  
 
2.4.1 Bisulfite modification of genomic DNA 
Extracted genomic DNA from both fresh frozen glioblastoma biopsies and short-term 
cultures were bisulfite treated for methylation assays, using EZ DNA Methylation 
Gold kit (Zymo Research, USA) in accordance with the manufacturer instructions. 
Sample concentrations of DNA were equalised to contain 1 μg in 20 μl (diluted 
where needed with nuclease-free water); 130 μl of CT conversion reagent was then 
added to the 20 μl of DNA sample. The sample was vortexed and incubated for 10 
minutes at 98ºC followed by 2.5 hours at 64ºC, after incubation the samples were 
transferred to ice. 600 μl of M-Binding buffer was then added to each sample, mixed 
and transferred to a Zymo-spin IC column and centrifuged at 14000 rpm for 30 
seconds. The spin column which contained the bisulfite treated DNA (bound to the 
filter membrane) was washed with 100 μl of M-Wash buffer and centrifuged at 
13000 rpm for 30 seconds. 200 μl of M-Desulphonation buffer was added to the 
spim columns and left to incubate for 15-20 minutes, after which the column was 
centrifuged at 13000 rpm for 30 seconds before being washed twice with 200 μL of 
M-Wash Buffer. The DNA sample was then eluted with 30 μL of M-Elution buffer and 
stored -20ºC until required.   
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2.4.2 Complementary DNA (cDNA) synthesis 
cDNA was synthesised from extracted total RNA from both fresh frozen glioblastoma 
biopsies and short-term cultures, using Quantitect Reverse Transcription Kit (Qiagen, 
UK). Sample concentrations of RNA were equalised to 500 ng/μl in a total of 12 μl 
(diluted where needed with nuclease-free water). 2 µL of gDNA Wipeout buffer was 
added to the solution and incubated at 42ºC for 2 minutes to eliminate genomic 
DNA. The samples were immediately placed on ice, and 6 µL of reverse-transcription 
master mix containing 1 µL Quantiscript reverse transcriptase, 1 µL RT Primer mix 
and 4 µL 5x Quantiscript RT buffer was added to each sample. The samples were 
incubated at 42ºC for 30 minutes, followed by a 95ºC step at 3 minutes to cause 
inactivation of the Quantiscript reverse transcriptase. The reactions were placed on 
ice for immediate use or stored -20 ºC until required. 
 
2.4.3 Methylation-Specific PCR (MS-PCR) 
Methylation-Specific (MS-PCR) primers were designed using MethPrimer software: 
(http://www.urogene.org/methprimer/) using specified settings in order to maximise 
amplification efficiency. The candidate gene CpG islands and sequence were 
obtained using Ensembl gene browser (https://www.ensembl.org/index.html) or 
UCSC Genome browser (http://genome.ucsc.edu/cgi-bin). Primers were designed to 
not contain recognition sequences (CGCG) and were designed to ensure they 
spanned and amplified 200-300 bp, across at least one CpG island (an area of 
multiple CpG sites), encompassing a minimum of at least 4CpG sites.  The oligo 
primers were ordered via Sigma (Sigma, UK), which were designed with a melting 
temperature (Tm) set between 55-60 ºC and were received at a concentration of a 
100 μM. (The list of primer sequences is provided in Appendix). MS-PCR protocol as 
follows: 2 μl of bisulfite modified DNA (1 μg) was amplified using gene specific 
primers, in a total reaction of 20 μl. The reaction master mix contained 2 µL 10xPCR 
Buffer, 0.4 µL forward primer, 0.4 µL reverse primer, 0.4 µL 2mM dNTPs, 0.8 µL 2.5 
mM MgCl2, 0.2 1UµL HotStarTaq DNA polymerase and 13.8 µL PCR grade water per 
sample. For each DNA sample two separate PCR reactions were performed, each 
reaction contained a pair of either methylated sequence primers or unmethylated 
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sequence primers. Universally methylated and unmethylated samples were used as a 
positive control, these were purchased from Zymo; additionally, a non-template 
control was utilized as a negative control to ensure PCR regents were contamination 
free. Once the PCR master mix was complete, the sample was transferred to a 
thermal cycler, the cycling conditions were: an initial heat activation at 94ºC for 15 
minutes, followed by 30 cycles of 94ºC for 1 minute, Tm (dependent on individual 
primer sets 55-60 ºC) for 1 minute and 72ºC for 1 minute, a final extension of 72ºC 
for 10 minutes completed the program. The products were then run immediately on 
a 2% agarose gel via electrophoresis or stored at 4 ºC overnight. 
Table 2.2 MS-PCR HK2 primers 
Primer Sequence 
HK2 methylated AGGTTTTATTGTTCGAGTGGAGTC 
HK2 unmethylated ATCTCCGAAAACGTAATTTTAAC 
 
 
 
2.4.4 Semi-quantitative RT- PCR  
RT-PCR primers were designed using Primer 3 software software: 
(http://primer3.ut.ee). Exon sequences of the desired genes were obtained using 
Ensembl gene browser (https://www.ensembl.org/index.html) or UCSC Genome 
browser (http://genome.ucsc.edu/cgi-bin). Primers were designed to not contain 
recognition sequences (CGCG) of the restriction enzyme, and were designed to 
ensure they spanned no greater than 200 bp. The oligo primers were ordered via 
Sigma (Sigma, UK), which were designed with a melting temperature (Tm) set 
between 55-60 ºC and were received at a concentration of a 100 μM. (The list of 
primer sequences is provided in Appendix). The design of the primers at the 
3‘complementarity was set to 0 to avoid primer-dimers, the primer pairs were also 
selected ensuring at least one would encompass an intron-exon junction in order to 
certify that the amplified product was from the sample cDNA and not from any other 
DNA contaminant. RT-PCR protocol as follows: 2 µl of sample cDNA (500 ng/μl) was 
amplified using gene specific primers, in a total reaction of 20 μl. The reaction 
master mix contained 2 µL 10xPCR Buffer, 0.4 µL forward primer, 0.4 µL reverse 
primer, 0.4 µL 2mM dNTPs, 0.8 µL 2.5 mM MgCl2, 0.2 1UµL HotStarTaq DNA 
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polymerase and 13.8 µL PCR grade water per sample. Once the PCR master mix was 
complete, the sample was transferred to a thermal cycler, the cycling conditions 
were: an initial heat activation at 94ºC for 15 minutes, followed by 30 cycles of 94ºC 
for 1 minute, Tm (dependent on individual primer sets 55-60 ºC) for 1 minute and 
72ºC for 1 minute, a final extension of 72ºC for 10 minutes completed the program. 
The house keeping gene, βactin was used as positive control. The products were 
then run immediately on a 2% agarose gel via electrophoresis or stored at 4 ºC 
overnight. 
 
Table 2.3 RT-PCR HK2 primers 
Primer Sequence 
Forward Primer AACAAATTTCCGGGTCCTGC 
Reverse Primer  GCCCATGTACTCGAGGAAGT 
 
 
 
2.4.5 Gel Electrophoresis  
The amplified PCR products were electrophoresed on a 2% agarose gel (Themo 
fisher), in 1 x TBE buffer (Geneflow). Ethidium bromide (SIGMA, MERCK) staining 
was utilized for visualisation via scanning using a Gel DocTM EZ imager, which was 
analysed with Syngene Gel software. A 50 bp DNA ladder (ThermoScientific, UK) was 
used as a comparison to confirm amplification of the product. 
 
2.4.6 Quantitative Real-time PCR (qPCR) 
Gene expression levels of selected candidate genes were determined using qPCR. 
Levels were quantified with the use of TaqMan assays (Fisher Life Technologies UK) 
with FAM dye reporter (Ogrean et al., 2010) via an Applied Biosystems 7500 Fast 
Real-Time PCR system. The TaqMan assay included a pre-designed primer pair and 
a probe that was unique for each specific gene target being investigated. cDNA that 
had previously been transcribed as defined in 2.4.2 was utilised with the qPCR 
protocol as follows: 2 µl of sample cDNA was added to the qPCR reaction mix of 
total volume 20 µl, which consisted of 10 µl of 2x TaqMan qPCR master mix, 1 µl of 
TaqMan gene expression Primer/Probe set and 7 µl of nuclease free PCR grade 
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water. GAPDH was used as endogenous reference control as well as a no-template 
control (NTC), which was included to assess reagent contamination. Additionally, all 
reactions were performed in triplicate in a 96 well plate which was sealed with sterile 
optical clear seal. The PCR cycling conditions were: Initial enzyme activation at 95ºC 
for 15 minutes, denaturation step at 95ºC for 1 minute followed by an annealing 
step at 60ºC for 1 minute for 40 cycles. The final extension was at 72ºC 10 minutes. 
The threshold cycle (Ct) baseline was manually defined using the log view of the 
amplification plots. A value above the background signal, but within the lower 1/3 of 
the linear phase of amplification was selected. Data was analysed through MS Excel 
and the relative level of gene expression fold change were calculated via 
comparative Ct (2 -ΔΔCt) method, whereby target gene expression is normalised to 
GAPDH and compared to the control sample. 
 
 
 
2.5 Flow Cytometry  
Flow cytometry was carried for multiple assays using a BD Accuri C6 Plus cell 
analyser (BD Biosciences UK). As defined by the manufacturer’s guidelines, all 
protocols were set to record 20,000 cell counts from the specific required gating. To 
ensure an accurate cell count, samples were run at a slow flow rate speed, at 14 µl/ 
minute (the lowest setting, keeping core stream size to a minimum), thus reducing 
the spread of coincidental events. Gating for each assay was initially set through the 
preliminary use of U251MG in order to extrapolate the most efficient settings, this 
was conducted with and without treatment of the control campthothecin. 
Campthothecin was utilized as a positive apoptotic control, cells were treated at the 
concentration of 100 µM over a 72-hour period to induce apoptosis. 
 
2.5.1 Detection of apoptosis 
The detection of apoptosis via flow cytometry was employed in order to assess the 
anti-proliferative effects of specific inhibitors upon the growth of glioblastomas cells, 
furthermore, to determine if the mechanism of action in which the inhibitors acted 
was via the apoptotic pathway. Early apoptosis was investigated using the BD 
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Pharmingen Annexin V FITC Apoptosis Detection Kit 1. Prior to flow cytometry, cells 
were seeded at 5 x 10³ in T25 flasks and incubated at 37ºC until the determined 
exponential growth phase was reached, as determined by growth rate analysis. After 
which Cells were then treated at the relevant ID50 values as detailed in 2.2.5 and left 
for 72 hours. To ensure a total cell population was analysed, all media was collected 
from the T25 flask, including both floating and adherent cells, which were detached 
using trypsin. The harvested cell pellet was then washed twice in cold PBS, 
centrifuged at 1200 rpm for 5 minutes before being resuspended in 1X binding 
buffer at a concentration of 1x10⁶ cells/ml, as set out in the manufacturer’s kit 
protocol. 1x10⁵ cells (100 µl) was then transferred to a sterile 25 ml universal where 
5μl of PI and 5μl of FITC Annexin V dye was added to the cell solution, the tube was 
then vortexed and incubated in the dark for 30 minutes at room temperature.  After 
incubation, 400 μl of 1X binding buffer was added to the tube, the cell suspension 
was gently mixed and transferred to a flow cytometry tube ready to be run. The 
gating parameter settings used in the analysis of early apoptosis was adapted from 
the template provided by BD Biosciences, as stated in 2.5, optimised for 
glioblastoma cells using U251. The gating was aligned for the untreated control of 
each culture used, to ensure the reading were accurate.     
 
2.5.2 Mitochondrial membrane potential  
Mitochondrial membrane potential was analysed in order to detect any membrane 
potential changes in cells, this was investigated using the cationic, lipophilic JC-1 dye 
(part of the JC-1 Mitochondrial Membrane Potential Assay Kit) (BD MitoScreen). JC-1 
in normal cells is taken up and concentrated within the mitochondrial matrix, when 
bound it forms red fluorescent aggregates. 
JC-10 in apoptotic and necrotic cells, however, diffuses out from the dysfunctional 
mitochondria  
And changes to a monomeric form, which stains cells with green fluorescence. The 
potential of the mitochondrial membrane (ΔΨ) was assessed by the shift in green 
emission, which was analysed in via fluorescence channel 1 (FL1), fluorescence 
channel 2 (FL2) detected the orange emission (Liu Z et al, 2014). Camptothecin was 
used as an apoptotic control, at 100μM over a 72-hours. Cells were seeded at 5 x 10 
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3 in T25 flasks and incubated at 37ºC until the determined exponential growth 
phase was reached. After which Cells were then treated at the relevant ID50 values 
as detailed in 2.2.5 and left for 72 hours. Cells were trypsinised and transferred to a 
10ml sterile universal and centrifuged for 1200 rpm for 5 minutes. The cell pellet 
was washed in 5ml of PBS before being resuspended in 500 μl JC-1 working 
solution, which was then incubated for 15 min in a 37ºC incubator. After incubation 
the cells were centrifuged at 1200 rpm and washed with 1x assay buffer before 
being analysed in a flow cytometer. The gating parameter settings used to analyse 
mitochondrial membrane potential was adapted from the template provided by BD 
Biosciences, as stated in section 2.5, and optimised for glioblastoma cells using 
U251. The gating was aligned for the untreated control of each culture used, to 
ensure the reading were accurate.     
 
 
 
2.6 Caspase pathway analysis  
The level of caspase 3/7 proteins present within the cultures were investigated with 
the selected inhibitors, to determine if a caspase-dependent apoptotic pathway was 
the main mechanism leading to cell death in glioblastoma cells. To assess levels, the 
Caspase-Glo® 3/7 Assay (Promega, UK) was utilized, which is a homogeneous 
luminescent assay allowing for caspase 3 and 7 activities to be measured. The kit 
contains a luminogenic caspase-3/7 substrate, which is a reagent containing a 
tetrapeptide sequence-DEVD, optimised for caspase and luciferase activity. The 
addition of the Caspase-Glo® 3/7 Reagent causes cell lysis, which results in caspase 
cleavage of the substrate and in turn leads to the generation of a luminescent signal 
produced from a luciferase reaction. The amount of luminescence detected by the 
plate reader is proportional to the amount of caspase activity present within the 
sample.  
Cells were seeded simultaneously at 4000 cells per well on two 96 well plates and 
incubated at 37ºC until the determined exponential growth phase was reached. After 
which cells were then treated at the relevant ID50 values as detailed in 2.2.5, in a 
100 µl of media and left for 72 hours. One plate was stained and analysed using the 
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SRB assay, as detailed in section 2.2.2. To the other plate, 200µl of Caspase-Glo® 
3/7 Reagent was added to the 200 µl of media in both treated and untreated wells, 
the contents were gently mixed for 10 minutes at 300 rpm on a plate shaker and 
incubated at room temperature for 1 hour in the dark. After incubation the plate was 
transferred to a 96 well white walled plate and analysed on a Promega Glomax plate 
reader to measure the luminesce. The Caspase-Glo measured values were then 
normalised against its respective sample value from the SRB plate, the normalisation 
ensured a better representation of caspase 3/7 activity per cell. Camptothecin was 
used as an apoptotic control, at 100μM over a 72-hours. 
 
2.7 CRISPR mediated gene knockout 
HK2 was knocked out using CRISPR in short-term patient-derived glioblastoma 
cultures and the established cell line U251MG. CRISPR vectors were purchased from 
OriGene All-in-one vector kit (Origene, USA). The kit contained 2 gRNA vectors and 
1 donor DNA and is a complete kit to knockout any coding gene and with a knock-in 
selection cassette. The gRNA vectors were provided in pCas-Guide vector with a 
target sequence cloned, with both target sequences located at the 5’ end of the 
ORF; gRNA vectors therefore will precisely cleave at the 5’ end of the ORF of the 
gene loci. with HDR-based (Homology Directed Repair) donor vector construction. A 
puromycin resistant gene was included within the donor construct. (Figure 2.4) The 
vector targeted sequences are: HK2 gRNA vector 1 in pCas-Guide vector, Target 
Sequence: AAGGTAAGTCAGCGCGGGCG, and HK2 gRNA vector 2 in pCas-Guide 
vector, Target Sequence: GAAGTAGGCAAGCAGATGCG. The donor plasmid was 
integrated into the genome via homology-directed repair (HDR) mechanism. A 
scrambled control vector was used as a negative control. 
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Figure 2.4 Scheme of genome-editing knockout kit Donor vector for each kit contains around 
600 bp locus specific homologous sequence on each side of the donor selection cassette. LHA – left 
homologous arm, RHA – right homologous arm (Origene, 2019). 
 
The CRIPSR protocol was adapted from the Origene template, where cells were 
seeded approximately 24 hours before transfection at 3x10⁵ cells per well in 2 ml of 
culture medium in T a 6-well plate, this ensured between 50-75% confluence for 
transfection the following day. Transfection was undertaken in complete culture 
medium, in three separate transfections (wells), one for each gRNA vector and the 
scramble control. In a sterile tube(s) the transfection reagents were added in a 
prescribed order, the order of which the reagents were added was important to 
optimise transfection success. 1 μg of each gRNA or scramble vector was diluted in 
250 μl of Opti-MEM 1 (Life Technologies) transfection media, and vortexed gently to 
mix. To each tube 1 μg of the donor DNA was added to the 250 µl of Opti-MEM I 
solution. Individual vectors were diluted into separate sterile tubes in order to test 
the gRNA transfection efficiency. To each tube 9 µl of TransFast™ Transfection 
Reagent (Promega, UK) was added and gently mixed, and incubated for 15 minutes 
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at room temperature. The ratio of transfection Reagent to donor DNA was 
optimised, following the initial guidelines of Origene. After incubation the 
transfection reagents mixture was added dropwise to the cells plated 24 hours prior 
(without media change). The 6-well plate was rocked gently to ensure the 
transfection complex was evenly distributed, the cells were incubated for 48 hours in 
a 5% CO2 incubator. After incubation the cells were split 1:10 and grown for an 
additionally 3 days, before being split again 1:10. This was repeated for a total of 7 
passages to ensure that the cells containing puromycin resistance from the plasmid 
donor DNA (before genomic integration) were diluted out of culture, increasing the 
amount of successful transfected cells to maintain puromycin resistance before 
applying the puromycin selection. After 7 passages cells were split 1:10 and grown 
in 10 cm dishes in media containing puromycin the range of puromycin used was 
1μg/ml to 5μg/ml). A dose curve was utilized to determine the lowest dose that 
killed non-transfected cells completely 7 days post selection, which was dependant 
on specific cultures. The media containing the puromycin was changed ever 2-3 
days.  After 7 days of selection, the surviving cell colonies were isolated using a 
dilution method, whereby cells were seeded <10 cells per well in a 96 -well plate. 
After 10 days, cells containing a single cell colony were expanded first into a 6 well 
plate and then into T25 flasks. The puromycin resistant cells were then analysed and 
verified via genomic qPCR to ensure the integration of the functional cassette. qPCR 
was conducted as detailed in section 2.4.6. 
 
2.8 Pyrosequencing 
Pyrosequencing was utilized to analyse and quantify levels of methylation of specific 
gene targets across the genome in glioblastoma cell cultures and fresh frozen biopsy 
tissue. Pyrosequencing was conducted using Qiagen’s PyroMark CpG Assays (Qiagen, 
UK), using pre-designed highly specific primers for pyrosequencing methylation 
analysis. The pre-designed primer set includes both the PCR and sequencing primers 
for the quantification of DNA methylation by Pyrosequencing. The PCR primers are 
biotinylated, generating biotinylated PCR product from the template bisulfite 
converted DNA. The biotinylated PCR product is then bound to streptavidin-coated 
sepharose beads, which are captured using a PyroMark Vacuum Workstation, where 
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they are washed and denatured resulting in a single-stranded DNA which is suitable 
for pyrosequencing. The single-stranded template DNA is transferred to a 
Pyrosequencing reaction plate which contains the sequencing primer provided with 
the PyroMark CpG Assay kit. After the sequencing primer had annealed the plate 
was sequenced on a PyroMark Q96 instrument using a specific sequence to analyse. 
The resulting data generated gave percentage of methylation across each CpG site 
within the sequence. The protocol was adapted and optimised from Qiagen template 
as follows. DNA was extraction, quantified and bisulfite treated as previously 
detailed. Bisulfited treated DNA was amplified using Qiagen PyroMark CpG PCR 
primers on a 96-well plate, the cycling conditions were: an initial heat activation at 
94ºC for 15 minutes, followed by 30 cycles of 94ºC for 1 minute, Tm (dependent on 
individual primer sets 55-60 ºC) for 1 minute and 72ºC for 1 minute, a final 
extension of 72ºC for 10 minutes completed the program. After amplification 37 μl 
of binding buffer and 3 μl of streptavidin-coated sepharose beads was added to each 
sample well. The plate was sealed with sterile film and placed on a plate shaker for 5 
minutes at 1300 rpm. 38.5 μl of annealing buffer and 1.5 μl of sequencing primer 
(10 pmol/ μl) was added to a separate sequencing plate, designed for the PyroMark 
Q96 instrument. After mixing the plate was taken to the PyroMark Vacuum 
Workstation, which consisted of a 4-step process. The probes of the hedgehog 
appliance were initially washed in distilled water, the hedgehog was then slowly 
lowered into the well of the 96-well plate in order to capture the DNA bound to the 
sepharose beads. Once captured the beads were washed in 100% ethanol for 5 
seconds, and then washed for an additional 10 seconds in a denaturising solution, as 
part of a kit (Qiagen, UK). The final step was to wash off excess denaturising 
solution with wash buffer before lowering the hedgehog over the sequencing plate. 
The vacuum Workstation was switched off and the beads were released into the 
annealing buffer containing the sequencing primer, the sequencing plate was placed 
immediately on a heat block at 80 ºC for 2 minutes. After the incubation the plate 
was transferred to the PyroMark Q96 instrument. Additionally, a Q96 cartridge was 
placed into the pyrosequencer, which was loaded with the correct DNTPs for the 
sequence to be analysed, the enzyme, substrate and RNA-free water. The amount of 
each reagent was specific for the sequence to analyse. 
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Figure 2.5. Showing pyrograms for DNA methylation analysis A hypothetical DNA sequence. 
The x-axis is the dispensation sequence (time), and the y-axis is the intensity of the bioluminescence. 
The presence of a peak indicates the injected dNTP was incorporated, whereas the absence of a peak 
indicates the polymerase was unable to incorporate the dispensed dNTP. Peak height is proportional 
to the number of deoxynucleotide triphosphates incorporated. A virtual pyrogram demonstrates that 
the height of the peaks is proportional to the number of nucleotides incorporated. For example, the 
first G peak is taller than the first T peak, indicating more deoxyguanosine triphosphates were 
incorporated compared to deoxythymidine triphosphate. The dispensation order was optimized by 
Qiagen for the known gene targets (Qiagen, 2019). 
 
 
Figure 2.6 Showing the location of the Qiagen pyrosequencing HK2 sequencing primer 
sets The location of the primers is labelled 1-4, incorporating multiple CpGs as listed in Table 2.2. 
 
Table 2.4 Pyrosequencing: HK2 sequencing primers 
Primers Sequence 
Primer set 1 CpG 1-4 Sequence to Analyse CTGCCGCCCCGCCCGCGC 
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Sequence After Bisulfite 
Treatment 
TTGTYGTTTYGTTYGYGT 
Primer set 2 CpG 5-7 
Sequence to Analyse CGGACACGTCGT 
Sequence After Bisulfite 
Treatment 
YGGATAYGTYGT 
Primer set 3 CpG 8-
11 
Sequence to Analyse ACGCGGCGCGT 
Sequence After Bisulfite 
Treatment 
AYGYGGYGYGT 
Primer set 4 CpG 12-
15 
Sequence to Analyse CGGCCGCGGTGAGCGC 
Sequence After Bisulfite 
Treatment 
YGGTYGYGGTGAGYGT 
Table showing the 4 Qiagen pyrosequencing HK2 sequencing primer sets. Primer set 1 spans CpGs 1-
4, set 2 spans CpGs 5-7, set 3 spans CpGs 8-11 and set 4 spans CpGs 12-15. 
 
 
Figure 2.7 Showing the location of the Qiagen pyrosequencing HK1 sequencing primer 
sets The selected primer set is highlighted in yellow, spanning multiple CpG sites. 
 
Table 2.5 Pyrosequencing: HK1 sequencing primers  
Primer 
set 
Sequence to Analyse GCCCGGCGACAGCTTCTCCGGGGCACCCGA 
Sequence After Bisulfite 
Treatment 
GTTYGGYGATAGTTTTTTYGGGGTATTYGA 
Table showing the pyrosequencing HK1 sequencing primer set. The primer set spans 4 CpGs and was 
selected due to maximum coverage across the HK1 promotor region.  
 
2.9 Expression Profiler Array  
Qiagen RT expression profiler arrays (Qiagen, UK) were utilized to analyse the 
expression of 84 key genes involved in the regulation and enzymatic pathway of 
glucose metabolism in glioblastoma biopsy tissue, patient derived short-term cell 
cultures and U251 MG. The profiler arrays were conducted using an optimized 
protocol from Qiagen. Extracted RNA was initially converted to cDNA using a cDNA 
Synthesis RT First Strand kit (Qiagen, UK), at an optimal concentration of 500 ng/μl 
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in a total of 10 μl (diluted where needed with nuclease-free water). 2 µL of gDNA 
Wipeout buffer GE was added to the solution at incubated at 42ºC for 5 minutes to 
eliminate genomic DNA. The samples were immediately placed on ice, and 10 µL of 
reverse-transcription master mix containing 4 µL Buffer BC3, 1 µL control P2, 1 µL 
RE3 Reverse Transcriptase mix and 3 µL nuclease-free water was then added to 
each sample. The samples were gently vortexed to mix, and incubated at 42ºC for 
15 minutes, followed by a 95ºC step at 5 minutes to cause inactivation of the 
Quantiscript reverse transcriptase. 91 µL nuclease-free water was then added to the 
sample to ensure the right concentration of cDNA was present (manufacturers 
protocol) for each well of the array plate. The array plate consisted of 84 target 
genes, 5 housekeeping genes and positive/negative controls, the primer/probe for 
each gene was pre-pelleted to each designated well. From the synthesised cDNA, 
102 µL was added into a SYBR Green master mix (Qiagen, UK) with a total volume 
of 2700 µL, this consisted of, 1350 µL of 2X RT SYBR Green master-mix and 1248 µL 
nuclease-free water. The master-mix was designed for a complete 96 well plate with 
300 µL excess volume for pipette carry over, and to perform any quality control 
analysis. 25 µL of master-mix containing the cDNA was transferred into each well of 
the 96- well array plate, the plate was sealed with optical adhesive seal and 
centrifuged at room temperature at 1000g for 1 minute. After centrifugation the 
plate was checked to ensure no bubbles were present in any well before being 
transferred to the Applied Biosystems 7500 Fast Real-Time PCR system. The PCR 
cycling conditions were initial Hot star DNA enzyme activation at 95ºC for 10 
minutes, denaturation step at 95 ºC for 15 seconds followed by an annealing step at 
60 ºC for 1 minute for 40 cycles. During the 40 cycles fluorescence data was 
collected. The threshold cycle (Ct) baseline was manually defined using the log view 
of the amplification plots. A value above the background signal, but within the lower 
1/3 of the linear phase of amplification was selected. The Ct values were exported to 
excel and then uploaded using Qiagen PCR array data analysis web-based software. 
2.10 Statistical Tests  
Most experiments conducted have a minimum of three biological repeats, to ensure 
for accurate statistical analysis. Standard deviation and standard error were carried 
out were appropriate on data sets to identify any significant trends. Graphs were 
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created on both Microsoft Excel Open office version 1701 and GraphPad Prism 7.03, 
error bars on all graphs show standard error of the mean for each sample based 
upon the biological replicates. Graph pad prism was utilised to determine ID50 values 
for all samples and to calculated linear regression.  
2.10.1 Student’s t-test  
The statistical significance of differences between two groups was determined using 
student’s t-test, by comparing the mean value of each data set. Student’s t-test was 
carried out using GraphPad Prism web tool software 
(http://www.graphpad.com/quickcalcs/contMenu/). Significant difference was 
defined as a p-value to be less than 0.05.  
2.10.3 Keplan-meir curve and Mantel-Cox test  
Compares two or more survival curves where some of the observations may be 
censored and where the overall grouping may be stratified. The methods are 
nonparametric in that they do not make assumptions about the distributions of 
survival estimates. The Mantel-Cox test statistic compares estimates of the hazard 
functions of the two groups at each observed event time. It is constructed by 
computing the observed and expected number of events in one of the groups at 
each observed event time and then adding these to obtain an overall summary 
across all-time points where there is an event. The tests were performed using 
GraphPad Prism 7.03. 
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Chapter 3 
 
Increased expression of 
HK2 in glioblastoma 
 
 
 
 
 
 
 
 
 
 
3.1 Introduction 
The development of novel therapeutic targets for the treatment of glioblastoma has 
had very limited success, despite continuous efforts, in in prolonging the survival and 
quality of life of patients (Zhang et al., 2012; Howlader et al., 2016). Primary 
management is surgical resection, radiation and concomitant treatment with 
temozolomide, however average survival is only 14 months (Stupp et al., 2015; Lee 
et al., 201). Effective drug treatments are hindered predominantly by the complex 
genetic background of glioblastoma, with significant intra- and inter- tumour 
heterogeneity drastically limiting monotherapies (Backes, et al., 2015). Another 
obstacle is the translation of validated molecular targets and inhibitors from in vitro 
studies through to in vivo models and into a clinical setting, largely due to 
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inadequate well-characterised pre-clinical models. For many years established cell 
lines have been principally used as experimental therapeutic models in vitro, and 
whilst these studies have contributed to the existing understanding of glioblastoma 
biology, these models do not accurately represent the genetic constitution seen 
within patient tumours, due to their tendency to acquire additional genetic 
alterations through increasing numbers of cell passage (Torsvik et al., 2014). The 
genetic and epigenetic heterogeneity found both within the same tumour and 
between different glioblastoma is fundamentally difficult to reiterate in vitro 
(Sottoriva et al., 2013; McGranahan and Swanton, 2015). However, primary cultures 
derived from tumour biopsies have been shown to maintain considerable genetic 
characteristics of the parent biopsy and studies have shown that glioblastoma 
derived cell cultures retain copy number changes, mutations, expression profiles and 
methylation status comparable to the original biopsy tissue (Potter et al., 2009; Yost 
et al., 2013). With substantial tumour heterogeneity across both the same tumour 
and between tumours, an alternative approach is to target abnormal metabolic 
pathways that are universally dysregulated in glioblastoma. Treatments which 
modulate metabolism are likely to be effective in a higher percentage of patients, 
whilst sparing normal cells and reducing negative side effects (Wolf et al., 2010). 
Studies have also shown an increased efficacy of conventional chemotherapeutic 
drugs in combination, in multiple tumour types that have also had their metabolism 
targeted, although the synergistic mechanism is yet to be fully understood (Bayat 
Mokhtari et al., 2018). The glycolytic enzyme hexokinase (HK), and its isoforms 1 
and 2 are associated with mitochondria and are implicated in cell survival, 
proliferation and in aerobic glycolysis in cancer cells including glioblastoma (Patra et 
al., 2013). There is evidence that HK2 overexpression in cancer cells increases 
tumour invasion and aggression as well as enhanced resistance to therapies (Wang 
et al., 2014; Anderson et al., 2016). There have been preliminary studies 
investigating the role of HK2 in glioblastoma, however the establishment of HK2 
overexpression is currently not fully understood (Wolf et al., 2011).  
The aim of this study was to further determine the role of Hexokinase 1 and 2 in the 
development of glioblastoma and to ascertain its apparent role in patient outcome; 
by investigating the expression levels of HK1 and HK2 in both patient biopsies and 
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patient derived glioblastoma derived cell cultures. In addition, epigenetic alterations 
were ascertained via methylation analysis and patient survival studies were 
conducted. Furthermore, the effective genetic representation of patient derived 
glioblastoma cultures, compared to biopsy material was established. The established 
cell lines U251MG and U87MG were utilized alongside 19 patient derived cultures 
(including both IN and UWLV cultures as shown in table 2.1) throughout this study. 
 
3.2 Quantitative assessment of Hexokinase 2 expression 
In order to determine alterations in expression of HK2 in glioblastoma, mRNA levels 
were analysed by real time quantitative PCR in 103 glioblastoma biopsies as well as 
in 5 normal brain tissue samples. Additionally, 19 glioblastoma patient-derived cell 
cultures and 2 established cell lines were investigated and compared to both NHA 
and normal brain samples.  
An increase in HK2 mRNA expression was observed in all 103 glioblastoma biopsies 
compared to normal brain tissue, as shown in Figure 3.1 and Table 3.1. 
Overexpression of HK2 ranged from 3.83 to 897.54-fold-change compared to normal 
brain tissue, normalised to 1-fold change (all normal brain samples showed little 
variance in fold change, with a fold change difference of 0.4), with significantly 
increased levels demonstrated in 101 biopsies (p<0.0001) (as determined via 
students t-test). HK2 overexpression was also observed in all glioblastoma patient-
derived cultures and the established cell lines U251MG and U87MG, as shown in 
Table 3.2 and Figure 3.2. Elevated levels of HK2 ranged from 85.73-fold change to 
995.12-fold change increase in glioblastoma patient-derived cultures compared to 
normal brain. The established cell line U87MG had an increased fold change of over 
1294, and U251MG demonstrated upregulation of approximately 1502.61-fold 
change increase compared to normal tissue. Furthermore, the level of mRNA 
expression was also increased in cultured normal human astrocytes in comparison to 
normal tissue, with an increase in fold change of 30.42.  
The data shows overexpression of HK2 is a frequent occurrence in glioblastoma, 
furthermore, the elevated change in mRNA expression is also maintained in vitro in 
 78 
 
patient-derived cultures. The level of HK2 expression was additionally compared to 
MGMT status for the 103 biopsy samples. The MGMT status for the samples was 
determined via MS-PCR. No significant correlation between the level of HK2 
overexpression and MGMT status was demonstrated in the biopsies. Average HK2 
expression for unmethylated MGMT biopsies was 204.5- fold change, comparatively 
the HK2 expression for methylated MGMT biopsies was 241.9- fold change. There 
was, however, a correlation with MGMT status and the level of HK2 expression in the 
culture samples, where average HK2 expression for unmethylated MGMT cultures 
was 207.7- fold change, compared to 661.1- fold for the methylated MGMT cultures. 
The data indicates that HK2 overexpression is independent of MGMT status in 
glioblastoma biopsies, and therefore is a potential additional therapeutic target for 
further stratification of patients. MGMT data is shown in the appendix.  
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Table 3.1 Expression fold change of HK2 in glioblastoma biopsies 
Biopsy Sample HK2 Fold Change (SD (±)) Biopsy Sample HK2 Fold Change (SD (±)) 
Normal 1 (0.62) 1342 148.30 (2.11) 
1014 3.82 (2.64) * 1176 159.44 (3.34) 
116 6.69 (1.24) * 1687 159.51 (0.12) 
1428 7.42 (4.45) 1000 159.83 (0.98) 
175 14.90 (3.46) 1446 163.25 (2.55) 
2229 18.38 (0.45) 1016 169.03 (3.17) 
343 20.06 (2.43) 769 172.1 (3.78) 
1437 21.91 (1.65) 911 172.11 (2.12) 
1606 22.35 (0.98) 1054 173.91 (2.11) 
1134 23.62 (3.56) 874 175.96 (0.87) 
860 26.13 (2.91) 733 176.43 (1.68) 
522 30.76 (1.66) 1617 178.38 (0.38) 
1902 31.09 (3.45) 110 186.29 (3.41) 
382 39.29 (0.54) 2242 189.65 (2.65) 
165 40.137 (2.45) 626 195.29 (0.91) 
103 41.05 (3.21) 792 195.96 (3.11) 
898 43.57 (1.73) 1006 198.95 (1.95) 
1100 43.7 (1.49) 849 205.23 (3.91) 
1745 43.80 (1.36) 813 216.01 (2.44) 
590 49.06 (2.46) 749 216.22 (0.68) 
640 51.06 (0.92) 994 221.62 (0.39) 
121 51.72 (3.12) 410 260.13 (3.1) 
204 57.37 (2.82) 122 263.73 (1.53) 
717 65.2 (4.59) 1565 269.09 (2.16) 
396 69.44 (3.65) 352 276.749 (2.72) 
85 75.21 (1.98) 820 283.29 (3.58) 
723 77.03 (0.21) 905 285.23 (3.18) 
970 78.72 (1.24) 743 285.95 (0.24) 
1098 86.34 (3.54) 1015 288.18 (1.25) 
535 87.79 (2.46) 819 288.41 (1.83) 
651 89.84 (2.99) 1417 315.68 (0.57) 
1643 98.54 (1.53) 1101 320.24 (2.65) 
472 99.50 (3.12) 781 320.44 (2.91) 
915 104.50 (0.47) 1178 346.43 (2.52) 
1547 106.30 (3.1) 876 358.76 (3.18) 
955 109.23 (2.66) 758 409.23 (0.49) 
1404 111.39 (2.29) 1595 425.07 (0.83) 
1091 115.78 (3.42) 850 475.89 (4.14) 
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1460 117.87 (1.97) 826 569.76 (3.95) 
377 120.25 (1.22) 1793 600.96 (1.17) 
411 120.72 (0.89) 445 669.94 (1.73) 
705 121.62 (3.54) 816 679.90 (2.72) 
848 122.11 (2.82) 822 763.67 (4.81) 
966 125.62 (2.11) 1728 764.9 (2.33) 
956 126.62 (2.43) 142 788.29 (3.3) 
436 127.23 (1.53) 693 819.78 (2.01) 
729 132.68 (1.6) 338 825.58 (2.78) 
374 136.68 (0.9) 746 867.61 (3.14) 
1062 136.68 (2.56) 793 875.78 (1.51) 
1414 140.13 (1.21) 916 883.25 (4.11) 
1549 142.07 (2.34) 859 897.54 (2.81) 
685 446.03 (2.73)   
Fold change has been normalised against average expression level of normal brain tissue. HK2 
expression is over-expressed across all glioblastoma biopsies compared to normal tissue. Standard 
deviation for each average is listed after each result (±). All samples show significantly (p<0.0001) 
increased fold change compared to normal unless denoted with *. 
 
 
 
Figure 3.2. Expression fold change of HK2 in glioblastoma cultures relative to normal 
tissue Real time qPCR analysis of HK2 glioblastoma cultures and cell lines. Fold change has been 
normalised against average expression level of normal brain tissue. HK2 expression is elevated in all 
glioblastoma cultures and established cell lines compared to normal tissue, indicative that 
overexpression occurring within glioblastoma is maintained in culture. HK2 expression was also 
increased in NHA compared to normal brain. Data shown is taken from an average fold change value 
of 3 replicates. 
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Table 3.2 Expression fold change of HK2 mRNA in glioblastoma cultures 
Culture Sample 
HK2 Fold Change (SD 
(±)) 
Normal 1 (1.23) 
NHA 30.42 (3.12) 
IN1461 85.73 (2.94) 
IN2132 88.35 (3.58) 
IN1265 97.35 (3.41) 
IN1682 120.54 (2.65) 
IN1612 126.63 (0.91) 
IN2093 132.75 (0.24) 
UWLV 212   145.42 (1.25) 
IN1760 201.96 (1.83) 
IN1951 210.63 (1.95) 
UWLV 48  211.43 (0.57) 
IN2045 219.82 (1.22) 
UWLV 152  289.65 (0.89) 
UWLV 156  306.89 (3.54) 
IN1528 385.95 (2.82) 
IN1472 403.36 (2.11) 
IN1979 574.39 (3.01) 
UWLV 53  589.16 (1.92) 
UWLV 22 637.35 (0.48) 
IN859 995.11 (1.54) 
U87MG 1294.26 (2.11) 
U251MG 1502.61 (1.96) 
Real time qPCR analysis of HK2 glioblastoma cultures and cell lines. Fold change has been normalised 
against average expression level of normal brain tissue. HK2 expression is elevated across all 
glioblastoma cultures and established cell lines compared to normal tissue. HK2 expression was also 
increased in NHA compared to normal tissue. Standard deviation for each average is listed after each 
result (±).  
 
Average expression of HK2 across the biopsies was approximately 229.4-fold change 
increase compared to normal tissue and median of the 103 biopsy samples was 154- 
fold change. The samples were separated into 2 groups for further analysis 
depending on the level of HK2 expression above or below the median value thus 
determining the cut off between subpopulations. The statistical significance between 
the subgroups, of <154-fold change and >154-fold change increase, was assessed 
via a students unpaired T-test, whereby a significant difference (p<0.0001) was 
perceived between the 2 groups of biopsy sub-populations as shown in Figure 3.3. A 
significant difference of p=0.0006 was also apparent between normal tissue and the 
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subgroup >154-fold change, and a significance of p=0.0003 was observed between 
normal tissue and the subgroup <154-fold change with respect to the level of HK2 
expression. Utilizing similar statistical methods, qPCR data revealed 2 divergent 
subtype populations across the glioblastoma cultures, with respect to HK2 
expression values. Average expression of HK2 across the glioblastoma cultures was 
approximately 410.5-fold change increase compared to normal tissue, with a median 
value of 220. The samples were separated into 2 groups for further analysis 
depending on the level of HK2 expression above or below the median value. A 
statistical significance (p=0.0004) between the subgroups was established, 
additionally, both glioblastoma culture subgroups demonstrated a significant 
difference of expression compared to both NHA (p=0.0019) and normal brain tissue 
(p<0.0001) as shown in Figure 3.4. 
 
Figure 3.3 Expression fold change of HK2 in subpopulations of glioblastoma biopsies 
relative to normal tissue Real time qPCR analysis of HK2 glioblastoma biopsies. Fold change has 
been normalised against average expression level of normal brain tissue. Two distinct populations of 
glioblastoma expressing upregulated HK2 levels, <154 -fold change increase and >154-fold change 
increase, p value significance is denoted with * between groups. The bars represent mean and SD 
deviation.  
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Figure 3.4 Expression fold change of HK2 in subpopulations of glioblastoma cultures 
relative to normal tissue Real time qPCR analysis of HK2 glioblastoma cultures. Fold change has 
been normalised against average expression level of normal brain tissue. Two distinct populations of 
glioblastoma expressing upregulated HK2 levels, <220- fold change increase and >220-fold change 
increase. p value significance is denoted with * between groups. The bars represent mean and SD 
deviation. 
 
  
3.3 Quantitative assessment of Hexokinase 2 methylation 
The methylation status of the promotor region of HK2 was investigated to determine 
whether epigenetic alternations occur in glioblastoma compared to normal tissue 
using both MS-PCR and pyrosequencing. The methylation status of HK2 was 
determined in 36 glioblastoma biopsies and 10 cultures by MS-PCR. More than 90% 
(n=33) of the biopsies showed some hypomethylation of HK2, including 5 biopsies 
(374, 110, 743, 705, 1617) that were completely hypomethylated. There was also 
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complete hypomethylation of HK2 in 4 cultures (U251MG, IN859, IN2093, IN1528), 
whereas the remaining 6 cultures had only partial methylation. Additionally, there 
was complete hypermethylation of HK2 present in 3 biopsy samples, as seen in 
Figure 3.5. Full quantification of the level of methylation in glioblastoma samples 
was then determined by pyrosequencing. Fifteen individual CpG sites were 
investigated across the promotor region of HK2 as shown in Figure 3.7. Ten 
glioblastoma biopsies and 2 normal brain tissue samples were initially investigated 
via pyrosequencing, using 4 Qiagen predesigned primer sets, as shown in 2.8, to 
determine which CpG sites were to be selected for further investigation for all the 
glioblastoma samples. A positive human methylated and unmethylated control was 
used, purchased from Zymo research. The data obtained is shown in Table 3.3 and 
Figures 3.8 and 3.9. Primer set 3, which included CpG site 8-11 was selected for 
further methylation analysis across the 103 biopsies, due to both its location on the 
promotor region and the substantial difference in levels of methylation between the 
glioblastoma samples (both biopsy tissue and culture) compared to normal brain 
tissue. Average percentage levels of methylation for normal tissue across CpG site 8-
11 was 26.2%. A significant reduced level (p<0.0001) of methylation was observed 
in both glioblastoma biopsies, with methylation level of 6.2% (a range of 1.8 - 
12.6%) and cell cultures of 4.1% (a range of 1.4-8.7%). The noteworthy change in 
hypomethylation was not as substantial across the other primer CpG regions 
(Average values: CpG 1-4 - normal 10.9%, biopsy 4.1%, culture 1.8%; CpG 4-7 - 
normal 6.3%, biopsy 12.5%, culture 6.3%; CpG 12-15 - normal 19.2%, biopsy 
4.8%, culture 5%), as shown in Table 3.3 and Figures 3.8 and 3.9. 
To further investigate the alterations in methylation levels across CpG sites 8, 9, 10 
and 11, 103 glioblastoma biopsies were investigated, with an additional 21 
glioblastoma patient-derived cell cultures and 2 established cell lines and compared 
to both NHA and 5 normal brain tissue samples. A positive methylation control was 
used as stated in 2.8. The average methylation across CpG sites 8-11 was 
significantly (p<0.0001) different between normal brain tissue and the 103 
glioblastoma samples. The percentage of methylation ranged from 1.2% to 17.6% in 
the biopsy samples, with an average methylation of 5.5% compared to an average 
methylation of 25.5% in the normal tissue samples with a range between 23.67% to 
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26.86%, as seen in Figure 3.10 and Table 3.4. Furthermore, a significant reduction 
(p<0.0001) in the level of methylation across these CpG sites was also demonstrated 
throughout the glioblastoma patient-derived cultures and established cell lines, 
where a loss of greater than 20% was demonstrated compared to normal brain 
tissue. The percentage of methylation ranged from 2.6% to 9.7% with an average of 
5.4%, as seen in Figure 3.11 and Table 3.5. The established cell lines exhibited a 
higher level of hypomethylation compared to the patient-derived cultures, with 
average levels of methylation of 2.8% contrasted to that of 5.6% respectively. 
Hypomethylation was also demonstrated in all glioblastoma cultures compared to 
NHA, which showed methylation levels of 16.8%. The reduction of methylation in 
NHA (16.8%) compared to normal brain tumour (25.5%) samples may be attributed 
to the NHA being foetal cells, where HK2 has been shown to be highly expressed in 
embryonic tissues (Wilson, 2003). Analysis of CpG 10 revealed the largest altered 
levels of methylation in the glioblastoma samples, where the average level of 
methylation in normal tissue was 42.1% compared to 5.4% average methylation in 
biopsy samples (p<0.0001) and 3.8% average methylation in cultures (p<0.0001). 
NHA also had a significantly (p<0.0001) reduced level of methylation of 14.74%, as 
shown in Figures 3.12 and 3.13 and Table 3.6 and 3.7. In both glioblastoma biopsy 
and culture, an average loss of 21% (p<0.0001) in the level of methylation across 
CpGs 8, 9, 10 and 11 was established compared to normal brain tissue, indicative 
that hypomethylation is a common occurrence in glioblastoma tissue, which is also 
maintained in cell culture. Individual CpG data is shown in the appendix Table A2.  
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Figure 3.5. MS-PCR gels for both biopsy and culture samples Methylation status of HK2 was 
determined in 36 glioblastoma biopsies and 10 cultures via MS-PCR. Partial hypomethylation was seen 
in 90% of the biopsy samples and 60% of the cultures. Complete hypomethylation was seen in 5 
biopsies (374, 110, 743, 705, 1617) and 4 cultures (U251MG, IN859, IN2093, IN1528). Additionally, 
total hypermethylation of HK2 was present in only 3 biopsy samples (484, 377, 717). M= methylated, 
U = unmethylated. DNA ladder on gels represent 50bp, amplified band size is 210bp. 
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Figure 3.6 Example of a pyrogram generated via the Q96 pyrosequencer  
Pyrogram showing levels of methylation (%) in 2 biopsy samples compared to normal brain tissue 
and a positive methylation control sample. CpG sites 8-11 are highlighted respectively in pale blue 
across the pre-designed Qiagen sequence. A loss of methylation is demonstrated in the glioblastoma 
samples compared to the control samples. Y-axis demonstrates % methylation, x-axis shows the 
nucleotide dispensation order.   
 
Figure 3.7 Qiagen primer sets and the location of the associated CpG CpG 1 to 15 shown 
with respect to HK2 promotor region.  
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Figure 3.8 HK2 methylation across 15 individual CpG sites within the promotor 
region Average methylation values are taken from 10 biopsies and 2 normal brain tissue 
samples. A loss of methylation is demonstrated across 12 of the CpG sites, with a 
significant reduction from CpG site 8-11 and 13-14. Red represents normal brain; blue 
represents biopsy samples.  
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Table 3.4. Average level of HK2 methylation (%) across glioblastoma biopsies, compared 
to expression fold change values 
Biopsy  
Average 
Methylation % 
Expression Fold 
Change (SD (±)) 
Biopsy  
Average 
Methylation % 
Expression Fold 
Change (SD (±)) 
411 1.18 120.72 (0.89) 729 4.62 132.68 (1.6) 
746 1.2 867.61 (3.14) 693 4.66 819.78 (2.01) 
820 1.21 283.29 (3.58) 1000 4.73 149.83 (0.98) 
436 1.22 127.23 (1.53) 651 4.74 89.84 (2.99) 
743 1.31 285.95 (0.24) 2242 4.76 189.65 (2.65) 
859 1.41 897.54 (2.81) 955 4.9 109.23 (2.66) 
1617 1.46 178.38 (0.38) 1549 4.905 142.07 (2.34) 
110 1.57 186.29 (3.41) 1054 5.15 173.91 (2.11) 
116 1.57 6.69 (1.24) 966 5.18 125.62 (2.11) 
522 1.63 30.76 (1.66) 374 5.19 136.68 (0.9) 
705 1.86 121.62 (3.54) 1404 5.34 111.39 (2.29) 
1793 1.9 600.96 (1.17) 1014 5.36 3.82 (2.64) 
723 1.99 77.03 (0.21) 793 5.43 875.78 (1.51) 
1178 2 346.43 (2.52) 1342 5.46 148.30 (2.11) 
956 2.07 126.62 (2.43) 781 6.04 320.44 (2.91) 
352 2.09 240.749(2.72) 1016 6.07 159.03 (3.17) 
994 2.16 221.22 (0.39) 1176 6.1 149.44 (3.34) 
1687 2.26 149.51 (0.12) 849 6.19 205.23 (3.91) 
758 2.28 409.23 (0.49) 1062 6.21 136.68 (2.56) 
142 2.29 788.29 (3.3) 1547 6.35 106.30 (3.1) 
1015 2.36 288.18 (1.25) 204 6.46 57.37 (2.82) 
905 2.43 285.23 (3.18) 410 6.55 260.13 (3.1) 
1728 2.49 764.9 (2.33) 1417 6.82 315.68 (0.57) 
626 2.51 195.29 (0.91) 1460 7.33 117.87 (1.97) 
338 2.52 825.58 (2.78) 1428 7.37 7.42 (4.45) 
769 2.52 172.1 (3.78) 1565 7.44 269.09 (2.16) 
819 2.59 288.41 (1.83) 1446 7.45 153.25 (2.55) 
122 2.6 263.73 (1.53) 121 7.63 51.72 (3.12) 
1101 2.73 320.24 (2.65) 377 7.97 120.25 (1.22) 
792 2.77 195.96 (3.11) 445 7.99 669.94 (1.73) 
813 2.9 216.01 (2.44) 165 8.03 40.137 (2.45) 
816 2.91 679.90 (2.72) 860 8.24 26.13 (2.91) 
85 2.92 75.21 (1.98) 911 8.69 172.11 (2.12) 
826 3.15 569.76 (3.95) 2229 8.76 18.38 (0.45) 
1414 3.17 140.13 (1.21) 396 8.86 69.44 (3.65) 
898 3.31 43.57 (1.73) 343 8.92 20.06 (2.43) 
1595 3.33 425.07 (0.83) 175 9.21 14.90 (3.46) 
970 3.43 78.72 (1.24) 382 9.21 39.29 (0.54) 
535 3.44 87.79 (2.46) 1643 10.09 98.54 (1.53) 
749 3.52 216.62 (0.68) 1098 10.89 86.34 (3.54) 
822 3.59 763.67 (4.81) 1100 11.34 43.7 (1.49) 
1134 3.65 23.62 (3.56) 1437 11.52 21.91 (1.65) 
472 3.73 99.50 (3.12) 1606 11.54 22.35 (0.98) 
685 3.78 446.03 (2.73) 1745 11.83 43.80 (1.36) 
1091 3.83 115.78 (3.42) 1902 12.4 31.09 (3.45) 
733 3.86 176.43 (1.68) 640 12.81 51.06 (0.92) 
876 3.91 358.76 (3.18) 590 14.82 49.06 (2.46) 
850 3.93 475.89 (4.14) 874 16.75 175.96 (0.87) 
916 3.98 883.25 (4.11) 717 17.13 65.2 (4.59) 
1006 4.01 198.95 (1.95) 848 17.58 122.11 (2.82) 
103 4.24 41.05 (3.21) Normal 25.54 1 (1.23) 
915 4.42 104.50 (0.47)    
Table showing average percentage levels of methylation across CpG sites 8-11 in glioblastoma biopsy samples, 
compared to normal brain tissue. Hypomethylation is seen across all biopsies, with average levels of methylation 
5.5% in glioblastoma biopsies compared to normal tissue (25.5%). HK2 fold change is also represented for 
comparison respectively.  
 94 
 
 
Figure 3.11. HK2 average methylation of glioblastoma cultures across CpG sites 8-11                                                                      
Average HK2 methylation percentage across CpG sites 8-11 within the promotor region. A significant 
(p<0.0001) loss of methylation is demonstrated across all 21 patient-derived cell cultures and 2 
established cell lines biopsy samples, with average levels of methylation 5.4% compared to normal 
tissue 25.5%. Hypomethylation is also seen in NHA, with average methylation of 16.8%. 
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Table 3.5. Average levels of HK2 methylation (%) across glioblastoma cultures, 
compared to expression fold change values 
Culture Sample 
Average Methylation 
% 
Expression Fold Change 
(SD (±)) 
U251MG 2.62 1502.61 (1.96) 
U87MG 3.07 1294.26 (2.11) 
IN1951 3.56 210.63 (1.95) 
IN859 3.57 995.11 (1.54) 
UWLV 53 3.58 589.16 (1.92) 
IN1528 4.25 385.95 (2.82) 
IN1682 4.52 120.54 (2.65) 
UWLV 22 4.56 637.35 (0.48) 
IN1979 4.72 574.39 (3.01) 
IN2045 4.82 219.82 (1.22) 
UWLV 156 4.82 306.89 (3.54) 
IN1472 5.11 403.36 (2.11) 
UWLV 152 5.15 289.65 (0.89) 
UWLV 48 5.21 211.43 (0.57) 
IN1760 4.82 201.96 (1.83) 
IN1612 6.36 126.63 (0.91) 
UWLV 212 7.47 145.42 (1.25) 
IN1265 7.58 97.35 (3.41) 
IN2093 7.73 132.75 (0.24) 
IN1461 8.92 85.73 (2.94) 
IN2132 9.67 88.35 (3.58) 
NHA 16.83 30.42 (3.12) 
Normal 25.55 1 (1.23) 
Table showing average percentage levels of methylation across CpG sites 8-11 in glioblastoma culture 
samples, compared to both NHA and normal brain tissue. Hypomethylation is seen across all cultures, 
with average levels of methylation 5.4% in glioblastoma cultures compared to normal tissue (25.5%). 
A loss in methylation is also seen in NHA, with average methylation of 16.8%. HK2 fold change is also 
represented for comparison respectively. 
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Table 3.6. CpG 10 methylation (%) across glioblastoma biopsies 
Biopsy Sample CpG 10 Methylation % Biopsy Sample CpG 10 Methylation %  
411 1.2 338 4.87 
820 1.21 1015 4.97 
436 1.22 626 5.1 
743 1.31 966 5.18 
859 1.41 640 5.19 
1617 1.46 377 5.22 
110 1.57 717 5.28 
116 1.57 781 5.28 
522 1.63 1549 5.63 
1793 1.9 374 5.83 
1178 2 1000 5.87 
956 2.07 849 6.02 
352 2.09 1404 6.13 
994 2.16 103 6.21 
142 2.29 916 6.32 
819 2.59 955 6.35 
1091 2.67 1014 6.39 
1728 2.86 1062 6.79 
813 2.9 1417 6.82 
816 2.91 590 6.92 
85 2.92 826 6.94 
1902 3.11 204 7.09 
1595 3.33 1176 7.11 
1054 3.44 1547 7.22 
410 3.54 1460 7.33 
850 3.74 1446 7.45 
792 3.75 1643 7.56 
685 3.78 793 7.79 
723 3.82 121 7.98 
733 3.86 165 8.25 
122 3.9 2229 8.25 
1101 3.9 175 8.27 
535 3.91 1098 8.28 
705 3.94 1565 8.35 
749 3.96 1745 8.45 
1414 3.96 1016 8.5 
876 4 860 8.83 
905 4 911 9.25 
1006 4.09 1428 9.56 
1687 4.15 396 9.98 
2242 4.23 1437 10.32 
651 4.33 445 10.35 
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898 4.34 1100 10.43 
1134 4.35 382 10.46 
693 4.42 343 10.99 
970 4.46 874 11.95 
1342 4.55 848 12.24 
915 4.58 1606 12.57 
729 4.62 Normal 42.98 
769 4.64 Normal 40.85 
822 4.64 Normal 41.78 
472 4.69 Normal 42.22 
758 4.7 Normal 42.43 
746 4.78  
Table showing HK2 methylation % in biopsies and normal tissue in CpG10 via pyrosequencing. CpG 
10 showed the highest level of deregulated methylation between normal tissue (average of 42.1%) 
and biopsies (average of 5.4%) and cultures (average of 3.8%). 
 
 
Figure 3.13 HK2 methylation of glioblastoma cultures in CpG 10 HK2 methylation percentage 
across CpG site 10 within the promotor region. A significant (p<0.0001) loss of methylation is 
demonstrated across all 21 patient-derived cell cultures and 2 established cell lines biopsy samples 
compared to normal tissue 25.5%. Hypomethylation is also seen in NHA, with average methylation of 
16.8%. 
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Table 3.7. CpG 10 methylation (%) across glioblastoma cultures 
Culture Sample 
CpG 10 HK2 Methylation 
% 
IN859 1.1 
IN1612 1.1 
IN1760 1.5 
U251MG 1.6 
U87MG 2.01 
UWLV 156 2.3 
IN1951 3.11 
IN1682 3.22 
UWLV 53 3.6 
UWLV 22 3.68 
IN1472 3.82 
IN2045 4.42 
IN1979 4.51 
IN2093 4.94 
UWLV 48 4.98 
UWLV 152 5.11 
IN1528 5.21 
UWLV 212 5.52 
IN1265 6.03 
IN1461 6.16 
IN2132 6.59 
NHA 14.74 
Table showing HK2 methylation % in cultures and NHA in CpG10 via pyrosequencing. 
 
3.4 Correlation of hypomethylation and levels of overexpression of HK2  
A loss in methylation was established across all glioblastoma samples including in 
both tissue and culture, with significant hypomethylation frequently occurring across 
multiple CpG sites. The diminished levels of HK2 methylation in glioblastoma was 
further investigated to determine if epigenetic alterations impacted mRNA 
transcription. The level of HK2 fold change expression attained from qPCR was 
compared to the methylation data from pyrosequencing for individual biopsies 
(n=103) and cultures (n=21) and compared to both NHA and normal brain tissue. A 
strong correlation between the percentage of methylation and level of expression 
across the CpG sites 8-11 (p< 0.0001) was demonstrated.  From this, samples were 
grouped dependant on the standard deviation above and below the average 
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methylation level. Figure 3.14 shows the differentiated groups, above and below 
5.5% methylation, with the corresponding HK2 expression. The comparative 
glioblastoma biopsy groups are significantly different with both methylation 
percentage (p< 0.0001) and levels of HK2 expression fold change. Samples 
exhibiting hypomethylation levels of <5.5% demonstrated considerably increased 
levels of HK2 expression, where fold change ranged from 3.8 to 897.5, with an 
average expression level of 297.3. This was significantly (p< 0.0001) different to the 
contrasting group, where levels of methylation were >5.5%, average HK2 
expression fold change was 99 with a fold change range of 7.4 to 320.2 (compared 
to normal tissue). Additionally, both subgroups of glioblastoma biopsy samples were 
significantly different to normal tissue (p< 0.0001), with average methylation values 
25.5% across CpG’s 8-11. The increased level of hypomethylation is indicative that 
epigenetic alternations influence mRNA transcription, contributing to elevated levels 
of HK2 expression in glioblastoma biopsies. Utilizing the same approach, 
glioblastoma cultures were grouped dependant on their average level of methylation, 
as stated above. From this samples were grouped dependant on the standard 
deviation above and below the average. Figure 3.15 shows the differentiated 
subgroups, above and below 5.4% methylation, with the corresponding HK2 fold 
change levels. Both glioblastoma culture subgroups were substantially different to 
normal brain tissue, with significantly (p< 0.0001) reduced levels of methylation (%) 
compared to normal tissue and NHA, additionally both subgroups also demonstrated 
significant variabilities in methylation levels (p< 0.0001). Samples exhibiting 
hypomethylation levels of <5.4% demonstrated considerably increased levels of HK2 
expression, where fold change ranged from 120.5 to 1502.6, with an average 
expression level of 529.5. This was statistically (p=0.0276) different to the 
contrasting group, where levels >5.4% methylation, average HK2 expression fold 
change was 112.7 with a range between 85.7 to 145.4- fold expression (compared 
to normal tissue). HK2 methylation levels in NHA were also significantly different to 
normal tissue (p=0.0003), and to both glioblastoma culture subgroups (p< 0.0001). 
This significant difference between the sample groups and NHA was also 
distinguishable with respect to expression fold change, with average levels of 27.93 
(p< 0.0001 compared to normal brain, p=0.0042 for <5.4% methylation group and 
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p=0.0130 for >5.4% methylation group). Hypomethylation was demonstrated in 
both glioblastoma biopsies and culture compared to NHA and normal brain tissue, 
furthermore the reduction in HK2 methylation corresponded with extensive 
overexpression in all glioblastoma cultures, indicating that hypomethylation is an 
influential factor for significantly increased levels of expression of HK2 in 
glioblastoma. 
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Figure 3.14 HK2 methylation levels compared to fold change expression in glioblastoma 
biopsies (n=103) compared to normal brain tissue. Differentiated subgroups of glioblastoma 
biopsies, show significant (p< 0.0001) differences, in samples where methylation is less than 5.5% 
HK2 expression is massively increased, with average levels of 297.3-fold compared to normal tissue. 
In comparison where methylation is greater than 5.5%, average HK2 expression is 99-fold when 
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compared to normal brain tissue. Both glioblastoma subtypes are significantly different to normal 
tissue, with extensive hypomethylation and sizeable overexpression of HK2. The bars represent mean 
and SD deviation. 
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Figure 3.15 HK2 methylation levels compared to fold change expression in glioblastoma 
cultures (n=21) and NHA compared to normal brain tissue. Differentiated subgroups of 
glioblastoma cultures show significant (methylation p< 0.0001, fold change p=0.0276) differences, in 
samples where methylation is less than 5.4% HK2 expression is greatly increased, with average levels 
of 529.5 compared to normal tissue. In comparison where methylation is greater than 5.4%, average 
HK2 expression is 112.7, when compared to normal brain tissue. Both glioblastoma subtypes are 
significantly (methylation p< 0.0001, fold change p=0.0130) different to normal tissue, with extensive 
hypomethylation and sizeable overexpression of HK2. NHA also demonstrated significant differences 
between both the glioblastoma samples (methylation p< 0.0001, fold change p=0.0042) and normal 
tissue (p=0.0003, fold change p< 0.0001), with reduction in methylation levels occurring and a 
noteworthy increase in HK2 expression. The bars represent mean and SD deviation. 
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3.5 Quantitative assessment of Hexokinase 1 expression 
In order to determine alterations in expression of HK1 in glioblastoma, mRNA levels 
were analysed by qPCR in 70 glioblastoma biopsies, 15 glioblastoma patient-derived 
cell cultures and established cell lines and compared to both NHA and 5 normal brain 
tissue samples.  
Sixty (85.7%) biopsies exhibited HK1 downregulation or no change in level of 
methylation ranging from 0.00034 to 1.12- fold change expression compared to 
normal brain tissue (normalised to 1-fold change), with significant loss of expression 
in 31 of the biopsies. Additionally, there were 10 biopsies with ranging from 1.2- to 
2.2- fold change increase in HK1 gene expression as shown in Figure 3.16. An 
altered level of gene expression was also determined across the glioblastoma 
cultures, where all 15 patient-derived and established cell lines demonstrated an 
increased level of HK1 expression, ranging from 1.2 up to 7.4 – fold change increase 
compared to normal brain (normalised to 1-fold change). Additionally, NHA exhibited 
an increase of 1.67- fold change expression, as shown in Figure 3.17. Detailed 
figures for each biopsy and culture fold change can be seen in Table 3.8 and 3.9. 
HK1 expression is downregulated in 84.2% of the biopsies, indicating a potential HK 
isoform switch in glioblastoma. Overexpression of HK1 was frequent in the culture 
samples, suggesting that the availability of nutrients in the in vitro microenvironment 
upregulates metabolic processes including HK1 whilst also manintaing the switch to 
HK2. 
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Table 3.8. Expression fold change of HK1 in glioblastoma biopsies   
Biopsy Sample 
HK1 Fold Change 
(SD (±)) 
Biopsy Sample 
HK1 Fold Change 
(SD (±)) 
Normal 1 (0.10) 733 0.22 (0.28) 
121 * 0.00034 (0.15) 876 0.28 (0.12) 
410 * 0.005 (0.05) 746 0.31 (0.31) 
103 * 0.0068 (0.14) 626 0.35 (0.02) 
436 * 0.007 (0.08) 693 0.35 (0.3) 
411 * 0.0072 (0.15) 685 0.43 (0.03) 
142 * 0.0075 (0.16) 816 0.6 (0.2) 
819 * 0.0077 (0.18) 898 0.61 (0.3) 
377 * 0.0078 (0.15) 915 0.65 (0.12) 
522 * 0.008 (0.11) 793 0.68 (0.31) 
175 * 0.0083 (0.12) 849 0.7 (0.22) 
122 * 0.0097 (0.17) 848 0.79 (0.13) 
956 * 0.0098 (0.08) 723 0.81 (0.11) 
85 * 0.011 (0.24) 717 0.85 (0.24) 
445 * 0.011 (0.2) 916 0.86 (0.05) 
101 * 0.012 (0.12) 705 0.86 (0.14) 
338 * 0.016 (0.13) 640 0.88 (0.31) 
1000 * 0.016 (0.21) 813 0.89 (0.32) 
535 * 0.017 (0.24) 743 1.02 (0.12) 
204 * 0.018 (0.15) 850 1.05 (0.34) 
110 * 0.02 (0.24) 859 1.08 (0.21) 
374 * 0.021 (0.05) 396 1.09 (0.14) 
165 * 0.022 (0.31) 820 1.09 (0.17) 
477 * 0.023 (0.23) 758 1.09 (0.31) 
352 * 0.027 (0.16) 729 1.12 (0.22) 
590 * 0.031 (0.28) 826 1.2 (0.16) 
472 * 0.033 (0.23) 651 1.24 (0.14) 
966 * 0.037 (0.21) 911 1.28 (0.22) 
1006 * 0.042 (0.22) 970 1.34 (0.31) 
860 * 0.068 (0.24) 343 1.57 (0.42) 
822 * 0.086 (0.14) 781 1.89 (0.12) 
769 * 0.097 (0.3) 874 1.96 (0.23) 
905 0.01 (0.24) 116 * 2.02 (0.14) 
994 0.12 (0.21) 792 * 2.09 (0.12) 
955 0.16 (0.13) 382 * 2.15 (0.06) 
749 0.19 (0.26) 
 
Table showing qPCR analysis of HK1 glioblastoma biopsies. Fold change has been normalised against 
average expression level of normal brain tissue. HK1 expression is downregulated in 84.2% of the 
biopsies compared to normal tissue. Standard deviation for each average is listed after each result 
(±). * denotes significant altered expression level compared to normal. 
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Figure 3.17 Expression fold change of HK1 in glioblastoma cultures relative to normal 
tissue. Real time qPCR analysis of HK1 glioblastoma cultures and cell lines (n=15). Fold change has 
been normalised against average expression level of normal brain tissue. HK1 expression is elevated 
across all glioblastoma cultures and established cell lines compared to normal tissue (n=5), indicative 
that overexpression is occurring within a cell culture environment. HK1 expression was also increased 
in NHA compared to normal tissue.  
Table 3.9. Expression fold change of HK1 mRNA in glioblastoma cultures 
Culture Sample HK1 Fold Change (SD (±)) 
Normal 1 (0.18) 
IN1979 1.21 (0.4) 
IN2093* 1.22 (0.42) 
IN1760* 1.43 (0.6) 
IN1472 1.48 (0.34) 
IN859 1.63 (0.53) 
NHA 1.67 (0.34) 
IN1682* 1.58 (0.53) 
IN1265 2.46 (0.8) 
IN1461* 2.74 (0.4) 
IN1951* 2.97 (0.33) 
IN2045 3.41 (0.27) 
IN2132* 3.83 (0.5) 
IN1612 4.21 (0.51) 
U251MG 6.12 (0.87) 
IN1528 6.47 (0.8) 
U87MG 7.39 (0.72) 
Real time qPCR analysis of HK1 glioblastoma cultures and cell lines. Fold change has been normalised 
against average expression level of normal brain tissue. HK1 expression is elevated across all 
glioblastoma cultures and established cell lines compared to normal tissue. HK1 expression was also 
increased in NHA compared to normal tissue. Standard deviation for each average is listed after each 
result (±). * denotes significant altered expression level compared to normal. 
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The data obtained from qPCR revealed a variation within the glioblastoma biopsy 
population, with respect to HK1 expression values. 10 biopsy samples from the 70-
cohort tested exhibited increased levels of HK1 expression, of which 3 samples had 
significantly (p=0.0003) increased expression (116, 792, 382) compared to normal 
brain tissue, furthermore this group was statistically different (p<0.0001) to the 
remaining 60 biopsy samples which demonstrated either a minor reduction in HK1 
expression (31 biopsies showed no HK1 expression) or no-change (n=28) compared 
to the control tissue. Additionally, HK1 over-expression was exhibited across all 
glioblastoma cultures and NHA compared to normal tissue.  
3.6 Quantitative assessment of Hexokinase 1 methylation 
HK1 methylation status was also investigated to reveal whether any epigenetic 
alternations occur in glioblastoma compared to normal tissue. Pyrosequencing was 
used to facilitate full quantification of the level of methylation in tumour samples. 
HK1 primers were selected from Qiagen pre-designed sequencing primers as stated 
in 2.8, spanning 4 CpGs and offering maximum coverage across the HK1 promotor 
region. Fifty glioblastoma biopsies and 15 glioblastoma patient-derived cell cultures 
and established cell lines (Table 3.11) were investigated and compared to both NHA 
and 5 normal brain tissue samples. The data revealed no significant differences 
between the average level of methylation in the biopsies (4.1%) and normal brain 
(6.9%), however 44 biopsies demonstrated reduced levels of methylation compared 
to normal brain tissue.  
The degree of methylation across the 50 glioblastoma samples ranged from 1.33% 
to 7.46% with an average of 4.05%, in comparison normal brain tissue methylation 
(6.9%), with a range between 5.78 % to 8.03%, as shown in Figure 3.18 and Table 
3.10. Furthermore, only 1 culture (IN1951) showed a significant (p=0.0063) 
reduction in the level of methylation compared to normal brain, no substantial 
alterations were demonstrated in the other cultures compared to normal brain tissue 
(p= 0.1431), or between NHA (p= 0.5100). The range in methylation across the 15 
cultures was from 2.47% to 9.67% with an average of 5.48%, in comparison NHA 
had a methylation level of 4.46% with normal brain at 6.95 as shown in Figure 3.19 
and Table 3.11. The data revealed no hypermethylation of HK1 occurring in normal 
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tissue, with a minor loss of methylation demonstrated across 44 biopsies, of which 
8% demonstrated a significant reduction compared to normal tissue. No significance 
alteration in the methylation state was shown across the cultures (except for 
IN1951). The data indicates that HK1 is expressed in normal tissue and methylation does 
not control gene expression, no universal deregulation in the level of methylation 
present in glioblastoma. 
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Table 3.10. Average level of HK1 methylation (%) across glioblastoma biopsies, 
compared to expression fold change values 
Biopsy 
Sample 
Methylation 
% 
HK1 Fold 
Change (SD 
(±)) 
Biopsy 
Sample 
Methylation 
% 
HK1 Fold 
Change (SD 
(±)) 
Normal 6.905 1 (1.32) 116 3.75 2.02 (2.56) 
850 1.33* 1.01 (1.89) 590 3.77 0.031 (0.72) 
733 1.35* 0.22 (0.35) 110 3.82 0.02 (4.05) 
685 1.48* 0.43 (1.38) 956 3.82 0.0098 (1.29) 
693 1.68* 0.35 (1.48) 1000 3.83 0.016 (3.17) 
142 2.06 0.0075 (3.67) 338 3.87 0.016 (4.22) 
746 2.22 0.31 (4.86) 1006 3.93 0.042 (0.62) 
472 2.37 0.033 (0.63) 874 4.13 1.96 (0.87) 
85 2.39 0.011 (4.13) 705 4.22 0.86 (4.57) 
876 2.45 0.28 (0.14) 445 4.56 0.011 (3.21) 
955 2.45 0.16 (4.68) 626 4.89 0.35 (1.63) 
436 2.53 0.007 (1.13) 994 4.89 0.12 (2.53) 
477 2.95 0.023 (1.72) 410 5.24 0.005 (2.47) 
859 3.03 1.08 (3.02) 175 5.28 0.0083 (4.82) 
822 3.05 0.086 (2.38) 749 5.39 0.19 (2.57) 
122 3.07 0.0097 (3.18) 103 5.6 0.0068 (1.64) 
352 3.09 0.027 (2.89) 374 5.92 0.021 (2.74) 
816 3.11 0.6 (0.73) 204 6.83 0.018 (1.59) 
522 3.16 0.008 (1.82) 769 6.89 0.097 (3.63) 
165 3.22 0.022 (3.16) 966 6.93 0.037 (2.34) 
905 3.33 0.099 (0.46) 819 6.98 0.0077 (2.72) 
860 3.37 0.068 (2.59) 377 7.03 0.0078 (3.11) 
743 3.56 1.02 (1.76) 101 7.32 0.012 (2.51) 
717 3.59 0.85 (1.74) 535 7.42 0.017 (2.81) 
411 3.61 0.0072 (0.32) 121 7.46 0.00034 (0.46) 
Table showing average percentage levels of methylation across 4 CpG sites in glioblastoma biopsy 
samples, compared to normal brain tissue. Hypomethylation is seen in some of the biopsies, with 
average levels of methylation 4.1% in biopsies compared to normal tissue (6.9%). HK1 fold change is 
also represented for comparison respectively.  * denotes statistical significance.  
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Figure 3.19 HK1 average methylation of glioblastoma cultures                                                                                 
Average HK1 methylation percentage across 4 CpG sites within the promotor region. An altered level 
of methylation is demonstrated across culture samples, with average levels of methylation 5.5% 
compared to normal tissue 6.9%. * denotes significance. 
 
Table 3.11. Average level of HK1 methylation (%) across glioblastoma cultures, 
compared to expression fold change values 
Culture Sample Methylation % 
HK1 Fold Change (SD 
(±)) 
Normal 6.94 1 (1.53) 
IN1951 2.47* 2.97 (3.65) 
IN2045 3.68 3.41 (0.47) 
IN1461 3.71 2.74 (4.59) 
IN859 3.79 1.63 (3.54) 
IN2132 3.85 3.83 (3.1) 
IN1265 3.95 2.46 (2.82) 
NHA 4.46 1.67 (2.46) 
U251MG 5.11 6.12 (1.53) 
IN1612 5.25 4.21 (2.99) 
IN2093 5.28 1.22 (1.98) 
IN1682 5.32 1.58 (2.66) 
IN1979 6.61 1.21 (3.12) 
U87MG 6.64 7.39 (0.58) 
IN1760 7.53 1.43 (0.21) 
IN1528 8.75 6.47 (3.12) 
IN1472 9.67 1.48 (1.24) 
Table showing average percentage levels of methylation across 4 CpG sites in glioblastoma culture 
samples, compared to both NHA and normal brain tissue. Hypomethylation is seen in 80% of the 
cultures, with average levels of methylation 5.5% in glioblastoma cultures compared to normal tissue 
(6.9%). A loss in methylation is also seen in NHA, with average methylation of 4.46%. HK1 fold 
change is also represented for comparison respectively.   
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The epigenetic deregulation of HK1 methylation in glioblastoma was further 
investigated to determine if it had any impact upon mRNA transcription, resulting in 
a change in level of HK1 expression. HK1 fold change expression attained from qPCR 
was compared to the methylation data from pyrosequencing for individual biopsies 
(n=50) and cultures (n=15) and compared to both NHA and normal brain tissue. 
Samples were grouped dependant on the standard deviation above and below the 
average. The comparative biopsy sub-populations are significantly different with 
levels of methylation (p< 0.0001), however there was no statistically significant 
differences illustrated with corresponding levels of expression. Samples exhibiting 
methylation levels of <4% did not demonstrate significantly increased levels of HK1-
expression.   
Utilizing the same approach, glioblastoma cultures were grouped dependant on their 
level of methylation, the average methylation level across the 15 cultures was 
calculated (as stated above). Samples exhibiting methylation levels of <5.5% 
demonstrated increased (p= 0.0112) levels of HK1 expression, there was no 
significant difference to the contrasting culture sub-population, where methylation 
levels >5.5%, average HK1 expression fold change was 3.6 with a range between 
1.21 and 7.39-fold change difference. The data suggests that levels of HK1 
methylation in glioblastoma biopsies does not have a critical function impacting HK1 
expression levels. Furthermore, the data concludes that the level of HK1 methylation 
does not impact upon mRNA expression in culture, were no significant correlations 
were determined in any of the cultures; overall a minor decrease in methylation was 
demonstrated in the biopsy samples, which did not translate into an increase in 
expression. The results indicate that a separate mechanism instead of methylation 
regulates HK1 expression, which may instead be driven through histone modification 
or miRNA interaction (Peschiarol et al., 2013). A potential hexokinase isoform switch 
may also be plausible, HK2 possesses two active catalytic domains with varying 
kinetic properties more suited for the metabolic nature of cancer cells, offering 
beneficial growth conditions (Wilson, 2003). 
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3.7 The relationship between Hexokinase 2 overexpression and outcome 
 
To investigate a potential association of raised levels of HK2 with patient outcome, 
expression data was compared to overall survival (OS) for 86 glioblastomas as 
shown in Figure 3.20. Linear regression was used to determine statistical 
significance, whereby the P value indicates whether the relationship between an 
independent variable (Days elapsed since diagnosis) and the dependent variable 
(Expression level of HK2) is statistically significant. Linear regression analysis 
revealed a statically significant (p=0.0017) intersect on the Y-axis at 340- fold 
change expression, indicating the level of HK2 expression to have a significant effect 
upon outcome. The biopsies were then grouped according to their HK2 fold change 
levels where the samples were either greater than 340-fold change increase or less 
than 340-fold increase compared to normal brain tissue levels of HK2.  
Survival data comparing the 2 biopsy groups illustrated a significant difference with 
regards to outcome as shown in Figure 3.21.  
In biopsy samples with HK2 levels >340-fold increase, median patient survival was 
102 days, with a range from 19 to 491 days post operation. In comparison 
glioblastoma samples with HK2 levels <340-fold increase, had significantly (Log-rank 
Mantel-Cox test, p=0.0002) longer median survival, at approximately 296 days post 
operation with a range from 12 to 1374 days.  
The correlation between HK2 expression and OS was also investigated when patients 
were grouped dependant on sex, allowing for further stratification and to determine 
the effectiveness of potential inhibitors. The 86 biopsies were grouped dependant on 
patient sex, according to their HK2 fold change levels, either greater than 340-fold 
change increase or less than 340-fold increase compared to normal brain, as shown 
in Figure 3.22. Significantly (p=0.0002) different survival times were determined in 
males (n=53), when HK2 fold change was >340, median survival time was 133 days 
(ranging from 12-1374) compared to 373 days (ranging from 19 to 768) post 
operation with HK2 fold change <340. No significance was determined between HK2 
expression levels and survival in females (n=33) where median survival time is 205 
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days compared to 316 days post operation between the respective groups (Mantel-
Cox test, p= 0.8532).   
 
Figure 3.20 Showing patient survival vs level of HK2 expression in glioblastoma biopsies 
Survival time shown in days compared to level of HK2 expression in glioblastoma. Linear regression 
was used to determine the statistical significance, where the relationship between days elapsed and 
level of HK2 is statistically significant. Linear regression analysis revealed a statically significant 
(p=0.0017) intersect on the Y-axis at 340- fold change expression, indicating the level of HK2 
expression to have a significant effect upon outcome. 
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Figure 3.21 Showing patient survival in percentage vs days, comparing 2 subgroups of 
glioblastoma biopsies. Survival time shown between 2 subgroups of glioblastoma determined via 
HK2 expression levels. Significantly (p=0.0002) different survival times were determined, when HK2 
fold change is >340, median survival time is 102 days compared to 296 days post operation with HK2 
fold change <340. 
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Figure 3.22 Showing patient survival in percentage vs days, comparing the sex of the 
patient. Survival time shown between 2 subgroups of glioblastoma determined via HK2 expression 
levels in both male and female patients. Significantly (p=0.0002) different survival times were 
determined in males (n=53), when HK2 fold change is >340, median survival time is 133 days 
compared to 373 days post operation with HK2 fold change <340. No significance was determined 
between HK2 expression levels and survival time in females (n=33) where median survival time is 
205 days compared to 316 days post operation between the respective groups. 
 
 
3.8 The relationship between Hexokinase 1 overexpression and outcome 
To investigate a potential association of HK1 with patient outcome, expression data 
was compared to OS for 70 glioblastomas as shown in Figure 3.23. The biopsies 
were grouped according to their HK1 fold change levels as shown in 3.3, the 
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grouping was determined by HK1 downregulation (n=32), no change of expression 
(n=28) or HK1 upregulation (n=10). Survival data comparing the groups illustrated 
no significant difference using Mantel-Cox test, with regards to patient prognosis. In 
samples where HK1 was downregulated, median patient survival was 328 days, in 
comparison samples demonstrating overexpressed levels of HK1, the median patient 
survival was 315 days and 244 days in samples showing no fold change (compared 
to normal tissue). Additional patient details are in the appendix, including Sex vs 
MGMT methylation for OS (Figure A4), Sex vs HK2 expression for OS (Figure A5) and 
Sex vs age for OS (Figure A6). Table A8 details patient biopsy information, including 
MGMT status, HK2 expression, sex and OS. 
 
Figure 3.23 Showing patient survival in percentage vs days, comparing HK1 expression in 
biopsies. Survival time shown between groups of glioblastoma biopsies determined via HK1 
expression levels, dependant on either overexpression (n=10), downregulation (n=32) or no change 
in expression (n=28) compared to normal tissue. No significance was determined between the level 
HK1 expression and survival time across elapsed days post operation.  
 
3.9 Growth curves  
All glioblastoma cultures were grown under conditions detailed in Section 2.1.4. 
Growth curves were completed for all cultures used. The doubling time for each of 
the cultures was calculated from measuring the highest gradient within the 
exponential growth phase. The doubling times for each culture are detailed in Figure 
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3.24 and Table 3.12. The times ranged from 24 hours to 70 hours with a median 
doubling time of 42 hours. In comparison the doubling time for NHA was 63 hours. A 
correlation between the rate of growth and HK2 expression was established, where 
significantly higher (p=0.0021) expressing cultures were shown to have a shorter 
doubling time. The data is shown in the appendix. The data here suggests HK2 
involvement with an increased rate of proliferation, this will be further explored in 
Chapter 4.  
 
 
Figure 3.24 Growth curve data for all glioblastoma cultures and NHA All cultures were 
seeded with 2x10⁵ cells at day zero. Two cell count readings were collected at 8 time points.  Data 
shown is averaged from three replicate time courses. Doubling times were each culture was 
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determined from the highest gradient in its exponential growth phase. y-axis represents cells/cm2 of 
growth media. 
Table 3.12 Doubling time of culture panel 
Culture 
Doubling time 
(Hours) 
HK2 expression Culture 
Doubling time 
(Hours) 
HK2 expression  
U251MG 24 (±1.56) 1502.61 (1.96) IN2132 44 (±2.56) 88.35 (3.58) 
U87MG 24 (±2.01) 1294.26 (2.11) IN1472 45 (±1.75) 403.36 (2.11) 
IN859 24 (±2.22) 995.11 (1.54) IN1682 50 (±1.42) 120.54 (2.65) 
IN1612 28 (±1.5) 126.63 (0.91) IN1265 50 (±2.8) 97.35 (3.41) 
IN1528 32 (±1.26) 385.95 (2.82) IN1951 55 (±2.08) 210.63 (1.95) 
IN1979 34 (±2.51) 574.39 (3.01) IN1461 60 (±1.82) 85.73 (2.94) 
IN2045 36 (±1.64) 219.82 (1.22) NHA 63 (±2.62) 30.42 (3.12) 
IN1760 40 (±3.1) 201.96 (1.83) IN2093 70 (±3.22) 132.75 (0.24) 
All cultures were seeded with 2x10⁵ cells at day zero. Two cell count readings were collected at 8 
time points. Data shown is averaged from three replicate time courses. Doubling times were each 
culture was determined from the highest gradient in its exponential growth phase. HK2 expression is 
shown for each culture.  
 
 
3.10 Discussion 
This chapter has focussed on the investigation of the differential mRNA expression of 
hexokinase isoforms in 103 glioblastoma biopsies compared to normal brain tissue, 
with the aim of understanding the potential involvement of HK2 overexpression in 
glioblastoma development. Patient-derived glioblastoma cell cultures were also 
investigated (n=21) to determine altered mRNA expression compared to NHA. 
Additionally, the epigenetic mechanism regulating hexokinase expression was 
identified through methylation studies utilizing pyrosequencing in both biopsy 
samples and cultures compared to both normal brain tissue and NHA. The findings 
of this study highlight the dysregulation of hexokinase expression in glioblastoma, 
and reiterate the altered metabolism associated within cancer cells (Goodwin et al., 
2015). Expression analysis in this study revealed distinct HK2 expression and 
methylation profiles in both glioblastoma biopsies and patient -derived cell cultures 
compared to their normal counterparts. A variation in mRNA overexpression of HK2 
was observed amongst the biopsies which may reflect the characteristic inter-tumour 
heterogeneity of heterogeneity of glioblastoma. 
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Hexokinase 2 overexpression is prevalent in glioblastoma  
In this study the gene expression profile of glioblastoma biopsies and patient-derived 
cell cultures investigated show altered levels of HK2 gene expression levels. Both 
glioblastoma biopsies (n=103) and patient-derived cell cultures (n=21) 
demonstrated overexpression of HK2 across all samples compared to normal brain 
tissue and NHA, with the average expression of HK2 in the biopsy samples 
approximately 229-fold change increase and 411-fold change increase in the cultures 
compared to normal tissue. The similar expression profiles of HK2 in both the biopsy 
samples and the patient-derived cultures in this study is encouraging and an 
important finding, the advancement of a more accurate model of glioblastoma is 
crucial for the development of therapeutic treatments. 
Overexpression of HK2 has been documented in range of cancers, including both 
lung and breast cancer (Wang et al., 2014; Anderson et al., 2016). One of the 
reasons for the upregulation of HK2 in glioblastoma may be attributed to the 
influence of the well-known metabolic transformation in cancer cells, with the 
increasing reliance upon the glycolytic pathway as the predominant mechanism for 
energy production; as a resultant requirement of increased amounts of energy to 
maintain augmented proliferation and cell survival (vander Haiden et al., 2009; Kami 
et al, 2013). Another plausible explanation for the selective overexpression of the 
HK2 isoform in cancer cells maybe a result of compatibility with cancer cells intrinsic 
properties, where HK2 unlike HK1 possesses two active catalytic domains in its 
amino- and carboxy- termini, in comparison HK1 only possess a single active 
catalytic domain in its carboxy-terminus. The two catalytic domains have different 
kinetic properties more suited for the metabolic nature of cancer cells with the 
advantage of HK2 retaining activity under conditions that are inhibitory for the single 
catalytic domain, such as hypoxia (Wilson, 2003). 
Overexpression of HK2 has also been shown to offer significant growth advantages 
in many tumours including ovarian, medulloblastoma and breast cancers (Jiang et 
al., 2012; Gershon et al., 2013; Siu et al., 2019). Its crucial catalytic role initiating 
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the glycolytic pathway has been associated with driving the accelerated glucose flux 
as seen in the Warburg effect cells as well as increasing tumour invasion, aggression 
and enhanced therapeutic resistance (Patra et al., 2013; Wolf et al., 2011 Galluzi et 
al, 2013; Lindgvist et al., 2018). The variation in the level of HK2 overexpression in 
glioblastoma tissue could be attributed to tumour heterogeneity (Verhaak et al., 
2010), or epigenetic alternations occurring to varying extents. The data obtained 
signifies HK2 overexpression as a common occurrence in glioblastoma which may 
well contribute to tumour growth. 
Hypomethylation of Hexokinase 2 drives overexpression 
Establishing the potential factors influencing the mechanism of HK2 overexpression 
occurring in glioblastoma is key for the stratification of patients, providing a further 
refinement in glioblastoma classification, with an increased potential at predicting 
patient outcome and may be translated into effective therapeutic strategies tailored 
to each patient. One approach to determine if HK2 overexpression is epigenetically 
regulated is to investigate alterations in methylation of the promotor region of the 
gene. Comprehensive changes of HK2 promotor hypermethylation in glioblastoma 
have not been previously investigated using pyrosequencing, however studies have 
shown extensive HK2 CpG island hypomethylation in hepatocellular carcinoma (Lee 
et al., 2016). The current study established a reduction in the level of HK2 
methylation to be present in all 103 glioblastoma biopsies, with an average 
methylation level 20% lower across 4 CpG sites (CpG 8, 9, 10, 11) compared to 
normal brain tissue (p<0.0001). Hypomethylation was also established in all patient-
derived cultures, with average levels of methylation of 5.4%, significantly 
(p<0.0001) lower than normal brain tissue. The greatest level of HK2 promotor 
hypomethylation in the biopsies was observed at CpG10, with a significantly 
(p<0.0001) reduced methylation level by 36.7% compared to normal tissue. 
Promotor hypomethylation was also seen in the culture samples with significantly 
(p<0.0001) reduced levels of methylation of 38.3% compared to normal tissue. NHA 
also had a significantly (p<0.0001) reduced level of methylation of 14.74%, which 
may be accounted for by its foetal origins. HK2 has been shown to be expressed in 
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embryonic tissues, involved with development but it is downregulated in healthy 
adult tissue except for adipose, skeletal, and cardiac muscle (Wilson, 2003). 
The distinct shifts in DNA methylation patterns are well documented in cancer cells, 
with the common occurrence of CpG island promoter hypermethylation often 
associated with the silencing of tumour suppressor genes (Miranda-Gonçalves et al., 
2018). The most recognised of these epigenetic disruptions are of the tumour 
suppressors BRCA1, CDKN2A, MLH1, and VHL, which have been identified as drivers 
for lung, colorectal, breast and renal cancer progression (Jones and Baylin, 2007; 
Esteller, 2000). A recently amended glioma classification utilises the molecular 
diagnosis of isocitrate dehydrogenase (IDH) mutational status, whereby IDH-mutant 
glioma manifest CpG island methylator phenotype (G-CIMP) (de Souza et al., 2018). 
The identification of clinically relevant subsets of G-CIMP tumours (G-CIMP-high and 
G-CIMP-low) provided an additional refinement for glioma classification, for the 
prediction of patient outcome (Malta et al., 2018). Global hypomethylation has also 
been associated with the activation of transcriptional protooncogenes, such as HRAS 
in melanoma, and with genomic instability leading to translocations and deletions 
(Ehrlich, 2009). Studies have also established the presence of global 
hypomethylation as a common occurrence in primary human glioblastomas, where 
elevated hypomethylation was associated with copy number alterations, suggesting 
that hypomethylation may be one factor predisposing to specific genetic alterations 
commonly occurring in glioblastoma (Cadieux et al., 2006). 
Promoter hypomethylation of HK2 has been associated with HK2 upregulation in a 
range of cancers including hepatocellular carcinoma and glioma cells, thus the 
epigenetic disruption primes the cells to favour the glycolytic flux (Wolf et al., 2011; 
Crispo et al., 2019). The data obtained shows that hypomethylation of HK2 is 
frequently occurring across multiple CpG sites.  
 
HK2 hypomethylation impacts mRNA expression  
The impact of HK2 hypomethylation on gene transcription was also investigated. A 
strong correlation between the percentage of methylation and level of expression 
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across the CpG sites examined (p< 0.0001) was demonstrated in all glioblastoma 
samples. Biopsies exhibiting hypomethylation levels of <5.5% demonstrated 
significantly (p< 0.0001) increased levels of HK2 expression, with a fold change 
average expression level of 297.3 compared to 99. Additionally, culture subgroups 
showed similarities, where hypomethylation levels <5.4%, a significantly (p=0.0276) 
increased level of HK2 expression was established, with an average fold change of 
529.5 compared to 112.7. Studies have shown the presence of hypomethylation of 
CpG islands within intron 1 of HK2 in both developmental human foetal brain and 
glioblastoma tissue via MS-PCR, where in both cases HK2 is abundantly expressed 
(Zhen and Hongjuan, 2018). Hypomethylation of HK2 was also shown to enhance 
levels of HK2 expression in hepatocellular carcinoma, in which the hypomethylation 
phenotype (HK2-CIMP) was associated with poor clinical outcome. (Lee et al., 2016). 
DNA hypomethylation has also been directly associated with increased upregulation 
across a range of genes in many cancer cells including lymphocytes, colorectal, 
gastrointestinal and gynaecologic cancers; studies have shown multiple genes to be 
perturbed in these cancer cells, with prevalent overexpression in tissues that are 
commonly  undetected in normal cells, (Ehrlich, 2009; Jeong et al., 2014; Wong et 
al., 2015). The methylation data in this study also revealed a variation in levels of 
methylation across the multiple individual CpGs investigated. Promoter 
hypomethylation varied >15% across 4 CpGs (8,9,10,11) in the 103 biopsies that 
were investigated, highlighting the occurrence of single base-pair DNA methylation 
changes involved with progressive epigenetic alterations during tumour evolution. A 
study employing genome-wide DNA methylation profiling established highly variable 
individual CpG methylation levels in a large proportion of the genome in a range of 
cancer samples including colorectal, breast, liver, glioma, neuroblastoma, prostate 
and lung, opposed to their invariant normal counterparts. It was suggested that the 
single base-pair DNA methylation changes showed evidence of positive selection, 
mutual exclusivity and tissue specificity with potential cancer-driving effects 
participating in neoplastic transformation (Vidal et al., 2017). 
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Association of HK2 overexpression and patient outcome   
Increased HK2 overexpression correlated to poorer patient outcome. A significant 
difference (P<0.0001) of 194 days was revealed between the median outcome in the 
group of biopsy samples expressing less than 340- fold change compared to samples 
expressing greater than 340- fold change. Furthermore, different survival times were 
determined in male patients (n=53), where increased HK2 overexpression correlated 
to poorer patient outcome. A significant difference (p=0.0002) of 240 days was 
revealed between the median outcome in the group of biopsy samples expressing 
less than 340- fold change. No significance was determined between HK2 expression 
levels and survival in female patients (n=33) where median survival was 205 days 
compared to 316 days post operation between the respective groups. The 
association of outcome with HK2 overexpression has been previously documented in 
other cancers. Studies have shown when stratified by tumour type, the impact of 
HK2 overexpression on poor prognosis was observed in a range of digestive cancers 
including gastric and colorectal cancers, where elevated HK2 expression was 
significantly associated with shorter OS. The negative effect of HK2 overexpression 
on OS was observed in hepatocellular carcinoma, gastric and colorectal cancer but 
not in pancreatic cancer (Liu et al., 2016; Wu et al., 2017). Additionally, the 
correlation between HK2 and OS was independent of MGMT status, as shown in 
Appendix table A2. The association between HK2 expression and outcome offers an 
important insight to a potential prognostic marker for both the impact and additional 
stratification of glioblastoma patients. The stratification of patients separated by the 
prognostic expression biomarker is beneficial for the utilization of treatments that 
target HK2. High expression of HK2 may not only predict poor prognosis but also be 
a potential promising therapeutic approach to develop strategies against this protein. 
 
HK1 is downregulated in a subset of glioblastoma Sixty (85.7%) biopsies 
exhibited HK1 downregulation or no change in the level of methylation compared to 
normal brain tissue. Additionally, 44% of these biopsies demonstrated a significant 
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loss in expression (p=0.0006). No significant upregulation was determined however 
10 biopsies did demonstrate slight increased level of expression. An altered level of 
gene expression was also determined across the glioblastoma cultures, where all 
patient-derived and established cell lines demonstrated an increased level of HK1 
expression, NHA also exhibited an increase. Both HK1 and HK2 are associated with 
mitochondria and are implicated in cell survival and proliferation (Gottlob et al., 
2001, Majewski et al., 2004).  Although HK2 is overexpressed in a range of cancers, 
including lung and breast, there is no significant change in expression levels of HK1 
in these cancers (Patra et al., 2013). It is thought cancer cells favour the higher 
activity of HK2 which possesses two active catalytic domains with the potential to 
maintain metabolic activity in adverse environments, presenting a potential 
explanation for the selective isoform switch from HK1 to the overexpression of HK2 
in cancer cells (Wilson, 2003). The study also concluded that normal brain tissue 
preferentially expresses HK1 and undergoes oxidative glucose metabolism. A recent 
study concluded that HK2 overexpression was a key driver of metabolic regulation in 
glioblastoma, and that the function of HK2 is independent of its isoform HK1 
(Sameer et al., 2018). HK1 expression was shown to be downregulated in over 84% 
of the glioblastoma biopsies, indicating a potential HK isoform switch in 
glioblastoma. 
Altered expression of Hexokinase 1 is not methylation-specific  
The change in methylation status was investigated to determine if the deregulated 
expression of HK1 is epigenetically driven. In this study the methylation profiles of 
glioblastoma biopsies and patient-derived cell cultures were investigated, 
comprehensive changes of HK1 methylation in glioblastoma have not previously 
been investigated by pyrosequencing. There were no significant differences between 
the average level of methylation in the biopsies (4.1%), ranging from 1.33% to 
7.46% and normal brain (6.9%), however a small subset of biopsies (n=4) 
demonstrated significant reduced levels of methylation (p= 0.0008). Furthermore, 
only 1 culture (IN1951) showed a significant (p=0.0063) reduction in the level of 
methylation compared to normal brain, no substantial alterations were demonstrated 
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in the other cultures compared to normal brain tissue. This data confirms that down-
regulation of HK1 in glioblastoma is not due to hypermethylation.  
 
Studies investigating the various hexokinase isoforms state that although HK1 is the 
most highly expressed hexokinase isoform, there is little evidence to suggest it has a 
function in human cancer, with little significant alterations in levels of expression or 
methylation (Peschiaroli et al., 2013; Kim et al., 2019). In another study it was 
shown that although deregulation of methylation is not a frequent occurrence in 
cancer cells, there is evidence of the occurrence of histone modification, with 
reported HK1 phosphorylation of histones sites H1 and H2A (Ignacak and 
Stachurska, 2003). Currently however little is known about these phosphorylation 
sites and their biological functions in cancer (Qin et al., 2019). Histone 
posttranslational modifications represent a versatile set of epigenetic features 
involved in dynamic cellular processes which include transcription and DNA repair, 
studies have identified a range of deregulated histone modifications known to impact 
cellular function. The impact of miRNAs associated with metabolic reprogramming to 
oncogenesis is of growing interest. A range of miRNAs are responsible for driving 
altered gene expression. mir-143 has been shown to correlate to HK2 expression in 
lung tumours and has demonstrated effective inhibition of HK2, disrupting glucose 
metabolism in colon cancer cells. (Gregersen et al., 2012; Peschiarol et al., 2013). 
Additionally, it has also been suggested that mir-143 also targets HK1 as well as 
other glucose pathway components (Hatziapostolou et al., 2013). The biopsies that 
did show significant HK1 hypomethylation may be impacted by global methylation -
associated in glioblastoma. Aberrant DNA methylation patterns are common events 
in the genesis and progression of tumours (Jones et al., 2007). It has been shown 
that in general a global loss in the level of methylation (genomic hypomethylation) 
occurs in cancer cells increasing genomic instability. Currently the perturbed DNA 
methylation on a genome-wide scale is still not fully understood in glioblastoma, 
however a recent study utilizing next-generation sequencing identified a total of 104 
hypomethylated and 524 hypermethylated regions in glioblastoma, indication the 
potential aberrant global methylation present in glioblastoma  (Li and Wu, 2017). 
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Another study showed that intratumor DNA methylation heterogeneity is present 
within glioblastoma; in biopsies classified as IDH wt/mutated by methylation 
analysis, the intratumor DNA methylation differed in samples from the same patient 
(Wenger et al., 2019). The data presented here suggests that the level of HK1 
methylation in glioblastoma does not have a critical function impacting HK1 
expression levels, the occurrence of HK1 downregulation in glioblastoma may be 
instigated through histone modification and/or miRNA activity.  
 
The impact of Hexokinase 1 altered expression related to outcome   
To investigate the effect of altered levels of HK1 on survival prognosis, expression 
data was compared to patient survival information. The biopsies were grouped 
according to their HK1 fold change levels, the grouping was determined by HK1 
downregulation (n=32), no change of expression (n=28) or HK1 upregulation 
(n=10). Survival data comparing the groups illustrated no significant difference using 
Mantel-Cox test, with regards to patient prognosis. In samples where HK1 was 
downregulated, average OS was 328 days, in comparison samples showing no fold 
change OS survival was 244 days. The data here concludes that altered levels of 
HK1 does not impact outcome in glioblastoma, this has also been shown in other 
studies which state that HK2 not HK1 impact tumour metabolism and cell growth 
resulting in an undesirable clinical outcome, specifically poor prognosis in patients 
(Vartanian et al., 2014). HK1 is associated with catabolism and the regulation 
whereas HK2 is associated with the anabolic roles driving proliferation. A recent 
study focused on gastric cancer and lymphatic metastasis stated patients with HK1 
expression showed remarkable shorter survival duration, and that overexpression of 
HK1 was significantly associated with lymphatic metastasis and unfavourable 
prognosis in gastric cancer (Gao et al., 2015). 
 
Conclusion 
The study highlights the importance of HK2 promotor hypomethylation leading to 
gene dysregulation and mRNA overexpression in glioblastoma, impacting negatively 
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on overall survival. In comparison, expression of HK1 was decreased in over 75% of 
biopsy samples compared to normal tissue, demonstrating a potential shift in 
expression of HK isoforms in tumour tissue. HK1 downregulation in glioblastoma may 
be instigated via histone modification and/or miRNA activity, independent of 
methylation. 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
HK2 promotes tumour 
growth and 
chemoresistance in 
glioblastoma 
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4.1 Introduction 
Genetic analysis of 103 biopsies (detailed in Chapter 3, Section 3.2) established that 
overexpression of HK2 is prevalent in glioblastoma, with significant upregulation 
frequently occurring compared to normal brain tissue. A potential therapeutic HK2 
inhibitor is 3-bromopyruvic acid (3-BPA), which is a synthetic derivative of pyruvic 
acid. 3-BPA has been shown to have an inhibitory effect on a range of tumour cells 
including liver and breast cancers although, currently there is no data for its efficacy 
in glioblastoma (Gandham, et al., 2015). 3-BPA causes dissociation of HK2 from its 
mitochondrial bound complex through covalent modification, resulting in HK2 being 
subsequently released into the cytosol and the stimulation of apoptosis inducing 
factor (AIF) which consequently leads to cell death (Gandham, et al., 2015). Another 
HK2 inhibitor, lonidamine (LND) has been shown to inhibit aerobic glycolysis in 
cancer cells by targeting condensed mitochondria and inhibiting mitochondrially 
bound hexokinases in tumour cells, leading to a decrease in glycolysis and cellular 
ATP (Caputo, et al., 1984). Studies have also shown the major metabolic changes 
induced by LND are inhibition of lactate transport and its accumulation which leads 
to intracellular acidification (Nancolas et al., 2016). More recently it was suggested 
that using LND in combination treatment with TMZ increased the effectiveness of 
TMZ at inhibiting tumour growth in glioblastoma cells, and importantly reduce the 
dose of temozolomide required for radio sensitization of brain tumours (Prabhakara 
et al., 2008). Another potential HK2 inhibitor is the anti-diabetic drug metformin. 
Studies have shown its effectiveness as an anti- cancer therapeutic in a range of 
tumours targeting deregulated glycolytic metabolism (Saber et al., 2018). The 
reduction in glucose has been shown to significantly increase survival rates in a 
range of cancers, with significant reductions in proliferation due to a lack of energy 
source (Thi Tieu et al., 2015). A recent clinical trial for early stage breast cancer 
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noted the significant reduction of cancer biomarkers with the addition of metformin 
(Dowling et al., 2018). Population studies have also demonstrated that type II 
diabetes patients treated with metformin had a reduced risk of cancer (Evans et al., 
2005). The mechanism of the anti-tumour effects is not fully understood although 
there is some evidence that metformin affects the activation of AMPK and the 
inhibition of the mTOR pathway (He et al., 2015). HK2 inhibitors and metformin 
offer therapeutic potential in the treatment of glioblastoma. The inhibitors are in 
relatively stable form making them potentially ideal agents to test in both In vitro 
and In vivo models. The drugs dissolve in water and/or DMSO allowing for stable 
and successful delivery for cell culture (Sankar et al., 2013). The analysis of the 
inhibitors via cell culture is crucial for the advancement in understanding the 
mechanisms of action, the anti-tumour effect they elicit in glioblastoma cells; and to 
also ascertain their potential as effective anti-cancer agents. The microenvironment 
created in tissue culture is often altered in comparison to the natural cellular 
environment which can generate genetic alterations, for example the concentration 
of glucose available to the cell. A healthy adult on average has circulating glucose 
levels around 5-6mmol/l, in comparison the glucose concentration in average tissue 
culture media ranges from 10-25 mmol/l. To address this discrepancy the use of an 
alternative culture media that has a similar glucose concentration was used, Hams F-
10, which has a 6mM concentration of glucose, comparable to the circulating blood 
glucose of the human body. The exaggerated abundance of glucose in the culture 
media can have detrimental and inaccurate effects on cellular responses to inhibitory 
molecules such as ketone bodies, glucose pathway inhibitors and metformin, the 
latter of which has been shown to have reduced efficacy in both breast and ovarian 
cancer in such cases (Wahdan-Alaswad, et al., 2013; Litchfield, et al., 2015). 
The aim of this current study was to investigate the anti-proliferative effectiveness of 
selected HK2 inhibitors, assessed across a panel of 13 patient-derived glioblastoma 
cultures (IN lines only, UWLV cultures were not accessible at this time in the study) 
and 2 established cell lines (U251MG AND U87MG) as shown in Table 2.1. The 
mechanisms of action were investigated via flow cytometry. Additionally, the ketone 
body 3-hydroxybuterate (3-HB) was used to establish any comparable effects of the 
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downregulation of HK2 via the reduction of glucose, and to determine the impact of 
ketogenesis on glioblastoma cell proliferation. 
 
 
 
 
4.2 CRISPR-mediated HK2 knockout 
CRISPR knockout was utilised to investigate the effect of inhibiting HK2 on 
proliferation in glioblastoma cultures and to determine the role of HK2 in 
chemoresistance. HK2 is the initial rate limiting step in the glycolytic pathway (Wolf 
et al., 2011). The effectiveness of inhibitors (including 3-BPA, TMZ and metformin) 
were also investigated in the presence of HK2-KO in the glioblastoma cultures.  
4.2.1 Verification of stable HK2 downregulation 
HK2 was knocked out in three patient-derived cultures (IN1979, IN859 and IN2045) 
and the established cell line U251MG, a using CRISPR all-in-one vectors (Origene) 
which contain both guide RNA, Cas9 expression, T7 vectors, gRNA and Cas9 
separate vectors; with HDR-based (Homology Directed Repair) donor vector 
construction, as stated in 2.7. The selected glioblastoma cultures represented both 
high and low expressing HK2, Chapter 3 demonstrated that cultures with the higher 
levels of HK2 expression had faster growth rates and doubling times (p=0.0021). 
After transfection, a puromycin dose curve was established to determine the lowest 
dose that killed non-transfected cells completely, 7 days post selection. The range of 
puromycin used was 1μg/ml to 5μg/ml, dependant on specific cultures.  After 7 days 
of treatment the surviving cell colonies were isolated using a dilution method, 
whereby cells were seeded <10 cells per well in a 96 -well plate. After 10 days, wells 
containing a single cell colony were expanded first into a 6 well plate and then into 
T25 flasks. The puromycin resistant cells were then analysed and verified via 
genomic qPCR to ensure the integration of the functional cassette. The 
downregulation of HK2 was shown in all CRISPR treated cultures compared to the 
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respective parent culture, with an average reduction in HK2 expression of 0.94 – fold 
change, as shown in Figure 4.1. 
 
 
Figure 4.1 Downregulation of HK2 in CRISPR treated cultures 
qPCR data for each CRISPR treated culture compared to parent culture, showing downregulation of 
HK2. Puromycin selection was utilized to kill non-transfected cells, surviving colonies were isolated 
and expanded giving successful HK2 knockout cultures. Expression reduction values for each culture 
compared to parent culture are: IN859 HK2-KO = 0.046, IN1979 HK2-KO= 0.034, IN2045 HK2-KO= 
0.088, U251MG HK2-KO= 0.048. 
 
4.3 The effect of HK2 downregulation on cell proliferation 
Once established, the 4 HK2-KO cultures (IN1979, IN859, IN2045 and U251MG) 
were grown under conditions detailed in Section 2.1.4. Growth curves were 
established on all CRISPR HK2- KO cultures and parent cultures, as shown in Figure 
4.2.  
A significant (p<0.007) decrease in cell growth between 38 to 44% was 
demonstrated in CRISPR HK2-KO modified cultures after 7 days compared to parent 
cultures, as shown in Figure 4.2. The largest reduction in cellular proliferation 
occurred in U251MG-HK2-KO and IN859-HK2-KO (p<0.001), where growth rates 
were reduced by >40% after 7 days. Notably, the parent cultures had previously 
shown the highest levels of HK2 overexpression, 1502.6 and 995.1 expression fold 
change for U251MG and IN859, respectively, compared to normal tissue. In 
comparison, the parent IN1979 and IN2045 cultures had substantially lower levels of 
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overexpression, with values of 574.4 and 219.8respectively, compared to normal 
brain tissue. Chapter 3 demonstrated that cultures with higher levels of HK2 
expression had faster growth rates and doubling times, the data here shows the 
impact of HK2 downregulation upon the rate of proliferation in glioblastoma cultures 
(p=0.0021), suggesting its potential role in promoting tumour growth in 
glioblastoma.  
 
Figure 4.2 Comparing the level of proliferation between HK2-KO and parent respective 
cultures. The growth curve data for each CRISPR treated culture compared to the parent culture. A 
significant decrease in cell growth between 38 to 44% was demonstrated in all CRISPR HK2-KO 
modified cultures after 7 days compared to parent cultures respectively (IN2045 p=0.011, IN859 
p=0.005, U251MG p=0.003, IN1979 p=0.008). y-axis represents cells/cm2 of growth media. 
 
4.4 Growth inhibition 
4.4.1 3-Bromopyruvic Acid 
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All glioblastoma cultures treated for 72 hours with 3-BPA demonstrated an inhibitory 
response and the ID50 values ranged from 12.9 – 61.4µM, as shown in Figures 4.3 
and 4.4 and Table 4.1. U251MG (14.3 µM) and U87MG (12.9 µM) were the most 
sensitive cultures after 72 hour treatment and IN1979 was the short-term culture 
that demonstrated the highest sensitivity to 3-BPA with an ID50 value of 19.4 µM. 
NHA had a high tolerance of 3-BPA with the highest ID50 value (62.3 µM)  compared 
to all the glioblastoma cultures, as expected for a non-tumour control. Glioblastoma 
cultures were grouped according to HK2 expression, whereby the cultures were 
grouped dependent on the median value of fold change (219.8- fold change). 
Cultures that expressed higher levels of HK2 were more sensitive to 3-BPA and 
generally had lower ID50 values compared to cultures that exhibited lower levels of 
HK2. A significant difference in ID50 values (p= 0.0079) was seen between cultures 
with >219.8- fold change expression and those with <219.8- fold change increase, 
where average ID50 values were 18.9 µM compared to 37.8 µM respectively, as 
shown in Figure 4.4.  
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Figure 4.3 SRB cytotoxicity assay results for the glioblastoma cultures after 72 hours 
treatment with 3-BPA. Cell survival percentage is measured through the comparison of each 
optical density value to the value of the control wells (0µM 3-BPA + Tris buffer). Error bars represent 
standard deviation averaged from 3 replicate assays. Serial dilution of 3-BPA ranged from 100 to 
0.78125 µM. 
 
 
Figure 4.4 ID50 values for each glioblastoma culture and NHA after 72- hour treatment 
with 3-BPA. Cultures are ordered lowest to highest based on the ID50 value after 72-hours 
treatment with 3-BPA. Error bars represent standard deviation averaged from 3 replicate assays.  
 
Table 4.1 ID50 values for all cultures treated with 3-BPA 
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Culture 
3-BPA ID50 72 hours 
(µM) 
HK2 Expression 
Fold Change 
U87 12.9 (±1.21) 1294.3 
U251 14.3 (±2.43) 1502.6 
IN1979 19.4 (±3.74) 574.4 
IN859 20.6 (±3.62) 995.1 
IN1472 22.8 (±5.20) 403.36 
IN2045 23.3 (±6.23) 219.8 
IN1951 24.4 (±2.46) 210.6 
IN1612 24.6 (±4.43) 126.6 
IN1682 25.8 (±4.59) 120.6 
IN1528 32.7 (±1.21) 386 
IN1760 37.6 (±4.59) 202 
IN1461 58.2 (±6.78) 85.7 
IN1265 61.4 (±3.56) 97.4 
NHA 62.3 (±7.27) 30.4 
Table showing 3-BPA ID50 concentration for all cultures. Standard deviation for each average is listed 
after each result (±). Cultures are ordered lowest to highest based on the ID50 value after 72-hours 
treatment with 3-BPA ID50. HK2 expression fold change compared to normal brain is also shown for 
each culture. Higher expressing cultures had lower ID50 values.  
 
4.4.2 Metformin 
All glioblastoma cultures treated for 72 hours with metformin demonstrated an 
inhibitory response and the ID50 values ranged from 8.7 – 68.55 mM, as shown in 
Figures 4.5 and 4.6 and Table 4.2. U251MG (9.4 mM) and U87MG (8.7 mM) were 
the most sensitive cultures after 72- hour treatment and IN1472 was the patient-
derived culture that demonstrated the highest sensitivity to metformin with an ID50 
value of 9.75 mM. NHA had a high tolerance of metformin with the highest ID50 
value (84.7 mM) compared to all the glioblastoma cultures, as expected for a non-
tumour control. Glioblastoma cultures were grouped according to HK2 expression, 
whereby the cultures were grouped dependent on the median value of fold change 
(219.8- fold change). Cultures that expressed higher levels of HK2 did not correlate 
with increased sensitivity to metformin, no significant difference in ID50 values (p= 
0.0729) were determined compared to cultures that exhibited lesser levels of HK2. 
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Figure 4.5 SRB cytotoxicity assay results for the glioblastoma cultures after 72 hours 
metformin treatment. Cell survival percentage is measured through the comparison of each optical 
density value to the value of the control wells (0mM metformin). Error bars represent standard 
deviation averaged from 3 replicate assays. Serial dilution of metformin ranged from 100 to 0.781 
mM. 
 
 
 
 
 
 
Table 4.2 ID50 values for all cultures treated with metformin 
Culture 
Metformin ID50 72 hours 
(mM) 
HK2 Expression Fold 
Change 
U87 8.7 (±1.74) 1294.3 
U251 9.4 (±1.21) 1502.6 
IN1472 9.7 (±3.11) 403.3 
IN2045 15.6 (±2.47) 219.8 
IN1612 15.7 (±2.78) 126.6 
IN1528 19.2 (±1.52) 386 
IN859 23.2 (±5.24) 995.1 
IN1760 26.6 (±8.78) 202 
IN1682 28.1 (±3.27) 120.6 
IN1979 35.7 (±4.27) 574.4 
IN1265 41.2 (±5.89) 97.4 
 137 
 
IN1951 58.8 (±7.69) 210.6 
IN1461 68.5 (±5.27) 85.7 
NHA 84.7 (±6.43) 30.4 
Table showing metformin ID50 values for all cultures. Standard deviation for each average is listed 
after each result (±). Cultures are ordered lowest to highest based on the ID50 value after 72-hours 
treatment with metformin. HK2 expression fold change compared to normal brain is also shown for 
each culture. 
 
 
Figure 4.6 ID50 for each glioblastoma culture and NHA after 72- hour treatment with 
metformin. Cultures are ordered lowest to highest based on the ID50 value after 72-hours treatment 
with metformin. Error bars represent standard deviation averaged from 3 replicate assays. 
 
4.4.3 Lonidamine  
All glioblastoma cultures treated for 72 hours with LND demonstrated an inhibitory 
response and the ID50 values ranged from 211.4 – 763.5 µM, as shown in Figures 
4.7 and 4.8 and Table 4.3. IN2045 was the most sensitive culture after the 72- hour 
treatment which demonstrated the highest sensitivity to LND with an ID50 value of 
211.4 µM, followed by U251MG (235.9 µM) and U87MG (228.4 µM). NHA had a high 
tolerance of LND with the highest ID50 value (865.2 µM) compared to all the 
glioblastoma cultures, as expected for a non-tumour control. Glioblastoma cultures 
were grouped according to HK2 expression, whereby the cultures were grouped 
dependent on the median value of fold change (219.8- fold change).  
Cultures that expressed higher levels of HK2 were more sensitive to LND and 
generally had lower ID50 values compared to cultures that exhibited lesser levels of 
HK2. A significant difference in ID50 values (p= 0.0039) was seen between cultures 
with >219.8- fold change expression and those with <219.8- fold change increase, 
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where average ID50 values were 572.9 µM compared to 312.8 µM respectively, as 
shown in Figure 4.8. 
 
 
Figure 4.7 SRB cytotoxicity assay results for the glioblastoma cultures after 72 hours 
lonidamine treatment. Cell survival percentage is measured through the comparison of each 
optical density value to the value of the control wells (0µM lonidamine). Error bars represent standard 
deviation averaged from 3 replicate assays.  
 
 
 
 
 
Table 4.3 ID50 values for all cultures treated with lonidamine 
Culture reference 
Lonidamine ID50 
(µM) 
HK2 Expression Fold 
Change 
IN2045 211.4 (±31.34) 219.8 
U87MG 228.4 (±27.21) 1294.3 
U251MG 235.9 (±34.2) 1502.6 
IN1528 387.3 (±24.83) 386 
IN1979 398.4 (±18.46) 574.4 
IN859 415.6 (±29.73) 995.1 
IN1682 475.8 (±23.57) 120.6 
IN1760 483.4 (±27.33) 202 
IN1612 494.2 (±24.43) 126.6 
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IN1951 647.5 (±28.27) 210.6 
IN1461 763.5 (±43.99) 85.7 
NHA 865.2 (±47.04) 30.4 
Table showing metformin ID50 values for all cultures. Standard deviation for each average is listed 
after each result (±). Cultures are ordered lowest to highest based on  the ID50 value after 72-hours 
treatment with lonidamine. HK2 expression fold change compared to normal brain is also shown for 
each culture. 
 
Figure 4.8 ID50 for each glioblastoma culture and NHA after 72- hour treatment with 
lonidamine. Cultures are ordered lowest to highest based on the ID50 value after 72-hours 
treatment with lonidamine. Error bars represent standard deviation averaged from 3 replicate assays.  
 
4.5 Hypoxia  
Hypoxia is common characteristic of tumour microenvironments. It is well 
documented that hypoxic tumours are significantly more malignant as their 
increased proliferation out-grows their ability to generate a blood supply, as well as 
being associated with chemoresistance and poorer patient prognosis (Vaupel et al, 
2004). The effectiveness of 3-BPA and metformin under hypoxic conditions were 
investigated. All glioblastoma cultures treated for 72 hours with 3-BPA demonstrated 
an inhibitory response under hypoxic conditions, the ID50 values ranged from 42.23 
– 76.18 µM, as shown in Figures 4.9 and 4.10 and Table 4.4. U251MG (44.9 µM) and 
U87MG (42.2 µM) were the most sensitive cultures after 72 hour treatment under 
hypoxia and IN1979 was the patient-derived culture that demonstrated the highest 
sensitivity to 3-BPA with an ID50 value of 47.41 µM. NHA had a high tolerance of 3-
BPA with the highest ID50 value (81.3 µM) compared to all the glioblastoma cultures, 
as expected for a non-tumour control. A significant difference in ID50 values (p 
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<0.0001) was seen between all glioblastoma cultures treated for 72 hours with 3-
BPA under hypoxic conditions compared to normoxia. Under hypoxic conditions all 
glioblastoma cultures acquired an increased tolerance of 3-BPA treatment, with an 
average increase of 56.6% in ID50 values. Under hypoxic conditions the ID50 values 
of the cultures ranged from 42.23 to 76.18 µM with an average ID50 value of 54.53 
µM, in comparison the ID50 values in the same cultures treated in normoxia ranged 
from 12.9 to 37.6 µM with an average value of 23.56 µM. The greatest change in 
ID50 values were seen in cultures that expressed higher levels of HK2, including 
U87MG, U251MG, IN1979 and IN1528 which had a 57 to 69% increase in ID50 
values. The comparatively lower HK2 expressing cultures, IN1760, IN2045 and 
IN1612 had an increased ID50 change between 41 and 53% as seen in Table 4.4. A 
similar trend was also exhibited in NHA where 3-BPA ID50 values increased by 
23.44% in hypoxia, although this wasn’t significant. HK2 expression was shown to 
be higher in cultures grown under hypoxic conditions (as shown in table 4.4) 
however, the increased tumour cell resistance to therapeutic agents linked with 
secondary mechanisms associated with hypoxic augments survival adaptation in 
cancer cells (Mathupala et al., 2001). 
 
Figure 4.9 SRB cytotoxicity assay results for the glioblastoma cultures after 72 hours 3-
BPA treatment under hypoxic conditions. Cell survival percentage is measured through the 
comparison of each optical density value to the value of the control wells (0µM 3-BPA). Error bars 
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represent standard deviation averaged from 3 replicate assays. Serial dilution of 3-BPA ranged from 
100 to 0.78125 µM. 
 
 
Table 4.4 ID50 values for all cultures treated with 3-BPA in both normoxia and hypoxia 
Culture 
3- BPA ID50 
(µM) 
3-BPA 
Hypoxia 
ID50 (µM) 
% change in 
ID50 value 
HK2 
expression 
normal 
HK2 
expression 
hypoxia 
U87MG * 12.9 (±1.21) 42.2 (±9.28) 69.4 1294 1350 
U251MG * 14.3 (±2.43) 44.9 (±14.3) 68.2 1743 1810 
IN1979 * 19.4 (±3.74) 47.4 (±2.34) 59 574 620 
IN859 * 20.6 (±3.62) 55.98(±8.32) 54.2 1095 1099 
IN2045 * 23.3 (±6.23) 49.2 (±12.51) 52.7 220 228 
IN1951 * 24.4 (±2.46) 53.4 (±9.65) 54.3 206 224 
IN1612 * 24.6 (±4.43) 52.56(±9.73) 53.2 127 131 
IN1682 * 25.8 (±4.59) 59.4 (±6.46) 56.6 121 136 
IN1528 * 32.7 (±1.21) 76.1 (±14.6) 57.1 386 391 
IN1760 * 37.6 (±4.59) 63.8 (±3.56) 41.1 196 232 
NHA 62.3 (±7.27) 81.3 (±13.3) 23.4 30 41 
Table showing 3-BPA ID50 values for all cultures in normoxia and hypoxia. Standard deviation for each 
average is listed after each result (±). Cultures are ordered lowest to highest based on the on the 
ID50 value after 72-hours treatment with 3-BPA. * denotes significant change in ID50.  
 
 
Figure 4.10 ID50 for each glioblastoma culture and NHA after 72- hour treatment with 3-
BPA in both normoxic and hypoxic conditions. Cultures are ordered lowest to highest based on 
the ID50 value after 72-hours treatment with 3-BPA. Error bars represent standard deviation averaged 
from 3 replicate assays. All cultures showed a significant increase in ID50 value, except for NHA. 
All glioblastoma cultures treated for 72 hours with metformin demonstrated an 
inhibitory response under hypoxic conditions, the ID50 values ranging from 32.85 to 
71.28 mM, as shown in Figures 4.11 and 4.12 and Table 4.5. U251MG (37.2 mM) 
and U87MG (32.8 mM) were the most sensitive cultures after 72- hour treatment 
under hypoxia and IN1612 was the short-term culture that demonstrated the highest 
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sensitivity to metformin with an ID50 value of 37.25 mM. NHA had a high tolerance 
of metformin with the highest ID50 value (97.4 mM) compared to all the glioblastoma 
cultures, as expected for a non-tumour control. A significant difference in ID50 values 
(p=0.0125) was seen between cultures treated for 72 hours with metformin under 
hypoxic conditions compared to normoxia. Under hypoxic conditions all glioblastoma 
cultures acquired an increased tolerance of metformin treatment, an increase in ID50 
values was demonstrated in all culture samples, with an average increase of 56.1%. 
Under hypoxic conditions the ID50 values of the cultures ranged from 32.85 to 71.28 
mM with an average ID50 value of 50.61 mM. In comparison, the ID50 values in the 
same cultures treated in normoxia ranged from 8.7 to 58.85 mM with an average 
value of 24.12 mM. A similar trend was also exhibited in NHA where metformin ID50 
values increased by 13.09% in hypoxia. Notably, both IN1951 and NHA had 
substantially lower changes in ID50 values in hypoxia compared to the rest of the 
cultures, with a 17.3% and 13.1% change respectively, >30% less than the other 
cultures. The differences in ID50 values was not dependent on the level of HK2 
expression in normoxia. 
 
Figure 4.11 SRB cytotoxicity assay results for the glioblastoma cultures after 72- hour 
treatment with metformin in both normoxic and hypoxic conditions. Cell survival percentage 
is measured through the comparison of each optical density value to the value of the control wells 
(0mM metformin). Error bars represent standard deviation averaged from 3 replicate assays. Serial 
dilution of metformin ranged from 100 to 0.78125 mM. 
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Table 4.5 ID50 values for all cultures treated with metformin in both normoxia and 
hypoxia 
Culture 
Metformin 
ID50 (mM) 
Metformin 
Hypoxia ID50 
(mM) 
% change in 
ID50 value 
U87MG 8.7 (±1.74) 32.8 (±2.56) 73.5 
U251MG 9.4 (±1.21) 37.2 (±4.21) 75.1 
IN2045 15.6 (±2.47) 40.6 (±5.83) 61.6 
IN1612 15.7 (±2.78) 37.2 (±6.74) 57.8 
IN1528 19.2 (±1.52) 47.3 (±12.59) 59.4 
IN859 23.27 (±5.24) 59.3 (±11.45) 60.8 
IN1682 28.1 (±4.41) 42.9 (±9.89) 45.8 
IN1760 26.66 (±8.78) 65.4 (±8.32) 59.3 
IN1979 35.76 (±4.27) 71.2 (±8.29) 49.8 
IN1951 58.85 (±7.69) 71.2 (±12.63) 17.3 
NHA 84.7 (±6.43) 97.4 (±10.7) 13.1 
Table showing metformin ID50 values for all cultures in normoxia and hypoxia. Standard deviation for 
each average is listed after each result (±). Cultures are ordered lowest to highest based on the ID50 
value after 72-hours treatment with metformin. 
 
 
Figure 4.12 ID50 for each glioblastoma culture and NHA after 72- hour treatment with 
metformin in both normoxic and hypoxic conditions. Cultures are ordered lowest to highest 
based on the 72-hour metformin ID50. Error bars represent standard deviation averaged from 3 
replicate assays. * indicated no significant change. 
 
4.6 Assessing drug synergy in glioblastoma cultures  
4.6.1 The effect of HK2-KO with response to inhibitors 
4.6.1.1 3-BPA 
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There was a considerable difference in the response of HK2 –KO cultures to 
inhibitors. All HK2 –KO cultures treated for 72 hours with 3-BPA showed significantly 
diminished sensitivity (p<0.0001) with the absence of the HK2 target, as shown in 
Table 4.7. All cultures demonstrated an increased tolerance to 3-BPA, with ID50 
values significantly increased in all KO cultures (p<0.0001). The effectiveness of 3-
BPA was reduced through the loss of the HK2 target, with an average ID50 value 
increase of 93% across the HK2-KO cultures compared respectively to the parent 
culture, as shown in Figure 4.13. The greatest increase was observed in IN1979-
HK2-KO, which had an ID50 value of 42.6 µM, a 120% increase compared to the 
parent IN1979 culture, which had an ID50 value of 19.4 µM.  IN2045-HK2-KO had 
the smallest increase, of 67% with an increase in ID50 value from 23.3 to 38.9 µM in 
the parent and HK2-KO cultures, respectively.  
 
 
 
4.6.1.2 Temozolomide 
Temozolomide is currently the most effective drug used to treat glioblastoma 
(Messaoudi et al., 2015; Lee et al., 2017), and hence, it was assessed as a potential 
synergistic partner with 3-BPA and metformin and HK2-KO cultures. The 6 
glioblastoma cultures were treated with TMZ and a cytotoxic response was shown 
after 72- hours. TMZ was re-supplemented daily during the 72- hour incubation due 
to its short half-life, of approximately 2 hours at pH7 (Brian et al., 1994; Patel et al., 
2003). No additional fresh media or glucose was provided to the cells during TMZ 
supplementation to prevent the increase in cell growth via extra nutrients. U251MG 
had the highest sensitivity to TMZ with an ID50 value of 145.29 μM, IN1760 had the 
highest tolerance with an ID50 value of 363.7 μM., as detailed in Table 4.6. Recent 
studies have shown TMZ to have an increased efficiency in glioblastoma samples 
with methylated MGMT, cultures presenting methylated MGMT would have expected 
increased sensitivity to TMZ (Tosoni et al., 2017; Bell et al., 2018). No substantial 
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pattern was determined from the comparison of ID50 values and MGMT status of the 
cultures tested, MGMT status for the culture panel is shown in the appendix.   
Table 4.6 ID50 values for all cultures treated with TMZ 
Culture 
Temozolomide ID50 72 hours 
(μM) 
MGMT 
Status 
U251MG 148.2(±2.62) Methylated 
IN1528 195.53 (±3.78) Methylated 
IN859 280.3 (±5.31) Methylated 
IN1951 328 (±2.88) Unmethylated 
IN2045 360.1 (±5.63) Methylated 
IN1760 363.7 (±4.72) Methylated 
ID50 values for temozolomide at 72 hours. Cultures ordered lowest ID50 to highest. MGMT methylation 
is a known factor in the sensitivity of tumour response to temozolomide. 
 
All HK2 –KO cultures treated for 72 hours with TMZ showed significantly increased 
(p<0.0001) sensitivity in the absence of the HK2 expression with ID50 values 
significantly decreased (p<0.0001) in all KO cultures as shown in Table 4.8. The 
effectiveness of TMZ was increased, with an average ID50 value decrease of 42.5% 
across the HK2-KO cultures compared respectively to the parent culture, as shown in 
Figure 4.14. The greatest change in sensitivity was observed in IN859-HK2-KO which 
had an ID50 value of 126.5 µM, a 55% decrease compared to the parent IN859 
culture, which had an ID50 value of 280.3 µM. IN2045-HK2-KO had the smallest 
decrease, with an ID50 value of 249.4 µM, a 67% decrease compared to the parent 
IN2045, which had an ID50 value of 360.1 µM. 
4.6.1.3 Metformin 
All HK2 –KO cultures treated for 72 hours with metformin showed significantly 
increased (p<0.0001) sensitivity in the absence of the HK2 expression, with an 
average ID50 value decrease of 46.8% across the HK2-KO cultures compared 
respectively to the parent culture, as shown in Table 4.9 and Figure 4.15. The 
greatest change in sensitivity was observed in U251MG-HK2-KO which had an ID50 
value of 3.6 mM, a 61.1% decrease compared to the parent culture, which had an 
ID50 value of 9.4 mM. IN2045-HK2-KO had the smallest decrease, with an ID50 value 
of 9.8 mM, a 37% decrease compared to the parent IN2045, which had an ID50 
value of 15.6mM µM. IN2045 is the lowest expressing HK2 culture in the sample 
 146 
 
cohort, cultures expressing higher levels of HK2 showed greater alterations in 
response to the inhibitors. 
 
 
Figure 4.13 ID50 values for each HK2-KO and respective parent culture after 72- hour 
treatment with 3-BPA. A significant (p<0.001) increase in ID50 values was shown in HK2-KO 
cultures compared to respective parent cultures after 72- hour treatment with 3-BPA. An average 
increase of 50% in ID50 values were demonstrated across all cultures in the absence of HK2. 
Table 4.7 ID50 values for after treatment with 3-BPA for 72 hours in parent and HK2-KO 
cultures 
Culture 
Parent ID50 
(µM) 
HK2 KO ID50 
(µM) 
ID50 Change p values 
U251 14.3 29.6 107% <0.0001 
IN1979 19.4 42.6 120% <0.0001 
IN2045 23.3 38.9 67% <0.0001 
IN859 25.6 45.4 77% <0.0001 
ID50 values of the HK2 inhibitor 3-BPA were compared between parent and CRISPR HK2-KO cell 
cultures. A significant increase in ID50 values was exhibited across all cultures with HK2-KO compared 
to the respective parent culture.   
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Figure 4.14 ID50 values for each HK2-KO and respective parent culture after 72- hour 
treatment with TMZ. A significant (p<0.001) decrease in ID50 values was shown in HK2-KO 
cultures compared to respective parent cultures after 72- hour treatment with TMZ. An average 
decrease of 77.5% in ID50 values was demonstrated across all cultures in the absence of HK2. 
Table 4.8. ID50 values for after treatment with TMZ for 72 hours in parent and HK2-KO 
cultures 
Culture 
Parent ID50 
(µM) 
HK2 KO ID50 
(µM) 
 ID50 Change p values 
U251 148.2 95.3 -37% <0.0001 
IN1979 295.7 156.8 -47% <0.0001 
IN2045 360.1 249.4 -31% <0.0001 
IN859 280.3 126.5 -55% <0.0001 
ID50 values of TMZ were compared between parent and CRISPR HK2-KO cell cultures. A significant 
decrease in ID50 values was exhibited across all cultures with HK2-KO compared to the respective 
parent culture.   
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Figure 4.15 ID50 values for each HK2-KO and respective parent culture after 72- hour 
treatment with metformin. Average metformin ID50 values for CRISPR treated culture compared 
to parent culture. A significant (p<0.001) decrease in ID50 values was shown in HK2-KO cultures 
compared to respective parent cultures after 72- hour treatment with metformin. A decrease of 
95.8% in ID50 values was demonstrated across all cultures in the absence of HK2. 
 
Table 4.9. ID50 values for after treatment with metformin for 72 hours in parent and HK2-
KO cultures 
Culture 
Parent ID50 
(mM) 
HK2 KO ID50 
(mM) 
 ID50 Change p values 
U251 9.4 3.6 -61% <0.0001 
IN1979 35.8 18.8 -47% <0.0001 
IN2045 15.6 9.8 -37% <0.0001 
IN859 28.1 16.3 -42% <0.0001 
Showing ID50 values of metformin comparing parent to CRISPR HK2-KO cell cultures. A significant 
decrease in ID50 values was exhibited across all cultures with HK2-KO compared to the respective 
parent culture.   
4.6.3 The effect of HK2-KO on cell survival Cell survival post HK2 knockout was 
also analysed over a 120-hour time course, when cultures were treated with 3-BPA, 
metformin and TMZ. With both metformin and TMZ treatments, the percentage of 
cell survival was significantly (p<0.0001) decreased in HK2 -KO cultures compared 
to the respective parent cultures.  The average reduction in cell survival seen across 
all HK2-KO cultures was 19.9% compared to the parent cultures after 120 hours of 
metformin treatment.  The highest change in survival was in U251MG HK2-KO with a 
25% reduction compared the parent culture. IN2045 had the lowest alteration in cell 
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survival after 120 hours of metformin treatment, with a 16.8% reduction in the 
absence of HK2. A similar reduction in cell survival after 120 hours of TMZ treatment 
(retreated daily) was demonstrated in HK2-KO cultures, where average reduction 
was 20.5% compared to parent cultures. The highest change in survival was in 
U251MG HK2-KO with a 28.6% reduction compared the parent culture. IN2045 had 
the lowest alteration in cell survival after 120 hours of TMZ treatment, with a 18.4% 
reduction in the absence of HK2. Treatment with 3-BPA over 120 hours reiterated 
the data presented in Section 4.6.1, with cell survival significantly (p=0.0024) 
increased in all HK2-KO cultures compared to parent cultures. IN859 had the highest 
change in cell survival with a 34.7% increase in the absence of HK2. Eliminating the 
HK2 target reduces the effectiveness of 3-BPA, verifying the specificity of the 
inhibitor. There was an improved effectiveness of metformin and TMZ in the absence 
of HK2, which has been shown to increase chemoresistance and is associated with 
HIF-1, which has been shown to enhance cell survival (Menendez et al., 2015). 
Metformin’s ability to activate AMPK may potentially be increased in the absence of 
HK2, resulting in the inhibition of the mTOR pathway reducing proliferation and 
survival (Pollak, 2012; He and Wondisford, 2015). HK2 knockout via CRISPR 
revealed considerable increases in sensitivity to both metformin and TMZ in all 
glioblastoma cultures, signifying the potential of HK2 inhibition as a novel therapy in 
a significant subset of glioblastoma. 
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Figure 4.16 Cell survival over 120 hours in HK2-KO cultures treated with 3-BPA. Cell 
survival over 120 hours in glioblastoma cultures treated with 3-BPA compared to corresponding 
CRISPR HK2-KO cultures. An increase in cell survival across all HK2-KO cultures was shown compared 
to parent cultures.  
 
 
Figure 4.17 Cell survival over 120 hours in HK2-KO cultures when treated with 
metformin. Cell survival over 120 hours in glioblastoma cultures treated with metformin compared 
to corresponding CRISPR HK2-KO cultures. A decrease in cell survival across all HK2-KO cultures was 
shown compared to parent cultures.  
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Figure 4.18 Cell survival over 120 hours in HK2-KO cultures when treated with TMZ. Cell 
survival over 120 hours in patient derived glioblastoma cultures treated with TMZ compared to 
corresponding CRISPR HK2-KO cultures. A decrease in cell survival across all HK2-KO cultures was 
shown compared to parent cultures. 
 
4.6.2 Combination treatments  
3-BPA and metformin demonstrated a growth inhibitory response after 72- hour drug 
treatment as monotherapies. An increased effectiveness in combination treatment, 
however, would offer a greater potential of use in clinical trials (Aldea et al., 2014). 
The potential synergistic partners that were assessed were 3-BPA, metformin and 
temozolomide, using an SRB assay to determine the combined treatment effect. The 
concentrations used in the combined drug wells were equimolar to the equivalent 
wells of the mono-drug treatment. These 2 HK2 inhibitors were selected based on 
their inhibitory efficacy, and TMZ was included due to its pre-existing importance as 
a therapeutic agent in glioblastoma treatment (Messaoudi et al., 2015). Five patient 
derived cultures (IN1760, IN859, IN1528, IN2045, IN1951) and U251MG were 
assessed and included a range of HK2 expression levels. Table 4.10 shows the 
comparative drug combinations. Synergy of combination drug treatments were 
analysed using the cho-talay therom (Chou., 2010), which generates a combination 
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index. The CI measures the effectiveness of each drug as both a monotherapy and 
when paired.  
Table 4.10 Drug concentrations used in synergy analysis 
Drug Units Drug Concentration 
3-BPA μM 100 50 25 12.5 6.26 3.125 1.563 0.781 0 
Metformin μM 100000 50000 25000 12500 6250 3125 1563 781 0 
Temozolomide μM 500 250 125 62.5 31.25 15.62 7.81 3.9 0 
All drugs were utilized both individually and in equimolar doses. All drugs tested for synergy analysis 
were dissolved in water. All experiments compared ID50 independently and combined. Control values 
in wells with Tris buffer only. 
 
4.6.2.1 Combination of 3-BPA and metformin 
The combination of 3-BPA and metformin was investigated, to determine whether 
targeting the HK2 protein with 3-BPA in combination with metformin replicates the 
same effect seen in metformin treatment in HK2-KO cells. Cultures treated in 
combination did not demonstrate any altered sensitivity, with no significant 
alterations in ID50 values, compared to when treated individually with both 3-BPA 
and metformin, as seen in Figure 4.19. The combination treatment showed no 
synergistic inhibitory effects in any of the 6 cultures, with all cultures exhibiting a 
combination index value greater than 1, suggesting an antagonistic effect with the 
combination of 3-BPA and metformin (Table 4.11). The lowest CI index value was 
1.02 seen in IN1528. The combination dose curves exhibit similar trends to both the 
3-BPA and metformin curves. 
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Figure 4.19 Drug combination synergy treatments of 3-BPA and metformin. All cultures 
tested in both mono- and combination treatment in equimolar dosages over a 72-hour period. 
Combination treatments show no synergistic properties. 
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Table 4.11 Drug synergy analysis of metformin and 3-BPA  
Metformin and 3-BPA combination Test 
Culture CI Index Result 
U251MG 1.34 (±0.192) Antagonism 
IN859 1.83 (±0.179) Antagonism 
IN1528 1.02 (±0.097) Antagonism 
IN1760 1.41 (±0.325) Antagonism 
IN2045 1.33 (±0.122) Antagonism 
IN1951 1.26 (±0.138) Antagonism 
Combination index result as a measure of synergy comparing each drug individually to an equimolar 
combination. Synergy analysis based on average combination index result. All cultures showed an 
antagonistic response. CI Index >1 – Antagonism, CI Index = 1 – Additive, CI Index <1 = Synergy. 
 
4.6.2.2 Combination of 3-BPA and TMZ 
The combination of 3-BPA and TMZ treatment demonstrated synergy in 2 of the 6 
cultures as shown in Table 4.12, with CI values <1 for U251MG (CI=0.88) and 
IN1760 (CI= 0.97).  Both cultures were MGMT methylated.  An antagonist response 
was shown in the other 4 cultures with CI values all >1. The concentration range of 
the inhibitors is shown in Table 4.9. The glioblastoma cultures in the synergy and 
antagonism groups share no common factor that distinguishes them. U251MG 
expresses high levels of HK2 (1502.6 increased fold change compared to normal 
tissue) and has demonstrated a higher sensitivity to HK2 inhibitors (3-BPA ID50 
=14.3 μM), however IN1760 has been shown to have significantly lower HK2 levels 
(202.0 increased fold change compared to normal tissue) and has demonstrated a 
higher tolerance to HK2 inhibitors (3-BPA ID50 = 27.6 μM). 
Table 4.12 Drug synergy analysis of 3-BPA and TMZ  
3-BPA and TMZ combination Test 
Culture CI Index Result 
U251MG 0.88(±0.10) Synergism 
IN859 1.08(±0.16) Antagonism 
IN1528 1.22(±0.14) Antagonism 
IN1760 0.97(±0.7) Synergism 
IN2045 1.04(±0.12) Antagonism 
IN1951 1.16(±0.15) Antagonism 
Combination index result as a measure of synergy comparing each drug individually to an equimolar 
combination. Synergy analysis based on average combination index result. 2 cultures showed a 
synergistic response and 4 showed an antagonistic response. CI Index >1 – Antagonism, CI Index = 
1 – Additive, CI Index <1 = Synergy. 
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4.6.2.3 Combination of metformin and TMZ 
The combination of metformin and TMZ treatment demonstrated synergy in 3 of the 
6 cultures as shown in Table 4.13, with CI values <1 for U251MG (CI=0.93), IN1760 
(CI= 0.87) and IN2045 (CI=0.89). All three cultures were MGMT methylated.  An 
antagonist response was shown in the other 3 cultures with CI values >1 and these 
cultures displayed an increased ID50 when treated in monotherapy, compared to 
when treated in combination. The 3 cultures exhibiting synergy had extensive 
variation in the level of overexpression of HK2 (U251MG =1502.6, IN1760 =202.0 
and IN2045= 219.8 increased fold change compared to normal tissue). Furthermore, 
these cultures also showed substantially different levels of sensitivity to metformin 
treatment, with ID50 values ranging from 9.4 mM (U251MG) to 26.7mM (IN1760). 
Table 4.13 Drug synergy analysis of metformin and TMZ  
Metformin and TMZ combination Test 
Culture CI Index Result 
U251MG 0.93(±0.05) Synergism 
IN859 1.34(±0.11) Antagonism 
IN1528 1.06(±0.42) Antagonism 
IN1760 0.87(±0.11) Synergism 
IN2045 0.89(±0.9) Synergism 
IN1951 1.41(±0.18) Antagonism 
Combination index result as a measure of synergy comparing each drug individually to an equimolar 
combination. Synergy analysis based on average combination index result. 3 cultures showed a 
synergistic response and 3 showed an antagonistic response. CI Index >1 – Antagonism, CI Index = 
1 – Additive, CI Index <1 = Synergy. 
The combination drug treatments were analyzed using the strict separation used by 
the Chou-Talay method. Additive effects are hard to determine using this 
methodology resulting in cultures exhibiting antagonistic effects. For example, for 
the combination of 3-BPA and TMZ the cultures IN2045 (CI =1.04) and IN859 (CI 
=1.08) are classed as antagonistic, however considering the standard deviation 
values of the repeats the value could be interpreted as synergistic with a CI value 
less than 1. U251MG in both 3-BPA -TMZ, and metformin - TMZ combinations had 
synergistic values and this could potentially be accounted for due to it being a long-
term cell culture resulting in altered genetic and metabolic characteristics (Torsvik, 
et al. 2014). Additionally, the short half-life of temozolomide and its pH dependency 
to remain stable could potentially factor. Although fresh TMZ was added daily during 
 156 
 
the 72- hour treatments, the media was not changed (to ensure experimental 
conditions with regard to glucose availability were maintained), and the pH towards 
the end of the experiment may have altered. The measurement of pH changes in 
culture media over a time course would be an important future study.  
 
4.7 Mechanisms of cell death induced by HK2 inhibitors  
Programmed cell death via apoptosis is a crucial cellular mechanism for the 
maintenance of a healthy equilibrium, of cells in the human body, with the 
destruction and removal of cells in a controlled manner. Apoptosis in cancer is 
frequently disrupted, with tumour cells acquiring adaptations in order to prevent and 
block apoptotic pathways. Examples include mutations in key pro-apoptotic genes 
such as the cell surface receptors CD95 or TNF-related apoptosis-inducing ligand 
(TRAIL) which are responsible for the induction of caspase dependant apoptosis 
(Song et al., 2008; Fulda and Debatin 2006). Studies have shown that the 3-BPA 
affects mitochondria through the targeting of HK2 bound complex which results in 
subsequent stimulation of apoptosis inducing factor (AIF) consequently leading to 
cell death (Gandham, et al., 2015), although this has not been shown in 
glioblastoma cells. The anti-tumour mechanisms of metformin are still not fully 
clarified (Chae et al., 2016). Metformin has also been shown to affect the 
mitochondria via multiple pathways leading to mitochondrial stress resulting in 
apoptosis. Its mechanisms of action has been shown to differ based on the type of 
cancer; the inhibition of mTOR through AMPK activation has been shown to be a 
dependency for tumour inhibition in several cancers and independent in others (Liu 
et al., 2014). Identifying specific mechanism and pathways through which these 
inhibitors act on glioblastoma is an important factor to assess their potential use as a 
cancer therapeutic.  
 
4.7.1 Apoptosis  
Apoptosis was assessed via flow cytometric analysis, utilizing Annexin V and 7-AAD 
cellular staining. The flow cytometry technique allows for the tracking of the 
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progression of cellular populations across three pre-defined gated quadrants, 
determined by the level of binding of the specific fluorophores. The quadrant in the 
lower left is representational for live cells, which are negative for both annexin V and 
7-AAD. The second quadrant positioned on the lower right, represents apoptotic 
cells, indicative of positive binding of annexin V via the protein phospholipid 
phosphatidylserine. This protein is associated with extracellular signaling in apoptotic 
pathways and under normal conditions, it is positioned facing the cytosolic (inner) of 
the cell membrane (Segawa and Shigekazu, 2015). The proteins, however, become 
exposed during early apoptosis (Koopman et al., 1994) and once the cell enters a 
later stage of cell death, an increase in the permeability of the cell membrane 
occurs, resulting in the diffusion of annexin V into the cystol and interacting with the 
internal membrane. The third quadrant (top right) is an indication of cell death, 
representational of positive binding by 7-AAD, which distinguishes healthy and dead. 
The dye binds to DNA, inserting between cytosine and guanine bases (Xiucai et al., 
1991; Philpott et al., 1996). 7-AAD, however, lacks the ability to penetrate cellular 
membranes. Therefore, 7-AAD positive bound cells are characterized as having 
damaged cellular membranes, whereas negatively bound cells still possess a 
functional membrane. The top left quadrant represents cellular necrotic markers; 
however, the flow cytometry assay is unable to accurately distinguish the later stage 
methods of cell death once the cells have reached the upper left quadrant. These 
mechanisms of cell death include autophagy, necrosis and late-stage apoptosis. In 
these mechanisms, the membrane permeability has already been altered, so flow 
cytometry is unable to distinguish between early and late cell death. Using this flow 
cytometry method, early apoptosis is defined as the positive binding of annexin V, 
which results in an increase in the FL2 channel and thus an increase in cell 
population in the second quadrant. An increase in quadrant three through increased 
binding to 7-AAD, indicate a compromised membrane representational of late stage 
cell death. The quadrants outcomes from flow cytometric analysis are summarized in 
Figure 4.20 and the potential outcomes are summarised in Table 4.18.  
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Figure 4.20 Identification of apoptosis through flow cytometry. A: Showing an untreated 
sample, a dense population of cell in the 1st (bottom left) quadrant. B: Showing samples treated with 
the control campthothecin (100 µM over a 72-hour period). A second population of cells in the second 
quadrant representing positive apoptotic cells through positive binding of annexin V. 7-AAD negative 
binding in these cells indicating a functional cell membrane. C: Showing cells treated with 
campthothecin for 96 hours. The cell population has shifted to the third quadrant, and are positively 
bound with 7-AAD, indicating a permeable membrane and cell death. 
 
Table 4.14 Interpretation of the binding of the two fluorochromes to measure apoptosis 
Quadrant  Label  
Annexin V 
(FL2)  
7-AAD (FL1)  
Lower left  Live cells  Negative  Negative  
Lower right  Apoptotic cells  Positive  Negative  
Upper right  Dead cells  Positive  Positive  
Upper left  Necrotic cells  Negative  Positive  
Shows the potential outcomes from flow cytometry analysis of apoptosis. 
 
 
4.7.2 Apoptosis induced by 3-BPA 
Eight glioblastoma cultures (with various levels of HK2 expression) and NHA were 
treated with relevant ID50 concentrations of 3-BPA for 72 hours as determined in 
Section 4.4 and compared to an untreated control of the same culture. For all 
cultures a 72- hour treatment with 100μM camptothecin was used as a positive 
control for induction of apoptosis. Figure 4.21 shows a comparative flow cytometry 
chart showing both an apoptotic positive result and an untreated control.  
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Figure 4.21 Induction of apoptosis in U251MG, treated with 100 µM campthothecin after 
72- hours. Untreated U251MG cells show little positive binding to annexin V (2nd quadrant) 
compared to campthothecin treated U251MG cells, which show a large population of cells in the right 
quadrant, indicating positive binding of annexin V. Quadrants are colourised for graphical 
interpretation: Blue – live cells, Green- apoptotic and Red-dead cells.  
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Figure 4.22 Induction of apoptosis in IN859, treated with 3-BPA or 100 µM 
campthothecin after 72- hours. Untreated IN859 cells show little positive binding to annexin V 
(2nd quadrant) compared to the 3-BPA treated IN859 culture, which show a large population of cells 
in the right quadrant. An increase of 51.9% in apoptosis was demonstrated after 3-BPA treatment. 
Campthothecin treated IN859 also showed an increase in apoptosis. Quadrants are colourised for 
graphical interpretation: Blue – live cells, Green- apoptotic and Red-dead cells.  
 
 
An apoptotic sub-population was detected in all glioblastoma cultures after ID50 
treatments with 3-BPA compared to the respective untreated cultures, with an 
increase of the sub-population in the 2nd quadrant indicating positive binding of 
annexin V uptake. Figure 4.22 shows an example of untreated, 3-BPA treated and 
campthothecin treated (control) populations in IN859. In the group of high HK2 
expressing cell cultures (>220 – fold change), a significantly increased (p<0.0001) 
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level of apoptosis was observed, with an average increase of 38% in apoptosis, 
ranging from 30% to 52%.  The largest increase in apoptosis was observed in IN859 
(52%) (p<0.0001) and the lowest in IN1979 (30%) (p<0.0001), as shown in Table 
4.15. The high HK2 expressing cultures had a greater increase in levels of apoptosis 
after 3-BPA treatment, in comparison to cultures that had a lower HK2 expression. 
The lower expressing cultures showed, with an average increase of 9.3 % apoptosis 
after 3-BPA treatment, ranging from 7% to 14%. This increase was only significant 
in IN2045 which showed an increase of 14% (p=0.005), as shown in Table 4.15 
Furthermore, there was a slight increase in apoptosis induced by 3-BPA in NHA, with 
an increase of 3.8%, as expected or a non-cancer control. As expected, the live cell 
population was reduced in all treated samples at the same ratio as the increase in 
apoptosis. 3-BPA effectiveness across glioblastoma cultures is associated with levels 
of HK2 expression, with significantly higher levels (p= 0.0007) of early apoptosis 
occuring in cultures that have higher levels of HK2 expression (>220 – fold change).  
 
Table 4.15 Apoptosis induced by 3-BPA treatment  
High Expressing 
HK2 cultures 
Apoptosis (%) 
untreated 
Apoptosis (%) 3-
BPA treated 
Apoptosis (%) 
increase 
IN859 9.8 61.7 52* 
U251MG 15.9 52.6 36.7* 
IN1979 10.8 40.8 30* 
IN1528 11.7 45.7 34* 
Mean 12.1 50.2 38.175 
Low Expressing HK2 
cultures 
Apoptosis (%) 
untreated 
Apoptosis (%) 3-
BPA treated 
Apoptosis (%) 
increase 
IN1461 8.2 19.2 11 
IN1951 14.5 21.5 7 
IN1682 12.9 17.9 5 
IN2045 7.4 21.4 14 
Mean 10.8 20 9.25 
NHA 6.8 10.6 3.8 
Cultures expressing higher levels of HK2 showed increased levels of apoptosis treated with 3-BPA for 
72- hours compared with cultures expressing lower levels of HK2 mRNA overexpression (compared to 
normal brain tissue). * significance p > 0.005. 
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4.7.3 Apoptosis induced by metformin  
In contrast, no apoptosis was seen in glioblastoma cultures (n=6) following 72- 
hours treatment with metformin. Average levels of apoptosis increased by 2.1% 
(with a range of 1.6 – 2.7%) in high HK2 expressing cultures, and by 3.7% (with a 
range of 3- 4.4%) in low HK2 expressing cultures as detailed in in Figure 4.23 and 
Table 4.16.  NHA also showed no significant increase in the apoptotic population 
after metformin treatment. An increase in cells in the upper right quadrant was 
detected, which demonstrates the effect of metformin supplementation leading to 
cell death. The data indicates that metformin does not generate cell death via 
apoptosis in glioblastoma, but may act through another mechanism of cell death 
such as autophagy or necrosis. 
 
Figure 4.23 Apoptotic detection after 72- hour treatment with metformin and 100 µM 
campthothecin. Untreated IN859 cells show little positive binding to annexin V (2nd quadrant). No 
increase in apoptosis was detected after 72 hours metformin treatment at specific ID50, however an 
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increase in cell death was detected. Quadrants are colourised for graphical interpretation: Blue – live 
cells, Green- apoptotic and Red-dead cells.  
Table 4.16 No substantial apoptosis induced by metformin treatment 
High Expressing 
HK2 cultures 
Apoptosis (%) 
untreated 
Apoptosis (%) 
metformin treated 
Apoptosis (%) 
increase 
IN859 4.5 6.5 2 
U251MG 5.9 8.6 2.7 
IN1528 8.8 10.4 1.6 
Mean 6.4 8.5 2.1 
Low Expressing HK2 
cultures 
Apoptosis (%) 
untreated 
Apoptosis (%) 
metformin treated 
Apoptosis (%) 
increase 
IN1951 7.4 10.4 3.0 
IN1682 5.9 9.7 3.8 
IN2045 8.2 12.6 4.4 
Mean 7.2 10.9 3.7 
NHA 5.9 11.5 5.6 
No significant apoptosis was demonstrated across any glioblastoma culture treated with metformin 
72- hours. 
 
4.7.1.2 Apoptosis of cells grown under hypoxia   
The analysis of cells for apoptotic markers was also completed over a 72- hour time 
course under hypoxic conditions, to determine the effectiveness of 3-BPA in 
generating early apoptosis under depleted oxygen, as commonly exhibited in the 
tumour microenvironment. Cultures were treated with relevant hypoxic ID50 values 
for 3-BPA as determined in Section 4.3.4 and compared to an untreated control of 
the same culture. For all cultures a 72- hour treatment with 100μM campthothecin 
was used as a positive control for induction of apoptosis. All cultures were grown in 
a sealed hypoxic incubator. An apoptotic sub-population was detected in all 
glioblastoma cultures after ID50 treatments with 3-BPA compared to the respective 
untreated cultures, with an increase of the sub-population in the 2nd quadrant 
indicating positive binding of annexin V uptake. Figure 4.24 shows an example of 
both untreated, 3-BPA treated and campthothecin treated (control) in hypoxia and 
Table 4.17 shows percentage of apoptosis under hypoxic conditions for all cultures 
tested.  
A significantly increased (p<0.0001) level of apoptosis was exhibited in all cultures 
expressing higher levels of HK2 under hypoxic conditions, as seen similarly under 
normoxic conditions.  In the panel of high HK2 expressing cell cultures, there was an 
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average decrease of 19.5% in apoptosis ranging from 13.4% to 33.5%.  The largest 
decrease in apoptosis was observed in IN859 (33.5%) (p<0.0001) and the lowest in 
IN1528 (13.4%) (p<0.0001), as shown in Table 4.17. The high HK2 expressing 
cultures had a greater decrease in levels of apoptosis after 3-BPA treatment under 
hypoxic conditions in comparison to cultures that had a lower HK2 expression, which 
showed significantly different (p<0.0001) levels of apoptosis. The lower expressing 
cultures showed a slight decreased level of apoptosis after 3-BPA treatment in 
hypoxia, with an average decrease of 3.7% ranging from 1.3% to 6.3%. No 
significant change in apoptosis was detected in these cultures, as shown in Table 
4.17. Furthermore, there was no decrease in apoptosis induced by 3-BPA in NHA. 
Additionally, there was significant (p= 0.0091) differences between levels of 
apoptosis in high HK2 expressing cultures treated under normoxic and hypoxic 
conditions. There was an 19% change in average apoptotic levels, with average 
levels of apoptosis across high expressing cultures in normoxia of 50.2% after 72-
hour treatment with 3-BPA, compared to 19.2% under hypoxia conditions. The level 
of apoptosis ranged from 40.8% (IN1979) to 61.7% (IN859) in normoxia treated 
cultures compared to 16.5% (IN1979) to 18.5% (IN859) in hypoxia treated cultures. 
The highest change in apoptotic levels between normoxic and hypoxic conditions 
was demonstrated in IN859 with a 33.5% reduction exhibited after 3-BPA treated in 
deprived adequate oxygen supply. There was no significant difference between 
levels of apoptosis in lower HK2 expressing cultures in normoxia or hypoxia with 
average levels of 9.3% and 5.6 respectively. The level of apoptosis ranged from 5% 
(IN1682) to 13% (IN2045) in normoxia treated cultures compared to 3.7% (IN1682) 
to 7.9% (IN2045) in hypoxia treated cultures as shown in Table 4.17. Levels of 
apoptosis across all cultures under normoxic and hypoxic conditions can be seen in 
Figure 4.25.  
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Figure 4.24 Induction of apoptosis in IN859, treated with 3-BPA after 72- hours under 
hypoxic conditions. Untreated IN859 cells show little positive binding to annexin V (2nd quadrant) 
compared to the 3-BPA treated IN859 culture, which show an increased population of cells in the 
right quadrant. An increase of 19.2% in apoptosis was demonstrated after 3-BPA treatment under 
hypoxia. A significant (p<0.0001) increase of 67.3% in dead cells was also observed. Quadrants are 
colourised for graphical interpretation: Blue – live cells, Green- apoptotic and Red-dead cells. 
 
Figure 4.25 Induction of apoptosis in all glioblastoma cultures treated with 3-BPA after 
72- hours in normoxic and hypoxic conditions. The percentage of apoptosis was reduced across 
all cultures after 3-BPA treatment under hypoxia. Cultures expressing higher levels of HK2 showed a 
significantly (p<0.0001) decreased levels of apoptosis after 3-BPA treatment under hypoxic 
conditions; compared with cultures expressing lower levels of HK2 mRNA overexpression (compared 
to normal brain tissue). * indicates high expressing cultures. 
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Table 4.17 Reduced levels of apoptosis induced by 3-BPA treatment under hypoxic 
conditions  
High Expressing 
HK2 cultures 
Apoptosis (%) 
Hypoxia 
Apoptosis (%) 
% Change in 
Apoptosis 
IN859 52 18.5 33.5* 
U251MG 36.7 21.3 15.4* 
IN1528 34 20.6 13.4* 
IN1979 30 16.5 13.5* 
Mean 38.2 19.2 19* 
Low Expressing 
HK2 cultures 
Apoptosis (%) 
Hypoxia 
Apoptosis (%) 
% Change in 
Apoptosis 
IN2045 13 7.9 5.1 
IN1461 12 5.7 6.3 
IN1951 7 5 2 
IN1682 5 3.7 1.3 
Mean 9.25 5.6 3.675 
Table showing percentage of apoptosis in both hypoxia and normoxia across all cultures after 72- 
hour treatment with 3-BPA. The level of apoptosis percent was reduced across all cultures under 
hypoxia after 3-BPA treatment. Cultures expressing higher levels of HK2 showed a significantly 
(p<0.0001) decreased levels of apoptosis after 3-BPA treatment under hypoxic conditions; compared 
with cultures expressing lower levels of HK2 mRNA overexpression (compared to normal brain tissue). 
* denotes significance.  
 
 
4.7.1.3 Apoptosis induced by HK2 inhibitors in HK2-KO cultures 
The analysis of cells for apoptotic markers was also completed over a 72- hour time 
course in four CRISPR induced HK2- KO cultures, to demonstrate the mechanism of 
3-BPA in generating early apoptosis is fundamentally specific to the HK2 target. 
Cultures were treated with the relevant HK2- KO ID50 values for 3-BPA as determined 
in 4.5, with normal growth media (F10) and compared to an untreated control of the 
same culture. For all cultures a 72- hour treatment with 100 μM camptothecin was 
used as a positive control for induction of apoptosis.  As expected no substantial 
levels of apoptosis were detected across any of the HK2-KO glioblastoma cultures 
after the 72- hour treatment with 3-BPA, the average percentage of apoptosis across 
all cultures after 3-BPA treatment was 0.68% compared to the untreated HK2-KO 
cultures, as shown in Table 4.18 and Figure 4.26. Additionally, there was significant 
(p<0.0001) reduction in the percentage of apoptotic sub-population detected across 
all HK2-KO cultures compared to the respective parent cultures after 3-BPA 
treatment. Average percentage of apoptosis in 3-BPA cultures were 38.2%, 
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compared to the respective HK2-KO cultures where there was a substantial loss of 
apoptosis, with a value of 0.58%. Campthothecin positive apoptotic control 
illustrated apoptosis in all cultures after 72- hour treatment, validating results 
generated after 3-BPA treatment. Notably, levels of apoptosis in the untreated HK2-
KO cells were lower in comparison to the parent cultures (IN2045 3.9% reduction, 
IN1979 9.4% reduction, IN859 7.4% reduction and U251MG 11.3% reduction). The 
loss of the HK2 target in the CRISPR transfected cultures demonstrates the 
specificity of 3-BPA, in the absence of the HK2 protein, the inhibitor has minimal 
cytotoxic effect upon the cells, leading to no initiation of the early apoptotic 
pathway.  
Table 4.18 Reduced levels of apoptosis induced by 3-BPA treatment in HK2-KO cultures  
Cultures 
Apoptosis (%) 
untreated 
Apoptosis (%) 3-
BPA treated 
% Change in 
Apoptosis 
IN2045- HK2-KO 3.5 5.1 1.6 
IN1979- HK2-KO 1.4 1.5 0.1 
IN859- HK2-KO 2.4 2.8 0.4 
U251MG- HK2-KO 4.6 5.2 0.6 
Table showing percentage of apoptosis in HK2-KO cultures after 72- hour treatment with 3-BPA. No 
significant levels of apoptosis were demonstrated in any of the HK2-KO cultures after 72- hour 
treatment with 3-BPA compared to untreated cultures.   
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Figure 4.26 Level of apoptosis in IN2045 and IN1979 HK2-KO cultures, treated with 3-
BPA after 72- hours. Both untreated and treated cultures show little positive binding to annexin V 
(2nd quadrant). No significant increase in the percentage of apoptosis was demonstrated after 3-BPA 
treatment in the HK2-KO cultures. Quadrants are colourised for graphical interpretation: Blue – live 
cells, Green- apoptotic and Red-dead cells.  
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4.7.2 Mitochondria potential 
 
The analysis of mitochondrial membranes was investigated using flow cytometry, to 
further investigate the mechanism of action of 3-BPA. 3-BPA has been shown to 
interact with the mitochondrial membrane, causing the dissociation of HK2 from its 
mitochondrial complex via covalent modification, resulting in the release of apoptosis 
inducing factor (AIF) into cytosol leading to cell death. JC-1 is a membrane-
permeable lipophilic cationic fluorochrome that penetrates both the cellular and 
mitochondrial membrane (Darzynkiewicz et al., 2001, Cossarizza et al., 1993). An 
emission spectrum is created based on the relative concentration of JC-1 bound 
within cells, which is dependent upon the mitochondrial membrane potential (ΔΨ). 
In low concentrations, JC-1 forms into monomers; however, in higher concentrations 
JC-1 aggregates into larger structures, enabling the emission spectra profile to be 
separated with flow cytometry. In healthy cells, the mitochondrial membrane has a 
polarized ΔΨ. JC-1 is taken up into the cell initially in a monomer form, from which it 
penetrates the mitochondrial membrane and accumulates forming larger complex 
aggregates. When the mitochondrial ΔΨ is depolarized, the JC-1 is unable to 
penetrate the mitochondrial membrane and it remains in its monomer form within 
the cytoplasm of the cell. Detection via flow cytometry separates JC-1 based on its 
structure utilizing 2 channels. The first channel, FL-1 (green) identifies both forms of 
JC-1 and the second channel, FL-2 (red) identifies only the aggregated JC-1 due to 
the formation of the aggregates causing a shift in the red emission spectrum. 
Separation of the channels is achieved through gating, where changes to the 
parameters between the populations of monomer and aggregate can be measured, 
to determine any changes in ΔΨ as shown in Figure 4.27. 
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Figure 4.27 Flow cytometry gating in the separation of JC-1 fluorochrome. Gating to 
separate JC-1 populations of monomer and aggregates within the glioblastoma cultures. Red gating 
shows JC-1 aggregated within the mitochondrial matrix, where green gating shows JC-1 monomers 
unable to enter through the mitochondrial membrane. Cell populations in the red gate have a 
polarised mitochondrial membrane allowing JC-1 monomers to enter the mitochondria, thus 
increasing leading to the formation of aggregates. The populations in the green gate have de-
polarised mitochondrial membrane which blocks Jc-1 monomers, the monomers remain in the 
cytoplasm of the cell without the formation of aggregates. 
 
  
ΔΨ polarised membrane 
JC-1 aggregate gate 
ΔΨ depolarised 
membrane JC-1 
monomer gate 
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Figure 4.28 Depolarisation of the mitochondrial membrane by campthothecin. U251MG 
cells were treated with 100 μM camptothecin for 72 hours. FL1-A and FL2-A channels determine 
depolarisation values. Apoptosis induced by camptothecin leads to depolarisation of the ΔΨ, shown 
with a shift in the FL-1A channel. The gating protocol is from the BD Biosciences template and was 
adapted for glioblastoma cells. Red gating shows JC-1 aggregated within the mitochondria, where 
green gating shows JC-1 monomers unable to enter through the mitochondrial membrane.   
 
 
Three glioblastoma cultures and the respective HK-KO (CRISPR transfected cultures) 
varients were assessed by flow cytometry for depolarisation of the mitochondrial 
membrane potential after treatment with 3-BPA for 72 hours at the determined ID50 
concentrations. Positive depolarisation was determined via camptothecin treatment, 
where a shift in the population of cells from the red gate to green gate, also a higher 
reading in the FL-1 channel was seen. Examples of mitochondrial depolarisation after 
72 hours of 100 μM camptothecin treatment are given in Figure 4.28. 
A significant (p<0.0001) reduction in all JC-1 aggregate populations and an increase 
in monomer population was demonstrated for all parent (non-CRISPR transfected) 
cultures when treated with 3-BPA. An average of 44.5% change in depolarisation 
(JC-1 monomer form detected) in treated cultures compared to non-treated cells. A 
similar reduction in aggregate populations when treated with 3-BPA was not 
demonstrated in HK2-KO cultures, with an average change of 1.3% in depolarisation 
(JC-1 monomer form detected) in treated cultures compared to non-treated cells. 
This illustrates the significant effect of 3-BPA on depolarising the mitochondrial 
membrane when its HK2 target is present, as demonstrated previously in the 
absence of HK2 3-BPA effectiveness is substantially reduced. The lowest monomer 
levels were seen in U251MG, with HK2-KO 15.7% and the lowest response of 0.4% 
change post treatment with 3-BPA. The highest values were seen in IN1979, with 
82.7% and the highest response of 67% change post treatment with 3-BPA as 
shown in Table 4.19 and 4.20. Examples of results for the cultures are shown in 
Figure 4.29. The results indicate significant depolarisation of the mitochondrial 
membrane occurring after 72-hour 3-BPA treatment, the cytotoxic effect of 3-BPA 
has an impact on the membrane and functions of mitochondria.  
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Figure 4.29 Measurement of mitochondrial membrane potential in HK2-KO and respective 
parent cultures with 3-BPA treatment. Untreated cultures are shown on the left (U), 3-BPA 
cultures treated for 72- hours on the right (T). 3-BPA treatment leads to depolarisation of the ΔΨ in 
parent cultures, shown with a shift in the FL-1A channel (increase in monomer % (green value)). No 
change in depolarization % was seen in HK2-KO cultures. Red gating shows JC-1 aggregated within 
the mitochondria, where green gating shows JC-1 monomers unable to enter through the 
mitochondrial membrane.  
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Table 4.19 Mitochondrial membrane potential depolarisation  
 Untreated 3- BPA Treated 
Sample Aggregate % Monomer % Aggregate % Monomer % 
U251MG* 40.5 53.2 13.5* 84 * 
IN2045* 59.6 34.5 25.7* 70.2 * 
IN1979* 81.3 15.7 14.9* 82.7 * 
U251MG CRISPR 80.3 15.3 81.3 15.7 
IN2045 CRISPR 69.5 26.4 68.6 27.6 
IN1979 CRISPR 32 64.2 29.1 67.1 
Table showing mitochondrial membrane assessment across all cultures. Aggregate % represents JC-1 
crossing and accumulating within the mitochondrial membrane. Monomer % represent JC-1 
accumulating in the cytoplasm of cells in a monomer form. Statistical significance denoted by *. 
 
Table 4.20Mitochondrial membrane potential change with 3-BPA treatment 
Sample 
Untreated % 
of 
depolarisation 
3-BPA treated 
% of 
depolarisation 
% Change in 
depolarisation 
p value 
U251MG 53.2 84 30.8  <0.0001 * 
IN2045 34.5 70.2 35.7  <0.0001 * 
IN1979 15.7 82.7 67  <0.0001 * 
U251MG CRISPR 15.3 15.7 0.4 0.0876 
IN2045 CRISPR 26.4 27.6 1.2 0.0565 
IN1979 CRISPR 64.2 67.1 2.2 0.1306 
Table showing mitochondrial membrane assessment across all cultures. Change in depolarisation % 
represents the change in detected monomer values, where JC-1 accumulates in the cytoplasm of cells 
in a monomer form, after 3-BPA treatment. Statistical significance denoted by *. 
 
4.7.3 Caspase 
Caspase 3/7 analysis was carried out on three glioblastoma cultures and their 
respective HK-KO cultures to assess levels of caspase activity after treatment of 3-
BPA for 72 hours at the determined ID50 concentrations. The level of caspase activity 
was measured along with a SRB, which gave a background measurement in which to 
normalise the caspase results. The positive control for apoptosis was generated 
using 100 μM camptothecin. The normalised caspase value (relative light units – 
RLU) showed a significant (p<0.0001) increase in caspase 3/7 readings across all 
parental glioblastoma cultures after 72- hour 3-BPA treatment. The average 
normalised caspase 3/7 value for 3-BPA parent cultures was 1379781.8 RLU, a 
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75.3% increase compared to the untreated cultures where the average value was  
341158.2 RLU. No significant increase was determined in the caspase 3/7 values in 
any of HK2-KO cultures, with caspase 3/7 values for 3-BPA treated cultures 539210 
RLU compared to 201615 RLU in the untreated HK2-KO cultures, as shown in Figure 
4.30 and Table 4.21. Camptothecin treated cultures exhibited an effective induced 
level of caspase 3/7 across all parental and HK2-KO cultures after 72- hour 
treatment. The results show that 3-BPA affects the caspase 3/7 activity after 72- 
hour treatment in glioblastoma cultures, furthermore in the absence of the HK2 
target (HK2-KO cultures), 3-BPA is ineffective at influencing caspase 3/7 activity. The 
results indicate that one of the potential mechanisms of cell death, following 3-BPA 
treatment in glioblastoma cultures is dependant on the increase in caspase 3/7 
activity. 
 
 
Figure 4.30 Measurement of Caspase 3/7 assay across all cultures after 3-BPA treatment. 
Results show the normalised level of activity of caspase 3/7 in HK2-KO and respective parental 
cultures after 72- hour 3-BPA treatment. A significant (p<0.0001) increase in caspase 3/7 is 
demonstrated across all parental cultures, no significant changes in caspase 3/7 levels were 
determined in HK2-KO cultures. Normalised caspase value measured in relative light units normalised 
by an SRB control. 100μM campthothecin was used to induce positive apoptosis. 
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Table 4.21Level of activity of caspase 3/7 in HK2-KO and parental cultures after 3-BPA 
treatment 
Culture 
Untreated 
(RLU) 
3-BPA treated 
(RLU) 
p- value 
U251MG 304665 1456421 <0.0001 * 
U251MG CRISPR 258567 587538 0.295 
IN2045 505564 1300866 <0.0001 * 
IN2045 CRISPR 306206 557646 0.638 
IN1979 268937 1356421 <0.0001 * 
IN1979 CRISPR 115260 485827 0.26 
IN859 285467 1405421 <0.0001 * 
IN859 CRISPR 126425 525827 0.374 
Table showing the results of the normalised level of activity of caspase 3/7 in HK2-KO and respective 
parental cultures after 72- hour 3-BPA treatment. A significant (p<0.0001) increase in caspase 3/7 is 
demonstrated across all parental cultures, no significant changes in caspase 3/7 levels were 
determined in HK2-KO cultures. Normalised caspase value measured in relative light units normalised 
by an SRB control. Statistical significance denoted by *. 
 
 
4.8. Recapitulating the ketogenic diet in vitro with 3-Hydroxybuterate 
Substantial alterations in the response to inhibitors were demonstrated in 
glioblastoma cultures when HK2 expression was knocked out by CRISPR. An increase 
in drug sensitivity to both metformin and TMZ was observed with the loss of HK2. 
The success of the CRISPR transfection knockout however cannot currently be 
reproduced in vivo. An alternative to HK2 knockout is to restrict the level of glucose 
available to the glioblastoma cells, leading to the downregulation of the glucose 
pathway. One approach is to use a ketogenic diet (KD) to increase blood ketones to 
support the energy needs of normal tissues as an alternative substrate to glucose 
during prolonged starvation, (Woolf et al., 2016). It is well documented that cancer 
cells rely increasingly on the glycolytic pathway as the predominant mechanism for 
energy production (Kazue et al., 2011), and are unable to process ketone bodies. KD 
has also been shown to increase circulating levels of ketone bodies such as β-
hydroxybutyrate and can impact metabolism leading to systemic metabolic changes. 
(Shukla, et al., 2014).  It has also been shown that the incorporation of a KD leads 
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to the reduction in tumour growth, along with the reduction in angiogenesis, 
inflammation, migration and invasion (Marsh et al., 2008; Shelton et al., 2010). A 
considerable setback of the ketogenic diet is patient accountability, and the 
difficulties in maintaining a strict diet; however, the development of a ketone 
compound would eliminate patient discrepancies. 
This study investigated the ketone body 3-hydroxybuterate (3-HB) to determine the 
effects of ketone supplementation upon glioblastoma culture proliferation, compared 
to NHA in the absence or reduction of the availability of glucose. Four glioblastoma 
cultures IN2045, IN1979, IN859 and U251MG and an NHA control, were grown in 
the presence of 3-HB with either 6mM of glucose, 3mM of glucose or in the absence 
of glucose. All cells were seeded at 12000 cells in a T25 flask at day zero and 
counted in duplicates using a Countess Cell Counter as Stated in 2.1.5. Triplicate 
experiments were completed, with average data collected.  
A reduction in proliferation was demonstrated in reduced glucose concentrations 
with the supplementation of 3-Hb compared to normal culture levels of 6mM of 
glucose (+ 3-HB). An average reduction of 53.8% across the 4 glioblastoma cultures 
was seen when grown in 3mM of glucose compared to cultures grown in normal 
glucose (6mM) + 3-HB. The range of reduction was 46.9% (IN2045) (p=0.0001), 
54.2% (U251MG), 55.2% (IN1979) and 58.8% (IN859) (p<0.0001). Cell 
proliferation in the cultures was significantly (p<0.0001) diminished when 
glioblastoma cultures were grown in 0mM glucose (glucose free-Hams F10 media 
with no supplements), with the average reduction of 87.7%. The range of reduction 
was 71.5% (IN2045), 93.1% (U251MG), 93.4% (IN1979) and 92.9% (IN859) 
(p<0.0001). A similar trend was exhibited when 3-HB (and 0mM glucose) was 
supplemented as a replacement for glucose in cultures, where the average reduction 
in cell proliferation was significant (p<0.0001) at 90.2% compared to the respective 
cultures grown in 6mM glucose. The range of reduction was 74.6% (IN2045), 95.3% 
(U251MG), 95.5% (IN1979) and 95.6% (IN859) (p<0.0001), as seen in Figure 4.31 
and Table 4.22. IN2045 however showed a reduced effect in both conditions, with 
>20% less change in proliferation compared to the other glioblastoma cultures. 
IN2045 in comparison is a lower HK2 expressing culture and additionally has a 
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slower doubling time of 36 hours compared to U251MG and IN859 (24 hours) and 
IN1979 (34 hours), which may potentiate the altered effect of glucose reduction 
over the 8- day period. NHA showed a similar trend to the glioblastoma cultures, 
when glucose was reduced to 3mM the reduction in proliferation was 40%, 
furthermore, there was a significant loss (p<0.0001) in proliferation when grown in 
0mM glucose media, where the reduction was 66.4%.  
Importantly however, with the substitution of 3-HB added to the culture media (in 
the absence of glucose), NHA demonstrated an ability to proliferate under ketogenic 
conditions, where there was an 51.6% increased level of cell proliferation compared 
to that seen under 0mM glucose (glucose free-Hams F10 media with no 
supplements) conditions, contrary to the data generated from the glioblastoma 
cultures. NHA proliferation was reduced in cultures supplemented with just 3-HB 
compared to 6mM glucose + 3HB, where there was a 30.6% reduction (p=0.0287) 
in the level of proliferation, however compared to the glioblastoma cultures under 3-
HB supplementation, NHA showed an increase of 59.8% in the level of proliferation, 
as seen in Figure 4.31 and Table 4.22. The data suggests that in the presence of 
reduced glucose, the glioblastoma cells lack the ability to metabolise the ketone 
body 3-HB, which was shown to support cell proliferation in NHA.  
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Figure 4.31 Cell proliferation in glioblastoma cultures and NHA, with varying levels of 
glucose and 3-HB. Cells were seeded at 12000 cells per flask and grown over 8 days, cells were 
counted in duplicates at each time point. Triplicate assays were conducted, and average values 
calculated. A significant (p<0.0001) reduction in glioblastoma proliferation was demonstrated with 
reduced levels of glucose and with the supplementation of 3-HB across all cultures. NHA cells showed 
the ability to proliferate when supplemented with 3-HB. 
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Table 4.22. Cell proliferation in glioblastoma cultures and NHA, with varying levels of 
glucose and 3-HB 
IN2045 Cell count (Days) % Change 
from 6mM 
+3-HB 
glucose 
Day 0 2 4 6 8 
6mM Glucose 
+3-HB 
1.2x104 8.5x105 1.1 x106 1.2 x106 1.3 x106 0 
3mM Glucose 
+3-HB 
1.2x104 4.5 x105 5.5 x105 6.4 x105 6.9 x105 46.9* 
0mM Glucose 1.2x104 3.2 x105 4.4 x105 4.2 x105 3.7 x105 71.5* 
3-HB 1.2x104 3 x105 3.9 x105 3.8 x105 3.3 x105 74.6* 
 
 
IN859 Cell count (Days) % Change 
from 6mM 
+3-HB 
glucose 
Day 0 2 4 6 8 
6mM Glucose 
+3-HB 
1.2x104 
1.3 x106 2.7 x106 3.2 x106 3.4 x106 0 
3mM Glucose 
+3-HB 
1.2x104 
6.2 x105 8.60000 1.1 x106 1.4 x106 58.8* 
0mM Glucose 1.2x104 3 x105 3.3 x105 3 x105 2.4 x105 92.9* 
3-HB 1.2x104 2.6 x105 2.9 x105 2.5 x105 1.5 x105 95.6* 
 
 
NHA Cell count (Days) % Change 
from 6mM 
+3-HB 
glucose 
Day 0 2 4 6 8 
6mM Glucose 
+3-HB 
1.2x104 
7.6 x105 1 x106 1.1 x106 1.1 x106 0 
3mM Glucose 
+3-HB 
1.2x104 
4. x105 5.2 x105 6 x105 6.6 x105 40* 
0mM Glucose 1.2x104 3.2 x105 3.7 x105 3.8 x105 3.7 x105 66.4* 
3-HB 1.2x104 4 x105 5.8 x105 6.6 x105 7.6 x105 30.6 
Tables showing cell counts for glioblastoma cultures and NHA across 8 days. A significant (p<0.0001) 
reduction in glioblastoma proliferation was demonstrated with reduced levels of glucose and with the 
supplementation of 3-HB across all cultures. A significant (p<0.0001) reduction in NHA proliferation 
was demonstrated in the absence of glucose. NHA cells showed the ability to proliferate when 
supplemented with 3-HB. Significance denoted with *. 
 
IN1979 Cell count (Days) % Change 
from 6mM 
+3-HB 
glucose 
Day 0 2 4 6 8 
6mM Glucose 
+3-HB 
1.2x104 
9 x105 2.4 x106 2.8 x106 2.9 x106 0 
3mM Glucose 
+3-HB 
1.2x104 
4.9 x105 7.2 x105 1.2 x106 1.3 x106 55.2* 
0mM Glucose 1.2x104 3.5 x105 3.5 x105 2.8 x105 1.9 x105 93.4* 
3-HB 1.2x104 2.7 x105 3.3 x105 2.3 x105 1.3 x105 95.5* 
U251MG Cell count (Days) % Change 
from 6mM 
+3-HB 
glucose 
Day 0 2 4 6 8 
6mM Glucose 
+3-HB 
1.2x104 
1.6 x106 3.2 x106 3.5 x106 3.6 x106 0 
3mM Glucose 
+3-HB 
1.2x104 
5.4 x105 8.8 x105 1.3 x106 1.6 x106 54.2* 
0mM Glucose 1.2x104 3.1 x105 3.6 x105 2.8 x105 2.5 x105 93.1* 
3-HB 1.2x104 2.9 x105 3 x105 2.3 x105 1.7 x105 95.3* 
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4.9 Discussion 
This chapter focussed on investigating the effect of HK2 on proliferation and its 
potential as a therapeutic target. The efficacy of a range of potential HK2 inhibitors 
for suppressing tumour growth was assessed, in both mono-treatments and in drug 
combination. Furthermore, their mechanisms of action were explored through use of 
flow cytometry and the mitochondrial membrane potential functional assay. The 
replacement of glucose with the ketone 3-HB was also explored as an alternative 
option for suppressing tumour growth. The findings of this study highlight the 
fundamental role of HK2 in promoting tumour growth in glioblastoma, where the 
impact of HK2 downregulation via CRISPR mediated knockout revealed significant 
reduction (p<0.007) in cell growth in patient-derived glioblastoma cultures. The HK2 
inhibitors 3-BPA and LND along with metformin demonstrated anti-proliferative 
effects under both normoxic and hypoxic conditions, with significant reductions in 
cell growth. 3-BPA was shown to induce significant depolarisation of the 
mitochondrial membrane and initiate apoptosis across all glioblastoma cultures as 
shown with flow cytometry and caspase 3/7 pathway functional assays. The 
reduction in glucose was shown to suppress growth and, the glioblastoma cells 
demonstrated their ineffectiveness at metabolizing the ketone body 3-HB as a 
replacement, resulting in the inhibition of growth. 
 
HK2 drives increased proliferation in glioblastoma  
In this study HK2 was knocked out using CRISPR in patient-derived cultures 
(IN1979, IN859, IN2045) and the established cell line U251MG. CRISPR-mediated 
HK2 knockout led to a significant decrease (p<0.007) in cell growth of up to 44% 
after 7 days compared to parent cultures. The greatest reduction in proliferation was 
in cultures that had expressed the highest level of HK2 overexpression. The impact 
of HK2 downregulation upon the rate of proliferation in the cultures indicates its 
fundamental role in promoting tumour growth in glioblastoma, and its potential as a 
therapeutic target. Studies have shown increased levels of HK2 to be associated with 
significant growth advantages in many tumours, which include medulloblastoma and 
breast cancers (Jiang et al., 2012; Gershon et al., 2013) and more recently, ovarian 
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cancer (Siu et al., 2019). It is documented that cancer cells require increased 
amounts of energy in order to maintain the augmented rates of proliferation and 
survival, where cells undergo a metabolic transformation relying increasingly on the 
glycolytic pathway as the predominant mechanism for energy production (vander 
Haiden et al., 2009; Kami et al, 2013). It has been proposed that the function of the 
metabolic switch is for the increased production of ATP, where glycolysis has been 
shown to drive ATP production at an amplified rate essential to support the 
increased energy demands in cancer cells (Cairns et al., 2011). HK2 has a crucial 
catalytic role in the initiation of the glycolytic pathway and has been shown to be 
associated with an increased glucose flux as well as increasing tumour invasion, 
aggression and enhanced therapeutic resistance (Patra et al., 2013; Wolf et al., 2011 
Galluzi et al, 2013; Lindgvist et al., 2018).  
HK2 has been shown to bind to the voltage-dependent anion-selective channel 
(VDAC) releasing mitochondrial ATP to further fuel the glycolytic process (Palmieri et 
al., 2009). A recent study demonstrated the effect of HK2 knockdown in a range of 
cell lines (including non-small-cell lung cancer (H460), glioblastoma cell line (U87) 
and liver cancer cell lines (Hep3B and HepG2) to result in the inhibition of cell 
proliferation, colony formation and xenograft tumor progression (Xu et al., 2018). 
The data presented in the current study indicates the potential therapeutic 
advantages of targeting HK2 in glioblastoma, where HK2 downregulation leads to 
the significant reduction in cell proliferation. 
Increased sensitivity to TMZ in the absence of HK2 in glioblastoma  
The sensitivity to TMZ was significantly increased (p<0.0001) in HK2 KO cultures, 
with average ID50 values decreased by 42.5% respectively compared to parent 
cultures. Additionally, a reduction in cell survival was also exhibited in the HK2 KO 
cultures with TMZ, with an average reduction of 19.9% % respectively compared to 
parent cultures. The data reiterates the importance of HK2 as a key mediator driving 
glycolysis and signifies the potential therapeutic advantages of targeting HK2 in 
glioblastoma, where downregulation was shown to significantly increase the 
effectiveness of the therapeutic agent TMZ. The novel data presented in this study 
indicates the potential therapeutic advantages of targeting HK2 in glioblastoma. 
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3-Bromopyruvic acid inhibits HK2 in glioblastoma, initiating early 
apoptosis  
All cultures treated with 3-BPA demonstrated an anti-proliferative response after 
treatment. Additionally, cultures expressing higher levels of HK2 were more sensitive 
to 3-BPA and generally had significantly lower ID50 values (p= 0.0192), indicating 
the specificity of 3-BPA in targeting HK2 causing dissociation from its mitochondrial 
bound complex. The substantial difference in the cytotoxic response of the 
glioblastoma cells to NHA demonstrates that 3-BPA mechanism of action relates 
specifically to cancer cells, via the targeting of mitochondrial bound HK2, as shown 
in Chapter 3 to be overexpressed in glioblastoma. Studies have also shown direct 
inhibition of mitochondrial HK2 via covalent modification of its cysteine residues, 
resulting in its dissociation from the mitochondria (Ko et al., 2001; Chen et al., 
2009). The dissociation of HK2 induces the release of mitochondrial apoptosis-
inducing factor (AIF) to the cytosol resulting in cell death. In another study 3-BPA 
was shown to inhibit the expression of HK2 at mRNA and protein levels in both lung 
and liver cancers (Yadav et al., 2017).  
The effects 3-BPA upon cell proliferation were also investigated under hypoxic 
conditions. Hypoxia is a distinguishing feature associated with tumour 
microenvironments; therefore, the effectiveness of a therapeutic molecule in 
generating an inhibitory response needs to be assessed under hypoxic conditions. It 
has been shown that hypoxia inducible factor 1 (HIF1) up-regulates many enzymes 
of the glycolytic pathway, including HK2, through binding to the hypoxia-responsive 
elements (HREs) in the HK2 promoter (Mathupala et al., 2001). Under hypoxic 
conditions, ID50 values significantly increased (p <0.0001) in all culture samples, 
indicating an increased tolerance of 3-BPA. A similar trend was also exhibited in 
NHA. Increased resistance may be mediated through hypoxia induced proteomic and 
genomic changes. These changes often lead to angiogenesis activation and 
anaerobic metabolism to aid in survival, and lead to the release of proteins such as 
the transcription factor hypoxia-inducible factor 1 (HIF1), which regulates tumour 
cell adaption (Majmundar et al, 2010). HIF-1 increases tumour cell resistance to 
therapeutic agents and to hypoxic stress, leading to the generation of more 
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aggressive clones with greater resistance to therapeutic agents, eventually becoming 
the dominant cell type within the tumour (Sun et al., 2011). HIF1 overexpression 
has been linked with the regulation of secondary mechanisms associated with 
survival adaptation in cancer cells, which are upregulated by the PI3K/Akt1/mTOR 
pathway (Wouters and Koritzinsky, 2008). HIF1 has also been shown to enhance 
cellular glycolytic potential by increasing the transcription of glucose transporters 
and glycolytic enzymes (Semenza, 2013). The effects of 3-BPA were shown to be 
reduced in cultures that had been CRISPR HK2-KO modified, where a significantly 
increased (p<0.0001) tolerance to 3-BPA was demonstrated after 72-hour treatment 
with average ID50 values 50% greater across HK2-KO cultures compared respectively 
to the parent culture. Cell survival was also shown to be significantly increased 
(p=0.0024) in all HK2-KO cultures compared to parent cultures after 3-BPA 
treatment. The elimination of the HK2 target reduces the effectiveness of 3-BPA, 
verifying the specificity of the inhibitor.  
Apoptosis was induced by 3-BPA in all glioblastoma cultures, where significantly 
higher apoptosis (p<0.0001) was exhibited in cultures expressing higher levels of 
HK2. The average apoptotic value was 30% greater in these cultures compared to 
lower HK2 overexpressing cultures. Furthermore, there was also a significant 
difference (p= 0.0091) between levels of apoptosis in high HK2 expressing cultures 
treated under normoxic and hypoxic conditions. The data suggests that 3-BPA is less 
effective under hypoxic conditions, a reason for the reduced efficiency may be 
impacted by increased resistance through hypoxia induced proteomic and genomic 
changes, as previously stated above. HIF1 upregulation has also been shown to 
have inhibitory effects on a range of factors involved in apoptosis and the regulation 
of cell death mechanisms in glioblastoma (Yang et al., 2012). The cultures that had 
the greatest change in apoptotic levels were those expressing higher HK2 levels, the 
reduction in 3-BPA effectiveness at generating early apoptosis may be part due to 
increased resistance through hypoxic generated transcription factors. Additionally, 
these cultures have generally faster doubling times which would lead to more 
hypoxic stress-adapted cells, resulting in an increased resistance of 3-BPA during the 
72-hour treatment. The same significant reduction of apoptosis is not seen in lower 
HK2 expressing cultures, which may be due to there being a reduced HK2 target for 
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3-BPA, thus the increased levels of hypoxia transcription factors have a lessened 
impact on its effectiveness. Additionally, the effects of 3-BPA were shown to be 
reduced in cultures that had been CRISPR HK2-KO modified, where a significant 
reduction (p<0.0001) in apoptosis was exhibited compared to the respective parent 
cultures after 3-BPA treatment. The data indicates that in the absence of HK2, 3-BPA 
has a minimal cytotoxic effect upon the cells, failing to induce early apoptosis.  
Finally, a significant increase (p<0.0001) in the level of caspase was detected in all 
3-BPA treated cultures, with an average increase of 75.3%, comparatively, no 
significant increase was determined in in any of the HK2-KO cultures. The data from 
this study shows that 3-BPA effects the caspase 3/7 activity in glioblastoma cultures, 
suggesting that one of the potential mechanisms of cell death following 3-BPA 
treatment in glioblastoma is dependent on the increase in caspase 3/7 activity. The 
data obtained from the functional assay reiterates the flow cytometry data, that in 
the absence of the HK2 target, 3-BPA is ineffective at influencing apoptosis and 
caspase 3/7 activity. Caspase 3/7 are primary effectors at the end of the apoptotic 
caspase pathway,  the combined experiments show strong evidence that the 
caspase dependent apoptotic pathway is induced as the main mechanism of cell 
death in glioblastoma from 3-BPA treatment. Additionally, significant depolarisation 
(p<0.0001) of the mitochondrial membrane was seen across all glioblastoma 
cultures after treatment with 3-BPA; with an average depolarisation change of 
44.5%. Comparatively no reduction was demonstrated in HK2-KO cultures. It is well 
established that the apoptotic intrinsic pathway is regulated by mitochondria, 
through downstream caspase effectors, eventually activating caspase 3 and 7 which 
destroy the cell from within (Hunt, 2002; Boehning et al., 2003). Mitochondrial 
activity is therefore fundamental for the activation of apoptotic factors, which itself is 
dependent upon the mitochondrial membrane potential (Δψ). It has been shown 
that the combination of apoptogenic factors released by the mitochondria with the 
addition of the depolarisation of the transmembrane potential and the loss in 
oxidative phosphorylation are key factors in eliciting the intrinsic apoptotic pathway 
(Martínez-Reyes et al., 2016). 3-BPAs cytotoxic effect causes apoptosis in 
glioblastoma cells, impacting on the membrane functions, leading to the 
depolarisation of the mitochondrial membrane. In the absence of HK2 3-BPA 
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effectiveness is substantially reduced. Gandham et al. (2015) showed that 3-BPA 
affects mitochondria through the targeting of HK2 bound complex which results in 
subsequent stimulation of AIF consequently leading to cell death. AIF initiates a 
caspase-independent pathway of apoptosis via DNA fragmentation and chromatin 
condensation. However, other studies have demonstrated 3-BPA effectiveness at 
generating apoptosis via a caspase mediated pathway, where the expression of 
caspase-3 increased in breast cancer cells ( MDA-MB-231) following 3-BPA treatment 
(Chen et al., 2018). Inhibition of HK2 by 3-BPA has been shown to decrease ATP 
and NADPH levels, thereby blocking glycolysis in tumour cells and halting growth 
(Chen et al., 2009; Galluzzi et al., 2012). 3-BPA has also been shown to induce 
apoptosis in breast cancer cells by downregulating induced myeloid leukaemia cell 
differentiation protein (Mcl-1) through PI3K/Akt signalling pathway and via the 
generation of reactive oxygen species leading to mitochondria-mediated apoptosis 
(Liu et al., 2014); as well as increasing mitochondrial membrane permeability 
through HK2 inhibition, activating caspase 9 resulting in cellular apoptosis (Ferraro 
et al. 2008; Zuo et al., 2011). The data presented here signifies the potential of 3-
BPA as a therapeutic for glioblastoma, where its effectiveness at inhibiting HK2 and 
to generate apoptosis via caspase dependant (and independent) pathways has been 
shown. Moreover, 3-BPA demonstrates increased effectiveness in higher HK2 
expressing glioblastoma cultures, indicating its promising ability at treating a 
significant subset of glioblastoma patients. 
 
LND also demonstrated an anti-proliferative response in all cultures, to a lesser 
degree. Cultures expressing higher levels of HK2 were more sensitive to LND and 
generally had significantly lower ID50 values (p= 0.0465). The data indicates the 
specificity of lonidamine to inhibit aerobic glycolysis in cancer cells through the 
targeting of condensed mitochondrion (Price et al., 1996), consequently inhibiting 
the mitochondrially bound HK2 in tumour cells. The inhibition of HK2 results in the 
reduction of glycolysis and cellular ATP (Nath et al., 2015). A recent study 
demonstrated the ability of LND to inhibit the monocarboxylate transporter (MCT), 
preventing oxidation of the accumulated L-lactate through its conversion to 
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pyruvate, consequently, blocking entry into the mitochondria and the citric acid cycle 
(Nancolas et al., 2016). The resultant effect would suggest the inability of the cell to 
compensate for the loss in glycolytic ATP additionally affected by HK2 inhibition. The 
substantial difference in the cytotoxic response of the glioblastoma cells to NHA 
demonstrates that the lonidamine mechanism of action relates specifically to cancer 
cells. Studies have shown LND to have low levels of toxicity to normal tissues  
(Prabhakara et al., 2008), suggesting its mechanism of action has a high affinity for 
targeting cancer cells, through the selective inhibition of HK2 and other glycolytic 
components that are overexpressed in cancer cells, via targeting the mitochondrially 
bound HK2. The data presented here has shown the anti-proliferative effects of both 
3-BPA and LND, highlighting the importance of 3-BPA inhibitory action upon 
glioblastoma, and its potential as a therapeutic agent in a subset of glioblastoma. 3-
BPA hampers ATP generation through predominantly targeting HK2, along with other 
metabolic targets including lactate dehydrogenase (LDH) (Lis et al., 2016), which are 
specifically upregulated in cancer cells. 3-BPA therefore offers a wide spectrum of 
glycolytic enzyme inhibitory potential, instigating complete breakdown of cancer cell 
metabolism whilst unaffecting healthy cell metabolism highlighting its 
chemotherapeutic potential. 
 
Metformin induces anti-proliferative effects in glioblastoma  
All glioblastoma cultures treated with metformin demonstrated an anti-proliferative 
response after treatment. No significant differences were determined between the 
response to metformin and the level of HK2 expression. NHA had a high tolerance of 
metformin with the highest ID50 value compared to all the glioblastoma cultures. The 
substantial difference in the cytotoxic response of the glioblastoma cells to NHA 
demonstrates that mechanism of action of metformin relates exclusively to cancer 
cells, although not specifically through HK2 (Wahl and Venneti, 2018). Metformin is 
a biguanide drug with a primary function of preventing the production of glucose in 
the liver, resulting in the nutrient deprivation for cancer cells that rely exclusively on 
glucose metabolites for energy production and proliferation. The data here indicates 
metformin inhibits growth of glioblastoma. The importance of glucose deprivation via 
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metformin supplementation has been shown to have an inhibitory response and 
induce cell death, similar correlations have been demonstrated in breast cancer cell 
lines (Menendez et al., 2012; Birsoy et al., 2014). It has also been suggested that 
p53 status impacts metformin effectiveness, with increased sensitivity reported in 
P53 aberrant colon cancer cell lines compared to P53 wild type cells (Buzzai et al., 
2007). The effects of metformin upon cell proliferation was also investigated under 
hypoxic conditions and ID50 values significantly increased (p <0.0125) in all culture 
samples, indicating an increased tolerance of metformin treatment. A similar trend 
was also exhibited in NHA. It has been suggested that metformin activates AMPK 
resulting in the inhibition of the mTOR pathway (Pollak, 2012; Liu et al., 2014; He 
and Wondisford, 2015).  AMPK is a metabolic kinase important in regulating cellular 
metabolism and proliferation (Mihaylova and Shaw, 2011).  
Additionally, metformin has also been shown to inhibit Akt (Mahvash et al., 2010). 
Deregulation of both Akt expression and mTOR pathway is a frequent occurrence in 
cancer cells and upregulation is associated with increased cell proliferation and 
survival (Sharma et al., 2015). In hypoxia HIF-1 is induced, which consequently 
induces upregulation of PDK1 in turn activating Akt as well as reducing oxidative 
phosphorylation and ROS via restricting pyruvate into the mitochondrial TCA cycle, 
thus promoting lactate production, further supplementing the up-regulation of 
glycolysis mediated by HIF1 (Kim et al., 2007; Lu et al., 2008). Notably, HIF-1 
upregulation of Akt counteracts the effectiveness of metformin inhibition, resulting in 
an increased tolerance. Similarly, HIF1 upregulation has been shown to inhibit on a 
range of factors involved in apoptosis and stress responses and in the regulation of 
glioblastoma (Trachootham et al., 2006; Yang et al., 2012). The metabolic and 
genetic changes instigated through hypoxia increase the chemoresistance of the 
glioblastoma cultures, reducing the effectiveness of metformin. The effects of 
metformin were shown to be increased in cultures that had been CRISPR HK2-KO 
modified, where a significantly increased (p<0.0001) sensitivity to metformin was 
demonstrated after 72-hour treatment with average ID50 values decreased by 46.8% 
across HK2-KO cultures compared respectively to the parent culture. Cell survival 
was also shown to be significantly reduced (p=0.0008) in all HK2-KO cultures 
compared to parent cultures after metformin treatment.  
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Significant levels of apoptosis were not induced by metformin any of the 
glioblastoma indicating  that metformin may act through another mechanism of cell 
death such as autophagy or necrosis. Metformin has been shown to induce 
autophagy flux through regulation of AMPK, triggered in response to cellular stress 
and increases in cellular metabolic demands (Zhang et al., 2017), as shown in 
thyroid and endometrial cancer cells (Song et al., 2016; Gu et al., 2017). Autophagy 
activation has also been seen in glioblastoma cell lines (U251MG/ U87MG), where an 
increase level of autophagy was detected after metformin treatment (Sesen et al., 
2015). Additionally, metformin has been shown to induce autophagy in glioblastoma 
cells via the activation of AMPK and REDD1, downregulating the mTOR pathway 
(2014; Sesen et al., 2015).  
 
3-HB supplementation induces an anti-proliferative effect in glioblastoma 
The reduction in glucose was shown to suppresses growth in all cultures. The 
glioblastoma cells demonstrated their ineffectiveness at metabolizing the ketone 
body 3-HB as a replacement, and cultures supplemented with 3-HB and no added 
glucose (Hams’ free glucose media) showed significantly reduced (p<0.0001) cell 
proliferation (average growth decrease of 90.2%), compared to the respective 
cultures grown in normal glucose conditions. The data indicates the potential 
therapeutic advantages of reducing the level of glucose, though the means of a 
ketogenic diet or through therapeutic agents including 3-HB and metformin. 3-HB 
has been shown to have a higher calorific value compared to glucose as well as an 
efficient provision of energy in cells with functioning mitochondria (Veech et al., 
2004). The reduction in the availability of glucose impacts cancer growth, restricting 
the glucose metabolite energy source tumour cells necessitate, whilst concurrently 
lacking the ability to metabolise ketone bodies resulting in the inhibition of growth 
and tumorigenesis.  
Studies have shown the effectiveness of 3-HB in reducing the proliferation of tumour 
cells in a range of cancers, including human glioblastoma cell lines (Woolf et al., 
2016). 3-HB treatment has also demonstrated the ability to increase the sensitivity 
of cancer cells to ionizing radiation, as well as the increased effectiveness of 
 189 
 
chemotherapeutic agents when used in combination in glioblastoma cells, for the 
potentiation of lower doses (Scheck et al., 2012; Rossi et al., 2015; Silva-Nichols et 
al., 2015). The switch to a ketogenic environment reduces the abundant availability 
of glucose. Cancer cells lack the ability to metabolise ketone bodies leading to a 
reduction in proliferation whilst unaffecting healthy cell growth with their ability to 
metabolise ketone bodies. The higher HK2 expressing glioblastoma cultures (IN859, 
U251MG and IN1979) exhibited a lower tolerance to reduced levels of glucose 
compared to IN2045. These samples also have faster doubling times. In comparison 
IN2045 has a slower doubling time of 36 hours which may potentiate the altered 
effect of glucose reduction over the 8- day period. It has also been proposed that 
the effect of ketone bodies upon cancer growth was dependent on the tumor’s 
energetic phenotype whereby cells with the predominant “glycolytic, Warburg-like 
phenotype” would be unable to metabolize 3-HB resulting in it accumulating 
intracellularly inhibiting tumor growth via signaling and epigenetic mechanisms; 
conversely tumours with “oxidative cells” would use 3-HB as an additional energy 
source resulting in an increased growth rate when this metabolite is available 
(Rodrigues et al., 2017; Bartmann et al., 2018). There are conflicting reports from 
studies, some demonstrate 3-HB to significantly reduce tumour growth in 
glioblastoma and pancreatic cancers (Shukla et al., 2014; Martuscello et al., 2016), 
whilst other studies state ketone bodies to be associated with cancer progression 
and metastasis, including epithelial and breast cancer (Bonuccelli et al., 2010; 
Martinez-Outschoorn et al., 2011). 
The microenvironment created in tissue culture is often altered in comparison to the 
natural cellular environment which can generate genetic alterations, such an 
example is the concentration of glucose available to the cell. A healthy adult on 
average has circulating glucose levels around 5-6mmol/l, in comparison the glucose 
concentration in average tissue culture media ranges from 10-25 mmol/l. To address 
this discrepancy the use of an alternative culture media that has a similar glucose 
concentration can be used, for example Hams F-10 which has a 6mM concentration 
of glucose, comparable to the circulating blood glucose of the human body. The 
exaggerated abundance of glucose in the culture media can have detrimental and 
inaccurate effects on cellular responses to inhibitory molecules such as ketone 
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bodies, glucose pathway inhibitors and metformin, the latter of which has been 
shown to have reduced efficacy in ovarian and breast cancers (Litchfield, et al., 
2015). 
The data obtained from this study would suggest that increased HK2 expression in 
cells would indicate higher energetic phenotypes with increased doubling times, as 
potentially seen in IN859, U251MG and IN1979. Importantly, NHA demonstrated the 
ability to successfully proliferate, albeit at a slightly reduced level under ketogenic 
conditions. This is promising for the application of potential therapeutic approach, as 
a non-cancerous cell NHA, demonstrated the ability to metabolise ketone bodies. 
The data also showed that 3-HB supplementation and an increased level of ketones 
were non-toxic to healthy cells. This study indicates the potential therapeutic 
advantages of targeting both HK2 and the glucose pathway, with both a reduction in 
cell proliferation and an increased chemosensitivity in a significant subset of 
glioblastoma.  
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Chapter 5 
Expression arrays: 
Deregulated glucose 
metabolism in 
glioblastoma 
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5.1 Introduction  
Qiagen RT expression profiler arrays (Qiagen, UK) were utilized to analyse the 
expression of 84 key genes involved in the regulation and enzymatic pathway of 
glucose metabolism in a panel of 6 glioblastoma biopsy tissues, 10 patient- derived 
cell cultures and the established cell line U251MG (as shown in Table 2.1) compared 
to normal brain tissue and NHA. The cumulative threshold (Ct) data obtained was 
normalised to 5 housekeeping genes (ACTB, B2M, GAPDH, HPRT1 and RPLP0). 
Alterations in the level of gene expression across the pathway were also determined 
in glioblastoma cell cultures grown under hypoxic conditions and post treatment 
conditions, including the addition of HK2 inhibitors and CRISPR mediated HK2 -KO. 
Un-abbreviated gene list is shown in full in the appendix. 
5.1 Differential expression of glycolytic genes in glioblastoma tissue 
Differential expression was investigated in 6 glioblastoma biopsy samples compared 
to 5 normal brain tissue samples.  Upregulations of 50 of 84 genes in the glucose 
pathway was identified, as shown in Figure 5.1.  The fold change increase in these 
50 genes ranged from 2.06 (AGL) to 6.85 (PCK2). Additionally, downregulation was 
demonstrated in 6 genes, ranging from -2.54 (SDHC) to -3.65 (UGP2).  
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Figure 5.1 Scatter plot comparing the level of fold change across 84 genes in 
glioblastoma biopsies (n=6) compared to normal tissue (n=5).  Each dot represents the 
expression of a gene. The y-axis represents fold-change expression of the glioblastoma sample, the 
x-axis represents expression of the normal tissue control. Genes (dots) further to the right show 
higher expression compared to normal tissue. Higher dots represented greater expression in the 
glioblastoma samples. 
The level of significance for each gene fold change was calculated using a Student’s 
t-test. Grouping the glioblastoma samples, a volcano plot approach was utilized to 
visually represent the significantly altered genes between samples, where 
representative samples were grouped to give a precise mean (Wentian et al., 2014). 
The volcano plot shows significance versus fold-change on the y and x axes, 
respectively. The Y-axis represents the log10 p-value whilst the X-axis shows the 
log2 fold change level. The larger the difference in expression of a gene the more 
extreme it will lie on the X-axis. The more significant the difference, the smaller the 
p-value and thus the higher the -log10p-value value on the Y-axis. Genes with highly 
significant differences will lie higher, in the upper left and upper right parts of the 
volcano plot. The statistical calculations and volcano plots were completed using 
Qiagen PCR array data analysis web-based software (version of software). 
Twenty-three genes showed highly significant differences in expression in the 
biopsies compared to normal tissue, comprising 19 of these genes were significantly 
overexpressed genes ranging from 2.99 (ALDOA) to 5.85 (PRPS1L1) (p<0.005) and 
4 genes with downregulation (p<0.005) in the glioblastoma samples, as shown in 
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Table 5.1 and Figure 5.2. The variance in fold change of the genes were also 
examined between the individual biopsies to establish the degree of homogeneity 
between expression levels. A variation in the individual gene expression between the 
biopsies was shown, where 15 of the 23 significantly altered genes had a >2- fold 
variation between samples. Additionally, 8 of the genes demonstrated little variance 
(≤2-fold change), as shown in Figure 5.3 (Table A6 shown in the appendix). The 
data suggests that significant alteration in multiple genes is occurring in glioblastoma 
biopsies compared to normal tissue, however varied expression is demonstrated in 
48% of the genes in the biopsy samples, indicative of the diverse heterogeneity of 
glioblastoma. The data indicates the occurrence of overexpression throughout the 
glucose pathway in glioblastoma tissue, with over 60% of the genes showing levels 
of overexpression ensuing within the tumour tissue. Furthermore, 19 of these genes 
(Table 5.1) demonstrated significant levels of upregulation across all 6 biopsy 
samples, indicating a substantially perturbed glucose pathway emerging in 
glioblastoma tissue. 
 
Figure 5.2 Volcano plot comparing the level of fold change across 84 genes in 
glioblastoma biopsies (n=6). Fold change compared to normal tissue. Represented genes above 
the threshold all show significant change (p<0.05). The volcano plot shows significance versus fold-
change on the y and x axes, respectively. The Y-axis represents the log10 p-value whilst the X-axis 
shows the log2 fold change level. 
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Table 5.1 Expression fold change values of glycolytic genes in glioblastoma biopsies 
compared to normal brain 
Gene 
Log2 Fold 
Change 
Gene Log2 Fold Change 
ALDOA 2.99 PCK1 3.74 
ALDOB 3.33 PCK2 3.75 
ENO1 5.07 PGK1 4.04 
FBP2 4.04 PGK2 3.28 
G6PC 3.78 PKLR 3.11 
GCK 4.47 PRPS1L1 5.85 
GYS1 5.43 RBKS 4.58 
GYS2 4.65 ACO2 -1.88 
HK2 5.58 ENO2 -2.3 
HK3 3.5 SUCLA2 -1.73 
MDH1 3.86 UGP2 -1.53 
MDH2 4.85 
 
Table showing changes in fold change in glioblastoma biopsies (n=6) compared to normal tissue 
(n=5). All genes show significant change (p<0.05) as represented in the Volcano plot. 
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5.2 Differential expression of glycolytic genes in glioblastoma culture 
The glycolytic expression patterns of 10 glioblastoma cultures were investigated, 
including patient-derived cultures and the established cell line U251MG. The samples 
were compared to both normal brain tissue and NHA. Thirty-three genes showed 
significant alterations in the cultures compared to NHA, of which 31 were 
overexpressed (p<0.005) in the glioblastoma cultures and 2 genes were 
downregulated (p<0.005), as shown in Table 5.2 and Figure 5.4. The increased fold 
change expression across the glycolytic genes in the cultures ranged from 1.82 
(GSK3A) to 6.21 (ACLY). The variance in fold change of the genes were also 
examined between the individual cultures to establish the degree of homogeneity of 
expression levels. Minor variation in the individual gene expression between the 
cultures was shown, where 82% of the significantly altered genes had ≤2- fold 
variation between the cultures, with only 6 genes demonstrating a variance ≥2-fold 
change, as shown in Figure 5.5 (Table shown in the appendix).  
 
 
Figure 5.4 Volcano plot comparing the level of fold change in glioblastoma cultures 
compared to NHA in 84 genes in glioblastoma cultures (n=10). Fold change compared to 
NHA. Represented genes above the threshold all show significant change (p<0.05). 
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Table 5.2 Expression fold change values of glycolytic genes in glioblastoma cultures 
compared to NHA 
Gene Log2 Fold Change 
ACLY 6.21 
ACO1 3.67 
ACO2 3.18 
 CS 3.06 
DLD 4.93 
DLST 3.25 
ENO3 4.42 
FH 1.86 
G6PD 3.18 
GSK3A 1.82 
H6PD 3.71 
HK2 3.87 
IDH2 3.24 
IDH3G 2.79 
MDH1 3.78 
MDH2 3.29 
OGDH 2.65 
PC 4.42 
PDHB 4.76 
PDK2 4.4 
PDP2 4.76 
PFKL 5.06 
PGAM2 3.61 
PGM3 2.86 
PHKG2 4.78 
PKLR 2.56 
PRPS1 3.99 
PRPS1L1 2.74 
RPE 3.24 
SDHA 1.84 
TKT 2.31 
 
Gene Fold Change 
SUCLA2 -1.80 
UGP2 -2.36 
Table showing fold changes in glioblastoma cultures compared to NHA. All genes show significant 
change (p<0.05) as represented in the Volcano plot. 
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Comparison of glioblastoma cultures to normal brain tissue revealed a perturbed 
expression, the cultures were grouped in order to perform statistical calculations. 
Fifty-two genes in all culture samples demonstrated highly significant differences 
compared to normal tissue, where 50 of the genes exhibited significant 
overexpression (p<0.005) in the glioblastoma cultures. Additionally, 2 genes 
exhibited significant downregulation (p<0.005) in the glioblastoma samples, as 
shown in Table 5.3 and Figure 5.6. The increased fold change expression across the 
glycolytic genes in the cultures ranged from 2.26 (PRPS1) to 8.26 (PCK2). The 
variance in fold change of the genes were also examined between the individual 
cultures to establish the degree of homogeneity of expression levels. Minor variation 
in the individual gene expression between the cultures was shown, where 92% of 
the significantly altered genes had ≤2- fold variation between the cultures, with only 
4 genes demonstrating a variance ≥2-fold change, as shown in Figure 5.7.  
 
Figure 5.6 Volcano plot comparing the level of fold change across 84 genes in 
glioblastoma cultures (n=10). Fold change compared to normal tissue. Represented genes above 
the threshold all show significant change (p<0.05). 
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Table 5.3 Expression fold change values of glycolytic genes in glioblastoma cultures 
compared to normal brain 
Gene 
Log2 Fold 
Change 
Gene 
Log2 Fold 
Change 
ACLY 6.18 OGDH 3.7 
ACO1 5.29 PC 4.4 
ACO2 3.99 PCK2 8.26 
ALDOA 2.93 PDHB 3.37 
BPGM 5.14 PDK1 2.59 
CS 6.45 PDK2 2.8 
DLD 4.88 PDP2 2.35 
DLST 4.92 PDPR 5.45 
ENO1 4.22 PFKL 2.36 
ENO3 3.44 PGAM2 5.69 
FH 4.15 PGK1 4.67 
G6PC 2.98 PGLS 2.83 
G6PC3 4.12 PGM1 3.89 
G6PD 5.14 PGM2 3.71 
GBE1 4.76 PGM3 2.14 
GPI 4.27 PHKB 3 
GSK3A 4.51 PHKG2 5.95 
GSK3B 3.63 PRPS1 2.26 
GYS1 5.46 PRPS1L1 3.21 
H6PD 4.11 PYGL 3.59 
HK2 6.67 RPE 3.05 
IDH2 4.53 RPIA 4.73 
IDH3G 2.45 SDHA 2.7 
MDH1 2.68 SUCLG2 2.57 
MDH2 3.57 TKT 3.22 
 
Gene 
Log2 Fold 
Change 
ALDOC -2.81 
PYGM -2.67 
Table showing fold changes in glioblastoma cultures biopsies compared to normal brain tissue. All 
genes show significant change (p<0.05) are represented in the Volcano plot. 
 
Overexpression of multiple genes were demonstrated in both the glioblastoma 
biopsies and cultures compared to normal brain tissue. Notably the level of 
overexpression in both the biopsies and cultures were comparable in 10 of the 
genes, as shown in Table 5.4. Additionally, levels of overexpression were similar in 
the glioblastoma cultures when compared to both normal brain tissue and NHA in 30 
genes as shown in Table 5.5. 
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Table 5.4 Expression fold change values of glycolytic genes in glioblastoma 
biopsies and cultures compared to normal brain 
 
Log2 Fold Change 
Gene Biopsy Culture 
ALDOA 2.99 2.93 
ENO1 5.07 4.22 
G6PC 3.78 2.98 
GYS1 5.43 5.46 
HK2 5.58 6.67 
MDH1 3.86 2.68 
MDH2 4.85 3.57 
PCK2* 3.75 8.26 
PGK1 4.04 4.67 
PRPS1L1 5.85 3.21 
Table showing fold change values in glioblastoma biopsies and patient derived cultures compared to 
normal brain tissue. All genes are significantly downregulated (p<0.005). * represents gene with fold 
change variation >2 between the biopsies and cultures. 
Table 5.5 Expression fold change values of glycolytic genes in glioblastoma 
cultures compared to normal brain and NHA 
Gene Culture vs NHA Culture vs normal Gene Culture vs NHA Culture vs normal 
ACLY 6.21 6.18 MDH2 3.29 3.57 
ACO1 3.67 5.29 OGDH 2.65 3.7 
ACO2 3.18 3.99 PC 4.42 4.4 
CS* 3.06 6.45 PDHB 4.76 3.37 
DLD 4.93 4.88 PDK2 4.4 2.8 
DLST 3.25 4.92 PDP2* 4.76 2.35 
ENO3 4.42 3.44 PFKL* 5.06 2.36 
FH* 1.86 4.15 PGAM2* 3.61 5.69 
G6PD* 3.18 5.14 PGM3 2.86 2.14 
GSK3A* 1.82 4.51 PHKG2 4.78 5.95 
H6PD 3.71 4.11 PRPS1 3.99 2.26 
HK2* 3.87 6.67 PRPS1L1 2.74 3.21 
IDH2 3.24 4.53 RPE 3.24 3.05 
IDH3G 2.79 2.45 SDHA 1.84 2.7 
MDH1 3.78 2.68 TKT 2.31 3.22 
Table showing fold change values in patient derived cultures compared to normal brain tissue and 
NHA. All genes are significantly downregulated (p<0.005). * represents genes with fold change 
variation >2 between the cultures. 
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5.3 Differential expression of glycolytic genes in paired glioblastoma 
biopsy tissue and derivative cell cultures 
The glycolytic expression patterns of 6 glioblastoma tissue biopsies and their 
derivative paired cultures were investigated to determine whether differential 
expression is maintained in vitro and to confirm the validity of using patient-derived 
cultures as a model to investigate potential metabolic therapies. Significant 
overexpression (p<0.005) was exhibited on average in 14 of the 84 glucose pathway 
genes in all cultures compared to their respective glioblastoma tissue samples (n=6). 
No downregulation was demonstrated across any gene in the 6 paired samples, as 
shown in Table 5.6 and Figure 5.8. The increased fold change in expression across 
the glycolytic genes in the cultures ranged from 1.9 (G6PC3) to 4.03 (PGM2). Minute 
variation (<2-fold change) in the level of fold change was shown in 79% of the 
deregulated genes across all samples, indicating that the altered expression is 
present to a similar degree in all cultures as shown in Figure 5.9 (Table A7 shown in 
the appendix).  
The expression profiler arrays determined overexpression in 17% glycolytic genes in 
the derivative cell cultures, with 14 of the 84 genes showing a significant increased 
level (p<0.005) of expression compared to their paired tissue samples. The data also 
shows the significant genetic similarity between the paired samples, with over 80% 
of the genes exhibiting comparable levels (<1-fold change) of expression across the 
glucose pathway, indicative of gene stability in the patient derived cultures, thus 
presenting as a useful tool and an accurate model for glioblastoma metabolism. 
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Figure 5.8 Volcano plot comparing the level of fold change across 84 genes in 
glioblastoma cultures. Fold change compared to the respective glioblastoma paired tissue in 6 
samples. Represented genes above the threshold all show significant change (p<0.05). 
 
Table 5.6 Expression fold change values of glycolytic genes in paired derivative cell 
cultures compared to glioblastoma biopsy tissue 
Gene  
Log2 Fold 
Change 
ACO1 2.42 
ACO2 3.21 
BPGM 3.86 
DLAT 3.87 
DLD 3.09 
DLST 3.78 
ENO1 2.62 
G6PC3 1.9 
G6PD 3.33 
HK2 2.13 
PDHA1 3.24 
PDK2 2.26 
PFKL 2.73 
PGLS 3.45 
PGM1 3.32 
PGM2 4.03 
PHKG2 3.42 
PYGL 3.6 
SDHB 2.89 
TKT 3.54 
Table showing changes in fold change in glioblastoma cultures compared to the respective 
glioblastoma paired tissue samples (n=6). Represented genes all show significant change (p<0.05) 
and represented in the Volcano plot, which graphs the log2 of the fold change in each gene's 
expression between the samples versus its p value from the t-test. 
 208 
 
 
 
F
ig
u
re
 5
.9
 B
a
r 
c
h
a
rt
 c
o
m
p
a
ri
n
g
 g
e
n
e
 e
x
p
re
s
s
io
n
 v
a
ri
a
ti
o
n
 b
e
tw
e
e
n
 t
h
e
 p
a
ir
e
d
 s
a
m
p
le
s
. 
T
h
e
 r
e
p
re
se
n
te
d
 g
e
n
e
s 
e
x
h
ib
it
 
si
g
n
if
ic
a
n
tl
y
 a
lt
e
re
d
 l
e
v
e
ls
 o
f 
e
x
p
re
ss
io
n
 i
n
 c
u
lt
u
re
 c
o
m
p
a
re
d
 t
o
 r
e
sp
e
ct
iv
e
 b
io
p
sy
 a
s 
sh
o
w
n
 i
n
 F
ig
u
re
 5
.8
 a
n
d
 T
a
b
le
 5
.6
. 
E
x
p
re
ss
io
n
 d
a
ta
 i
s 
sh
o
w
n
 f
o
r 
in
d
iv
id
u
a
l 
cu
lt
u
re
s 
to
 c
o
m
p
a
re
 l
e
v
e
ls
 o
f 
fo
ld
 c
h
a
n
g
e
. 
 
 209 
 
5.4 Differential expression of glycolytic genes in glioblastoma cultures 
under hypoxic conditions 
The glycolytic expression patterns of 3 glioblastoma cultures, including 2 patient-
derived cultures (IN859, IN2045) and the established cell line U251MG, were 
determined under hypoxic conditions compared to normoxia. Overexpression (≥2-
fold change) was exhibited in 31 of the 84 glucose pathway genes in glioblastoma 
cultures under hypoxic conditions compared to normoxia, with additional 
downregulation (≤2-fold change) demonstrated in 19 of the genes as shown in 
Figure 5.10.  The glioblastoma cultures were grouped to perform statistical 
calculations, where the hypoxic cultures were grouped and compared to the 
normoxic cultures. The data showed 13 genes with significant differences in cultures 
under hypoxic conditions compared to normoxia. Six of these genes were 
significantly overexpressed (p<0.005) in the hypoxic cultures, whilst a further 7 
genes exhibited significant downregulation (p<0.005) in the hypoxic glioblastoma 
samples compared to the normoxic conditions, as shown in Table 5.7 and Figure 
5.11. The increased fold change in expression across the glycolytic genes in the 
hypoxic cultures ranged from 5.03 (PGK2) to 6.31 (PGK1).  
The data suggests that expression change alterations occur across a range of 
glycolytic pathway genes in glioblastoma when hypoxic stress is instigated. Greater 
than 59% of the genes in the glucose pathway demonstrate perturbed levels of 
expression under hypoxic conditions across all 3 glioblastoma cultures, furthermore, 
significant altered (p<0.005) mRNA levels were revealed in 15.5% of the glycolytic 
genes.  
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Figure 5.10 Scatter plot comparing the level of fold change across 84 genes in 3 
glioblastoma cultures under hypoxic conditions compared to the respective normoxic 
cultures. Each dot represents the expression of a gene. The y-axis represents fold-change 
expression of the glioblastoma sample, the x-axis represents expression of the normal tissue control. 
Genes (dots) further to the right show higher expression compared to normal tissue. Higher dots 
represented greater expression in the glioblastoma samples. 
 
Figure 5.11 Volcano plot comparing the level of fold change across 84 genes in 3 
glioblastoma cultures under hypoxia. Fold change across 84 genes in 3 glioblastoma cultures 
under hypoxia compared to the respective cultures under normoxic conditions in. Represented genes 
above the threshold all show significant change (p<0.05). The Volcano plot graphs the log2 of the 
fold change in each gene's expression between the samples versus its p value from the t-test. 
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Table 5.7 Expression fold change values of glycolytic genes in hypoxic cultures compared 
to the respective normoxic cultures 
Gene Log2 Fold Change Gene Log2 Fold Change 
DLD 5.51 ACLY -2.22 
PGK1 6.31 ACO2 -2.73 
PGM2 5.76 DLST -3.52 
PGK2 5.03 GSK3A -1.02 
SUCLG1 5.89 H6PD -1.93 
UGP2 5.3 OGDH -2.62 
 
PFKL -3.39 
Table showing changes in expression levels of statistically significant genes (p=0.05) in 3 
glioblastoma cultures under hypoxic conditions compared to normoxia. 
 
Figure 5.12 Bar chart showing gene expression variation between hypoxic cultures. The 
represented genes exhibit significantly altered levels of expression in culture compared to their 
respective cultures grown in normoxic conditions, as shown in Figure 5.11 and Table 5.6.  
5.5 Differential expression of glycolytic genes after HK2 induced CRISPR 
Knockout  
The glycolytic expression patterns of 4 glioblastoma cultures, including 3 patient-
derived cultures (IN2045, IN859, IN1979) and the established cell line U251MG, 
were determined in CRISPR HK2- KO cultures compared to the respective parent 
cultures and NHA. Overexpression (>2-fold variation) was exhibited in 15 of the 84 
glucose pathway genes in HK2 - KO cultures compared to NHA, with downregulation 
demonstrated in 31 of the genes. The glioblastoma cultures were grouped to 
perform statistical calculations, where the CRISPR HK2- KO cultures were grouped 
and compared to NHA. The data showed 24 genes with highly significant differences 
in the HK2-KO cultures compared to NHA. Two of these genes were significantly 
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overexpressed (p<0.005) in the HK2-KO cultures, whilst a further 22 genes exhibited 
significant downregulation (p<0.005) in the HK2-KO glioblastoma samples compared 
to NHA, as shown in Table 5.8 and Figure 5.13. The downregulation in fold change 
expression across the glycolytic genes in the HK2-KO cultures ranged from -1.27 
(GSK3A) to -8.31 (HK2). The variance in fold change of the genes were also 
examined between the individual HK2-KO cultures to establish the degree of 
homogeneity in the levels of expression. An insignificant variation (<2-fold change) 
in the level of fold change was shown in 83% of the deregulated genes, indicating 
that the altered expression is present to a similar degree across all cultures. The 
HK2-KO cultures expression levels were also compared to the respective parent 
culture. Eighty- two of the 84 genes demonstrated altered expression values (>2-
fold variation), 80 genes were shown to have down-regulated expression and 2 
genes PYGM (4.21) and SDHC (2.41) exhibited overexpression across all HK2-KO 
cultures when compared to the parent cultures. 59 genes had significant 
downregulation (p<0.005) across all the HK2-KO cultures compared to the parent 
cultures as shown in Table 5.9 and Figure 5.14. The downregulation in fold change 
expression across the glycolytic genes in the HK2-KO cultures compared to the 
respective parent cultures ranged from -2.87 (RPIA) to -12.5 (HK2). Table 5.10 
highlights the significant changes (p<0.05) in mRNA values for 11 glycolytic genes 
across all the patient derived glioblastoma cultures and the corresponding CRISPR 
HK2-KO modified cultures compared to normal tissue. Significant overexpression of 
the 11 glycolytic genes are identified in all parent cultures compared to normal brain 
tissue, however, significant downregulation of the 11 glycolytic genes was 
demonstrated in the HK2-KO downregulated cultures across all 4 culture samples. An 
insignificant variation (<2-fold change) in the level of fold change was shown in 
93% of the deregulated genes, indicating that the altered expression is present to a 
similar degree across all cultures. CRISPR knockout of HK2 promoted 
downregulation of gene expression across the glucose pathway with over 70% of 
genes significantly downregulated (p<0.005) downstream of HK2, compared to the 
corresponding parent cultures. Furthermore, CRISPR HK2-KO cultures demonstrated 
a similar expression pattern to NHA, comparatively to the respective parent cultures, 
with a greater number of genes (n=9) within the HK2-KO cultures exhibiting similar 
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levels of expression to NHA. The data indicates that with the HK2-KO a universal 
reduction in glycolytic gene expression occurs in the glioblastoma cultures, resulting 
in a similar expression pattern to the non-cancerous NHA culture.  
 
Figure 5.13 Volcano plot comparing the level of fold change across 84 genes in 4 CRISPR 
HK2- KO modified glioblastoma cultures. Fold change across 84 genes in 4 CRISPR HK2- KO 
modified glioblastoma cultures compared to NHA. Represented genes above the threshold all show 
significant expression change (p<0.05). 
Table 5.8 Expression fold change values of glycolytic genes in HK2- KO cultures 
compared to NHA 
Gene Log2 Fold Change 
PGM2 2.44 
PGM3 2.6 
 
Gene Log2 Fold Change Gene Log2 Fold Change 
ACO2 -1.3 PC -6.5 
ALDOC -4.06 PCK1 -3.15 
ENO2 -3.47 PDK2 -6.48 
FBP1 -3.79 PDK3 -2.89 
GSK3A -1.27 PDK4 -5.9 
HK2 -8.31 PGAM2 -4.8 
HK3 -1.9 PYGM -3.02 
IDH3A -2.22 SDHA -2.88 
IDH2 -2.34 SDHC -3.59 
MDH1 -4.2 SUCLA2 -2.91 
MDH1B -3.15 UGP2 -1.54 
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Table showing changes in fold change average in 4 CRISPR HK2-KO modified glioblastoma cultures 
compared to NHA. Represented genes all show significant change (p<0.05).  
 
Figure 5.14 Volcano plot comparing the level of fold change across 84 genes in 4 CRISPR 
HK2- KO modified glioblastoma cultures. Fold change across 84 genes in 4 CRISPR HK2- KO 
modified glioblastoma cultures compared to the respective parent cultures. Represented genes above 
the threshold all show significant expression change (p<0.05). 
 
Table 5.9 Expression fold change values of glycolytic genes in HK2- KO cultures and 
parent cultures compared to normal brain tissue 
 Log2 Fold Change 
Gene Parent CRISPR 
ACO2 14.5 -4.52 
ALDOA 54.13 -6.61 
 GSK3A 32.4 -3.84 
HK2 820.97 -12.5 
HK3 4.63 -6.75 
IDH2 15.34 -6.65 
IDH3A 20.47 -4.1 
MDH1 11.83 -5.33 
PC 8.65 -4.47 
PDK2 19.58 -6.97 
PGAM2 11.98 -4.86 
Table showing changes in fold change values in patient derived glioblastoma cultures and 
corresponding CRISPR HK2-KO modified cultures compared to normal tissue. Represented genes all 
show significant change (p<0.05). 
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Table 5.10 Expression fold change values of glycolytic genes in HK2- KO cultures 
compared to the respective parent cultures 
Gene 
Log2 Fold 
Change 
Gene 
Log2 Fold 
Change 
ACLY -5.89 IDH2 -6.65 
ACO2 -4.52 IDH3A -4.1 
AGL -2.76 MDH1 -5.33 
ALDOA -6.61 MDH2 -5.01 
ALDOB -6.63 OGDH -7.09 
ALDOC -4.28 PC -4.47 
BPGM -4.18 PCK1 -5.36 
CS -4.67 PCK2 -5.3 
DLAT -3.46 PDK1 -4.59 
DLST -6.53 PDK2 -6.97 
ENO2 -5.47 PDK3 -3.99 
ENO3 -4.58 PDP2 -4.91 
FBP1 -4.76 PDPR -6.01 
FH -4.27 PFKL -6.3 
G6PC -6.95 PGAM2 -4.86 
G6PC3 -4.77 PGK2 -4.27 
G6PD -7.3 PGLS -6.6 
GALM -5.69 PGM2 -6.61 
GBE1 -6.19 PGM3 -5.7 
GCK -5.84 PHKB -5.13 
GPI -5.52 PHKG1 -6.28 
GSK3A -3.84 PKLR -4.6 
GSK3A -5.88 PYGM -5.14 
GSK3B -4.73 RBKS -4.77 
GYS1 -5.3 RPE -4.19 
GYS2 -6.93 RPIA -2.87 
H6PD -3.74 SDHA -4.87 
HK2 -12.5 SDHD -5.82 
HK3 -6.75 SUCLA2 -6.13 
Table showing changes in fold change values in CRISPR HK2-KO modified glioblastoma cultures 
compared to corresponding patient derived cultures. Represented genes all show significant change 
(p<0.05). 
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5.6 Differential expression of glycolytic genes via multiple inhibitory methods 
The glycolytic expression patterns of 3 glioblastoma cultures, including 2 patient-
derived cultures and the cell line U251MG, was investigated after treatment with a 
specific inhibitor compared to the respective untreated cultures. The selected 
cultures represented both a high (IN859) and a low (IN2045) expressing HK2 
sample.  
5.6.1 Differential expression of glycolytic genes after 3-HB supplementation 
Three glioblastoma cultures were supplemented with the ketone body 3-HB at 
500µM for 72 hours, as an alternative energy source in glucose deprived cultures, as 
described in Material and Methods and Chapter 4.6. The expression levels in the 
treated cultures were compared to the respective non-treated culture. Eighty- two of 
the 84 glycolytic genes displayed down-regulated expression (≤2-fold change) 
ranging from -1.96 to -9.8- fold change and 1 gene exhibited overexpression (2.5- 
fold change) across all 3-HB supplemented cultures when compared to the 
respective cultures grown in normal glucose (6mM) conditions. Sixty genes 
demonstrated significant downregulation (p<0.005) across all the 3-HB 
supplemented glioblastoma culture compared to the respective cultures grown in 
normal glucose conditions, as shown in Table 5.11 and Figure 5.17. 
 
Figure 5.17 Volcano plot comparing the level of fold change in gene expression across 84 
genes in 3 glioblastoma cultures supplemented with the ketone body 3-HB. Fold change in 
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gene expression compared to the respective cultures grown in normal glucose conditions. 
Represented genes above the threshold all show significant change (p<0.05) 
 
Table 5.11 Expression fold change values of glycolytic genes in 3-HB supplemented 
cultures compared to the respective cultures grown in normal glucose conditions 
Gene  
Log2 Fold 
Change 
Gene  
Log2 Fold 
Change 
ACLY -5.12 PCK2 -5.85 
ACO1 -7.75 PDHA1 -6.83 
ACO2 -6.48 PDHB -7.08 
AGL -6.96 PDK1 -7.87 
ALDOA -7.89 PDK2 -5.14 
BPGM -7.5 PDK3 -7.46 
CS -6.34 PDP2 -7.26 
DLAT -8.43 PDPR -6.81 
DLD -5.88 PFKL -7.59 
DLST -6.88 PGAM2 -6.21 
ENO2 -7.02 PGK1 -6.3 
FBP1 -6.41 PGLS -7.87 
FH -6.76 PGM1 -6.38 
G6PC3 -7.1 PGM2 -6.73 
G6PD -9.8 PGM3 -7.24 
GBE1 -7.98 PHKB -7.22 
GPI -6.98 PHKG1 -7.08 
GSK3A -5.96 PHKG2 -6.69 
GSK3B -6.35 PKLR -6.1 
GYS1 -7.78 PRPS1 -7.93 
H6PD -6.44 PRPS1L1 -5.65 
HK2 -8.29 PYGL -7.94 
HK3 -6.41 PYGM -6.4 
IDH2 -6.11 RBKS -7.62 
IDH3A -7.78 RPE -7.85 
IDH3B -5.06 RPIA -6.83 
IDH3G -6.41 SDHA -6.28 
MDH1 -5.32 SDHD -6.3 
MDH2 -5.98 SUCLG2 -6.84 
OGDH -6.19 TPI1 -7.52 
Table showing changes in fold change values in 3- supplemented cultures compared to the respective 
cultures grown in normal glucose conditions. Represented genes all show significant change 
(p<0.05). 
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5.6.2 Differential expression of glycolytic genes after 72-hour 3-BPA 
treatment 
Three glioblastoma cultures were treated with the HK2 inhibitor 3-BPA at culture-
specific ID50 values for 72 hours, as stated in 4.3.1. The expression levels were 
compared to the respective non-treated culture. 76 of the 84 genes demonstrated 
altered expression values, including 75 genes showing down-regulated expression 
(1.1 to 8.2- fold change) and 1 gene with overexpression (3.9- fold change) in all 
the 3-BPA treated cultures when compared to the respective non-treated cultures. 
42 genes demonstrating significant downregulation (p<0.005) across all the 3-BPA 
treated glioblastoma samples compared to the respective non-treated cultures, as 
shown in Table 5.12 and Figure 5.19. The downregulation in fold change expression 
across the glycolytic genes in the 3-BPA treated cultures ranged from -4.66 (FH) to -
8.35 (PCK2). An insignificant variation (<2-fold change) in the level of fold change 
was shown in 76% of the deregulated genes, indicating that the altered expression 
is present to a similar degree across all cultures. 
 
Figure 5.19 Volcano plot comparing the level of fold change across 84 genes in 3 
glioblastoma cultures treated with HK2 inhibitor 3-BPA. Fold change in gene expression at the 
relevant ID50 value, compared to the respective non-treated cultures. Represented genes above the 
threshold all show significant change (p<0.05). 
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Table 5.12 Expression fold change values of glycolytic genes in 3-BPA treated cultures 
compared to non-treated cultures 
Gene 
Log2 Fold 
Change 
Gene 
Log2 Fold 
Change 
ACLY -6.73 MDH1 -6.13 
ACO1 -5.47 MDH2 -5.67 
ACO2 -7.58 OGDH -5.7 
AGL -5.6 PC -7.51 
ALDOA -6.82 PCK2 -8.35 
BPGM -6.74 PDHA1 -5.26 
CS -5.76 PDHB -5.08 
DLAT -6.02 PDK2 -6.05 
DLST -5.4 PDP2 -6.91 
FH -4.66 PDPR -6.09 
G6PD -8.26 PFKL -7.72 
GPI -5.63 PGAM2 -4.84 
GSK3A -7.71 PGLS -8.08 
GSK3B -7.23 PGM1 -5.63 
GYS1 -6.87 PHKB -8.28 
H6PD -7.87 PHKG2 -5.78 
HK2 -8.15 PRPS1 -6.36 
IDH2 -7.69 PYGL -5.59 
IDH3A -6.2 RPIA -5.63 
IDH3B -7.84 SDHA -6.68 
IDH3G -6.75 TKT -7.75 
Table showing changes in fold change values in 3-BPA treated and corresponding non-treated 
glioblastoma cultures. Represented genes all show significant change (p<0.05). 
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5.6.3 Differential expression of glycolytic genes after 72-hour metformin 
treatment 
Three glioblastoma cultures were treated with metformin at culture specific ID50 
values over 72 hours, as stated in 4.3.2. The expression levels were compared to the 
respective non-treated culture, and 71 of the 84 genes demonstrated altered 
expression values, including 74 genes showing down-regulated expression (2.02 to 
7.98- fold change) and 1 gene exhibited overexpression (1.3- fold change) across all 
metformin treated cultures. 50 genes demonstrated significant downregulation 
(p<0.005) across all the metformin treated glioblastoma samples compared to the 
respective non-treated cultures, as shown in Table 5.13 and Figure 5.21. The 
downregulation in mRNA fold change expression across the glycolytic genes in the 
metformin treated cultures ranged from -3.33 (RPE) to -8.14 (PFKL). An insignificant 
variation (<2-fold change) in the level of fold change was shown in 84% of the 
deregulated genes, indicating that the altered expression is present to a similar 
degree across all cultures. 
 
Figure 5.21 Volcano plot comparing the level of fold change across 84 genes in 3 
glioblastoma cultures treated with metformin. Fold change in gene expression at the relevant 
ID50 value, compared to the respective non-treated cultures. Represented genes above the threshold 
all show significant change (p<0.05). 
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Table 5.13 Expression fold change values of glycolytic genes in metformin treated 
cultures compared to non-treated cultures 
Gene 
Log2 Fold 
Change 
Gene 
Log2 Fold 
Change 
ACLY -4.92 MDH2 -4.97 
ACO1 -6.47 OGDH -5.18 
ACO2 -7.51 PC -4.95 
AGL -5.22 PCK2 -5.49 
ALDOA -6.54 PDHA1 -6.25 
BPGM -7.16 PDHB -6.23 
CS -6.42 PDK1 -5.3 
DLAT -5.91 PDK2 -6.28 
DLD -6.73 PDP2 -7.83 
DLST -8.11 PDPR -6.34 
ENO1 -7.94 PFKL -8.14 
ENO3 -6.51 PGAM2 -6.67 
FH -7.83 PGK1 -4.56 
G6PD -7.91 PGLS -7.35 
GBE1 -4.72 PGM1 -5.89 
GPI -7.93 PGM2 -5.67 
GSK3A -6.1 PGM3 -4.34 
GSK3B -6.62 PHKB -6.97 
GYS1 -4.94 PHKG2 -7.65 
H6PD -4.03 PRPS1 -7.51 
HK2 -6.93 PYGL -5.34 
IDH2 -5.39 RPE -3.33 
IDH3A -5.01 RPIA -4.6 
IDH3G -7.05 SDHA -7.69 
MDH1 -5.09 TKT -7.95 
Table showing changes in fold change values in metformin treated and corresponding non-treated 
glioblastoma cultures. Represented genes all show significant change (p<0.05). 
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The data indicates differential expression between the cultures treated with the 
inhibitors compared to the non-treated cultures, across the genes in the glucose 
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pathway. The inhibitors metformin and 3-BPA, and the ketone body 3-HB were 
previously shown to have both a cytotoxic and anti-proliferative effect impacting 
glioblastoma cultures. The data presented here indicates that the inhibitors also 
have an impact upon the glucose pathway, with considerable downregulation of 
glycolytic genes across the entire pathway. Of the 84 genes tested in the arrays, 40 
showed significant downregulation across all three of the inhibitors analysed, with 
altered mRNA levels shown compared to non-treated glioblastoma cultures, as 
shown in Table 5.14 and Figure 5.23. The data also corresponds closely to the 
CRISPR HK2-KO figures, where the knockout of HK2 instigates downregulation of 
gene expression across the glucose pathway.  In both the treated and CRISPR 
modified cultures the array data revealed extensive changes in gene expression 
across the glucose pathway compared to the respective non-treated cultures, either 
through the loss or inhibition of HK2, in the case of 3-BPA and the CRISPR modified 
cultures, or via the deficit of glucose in the case of metformin and 3-HB. Both these 
mechanisms of action result in a similar genetic pattern with widespread significant 
(p<0.005) downregulation of genes across the glucose pathway. 
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Table 5.14 Expression fold change values of glycolytic genes in treated cultures 
compared to non-treated cultures 
 
Log2 Fold Change 
Gene HK2-KO 3-BPA Metformin 3-HB 
ACLY -5.89 -6.73 -4.92 -5.12 
ACO2* -4.52 -7.58 -7.51 -6.48 
AGL* -2.76 -5.6 -5.22 -6.96 
ALDOA -6.61 -6.82 -6.54 -7.89 
BPGM* -4.18 -6.74 -7.16 -7.5 
CS -4.67 -5.76 -6.42 -6.34 
DLAT* -3.46 -6.02 -5.91 -8.43 
FH* -4.27 -4.66 -7.83 -6.76 
G6PD* -7.3 -8.26 -7.91 -10.08 
GPI -5.52 -5.63 -7.93 -6.98 
GSK3A -5.88 -7.71 -6.1 -5.96 
GSK3B* -4.73 -7.23 -6.62 -6.35 
GYS1* -5.3 -6.87 -4.94 -7.78 
H6PD* -3.74 -7.87 -4.03 -6.44 
HK2* -12.5 -8.15 -6.93 -8.29 
IDH2 -6.65 -7.69 -5.39 -6.11 
IDH3A* -4.1 -6.2 -5.01 -7.78 
MDH1 -5.33 -6.13 -5.09 -5.32 
MDH2 -5.01 -5.67 -4.97 -5.98 
OGDH -7.09 -5.7 -5.18 -6.19 
PCK2* -5.3 -8.35 -5.49 -5.85 
PDK1* -4.59 -6.05 -5.3 -7.87 
PDP2* -4.91 -6.91 -7.83 -7.26 
PDPR -6.01 -6.09 -6.34 -6.81 
PFKL -6.3 -7.72 -8.14 -7.59 
PGAM2 -4.86 -4.84 -6.67 -6.21 
PGLS -6.6 -8.08 -7.35 -7.87 
PGM1 -6.61 -5.63 -5.89 -6.38 
PHKB* -5.13 -8.28 -6.97 -7.22 
RPIA* -2.87 -5.63 -4.6 -6.83 
SDHA* -4.87 -6.68 -7.69 -6.28 
Table showing fold change values in patient derived glioblastoma cultures treated with 3-BPA and 
metformin or modified with 3-HB supplementation or CRISPR HK2-KO, compared to corresponding 
non treated cultures. All genes are significantly downregulated in all 3 treatments (p<0.005). * 
represents genes with fold change variation >2 between the treatments.  
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Table 5.15 Expression fold change values of glycolytic genes in biopsy samples compared 
to treated/modified cultures 
Gene Biopsy HK2-KO 3-BPA Metformin 3-HB 
ALDOA 2.99 -6.61 -6.82 -6.54 -7.89 
ALDOB 3.33 -6.63 - - - 
ENO1 5.07 - - -7.94 - 
G6PC 3.78 -6.95 - - - 
GCK 4.47 -5.84 - - - 
GYS1 5.43 -5.3 -6.87 -4.94 -7.78 
GYS2 4.65 -6.93 - - - 
HK2 5.58 -12.5 -8.15 -6.93 -8.29 
HK3 3.5 -6.75 - - - 
MDH1 3.86 -5.33 -6.13 -5.09 -5.32 
MDH2 4.85 -5.01 -5.67 -4.97 -5.98 
PCK1 3.74 -5.36 - - - 
PCK2 3.75 -5.3 -8.35 -5.49 -5.85 
PGK1 4.04 - - -4.56 -6.3 
PGK2 3.28 -4.27 - - - 
PKLR 3.11 -4.6 - - -6.1 
PRPS1L1 5.85 - - - -5.65 
RBKS 4.58 -4.77 - - -7.62 
ACO2 -1.88 -4.52 -7.58 -7.51 -6.48 
ENO2 -2.3 -5.47 - - -7.02 
SUCLA2 -1.73 -6.13 - - - 
Table showing fold change values in glioblastoma biopsies compared to patient derived glioblastoma 
cultures treated with 3-BPA and metformin or modified with 3-HB supplementation or CRISPR HK2-
KO. Biopsy samples are compared to normal tissue and the cultures to their respective non-
treated/parent cultures. All treated/modified cultures show a reversal of fold change across numerous 
upregulated genes in glioblastoma. All genes are significantly downregulated in all 3 treatments 
(p<0.005). – indicates no significant change. 
 
 
5.7 Discussion  
This chapter has focused on the investigation of the differential expression across 84 
genes in the glucose pathway in glioblastoma biopsy (n=6) and patient- derived 
cultures (n=10) compared to normal brain tissue and NHA. Additionally, to 
determine the effects of HK2 downregulation through loss or inhibition, and the 
deficit of glucose, upon the gene expression profile in patient- derived cultures. 
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Qiagen RT expression profiler arrays have previously been used to determine 
alterations in cell metabolism and reprogramming across a diverse range of disease 
types, including the metabolic reprogramming of macrophages and the altered 
expression in oral squamous cell carcinoma (Freemerman et al., 2014; Pan et al., 
2017). The expression profiler arrays have also been utilized to determine genetic 
profiles and alterations for potential drivers of tumorigenesis, invasion and 
chemoresistance in a range of cancers, including human hepatocellular carcinomas 
(Govaere et al., 2014) and the growth and migration of hypopharyngeal squamous 
cells (Kelly et al., 2014). 
The array data in this study revealed recurrent gene overexpression throughout the 
glucose pathway in both glioblastoma biopsies and patient -derived cell cultures 
compared to their normal counterparts. A variation in gene overexpression was 
observed amongst the biopsies throughout the pathway, suggesting that although 
the significant alteration across multiple genes is occurring, there is variation of 
expression in the biopsies, which may reflect the characteristic heterogeneity of 
glioblastoma (Howlader et al., 2016). The study also showed that the differential 
expression is maintained in vitro, with similar expression patterns demonstrated 
between paired glioblastoma biopsy and culture samples. 
Overexpression of the glycolytic pathway is prevalent in glioblastoma  
Both glioblastoma biopsies (n=6) and patient-derived cell cultures (n=10) 
demonstrated gene overexpression, with over 60% of the genes showing 
upregulated levels within the tumour tissue and 88% in the cultures compared to 
normal brain tissue and NHA respectively. The biopsy samples were grouped for 
further analysis which revealed significant (p<0.005) upregulation in 22% of the 
glycolytic genes. Additionally, significant (p<0.005) upregulation was also seen in 
37% of the glycolytic genes in the cultures. HK2 overexpression was present across 
all glioblastoma samples, reiterating the qPCR data presented in Chapter 3.  It is well 
documented that the high mutation rate in cancer cells leads to aberrant cellular 
metabolism, alterations of metabolic pathways significantly contribute in the 
development and growth of many tumours including gliomas (Kazue et al., 2011; 
DeBerardinis and Tompson, 2012; Galluzi et al, 2013; Lindgvist et al., 2018). 
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Glioblastoma cells rely increasingly on the glycolytic pathway as the predominant 
mechanism for energy production, the switch from oxidative phosphorylation to 
glycolysis, along with the associated accumulation of lactate by-products in the 
tumour microenvironment, characterises the best-known alteration in cancer cell 
metabolism (vander Haiden et al., 2009; Kami et al, 2013). It has been suggested 
that the metabolic switch functions to allow for increased production of cellular 
energy in the form of ATP, crucial for the production of precursors for 
macromolecule biosynthesis for the support of cell growth development, which is 
driven at an enhanced rate via glycolysis compared to oxidative phosphorylation 
(Cairns et al., 2011). The array data highlights an increased level of expression 
occurring throughout the glucose pathway in glioblastoma, potentially as a result of 
the higher demand for the generation of cellular energy.  
Expression profile similarity between paired glioblastoma biopsies and 
cultures 
The glycolytic gene expression profiles of paired glioblastoma biopsies and the 
respective patient-derived cell culture (n=6) were investigated to establish whether 
differential expression is maintained in vitro. The data showed genetic similarity 
between the glioblastoma biopsies and the paired culture samples, with over 80% of 
the glycolytic genes exhibiting comparable levels of mRNA expression across the 
pathway, only 14 of the 84 genes showing a significant (p<0.005) increase in levels 
of mRNA expression in culture compared to the paired tissue samples. Importantly 
of the 14 genes that show significantly altered levels of expression between the 
paired samples, 12 of which are not significantly up or downregulated (p<0.005) in 
glioblastoma biopsies compared to normal tissue. Only ENO1 and HK2 were both 
significantly upregulated (p<0.005) in biopsy samples compared to normal tissue, 
with additional alterations between paired samples.  
The small amount of alterations in expression levels is suggestive of mRNA 
expression stability between the paired samples, presenting the patient-derived 
cultures as a useful tool for investigation and an accurate model for in vitro studies. 
Additionally, a comparability between the patient- derived cultures was shown, with 
minimal variance between individual glycolytic gene expression. The 
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microenvironment created in tissue culture is often altered to the natural cellular 
environment. Recent studies have highlighted the reliability of immortalised cell 
lines, where U251MG for example exhibits altered genotypic and phenotypical 
features compared to the progenitor sample, it has been documented that with 
increased passage U251MG loses its original glioblastoma signature, with the 
acquisition of additional genetic deletions (Torsvik et al., 2014). The use of patient-
derived cultures set at short-term low passages reduces the probability of both 
genetic and phenotypic deviations from the original sample whilst providing a 
function cellular system (Roberts et al., 2017). The expression similarities between 
the paired biopsy – culture obtained by the novel data from this profiler array is 
fundamental for the development of accurate models, crucial for the advancement of 
effective treatments. 
Hypoxia impacts the glycolytic pathway 
Under hypoxic conditions, cultures demonstrated altered levels of gene expression 
across the glucose pathway, with up to 60% of the genes in the pathway showing 
differential levels of mRNA expression compared to the respective normoxia cultures. 
Furthermore, 6 of the 84 genes (DLD, PGK1, PGM2, PGK2, SUCLG1, UGP2) showed a 
significant increase (p<0.005) in the level of mRNA expression in hypoxic conditions 
compared to normoxia with a further 7 genes (ACLY, ACO2, DLST, GSK3A, H6PD, 
OGDH, PFKL) exhibiting significant downregulation under hypoxic stress across the 3 
glioblastoma cultures. Interestingly, a study showed high PGK1 expression to be 
associated with poor prognosis in breast cancer, where PGK1 demonstrated a 
connection with HIF-1 which was shown to stimulate breast cancer progression and 
metastases (Fu et al., 2018). PGK1 overexpression has been associated with gastric 
cancer and has been found to increase the invasiveness of gastric cancer cells 
(Zieker et al., 2010). In addition, PGK1 phosphorylation was shown to correlate with 
macrophage-promoted tumour growth, with macrophage infiltration in glioblastoma, 
as well as an increased malignance and prognosis (Zhang et al., 2018). PGK1 may 
therefore serve as a promising biomarker and target therapy for a range of cancers. 
Hypoxia is common characteristic of tumour microenvironments and it is well 
documented that hypoxic tumours are significantly more malignant, metastatic, and 
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chemo resistant with a poorer patient prognosis. (Vaupel, 2004). The proteomic and 
genomic alterations often lead to angiogenesis activation and anerobic metabolism 
to aid in survival. It has been suggested that hypoxia-inducible factor (HIF-1) 
induces multiple genes integral to angiogenesis, such as vascular endothelial growth 
factor (VEGF), which has a key involvement in metastatic spread (Masoumi et al., 
2011). The upregulation of key genes driving glycolysis via hypoxia may be 
beneficial for the tumour for both cell growth and survival, studies have shown that 
aerobic glycolysis generates less reactive oxygen species (ROS) allowing the cells to 
adapt to intermittently hypoxic conditions, which is a common occurrence in poorly 
vascularized tumours (Cairns et al., 2011). The impact of hypoxia stress 
consequently effects metabolism, thus forcing genetic changes across the glucose 
pathway, as revealed in this data. 
HK2 knockout leads to the downregulation of gene expression across the 
glucose pathway 
HK2 knockout was shown to instigate the downregulation of gene expression across 
the glucose pathway in all cultures, with significant reduction (p<0.005) in 
expression in over 70% of the glycolytic genes, compared to the corresponding 
parent cultures. Furthermore, the HK2-KO cultures also exhibited similar levels of 
expression to NHA, with 60 of the 84 glycolytic genes demonstrating no significant 
fold change alterations. The data indicates a substantial divergence from the 
respective parent cultures, suggesting that the removal of HK2 downstream pathway 
expression of multiple genes. HK2 has been strongly implicated in aerobic glycolysis 
in cancer cells and has been shown to be abundantly overexpressed in a range of 
cancers, including glioblastoma as shown in Chapter 3 (Mathupala et al., 2001; 
Wang et al., 2014; Anderson et al., 2016). A study showed that the upregulation of 
HK2 in ovarian cancer cells led to increased stimulation of glycolysis, driving the 
glycolytic phenotype often associated in cancer cells (Mukherjee et al., 2015). The 
data has also revealed that the downregulation of HK2 results in the reduced 
expression of glycolytic genes downstream in the pathway, resulting in a similar 
genetic expression profile comparable to NHA. HK2-KO was shown to influence 
downregulation of multiple genes associated with glucose metabolism, including in 
glycolysis (ALDOA, ENO2, GALM, PGAM2, PGK2, PGM2), gluconeogenesis (FBP1, 
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G6PC, G6PC3, PC, PCK1, PCK2), and the TCA cycle (ACLY, ACO2, CS, DLAT, DLST, 
FH, IDH2, MDH1, SDHA, SDHD, SUCLA2). Importantly in the absence of HK2, the 
array data revealed the downregulation of regulatory genes (PDK1, PDK2, PDK3, 
PDP2, PDPR) associated with promoting glucose activity, and glycogen metabolism 
(GSK3A, GSK3B, PHKB). Interestingly, the pyruvate dehydrogenase kinase family 
(PDK 1-4) are gatekeeper enzymes that have been shown to implicated with altered 
glucose metabolism in tumours. PDK1 has been shown to be overexpressed in range 
of cancers including breast and colorectal cancer cell lines (Lu et al., 2011; Pe et al., 
2018). PDK1 overexpression has also been shown to shunt glucose metabolism 
towards glycolysis instead of oxidative phosphorylation, as well as being frequently 
associated with chemotherapy related drug resistance, invasion and metastasis (Cao 
et al., 2018). A study has shown PDK1 to upregulated in hypoxic cancer cells, 
interacting with HIF1, increasing hypoxic cell survival via the inhibition of apoptosis 
(Bonnet et al., 2007). The impact of HK2-KO consequently effects metabolism, 
forcing genetic changes across the glucose pathway, as revealed in this data 
 
3-BPA and metformin treatments and the supplementation of 3-HB lead to 
downregulation of gene expression across the glucose pathway 
The effects of two separate inhibitory molecules, 3-BPA and metformin and the 
supplementation of the ketone 3-HB as an alternative energy source, upon the 
glycolytic pathway were investigated via the profiler arrays, where the expression 
patterns of treated glioblastoma cultures were compared to the respective non-
treated cultures. Similar expression profiles were demonstrated in cultures treated 
with both the HK2 inhibitor 3-BPA and metformin at culture specific ID50 values over 
72 hours. Both 3-BPA and metformin have previously been shown to have a 
cytotoxic inhibitory effect in glioblastoma cultures, as shown in Chapter 3. Studies 
have shown 3-BPA to be an efficient energy blocker through its inhibitory ability 
targeting HK2, making it a potential candidate as an antitumor drug (Cardaci et al., 
2012; Azevedo-Silva et al., 2016; Lis et al., 2016). 3-BPA can inhibit the expression 
of HK2 at both mRNA and protein levels in glioblastoma, as shown in chapter 2, and 
in a range of other cancers as detailed in studies (Attia et al., 2015; Yadav et al., 
2017), with the advantage of a high affinity for targeting cancer cells. The disruption 
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of HK2 via 3-BPA treatment results in the downregulation of gene expression across 
the entire glucose pathway as shown in the array data, notably 3-BPA had a similar 
impact on the pathway as compared to CRISPR HK2-KO, making 3-BPA an effective 
candidate as an antitumor drug in which to target the distinguished deregulated 
glycolytic activity in glioblastoma.  
The array data also demonstrates that metformin causes a similar downregulation 
across genes in the glucose pathway. Metformin has been shown to posses’ anti-
tumour effects, clinical trials have demonstrated its promising additive effect in a 
range of cancers included (Lord et al., 2016; Dowling et al., 2018). The anti-tumour 
mechanism of metformin is not fully documented; data suggests metformin affects 
the activation of AMPK and has an inhibitory effect on the mTOR pathway (Pollak, 
2012; He and Wondisford, 2015). The mTOR isoform, mTORC2 has been shown to 
regulate both cell survival and glucose metabolism, with its inhibition leading to the 
deregulation of both pathways (Mao et al., 2018). The array data here shows 
metformin treatment causes universal downregulation of genes in the glucose 
pathway, suggesting the reduction in glucose and or the inhibition of mTOR impacts 
glycolytic activity.  
The ketone body 3-HB revealed comparable genetic expression values, the 
restriction of the level of glucose available to the glioblastoma cells, leads to the 
downregulation of the glucose pathway. Studies have shown the implementation of 
ketone bodies in culture, such as β-hydroxybutyrate, can impact cell metabolism, 
leading to systemic metabolic changes resulting in the depletion of an energy source 
for the glioblastoma cells, which are less effective at utilizing ketone bodies as an 
energy source (Shukla, et al., 2014; Martuscello et al., 2016). Additionally, 3-HB 
revealed comparable genetic expression values as seen in the HK2-KO cultures. 
Across both treated cultures over 70% of the genes showed similar significant 
downregulation (p<0.005) comprehensively across the glycolytic pathway. 3-BP, 
metformin and 3-HB (in the absence of glucose) were shown to influence 
downregulation of multiple genes associated with glucose metabolism, including 
those involved in glycolysis (ALDOA, BPGM, GPI, PFKL, PGAM2, PGM1), 
gluconeogenesis (PCK2), and the TCA cycle (ACLY, ACO1, ACO2, CS, DLAT, DLD, 
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FH, IDH2, MDH1, MDH2, SDHA). Importantly the array data revealed the 
downregulation of regulatory genes (PDK1, PDP2, PDPR) associated with promoting 
glucose and glycogen (GSK3A, GSK3B, PHKB, PHKG) metabolism, with the addition 
of the 3-BPA, metformin and 3-HB compounds. The importance of PDK1 driving 
tumorigenesis has already been highlighted, additionally GSK3A and GSK3B have 
been shown to have influential roles in many cancers, where overexpression has 
been established in colon, liver, ovarian, and pancreatic tumours (Mancinelli et al, 
2017). Notably, downregulation of these genes has been shown to impact rates of 
proliferation as well as decreased angiogenesis in pancreatic and colorectal cancer 
growth (Shakoori et al., 2005; Ougolkov et al., 2005). A recent study by Wang et al. 
(2017) showed PHKB to be overexpressed at both an mRNA and protein level in 
colorectal tissues, moreover higher expression of the gene was shown to correlate 
with tumour, node and metastasis (TNM) and distal metastasis. Additionally, PHKB 
knockdown was shown to impact proliferation and induced cell cycle arrest (Wang et 
al., 2017). The array data obtained in this study highlights the impact of HK2 upon 
downstream signalling in the glucose pathway, the data shows complex interactions 
where HK2 upregulation in glioblastoma results in additional genetic aberrations, 
driving altered glucose metabolism, increased chemotherapy related drug resistance, 
invasion and metastasis. The array data highlights the importance and the 
prospective advantages of targeting both HK2 and the abundant level of glucose in 
cancer cells to subsequently impact the genetic profile of the glycolytic pathway, 
leading to a potential metabolic reversal. Significant overexpression of genes 
throughout the glucose pathway were demonstrated in all glioblastoma samples, 
including both cultures and biopsy tissue. Furthermore, overexpression was 
augmented in cultures grown under hypoxic conditions, representational of the 
tumour microenvironment exhibited in glioblastoma. The removal of HK2 via CRISPR 
mediated knockout, and through specific targeting by the inhibitor 3-BPA revealed 
extensive downregulation across genes in the glycolytic pathway. Additionally, the 
reduction in the supply of glucose through the addition of metformin and the 
supplementation of the ketone body 3-HB, similarly demonstrated extensive 
universal downregulation across the glycolytic genes. Significant downregulation was 
seen in 46% of the glycolytic genes across all inhibitory methods, furthermore, the 
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variation of expression in the significantly altered genes between cultures 
demonstrated minimal fold change disparity, indicating the inhibitory effects are 
present to a similar extent across all cultures.  
 
HK2-KO switches overexpressed genes in glioblastoma biopsies  
Importantly HK2-KO resulted in significant downregulation (p<0.005) of multiple 
genes (n=18) that were shown to be upregulated in glioblastoma biopsies 
(compared to normal tissue). 3-BPA and metformin also revealed significant 
reduction (p<0.005) in these genes (6 and 8 genes respectively) that were shown to 
be upregulated in glioblastoma biopsies. 3-HB supplementation in the absence of 
glucose also demonstrated significant downregulation in 10 of the upregulated genes 
demonstrated in the biopsies, as shown in Table 5.14. ALDOA was revealed to be 
downregulated by both the targeting of HK2 via 3-BPA and HK2-KO and by the 
restriction of glucose availability (metformin and of 3-HB). ALDOA has been 
associated with increased proliferation and metastasis of pancreatic cancer cells, as 
well as a prognostic marker for poor patient survival (Ji et al., 2016). A recent study 
has shown ALDOA overexpression to lead to increased migration and invasion of 
lung cancer cell lines and metastasis in vivo (Chang et al., 2019). GYS1, MDH1 and 
PCK2 were also shown to be overexpressed in the biopsy samples but 
downregulated in the absence of HK2 and in reduced glucose. Both MDH1 and PCK2 
has been shown to be elevated in prostate cancer (New et al., 2019), it has also 
been suggested that PCK2 is responsible for the metabolic switch in prostate cancer 
as well as correlating with more aggressive tumours and lower survival rates (Zhao, 
et al 2017). In another study, GYS1 was shown to be upregulated in U87MG cell 
lines under hypoxia conditions (Zois and Harris, 2016). The data obtained in this 
study demonstrates the effectiveness at targeting HK2 as well as restricting glucose 
availability, whereby overexpressed genes present in glioblastoma, that are 
associated with increased proliferation and chemoresistance in multiple cancers were 
downregulated.  This study demonstrates the predominant role of HK2 within the 
glycolytic pathway, and its impact driving genetic alterations downstream, signifying 
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the importance in the development of inhibitors targeting HK2 and mediating the 
levels of glucose within glioblastoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
Expression arrays:  
Altered mTOR signalling 
in glioblastoma 
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6.1 Introduction 
mTOR is a serine/threonine protein kinase which integrates responses from many 
stimuli including nutrients, growth factors and cellular stresses in order to regulate 
cell growth, metabolism and survival (Saxton et al., 2017). mTOR has two distinct 
protein complexes, mTORC1 and mTORC2. The first complex is rapamycin-sensitive 
and is responsible for the regulation of protein synthesis, cell cycle progression and 
proliferation (Liu et al., 2013). mTORC2 is responsible for Akt activation, which is 
important for cell migration, proliferation and survival, as well as inhibiting apoptosis 
and autophagy. Although mTOR itself is not an oncogene, being part of the PI3K/Akt 
signalling pathway, it is an influential stimulator for cell proliferation and is 
frequently upregulated in cancer cells supporting tumour growth. mTORC1 has been 
shown to support rapid proliferation by activating transcription regulators including 
HIF1, which consequently drive and regulate the expression of genes involved in 
aerobic glycolysis (Liu et al., 2013; Han et al., 2015). Upregulation of mTORC2 also 
plays a role in cancer biology through the activation of PKC, SGK3 and FoxO1/3 
transcription factors, which promotes proliferation and survival under oxygen 
deprivation (Chiarini et al., 2015). Studies have shown the deregulation of multiple 
components of the mTOR pathway, such as PI3K amplification/mutation, the loss of 
PTEN function and the overexpression of AKT to be a common occurrence in many 
types of cancers (Pópulo, et al., 2012). The expression profiler arrays include genes 
involved in both complexes, with additional upstream regulators of numerous mTOR 
responses and downstream genes that are regulated by cellular processes via the 
activation of mTOR complex. The profiler arrays were conducted using an optimized 
protocol from Qiagen, where extracted RNA was converted to cDNA as stated in 2.9 
Materials and Methods. The Qiagen profiler arrays were used to identify and 
determine differences in mRNA expression across genes in the mTOR signalling 
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pathway occurring in glioblastoma cultures treated with metformin compared to the 
respective untreated cultures, previous studies have suggested that metformin 
affects the activation of AMPK and the inhibition of the mTOR pathway (He and 
Wondisford, 2015). Additionally, the profiler arrays were also used to determine any 
genetic alterations occurring in the mTOR pathway in the absence of HK2, utilizing 
HK2-KO modified CRISPR cultures. Un-abbreviated gene list is shown in full in the 
appendix. 
6.2 Differential expression of glycolytic genes via multiple inhibitory 
methods 
6.2.1. Differential expression of mTOR genes after HK2 induced CRISPR 
Knockout  
Dysregulated levels of expression were revealed across genes in the mTOR pathway 
in all 3 of the HK2-KO cultures compared to the respective parent cultures (cultures 
detailed in Table 2.1). Over 82% of the genes in the mTOR pathway exhibited 
altered levels in U251MG, with 67 presenting downregulated levels and 2 with 
upregulated expression. Furthermore, 54% of the genes demonstrated deregulated 
expression levels in the patient derived culture IN859 and 55% in IN2045, with over 
40 genes showing downregulation, as shown in Figure 6.1. Grouping the 
glioblastoma cultures to perform statistical calculations, showed 46 genes 
demonstrating a significant (p<0.005) altered level of expression across all the HK2-
KO cultures compared to the respective parent cultures. Forty-one of the genes 
exhibited significant (p<0.005) downregulated expression fold change in the HK2-KO 
cultures compared to the respective parent cultures. Furthermore, 5 genes showed 
significant (p<0.005) overexpression in the treated cultures, as shown in Table 6.1 
and Figure 6.2. The downregulation in fold change expression across the genes in 
mTOR pathway in the HK2-KO cultures ranged from -1.01 (RPTOR) to -7.35 
(PRKAG3). The variance in fold change of the genes were also examined between 
the individual cultures to establish the degree of homogeneity of expression levels. 
The variation of gene expression showed 89.1% of the significantly altered genes 
with less than 2- fold variation between the cultures, with only 5 genes 
demonstrating a variance greater than 2-fold change, as shown in Figure 6.3 (Table 
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shown in the appendix). The little variation in the level of fold change of the 
deregulated genes indicates that the altered expression is present to a similar 
degree across all HK2-KO cultures, suggesting the removal of HK2 causes 
downregulation of mTOR signalling. 
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Figure 6.1 Scatter plot comparing the level of fold change across 84 genes in the mTOR 
pathway in 3 glioblastoma HK2-KO cultures compared to the respective parent cultures. 
Each dot represents the expression of a gene. The y-axis represents fold-change expression of the 
glioblastoma sample, the x-axis represents expression of the normal tissue control. Genes (dots) 
further to the right show higher expression compared to normal tissue. Higher dots represented 
greater expression in the glioblastoma samples. 
 
 
Figure 6.2 Volcano plot comparing the level of fold change across 84 genes associated in 
the mTOR pathway in 3 glioblastoma HK2-KO cultures. Fold change in gene expression 
compared to the respective parent cultures. Represented genes above the threshold all show 
significant change (p<0.05). 
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Table 6.1 Expression fold change values of mTOR genes in HK2-KO cultures compared to 
respective parent cultures 
Gene Log2 Fold Change Gene Log2 Fold Change 
AKT1S1 -2.05 PIK3CG -2.23 
AKT2 -2.45 PLD2 -3.27 
AKT3 -2.36 PPP2R2B -1.78 
CAB39 -2.1 PPP2R4 -4.17 
CAB39L -1.76 PRKAG3 -7.35 
CDC42 -1.26 PRKCB -2.6 
CHUK -3.17 PRKCG -2.76 
DDIT4 -2.72 RHEB -6.34 
DEPTOR -1.68 RPS6KA1 -5.34 
EIF4E -2.53 RPS6KA5 -1.3 
EIF4EBP1 -1.98 RPS6KB2 -1.93 
EIF4EBP2 -2.67 RPTOR -1.01 
HRAS -2.64 SGK1 -1.26 
IGF1 -2.92 STK11 -5.24 
IGFBP3 -1.57 TELO2 -3.1 
IKBKB -1.26 TSC2 -4.74 
INS -3.85 ULK1 -6.13 
INSR -2.32 ULK2 -3.27 
IRS1 -3.08 AKT1 1.26 
MAPK1 -3.18 PRKAG2 1.06 
MLST8 -2.99 PRKCA 1.49 
PIK3C3 -2.1 RHOA 1.88 
PIK3CD -1.33 RPS6 1.61 
Table showing changes in fold change values in patient derived glioblastoma HK2-KO cultures 
compared to corresponding parent cultures. All genes are significantly downregulated (p<0.05). 
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6.2.2. Differential expression of mTOR genes after 72-hour metformin 
treatment 
Three glioblastoma cultures were treated with metformin at culture specific ID50 
values for 72 hours, as stated in 4.3.2. Dysregulated levels of expression were 
demonstrated throughout genes in the mTOR pathway in all 3 of the metformin 
treated glioblastoma cultures compared to the respective untreated culture. Over 
66% of the genes in the mTOR pathway exhibited altered levels in U251MG, with 46 
presenting downregulated levels and 10 with upregulated expression. Furthermore, 
50% of the genes demonstrated deregulated expression levels in both patient 
derived cultures, IN859 and IN2045, with over 30 genes showing downregulation, as 
shown in Figure 6.4. Grouping the glioblastoma cultures to perform statistical 
calculations, showed 44 genes demonstrating significant (p<0.005) altered levels of 
expression across all the metformin treated glioblastoma samples compared to the 
respective non-treated cultures. 33 of the genes exhibited significant (p<0.005) 
downregulated expression fold change in metformin treated cultures compared to 
the respective non-treated cultures, furthermore, 11 genes showed significant 
(p<0.005) overexpression in the treated cultures, as shown in Table 6.2 and Figure 
6.5. The downregulation in mRNA fold change expression across the gens in mTOR 
pathway in the metformin treated cultures ranged from -1.05 (RPTOR) to -5.69 
(INS). 
The variation of gene expression showed 84.8% of the significantly altered genes 
with less than 2- fold variation between the cultures, with 5 of the genes 
demonstrating a variance greater than 2-fold change, as shown in Figure 6.6 (Table 
shown in the appendix). The little variation in the level of fold change of the 
deregulated genes indicates that the altered expression is present to a similar 
degree across all cultures treated with metformin, suggesting metformin has an 
inhibitory impact on mTOR signalling. 
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Figure 6.4 Scatter plot comparing the level of fold change across 84 genes in the mTOR 
pathway in 3 glioblastoma cultures treated with metformin compared to the respective 
non-treated cultures. Each dot represents the expression of a gene. The y-axis represents fold-
change expression of the glioblastoma sample, the x-axis represents expression of the normal tissue 
control. Genes (dots) further to the right show higher expression compared to normal tissue. Higher 
dots represented greater expression in the glioblastoma samples. 
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Figure 6.5 Volcano plot comparing the level of fold change across 84 genes associated in 
the mTOR pathway in 3 glioblastoma cultures treated with metformin. Fold change in gene 
expression at the relevant ID50 value, compared to the respective non-treated cultures. Represented 
genes above the threshold all show significant change (p<0.05). 
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Table 6.2 Expression fold change values of mTOR genes in metformin treated cultures 
compared to non-treated cultures 
Gene Log2 Fold Change Gene Log2 Fold Change 
GSK3B 1.3 HIF1A -1.94 
PIK3CB 1.75 HRAS -2.09 
PRKAA2 1.15 IGF1 -1.85 
PRKAG2 2.83 IGFBP3 -1.27 
PRKCB 1.02 INS -5.69 
RHOA 1.13 INSR -1.38 
RPS6KB1 1.08 IRS1 -1.25 
RRAGC 1.37 MAPK1 -2.5 
RRAGD 1.74 MAPK3 -2.12 
SGK1 1.33 MLST8 -4.48 
TSC1 1.41 MYO1C -2.28 
AKT1S1 -1.58 PPP2R4 -2.19 
AKT2 -2.61 PRKAG3 -2.22 
AKT3 -1.49 RHEB -2.83 
CAB39L -1.66 RPS6KA5 -2 
CDC42 -1.37 RPS6KB2 -3.85 
CHUK -1.69 RPTOR -1.05 
DDIT4 -1.58 STK11 -4.31 
EIF4E -1.86 TP53 -2.33 
EIF4EBP1 -2.34 TSC2 -2.3 
EIF4EBP2 -1.66 ULK1 -2.63 
FKBP8 -2.07 ULK2 -1.06 
Table showing changes in fold change values in patient derived glioblastoma cultures treated with 
metformin compared to corresponding non treated cultures. All genes are significantly downregulated 
(p<0.05). 
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6.2.3. Differential expression of mTOR genes in HK2 -KO cultures after 72-
hour metformin treatment  
The mTOR pathway expression patterns of 3 glioblastoma cultures with CRISPR 
mediated HK2 knockout were compared to the respective parent cultures, all 
cultures were also treated with metformin at culture specific ID50 values over 72 
hours. Metformin demonstrated an increased effectiveness in the absence of HK2 as 
detailed in Chapter 4.6, where HK2 –KO cultures treated with metformin showed 
significantly increased sensitivity (p<0.0001).  Taking this into account, expression 
profiler arrays were utilised to investigate the effect of metformin on the mTOR 
pathway in the HK2-KO cultures, to further evaluate metformin potential increased 
effectiveness as an mTOR pathway inhibitor. 
Deregulated levels of expression were revealed across genes in the mTOR pathway 
in all 3 of the metformin treated HK2 knockout cultures compared to the respective 
parent cultures. Over 77% of the genes in the mTOR pathway exhibited altered 
levels in U251MG, with 57 presenting downregulated levels and 8 with upregulated 
expression. Additionally, 62% of the genes demonstrated deregulated expression 
levels in the patient derived culture IN859 and IN2045, with over 40 genes showing 
downregulation, as shown in Figure 6.7. The glioblastoma cultures were grouped to 
perform statistical calculations, which revealed 51 genes exhibiting a significant 
(p<0.005) altered level of expression across all the metformin treated HK2-KO 
cultures compared to the respective parent cultures. 43 of the genes exhibited 
significant (p<0.005) downregulated expression fold change in the cultures 
compared to the respective parent cultures, with a further 8 genes showing 
significant (p<0.005) overexpression in the treated cultures, as shown in Table 6.3 
and Figure 6.8. The downregulation in mRNA fold change expression across the 
gens in mTOR pathway in the HK2-KO cultures ranged from -1.09 (RPTOR) to -6.99 
(STK11). The variation of gene expression showed 92.2% of the significantly altered 
genes with less than 2- fold variation between the cultures, with 4 of the genes 
demonstrating a variance greater than 2-fold change, as shown in Figure 6.9 (Table 
shown in the appendix). The little variation in the level of fold change of the altered 
genes indicates that the expression fold change is present to a similar level across all 
HK2-KO cultures treated with metformin. The data shows a greater number of genes 
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were significantly altered in HK2-KO cells when treated with metformin, compared to 
the respective singular treatments, with extensive downregulation across the mTOR 
pathway. 
 
  
 
 
Figure 6.7 Scatter plot comparing the level of fold change across 84 genes in the mTOR 
pathway in 3 glioblastoma HK2-KO cultures treated with metformin compared to the 
respective parent non-treated cultures. Each dot represents the expression of a gene. The y-
axis represents fold-change expression of the glioblastoma sample, the x-axis represents expression 
of the normal tissue control. Genes (dots) further to the right show higher expression compared to 
normal tissue. Higher dots represented greater expression in the glioblastoma samples. 
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Figure 6.8 Volcano plot comparing the level of fold change across 84 genes associated in 
the mTOR pathway in 3 glioblastoma HK2-KO cultures treated with metformin. Fold 
change in gene expression at the relevant ID50 value, compared to the respective non-treated parent 
cultures. Represented genes above the threshold all show significant change (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 259 
 
Table 6.3 Expression fold change values of mTOR genes in metformin treated HK2-KO 
cultures compared to respective non-treated parent cultures 
Gene Log2 Fold Change Gene Log2 Fold Change 
AKT1S1 -1.3 PPP2CA -2.49 
AKT2 -2.49 PPP2R4 -2.19 
AKT3 -1.42 PRKAA1 -2.28 
CAB39 -2.18 PRKAB1 -1 
CDC42 -3.95 PRKAG3 -4.89 
CHUK -2.69 PRKCG -2.36 
DDIT4 -2.23 RHEB -1.15 
DDIT4L -2.31 RPS6KA1 -2.01 
DEPTOR -3.83 RPS6KA2 -2.76 
EIF4E -3.86 RPS6KA5 -1.99 
EIF4EBP1 -1.34 RPS6KB2 -4.79 
EIF4EBP2 -2.66 RPTOR -1.09 
FKBP8 -2.07 RRAGB -2.21 
HIF1A -3.38 STK11 -6.99 
HRAS -3.94 TSC2 -5.3 
IGF1 -1.73 ULK1 -1.29 
IGFBP3 -2.03 ULK2 -2.71 
INS -3.16 VEGFA -3.68 
INSR -2.85 PIK3CB 1.75 
IRS1 -2.35 PRKCB 1.02 
MAPK1 -2.25 PRKCE 1.39 
MLST8 -1.77 RHOA 1.31 
MYO1C -2.28 RPS6 1.4 
PIK3C3 -2.14 RPS6KB1 1.08 
PIK3CD -3.95 RRAGC 1.88 
PLD2 -2.62 RRAGD 2.47 
Table showing changes in fold change values in patient derived glioblastoma HK2-KO cultures treated 
with metformin, compared to corresponding non-treated parent cultures. All genes are significantly 
downregulated (p<0.05). 
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Table 6.4 Expression fold change variation values of mTOR genes in all treated cultures 
compared to respective non-treated parent cultures                                    
Log2 Fold Change 
Gene Metformin CRISPR CRISPR + Metformin 
RHOA 1.13 1.88 1.31 
AKT1S1 -1.58 -2.05 -1.3 
AKT2 -2.61 -2.45 -2.49 
AKT3 -1.49 -2.36 -1.42 
CDC42 -1.37 -1.26 -3.95 
CHUK -1.69 -3.17 -2.69 
DDIT4 -1.58 -2.72 -2.23 
EIF4E -1.86 -2.53 -3.86 
EIF4EBP1 -2.34 -1.98 -1.34 
EIF4EBP2 -1.66 -2.67 -2.66 
HRAS -2.09 -2.64 -3.94 
IGF1 -1.85 -2.92 -1.73 
IGFBP3 -1.27 -1.57 -2.03 
INS -5.69 -3.85 -3.16 
INSR -1.38 -2.32 -2.85 
IRS1 -1.25 -3.08 -2.35 
MAPK1 -2.5 -3.18 -2.25 
MLST8 -4.48 -2.99 -1.77 
PPP2R4 -2.19 -4.17 -2.19 
RHEB -2.83 -6.34 -1.15 
RPS6KA5 -2 -1.3 -1.99 
RPS6KB2 -3.85 -1.93 -4.79 
RPTOR -1.05 -1.01 -1.09 
STK11 -4.31 -5.24 -6.99 
TSC2 -2.3 -4.74 -5.3 
ULK1 -2.63 -6.13 -1.29 
ULK2 -1.06 -3.27 -2.71 
Table showing changes in expression values in all treated patient derived glioblastoma cultures, 
including HK2-KO, metformin and combination treatments, compared to corresponding non-treated 
parent cultures. All genes are significantly altered (p<0.05). Expression data is shown for individual 
treatments to compare levels of fold change.  
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6.3 Discussion 
This chapter has focused on the investigation of the differential mRNA expression 
across 84 genes associated with the mTOR signalling pathway in patient- derived 
glioblastoma cultures (n=2) and U251MG, with the aim to determine the effects of 
metformin supplementation and/or the downregulation of HK2 via CRISPR mediated 
knockout, upon the gene expression profile in the glioblastoma cultures. The array 
data in this study demonstrates differential expression across genes in the mTOR 
signalling pathway in both cultures where HK2 had been downregulated via CRISPR 
mediated knockout and treated with metformin compared to the respective parent 
cultures. The data highlights the importance of HK2 in mTOR signalling and the 
substantial inhibitory effect metformin has on the mTOR pathway. Previous studies 
have suggested metformin inhibits the mTOR pathway via the activation of AMPK 
(He, et al., 2015).  Additionally, a greater number of genes were significantly altered 
in HK2-KO cells treated with metformin, with extensive downregulation across the 
mTOR pathway, indicating the combined inhibitory effect of both methods, 
impacting mTOR signalling. 
HK2 knockout leads to significant downregulation across the mTOR 
pathway 
HK2 knockout was associated with the downregulation of gene expression across the 
mTOR pathway in all 3 of the HK2 knockout cultures compared to the respective 
parent cultures. Furthermore, 55% of genes demonstrated significant substantially 
altered levels of expression across all the HK2-KO cultures compared to the 
respective parent cultures, with 48% of the genes presenting significant 
downregulation (p<0.005). The data suggests the importance of HK2 role in the 
deregulation and frequently overexpressed mTOR signalling in glioblastoma. HK2-KO 
cultures revealed altered levels of expression in both mTOR upstream positive 
regulators AKT2 (-2.45), AKT3 (-2.36), HRAS (-2.64), IGF1 (-2.92), MAPK1 (-3.18 – 
fold change) and downstream positive regulators EIF4E (-2.53- fold change) CDC42 
(-1.26- fold change). Notably, both upstream and downstream negative regulators 
were upregulated in the HK2-KO cultures, including PRKAG2 (1.06-fold change) and 
PRKCA (1.49- fold change) compared to the parent cultures, further suggesting HK2 
as promoting mTOR activity.  It has also been suggested that mTORC1 activity is 
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decreased by glucose deprivation, signifying the role of HK2 as a mediator of mTOR 
signalling (Roberts, et al., 2014). The array data confirmed this, HK2-KO cultures 
showed mTORC1 significant downregulation (p<0.005) of genes associated with 
mTORC1 signalling, MLST8 (-2.99-fold change) and RPTOR (-1.01- fold change). The 
inhibition of mTORC1 activity results in driving autophagic processes associated with 
AMPK under glucose starvation. HK2 has been shown to obstruct autophagy via the 
regulation of AMPK, impacting autophagic responses and subsequently increasing 
mTORC1 signalling, where HK2 overexpression enhances the glucose dependent 
dephosphorylation of downstream targets of mTORC1. The knockdown of HK2 was 
shown to inhibit this response (Soliman et al., 2010). It has also been suggested 
that the depletion of HK2 via siRNA knockdown, increases energetic stress, resulting 
in the activation of AMPK, and subsequently the inhibition mTORC1 activity (DeWaal 
et al., 2018). Previous studies have also suggested that the activation of the 
Akt/mTORC1 pathway positively regulates HK2 expression (Bhaskar et al., 2009). 
The data suggests that HK2 expression is stimulated by mTORC1 to metabolically 
support cellular growth and protection. Furthermore, HK2 stimulates an inhibitory 
effect upon AMPK, resulting in the increased activity of mTORC1. In a glucose 
deprived environment, an increase in cellular stresses results in the activation of 
AMPK inducing autophagy; thus, providing an adaptive defence mechanism, 
preserving cellular integrity dependent on metabolic status (Roberts, et al., 2015). 
The data here denotes that HK2 overexpression also may perform a key function in 
the upregulation of the mTOR pathway driving cell cycle progression, growth and 
proliferation in glioblastoma. 
Metformin treatment induces significant downregulation across the mTOR 
pathway 
Metformin treatment was shown to induce the downregulation of gene expression 
across the mTOR pathway across all the cultures and 39% of genes exhibited 
significant (p<0.005) downregulated expression. Metformin have previously been 
shown to have a cytotoxic inhibitory effect in glioblastoma cultures, it has been 
suggested that metformin affects the activation of AMPK and has an inhibitory effect 
on the mTOR pathway (He et al., 2015, Zakikhani, et al., 2010, Fan, et al., 2018).  
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The addition of metformin revealed altered levels of expression in genes associated 
with the mTOR complex mTORC1, where treated cultures showed significant 
downregulation (p<0.005) of MLST8 (-4.48-fold change) and RPTOR (-1.05- fold 
change). Additionally, significant downregulation was shown in both mTOR upstream 
positive regulators AKT2 (-2.61), AKT3 (-1.49), HRAS (-2.09), IGF1 (-1.85), MAPK1 
(-2.5), MAPK3 (-2.12-fold change) and downstream positive regulators HIF1A (-1.94- 
fold change), CDC42 (-1.37 fold change). Markedly, both upstream and downstream 
negative regulators were upregulated in the metformin treated cultures, including 
PRKAA2 (1.15- fold change) PRKAG2 (2.83-fold change) and TSC1 (1.41- fold 
change) compared to the non-treated cultures. The array data indicates the potential 
mTOR inhibitory mechanism of metformin, resulting in the downregulation of 
upstream promotors and the upregulation of genes regulating mTOR activity.  
Studies have also stated that metformin inhibits respiratory complex I of the electron 
transport chain in mitochondria leading to the activation of AMPK and the inhibition 
of the mTOR pathway (Pollak, 2012; He and Wondisford, 2015). The data here 
shows the therapeutic potential of metformin treatment in glioblastoma, the 
investigation has shown metformin to have a substantial effect on mTOR signalling, 
causing significant reductions in gene expression across the inclusive pathway, 
highlighting its importance for targeting the frequently overexpressed mTOR 
signalling in glioblastoma (Han et al., 2015). 
Potential synergy between HK2-KO and metformin on mTOR activity. 
The combination of metformin treatment in the HK2-KO cultures revealed 
comparable genetic profiles as seen with the monotherapies, occurring across the 
mTOR pathway in glioblastoma cultures. The array data shows a greater number of 
genes were significantly altered in the HK2-KO cells when treated with metformin, 
compared to the respective singular treatments, with extensive downregulation 
across the mTOR pathway. Both mTOR upstream positive regulators AKT2 (-2.49), 
AKT3 (-1.42), HRAS (-3.94), IGF1 (-1.73), MAPK1 (-2.25– fold change) and 
downstream positive regulators EIF4E (-3.86) CDC42 (-3.95-fold change). The study 
demonstrates the potential advantages of both the downregulation of HK2 alongside 
the addition of metformin to induce significant universal downregulation of genes in 
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the mTOR pathway, resulting in the reduction of the abundantly overexpressed 
mTOR signalling frequently occurring in glioblastoma. HK2 has been shown to 
impact the mTOR pathway in cardiomyocytes (Roberts, et al., 2014), the knockdown 
of HK2 may lead to the increase of energetic stress, activating AMPK resulting in the 
inhibition mTORC1 activity; additionally, HK2 has been shown to enhance 
chemoresistance (Wolf et al., 2011), its downregulation may also potentially increase 
the effectiveness of metformin in regulating AMPK activation, thus increasing its’ 
inhibitory effect in the mTOR pathway in  glioblastoma. A study has also shown the 
synergistic effect of HK2 knockdown with the supplementation of metformin on 
mTORC1 activity, where the combination was shown to inhibit mTORC1 (DeWaal et 
al., 2018). The study also determined that even in the absence of AMPK, the 
combinatory effect of metformin treatment in HK2 depleted hepatocellular carcinoma 
cells led to an increase in the expression of REDD1, a known inhibitor of mTORC1 
(DeWaal et al., 2018), however the array data in this study determined that REDD1 
(DDIT4) expression was reduced (-1.58- fold change) in cultures treated with 
metformin and in the absence of HK2. Both the addition of metformin and the 
knockdown of HK2 demonstrated significant downregulation (p<0.005) of the 
mTORC1 associated genes MLST8 (-1.77- fold change) and RPTOR (-1.09- fold 
change); as well as significant downregulation (p<0.005) of multiple genes 
associated with the mTOR signalling pathway, many of which have been strongly 
associated with cancer progression and development. Examples include the 
Serine/threonine kinase 11 (STK11), which has been strongly associated with Peutz-
Jeghers syndrome, an autosomal disorder characterised by mucocutaneous melanin 
pigmentation, gastrointestinal polyposis, and an increased risk for the development 
of various neoplasms (Giardiello et al., 2000). STK11 has also been associated with 
somatic mutations in lung cancer, cervical, breast, intestinal, testicular, pancreatic 
and skin cancer (Lim et al., 2004; Sanchez-Cespedes, 2007; Jiang et al., 2018). 
HRAS is part of one of the most commonly deregulated pathways in human cancer 
and activating mutations in RAS genes occur in approximately 30% of all tumours 
(Ding et al, 2008). HRAS mutations are frequent in bladder and thyroid cancer 
(Sugita et al., 2018). Aberrant activation of Ras signalling is a frequent occurrence in 
glioblastoma, a study investigating the mutation analysis of NRAS, HRAS and KRAS 
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revealed somatic point mutations in 5% of the glioblastomas tested (Knobbe et al., 
2004). Additionally, the development of specific and competitive inhibitors is 
challenging, because the RAS protein lacks a druggable binding pocket (Cox et al., 
2014). This study also showed MAPK1 to be downregulated when HK2 was knocked 
out, and with the supplementation of metformin. PI3K/MAPK pathways have been 
shown to be mutated in 90% of glioblastoma, and have been associated with many 
cancer hallmarks, including increased survival, proliferation, and migration (Hanahan 
and Weinberg, 2011). Studies have also shown the activation of MAPK signalling is 
often through KRAS mutations (McNeill et al.,2017). The downregulation of multiple 
genes that have been shown to instigate or propagate tumorigenesis in many 
cancers is an important finding, via the inhibition of HK2 and through the inhibitory 
mechanisms of metformin. The array data has further confirmed the significance of 
HK2 and its impact on the progression and development in glioblastoma, the 
downregulation of HK2 shows the reversal of ubiquitous overexpression of mTOR 
genes, with substantial downregulation occurring across the pathway, compared to 
the parental cultures. Furthermore, the information presented here supplements the 
cytotoxic ability of metformin, which has previously been shown to impact the 
glucose pathway and cause anti-proliferative effects in glioblastoma cultures; the 
array data indicates metformin ability to target aberrant mTOR signalling in 
glioblastoma through potentially AMPK activation.  Finally, the array data reveals a 
promising novel mechanism of targeting the dysregulated mTOR signalling in 
glioblastoma, with the combination of HK2 KO and metformin increasing cellular 
stresses and leading to the potential activation of AMPK and/or the increased 
expression of REDD1 resulting in the inhibitor of mTORC1; highlighting the potential 
application of a therapeutic treatment in a substantial subset of glioblastoma. 
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CHAPTER 7 
Final discussion and 
conclusions 
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7.1 Discussion 
Glioblastoma are the most common high-grade primary brain tumour in adults that 
represent up to 65% of brain tumours. Glioblastoma classification stringently follows 
WHO guidelines which were updated in 2016 to include molecular subtyping to 
characterise 2 sub-groups, based upon the isocitrate dehydrogenase (IDH) mutation 
status (Arevalo et al., 2017).  Prognosis is extremely poor with median survival of 
approximately 15 months (Bleeker et al., 2012).  The primary current treatment 
methods for glioblastoma is a multimode approach which involves surgical resection 
of the tumour tissue, radiation treatment followed by concomitant chemotherapy 
with TMZ, effective in a subset of patients based on MGMT methylation status 
(Stupp et al., 2015). Furthermore, considerable side effects are regularly associated 
with treatment, impacting on the quality of life (Backes et al., 2015; Oberoi et al., 
2015). Effective drug treatments are hindered predominantly by the complex genetic 
background of glioblastoma, with significant intra- and inter- tumour heterogeneity, 
encompassing a broad range of mutations, deletions and other molecular aberrations 
drastically limiting monotherapies (Backes et al., 2015; Arevalo et al., 2017). An 
alternative approach is the targeting of abnormal metabolic pathways that are 
universally dysregulated in glioblastoma. Treatments that modulate metabolism offer 
a potential therapeutic avenue in which to treat a higher percentage of patients, 
whilst sparing normal cells and reducing negative side effects (Wolf et al., 2011). 
The development of therapeutic agents is crucial for improved patient stratification 
and for the advancement of glioblastoma treatment. This study has contributed to 
these areas with the identification of a promising molecular target. Analysis of 
glioblastoma biopsies in this study revealed the glycolytic enzyme HK2 to be 
significantly upregulated, with overexpression as a common occurrence. HK2 
overexpression was detected in all 103 biopsy samples and in 15 patient- derived 
cultures. These findings were comparable to the reported frequencies in other 
cancers, including both lung and breast cancer (Wang et al., 2014; Anderson et al., 
2016) and in glioblastoma cell lines (Wolf et al., 2011). To further determine the 
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deregulated expression of HK2, the association between genetic and epigenetic 
mechanisms in glioblastoma was investigated. Pyrosequencing technology was used 
to conduct methylation changes across multiple CpG cites in the HK2 promotor 
region in 103 biopsies and 15 patient- derived cultures and NHA. This study has 
identified genomic changes in glioblastoma distinct from normal brain tissue, with 
substantial epigenetic alterations present in glioblastoma. Hypomethylation was 
shown to be present in all the 103 biopsy samples compared to normal brain. Varied 
levels of reduction in promotor methylation was demonstrated across the multiple 
CpG sites (n=15) in the biopsies, with an average loss of 20% compared to normal 
brain tissue. Promotor hypomethylation was also established in the patient-derived 
samples with significantly reduced (p<0.0001) levels of methylation of 38.3% 
compared to normal tissue. These findings reflect previous studies, where global 
hypomethylation has been shown to be present in primary human glioblastomas 
(Cadieux et al., 2006). This study established a strong correlation between the 
percentage of hypomethylation and the level of HK2 expression in all glioblastoma 
samples. Hypomethylation of HK2 was also shown to enhance levels of HK2 
expression, demonstrated across all 103 biopsies and the 15 patient- derived 
cultures. This study also revealed elevated HK2 expression to be associated with 
outcome, where a significantly shorter (P<0.0001) OS was demonstrated in patient 
biopsy samples with higher HK2 expression. The data obtained here compares to 
previous studies in which elevated HK2 expression was significantly associated with 
shorter OS (Liu et al., 2016; Wu et al., 2017).  The association between HK2 
expression and outcome offers an important insight to a potential prognostic marker 
and for further stratification of glioblastoma patients, independent of MGMT status, 
where patients differentiated by expression levels may potentially benefit from 
treatments that target HK2. Taking this into account, this study also evaluated the 
effects of HK2 inhibition in glioblastoma, via in vitro studies using 15 patient- derived 
cultures. Array analysis of paired biopsy and culture samples revealed that the 
patient-derived glioblastoma cultures maintained a considerable proportion of gene 
expression present in the original tumour biopsies and may be used as an accurate 
pre-clinical model for glioblastoma molecular biology studies. Although there was a 
degree of differential expression in the cell cultures compared to the biopsies, 
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reflecting the influence of artificial culture conditions, the patient-derived cell 
cultures retained most of the characteristic signatures of glioblastoma making them 
appropriate in vitro models for the evaluation of targeted therapeutics.  
This study investigated HK2 inhibition through CRISPR-mediated knockout, the 
removal of HK2 demonstrated a significant decrease (p<0.007) in cell growth across 
all treated cultures compared to the respective parent cultures. Notably, cultures 
expressing increased levels of HK2 were more greatly affected, with higher 
reductions in proliferation. An important finding of this study is the significantly 
increased (p<0.0001) sensitivity to TMZ in HK2-KO cultures, with substantial 
reduction in both the ID50 values and in cell survival (20% reduction) after 
treatment, compared to the parent cultures. Similarly, the efficacy of metformin was 
significantly increased (p<0.0001) in HK2 depleted cultures, with average ID50 
values decreased by 46.8% compared respectively to the parent culture. Expression 
profiler arrays were utilized to determine the wider effect of HK2 knockout across 
the glycolytic pathway. HK2 knockout was shown to result in the downregulation of 
70% of the genes (59 of the 84), with significant reduction in expression across the 
glucose pathway in all cultures, compared to the corresponding parent cultures. This 
novel data suggests that targeting HK2 results in the universal downregulation of 
genes in the glucose pathway, consequently affecting downstream pathway 
expression, highlighting the importance of HK2 role in glycolysis, driving tumour 
growth and proliferation. The data here strongly supports the notion that HK2 
overexpression in cancer cells enhances resistance to therapies (Wolf et al., 2011); 
as well as HK2 influencing the magnitude of glucose within cells, driving an 
accelerated glucose flux in cells commonly associated with the Warburg effect (Patra 
et al., 2013; Mukherjee et al., 2015).  
This study also validated a HK2 specific inhibitor 3-BPA, as an effective anti-
proliferative agent in all cultures under normoxic and hypoxic conditions. Moreover, 
3-BPA demonstrated specificity in targeting HK2, where cultures expressing higher 
levels were more sensitive (p= 0.0192) to the inhibitor. An important finding was 
that 3-BPA anti-proliferative effects were specific to the glioblastoma cultures, whilst 
sparing healthy metabolising cells with a substantially lower inhibitory response in 
NHA. This study demonstrated that 3-BPA induces apoptosis in glioblastoma, where 
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significantly higher apoptosis (p<0.0001) was exhibited in cultures expressing higher 
levels of HK2. Additionally, a significant increase (p<0.0001) in the level of caspase 
3/7 was detected in all 3-BPA treated cultures. Caspase 3/7 are primary effectors at 
the end of the apoptotic caspase pathway and the primary data strongly indicates 
that the caspase dependent apoptotic pathway is induced as the main mechanism of 
cell death in glioblastoma from 3-BPA treatment.  
Importantly levels of apoptosis were reduced in the glioblastoma cultures under 
hypoxic conditions. The hypoxic data correlates to previous studies, where HIF1 
upregulation was shown to have inhibitory effects on a range of factors involved in 
apoptosis and the regulation of cell death mechanisms in glioblastoma (Trachootham 
et al., 2006; Yang et al., 2012).  
Expression profiler arrays were utilized to determine the wider effect of 3-BPA on the 
glycolytic pathway. Similarly to CRISPR-KO of HK2, 3-BPA supplementation was 
shown to result in the significant downregulation (p<0.005) of 50% of the genes (42 
of the 84), with reduction in expression across the glucose pathway in all cultures, 
compared to the corresponding non-treated cultures. Notably this study 
demonstrated the synergy between TMZ and 3-BPA in a subset (33%) of 
glioblastoma cultures. This novel data shows 3-BPA as an efficient energy blocker 
through targeting HK2, making it a potential therapeutic candidate as an antitumor 
drug in a subset of glioblastoma. The significance of this data strengthens previous 
studies, which have shown 3-BPA to cause cytotoxic effects in human myeloid 
leukaemia (HL60) cells, hepatocellular carcinoma (HCC) cells and breast cancer cells 
(MCF-7) via the inhibition of ATP-producing glycolysis and mitochondrial respiration 
(Ko et al., 2001; Calvino et al., 2014; Lee et al., 2017; Pulaski et al., 2018). 
The anti-diabetic drug metformin was also investigated in this study. The 
repurposing of existing licenced medication is advantageous in many aspects, 
reducing costs and time in the clinical trial process and offering a potential faster 
implementation of new therapeutic treatments for glioblastoma (Abbruzzese et al., 
2017). Metformin demonstrated an anti-proliferative effect in all cultures under 
normoxic and hypoxic conditions. Additionally, a substantial difference in the 
response of the glioblastoma cells compared to NHA, demonstrated that the 
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mechanism of action of metformin was exclusive to cancer cells, inhibiting 
glioblastoma proliferation through glucose deprivation, although not specifically 
through HK2. Similar correlations have been demonstrated in breast cancer cell lines 
(Menendez et al., 2012; Birsoy et al., 2014). Expression profiler arrays were also 
utilized to determine the wider effect of metformin on the glycolytic pathway. All 
cultures treated with metformin showed significant downregulation (p<0.005) in 
59% of the genes (50 of the 84) with reduction in expression across the glucose 
pathway in all cultures, compared to the corresponding non-treated cultures. 
Importantly this study demonstrated the synergistic affiliation between TMZ and 
metformin in a subset (50%) of glioblastoma cultures, indicating the potential 
therapeutic advantages of combination treatments, prospectively allowing for smaller 
TMZ dosages with reduced side effects. This study also verified that metformin does 
not induce apoptosis in glioblastoma and may act through another mechanism of cell 
death such as autophagy. Studies have suggested that metformin activates AMPK 
resulting in the inhibition of the mTOR pathway, impeding cellular proliferation 
(Pollak, 2012; Liu et al., 2014; He and Wondisford, 2015).  Taking this into account, 
expression profiler arrays were used to investigate the effect of metformin on the 
mTOR pathway, where treatment was shown to induce the downregulation of gene 
expression across the signalling pathway in all the glioblastoma cultures, with 39% 
of the genes exhibiting significant reduced expression (p<0.005). The data indicates 
that metformin has an inhibitory effect on mTOR signalling in glioblastoma cultures, 
resulting in genetic alterations and downregulation across the entire pathway. 
Notably CRISPR-KO of HK2 also generated similar results, with 48% of the genes 
presenting significant reduced expression (p<0.005), indicating universal mTOR 
pathway downregulation. Importantly the data shows a potential synergistic effect of 
HK2-KO and metformin on mTOR activity, with 61% of the mTOR genes exhibiting a 
significant altered level of expression (p<0.005). The data correlates to similar 
studies where HK2 has been shown to impact the mTOR pathway (Roberts, et al., 
2014) and where siRNA knockdown of HK2 was shown to inhibit mTORC1 (DeWaal 
et al., 2018). The knockout of HK2 may lead to the increase of energy stress, 
activating AMPK and resulting in the inhibition mTORC1 activity whilst simultaneously 
increasing the effectiveness of metformin at inhibiting the mTOR pathway in 
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glioblastoma. Finally, the glioblastoma cells were shown to be ineffective at 
metabolizing the ketone body 3-HB, however NHA demonstrated the ability to 
proliferate under ketogenic substrates. The data suggest the combination of a 
ketogenic diet with chemotherapy and/or radiotherapy may help improve tumour 
response and OS in glioblastoma patients. 
7.2 Limitations 
There are several limitations inherent to this study and its techniques used. 
The use of patient-derived cultures was a strong feature of the study as it provided 
a more representative model of glioblastoma tumours. The panel of patient-derived 
cultures used would benefit from further characterisation both genetically and 
epigenetically, in order to distinguish differing genomic characteristics. This would 
also enable a more complete understanding of the variation in cellular response and 
identify potential treatment sub-groups. Due to the large variations in the culture 
doubling times it became a logistical problem to maintain many different patient-
derived cultures, this resulted in smaller groups of cultures being utilised in some 
experiments, such as the CRISPR-HK2 KO, combination treatments and some of the 
flow cytometry work. Functional studies and analysis of the cell death pathways 
were limited in the amount of techniques and instrumentation available. The use of 
a Seahorse machine would be beneficial, to investigate mitochondrial membrane 
functionality with HK2 inhibition with various inhibitors. In addition, the study did not 
assess necrosis or autophagy as additional mechanisms of cell death with HK2 
inhibition. Finally, the pyrosequencing of the 103 biopsy samples was limited to a 
single set of primers covering CpGs 8,9,10 and 11. These primers were selected 
based on data interpretation from preliminary experimental runs of a subset of the 
biopsy samples. Ideally the methylation status of the 103 biopsies would have been 
investigated using all HK2 primer sets, however cost and time constraints resulted in 
limitations. Access to the pyrosequencing machine at the University of Birmingham 
was through a collaboration, therefore access was not always viable. 
7.3 Further study 
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This study has identified the important role that HK2 enacts within the development 
of glioblastoma and determined the potential therapeutic advantages of targeting 
HK2. There are several directions in which this research could progress. 
The HK2 inhibitors had a strong cytotoxic and metabolic effect on the cells. The 
work carried out in this study investigated genetic and cellular changes such as 
cytotoxicity assays. Further investigations of the effect of the inhibitors on a 
proteomic level through ELISA and western blotting would be beneficial in 
determining functional effects of the inhibitors and their impact upon glycolytic 
associated proteins. 
Cell culture modelling could be expanded with 3-D modelling and spheroid cultures 
offer a promising analytical tool, with more accurate representations of the authentic 
growing conditions and microenvironment of glioblastoma (Kaluzova et al., 2015). 
The inhibition of HK2 could be further studied in these models, whereby analysis of 
migration and invasion could be accurately gauged. The hypothesis is that with the 
downregulation of HK2, the glioblastoma cultures should demonstrate reduced 
invasive characteristics and display decreased migration. Additionally, following on 
from the 3D- modelling, xenograft mice models would be crucial for studying the 
effects of HK2-KO in terms of invasion, migration and chemoresistance in a system 
that better mimics the primary tumour as compared to cells grown in vitro, offering 
relevant predictive insights into clinical outcomes. The use of the patient-derived 
glioblastoma cultures as explants potentially would conserve original tumour 
characteristics such as heterogeneous histology, biomolecular signature, malignant 
genotype and phenotype, tumour architecture and tumour vasculature (Vandamme, 
2014). The inhibitor 3-BPA showed promising results, demonstrating a high affinity 
and specificity for targeting HK2. The development of a better drug delivery system 
to administer 3-BPA will significantly increase its practical application in a range of 
cancers whilst simultaneously reducing any adverse effects. The development and 
use of a biodegradable polymer offer substantially increased uptake to the target 
region, whilst reducing systemic toxicity (Wicks et al., 2015). Additionally, the 
application of nanotechnology offers many advantages such as increased BBB 
permeability for glioma tumours as well as lower effective dosages when in 
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combination with targeted liposomes such as folate or transferrin ligands (Gandham 
et al., 2015; Zhang et al., 2018; Fan et al., 2019). The development of 3-BPA would 
potentially increase its potential as a therapeutic agent in future clinical oncology. 
This could be achieved through biochemical analysis, with analogue development in 
which 3-BPA could be modified, offering varied bioactive compounds for potential 
increased effectiveness, increased BBB permeability and targeting potential, whilst 
retaining chemical and biological similarity with the original model compound. 
Appendix 
Table A1. Methylation % for individual CpG sites in 103 biopsies 
Biopsy  
CpG 8 
Methylation 
% 
CpG 9 
Methylation 
% 
CpG 10 
Methylation 
% 
CpG 11 
Methylation 
% 
85 7.47 3.64 2.92 4.19 
103 7 6.18 6.21 3.76 
110 6.29 1.28 1.57 6.2 
116 6.29 4.28 1.57 3.83 
121 6.87 6.39 7.98 9.27 
122 6.48 4.27 3.9 2.37 
142 9.14 3.92 2.29 5.37 
165 5.3 7.66 8.25 7.92 
175 6.88 7.24 8.27 5.46 
204 5.34 4.75 7.09 8.67 
338 5.19 4.22 4.87 6.37 
343 7.03 6.24 10.99 11.43 
352 4.49 3.86 2.09 6.38 
374 5.75 4.56 5.83 4.62 
377 5.55 7.81 5.22 8.53 
382 7.42 7.13 10.46 11.84 
396 6.69 8.32 9.98 8.43 
410 6.19 12.51 3.54 3.82 
411 4.72 11.67 1.2 3.21 
436 4.89 9.28 1.22 7.36 
445 6.66 5.49 10.35 9.48 
472 6.27 3.95 4.69 5.3 
522 6.53 6.24 1.63 5.73 
535 5.97 3.88 3.91 4.48 
590 1.93 16.64 6.92 10.99 
626 1.71 4.93 5.1 3.47 
640 9.52 17.71 5.19 18.8 
651 6.26 4.78 4.33 3.57 
685 15.75 11.35 3.78 8.47 
693 10.03 4.17 4.42 7.37 
705 3.5 3.82 3.94 5.13 
717 9.16 19.59 5.28 14.5 
723 4.15 5.53 3.82 4.61 
729 11.4 7.08 4.62 7.13 
733 15.43 9.48 3.86 6.76 
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743 1.64 5.22 1.31 3.27 
746 1.42 4.15 4.78 4.46 
749 3.52 2.65 3.96 3.94 
758 4.42 5.94 4.7 6.46 
769 5.43 7.01 4.64 5.35 
781 7.58 7.08 5.28 4.2 
792 3.58 9.44 3.75 3.73 
793 6.06 3.66 7.79 4.21 
813 3.98 4.14 2.9 3.46 
816 11.62 14.56 2.91 12.6 
819 5.33 5.03 2.59 6.63 
820 4.85 3.64 1.21 3.58 
822 5.37 4.33 4.64 6.84 
826 12.39 9.28 6.94 9.38 
848 8.57 17.84 12.24 14.67 
849 3.07 4.83 8.02 6.68 
850 4.36 3.01 3.74 4.62 
860 6.59 7.54 1.41 5.74 
874 9.87 3.2 8.83 4.38 
876 7.02 4.6 11.95 6.35 
898 5.12 1.33 4 3.79 
905 2.82 2.89 4.34 1.24 
911 14.39 11.1 4 7.53 
915 5.14 7.98 9.25 4.24 
916 4.98 4.62 4.58 3.24 
955 0 5.36 6.32 7.89 
956 4.07 4.21 6.35 5.92 
966 11.73 3.85 2.07 3.28 
970 4.9 4.37 5.18 7.53 
994 3.92 4.72 4.46 9.53 
1000 5.93 4.56 2.16 2.56 
1006 8.53 8.52 5.87 3.43 
1014 6.25 4.53 4.09 4.25 
1015 4.48 11.27 6.39 4.83 
1016 7.66 4.56 4.97 3.56 
1054 5.67 4.75 8.5 6.77 
1062 11.15 6.91 3.44 5.35 
1091 4.55 3.56 6.79 4.56 
1098 12.64 12.97 2.67 9.69 
1100 6.05 11.46 8.28 7.43 
1101 4.1 13.63 10.43 2.9 
1134 4.58 3.13 3.9 2.52 
1176 7.29 5.9 4.35 4.08 
1178 4.33 3.67 7.11 5.71 
1342 6.76 7.32 2 3.22 
1404 8.22 7 4.55 4.22 
1414 4.93 3.78 6.13 9.82 
1417 7.98 12.45 3.96 9.31 
1428 9.48 5.12 6.82 5.31 
1437 11.44 9.22 9.56 6.11 
1446 3.19 9.12 10.32 7.49 
1460 7.49 11.84 7.45 10.18 
1547 7.43 4.89 7.22 5.87 
1549 5.34 3.86 5.63 4.79 
1565 6.76 7.33 8.35 7.35 
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1595 5.54 4.19 3.33 3.57 
1606 12.32 9.93 12.57 11.34 
1617 5.84 10.2 1.46 3.42 
1643 10.23 9.35 7.56 7.23 
1687 4.88 5.74 4.15 8.27 
1728 3.97 3.13 2.86 12.2 
1745 1.76 8.52 8.45 12.62 
1793 7.58 7.4 1.9 9.13 
1902 9.35 13.84 3.11 9.29 
2229 5.3 7.66 8.25 3.86 
2242 5.24 5.46 4.23 4.11 
Normal 22.71 22.25 42.98 16.88 
Normal 24.35 20.38 40.85 18.52 
Normal 25.11 21.72 41.78 17.88 
Normal 23.16 24.25 42.22 16.91 
Normal 22.75 21.85 42.43 18.92 
+ve control 95.76 96.18 94.74 94.43 
Table showing HK2 methylation % in biopsies and normal tissue in CpG 8- 10 via pyrosequencing. 
CpG 10 showed the highest level of deregulated methylation between normal tissue (average of 
42.1%) and biopsies (average of 5.4%) and cultures (average of 3.8%). 
 
 
Table A2. HK2 fold change compared to MGMT status for 103 biopsies 
Biopsy 
HK2 fold 
change 
MGMT Status Biopsy 
HK2 fold 
change 
MGMT Status 
103 41.05 Methylated 165 40.14 Methylated 
110 186.30 Methylated 396 69.44 Methylated 
116 6.69 Methylated 445 43.57 Methylated 
122 263.74 Methylated 651 89.85 Methylated 
377 120.25 Methylated 1000 149.84 Methylated 
382 39.30 Methylated 1606 22.36 Methylated 
522 30.76 Methylated 1643 98.55 Methylated 
535 87.80 Methylated 343 20.06 Methylated 
590 49.07 Methylated 1793 600.96 Unmethylated 
626 195.30 Methylated 85 75.22 Unmethylated 
640 51.06 Methylated 121 51.72 Unmethylated 
685 446.04 Methylated 142 788.29 Unmethylated 
693 819.78 Methylated 175 14.90 Unmethylated 
705 121.62 Methylated 204 57.38 Unmethylated 
717 65.26 Methylated 338 825.59 Unmethylated 
723 77.04 Methylated 352 40.75 Unmethylated 
729 132.68 Methylated 411 120.73 Unmethylated 
733 276.44 Methylated 436 127.24 Unmethylated 
743 285.95 Methylated 472 99.50 Unmethylated 
746 867.62 Methylated 792 195.97 Unmethylated 
749 216.62 Methylated 874 175.97 Unmethylated 
758 409.23 Methylated 956 126.62 Unmethylated 
769 172.12 Methylated 966 125.62 Unmethylated 
781 320.24 Methylated 1006 298.95 Unmethylated 
793 875.78 Methylated 1014 3.83 Unmethylated 
813 216.62 Methylated 1015 288.42 Unmethylated 
816 679.91 Methylated 1054 173.92 Unmethylated 
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819 288.42 Methylated 1062 136.68 Unmethylated 
820 183.30 Methylated 1101 320.24 Unmethylated 
822 763.67 Methylated 1178 346.44 Unmethylated 
826 569.76 Methylated 1404 111.39 Unmethylated 
848 122.12 Methylated 1414 140.13 Unmethylated 
849 205.24 Methylated 1417 315.68 Unmethylated 
850 475.90 Methylated 1428 7.43 Unmethylated 
859 897.54 Methylated 1437 21.92 Unmethylated 
860 26.13 Methylated 1446 153.26 Unmethylated 
876 358.76 Methylated 1460 117.88 Unmethylated 
898 669.94 Methylated 1549 142.08 Unmethylated 
905 285.95 Methylated 1595 425.07 Unmethylated 
911 172.12 Methylated 1687 149.52 Unmethylated 
915 104.50 Methylated 1745 43.80 Unmethylated 
916 883.25 Methylated 1902 31.10 Unmethylated 
955 109.24 Methylated 374 136.68 Unmethylated 
970 78.73 Methylated 410 140.13 Unmethylated 
1016 159.04 Methylated 956 126.62 Unmethylated 
1098 86.34 Methylated 994 221.23 Unmethylated 
1100 43.78 Methylated 1091 115.79 Unmethylated 
1134 23.62 Methylated 1565 269.10 Unmethylated 
1176 149.45 Methylated 1617 178.40 Unmethylated 
1342 148.30 Methylated 1728 764.99 Unmethylated 
1547 106.31 Methylated 2242 189.65 Unmethylated 
2229 18.39 Methylated 
 
Table showing HK2 fold change compared to methylation status in 103 biopsies. No correlation 
between HK2 expression and MGMT status was determined. 
 
Table A3. HK2 fold change compared to MGMT status for 13 cultures 
Culture 
HK2 fold 
change 
MGMT Status 
U251MG 1502.6 Methylated 
IN 2045 219.8 Methylated 
IN 1760 202.0 Methylated 
IN 859 995.1 Methylated 
IN 1528 386.0 Methylated 
IN 1461 85.7 Unmethylated 
IN 1472 403.4 Unmethylated 
IN 1951 210.6 Unmethylated 
NHA 30.4 Unmethylated 
IN 1612 126.6 Unmethylated 
IN 2093 132.8 Unmethylated 
IN 1979 574.4 Unmethylated 
IN 1265 97.4 Unmethylated 
Table showing HK2 fold change compared to methylation status in 13 cultures. No correlation 
between HK2 expression and MGMT status was determined. 
 
Table A4. Doubling time of culture panel 
Culture 
Doubling time 
(Hours) 
Culture Doubling time (Hours) 
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U251MG 24 (±1.56) UWLV22 44 (±2.56) 
U87MG 24 (±2.01) IN1472 45 (±1.75) 
IN859 24 (±2.22) IN1682 50 (±1.42) 
IN1612 28 (±1.5) IN1265 50 (±2.8) 
IN1528 32 (±1.26) IN1951 55 (±2.08) 
IN1979 34 (±2.51) IN1461 60 (±1.82) 
IN2045 36 (±1.64) NHA 63 (±2.62) 
IN1760 40 (±3.1) IN2093 70 (±3.22) 
UWLV22 35 (±2.13) UWLV152 46 (±3.04) 
UWLV48 45 (±2.55) UWLV156 48 (±1.27) 
UWLV53 33 (±1.32) UWLV212 53 (±2.37) 
Table showing doubling times for cultures used in this study. 
 
Table A5. MGMT status of the glioblastoma culture panel 
CULTURE METHYLATION STATUS 
U251MG Methylated 
IN 2045 Methylated 
IN 1760 Methylated 
IN 1461 Unmethylated 
IN 1472 Unmethylated 
IN 1951 Unmethylated 
NHA Unmethylated 
IN 1612 Unmethylated 
IN 859 Methylated 
IN 1528 Methylated 
IN 2093 Unmethylated 
IN 1979 Unmethylated 
IN 1265 Unmethylated 
Table showing MGMT culture for cultures used in this study. 
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Figure A1 Showing induced apoptosis in HK2-KO cultures compared to parent cultures 
after 72-hour treatment with 3-BPA. The percentage of apoptosis was significantly (p<0.0001) 
reduced across all HK2-KO cultures compared to respective parent cultures. Cultures expressing 
higher levels of HK2 showed a greater decreased level of apoptosis in HK2-KO cultures compared 
with parent cultures. 
 
 
 
 
 
Table A5. Percentage of apoptosis in HK2-KO cultures compared to parent cultures 
Cultures Apoptosis (%) 
HK2-KO Apoptosis 
(%) 
% Change in 
Apoptosis 
IN859 52 0.4 -99.2* 
U251MG 36.7 0.2 -99.4* 
IN2045 13 1.6 -87.6* 
IN1979 30 0.1 -99.6* 
Mean 38.2 0.58 -98.4* 
Table showing percentage of apoptosis in HK2-KO cultures compared to parent cultures after 72-hour 
treatment with 3-BPA. Significantly (p<0.0001) reduced apoptosis was exhibited across all HK2-KO 
cultures compared to respective parent cultures. Cultures expressing higher levels of HK2 showed a 
greater decreased level of apoptosis in HK2-KO cultures compared with parent cultures. 
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Figure A2 Showing the measurement of mitochondrial membrane potential in HK2-KO 
and respective parent cultures with 3-BPA treatment. Untreated cultures are shown on the left 
(U), 3-BPA cultures treated for 72- hours on the right (T). 3-BPA treatment leads to depolarisation of 
the ΔΨ in parent cultures, shown with a shift in the FL-1A channel (increase in monomer % (green 
value)). No change in depolarization % was seen in HK2-KO cultures. Red gating shows JC-1 
aggregated within the mitochondria, where green gating shows JC-1 monomers unable to enter 
through the mitochondrial membrane. 
 
Table A6. Glucose array showing gene expression in biopsies 
Gene UWLV 53 UWLV 22 UWLV 48 UWLV 156 UWLV 152 UWLV 212 
ALDOA 2.0 1.5 1.1 1.2 1.4 1.2 
ALDOB 1.7 4.2 1.7 2.1 1.7 3.6 
ENO1 2.0 3.1 1.6 1.5 1.5 1.2 
FBP2 1.8 6.5 6.4 3.3 1.8 4.1 
G6PC 1.8 5.9 3.3 4.9 2.1 4.5 
GCK 2.2 6.4 3.2 3.3 6.2 4.5 
GYS1 6.2 3.7 1.8 3.5 6.2 2.2 
GYS2 2.8 5.6 3.1 1.9 5.1 2.9 
HK2 4.6 7.1 5.9 4.8 6.1 5.2 
HK3 3.3 7.0 6.2 2.0 5.4 7.3 
MDH1 5.3 4.5 3.1 3.6 5.7 6.0 
MDH2 1.3 2.4 2.9 3.3 3.3 2.3 
PCK1 4.5 5.4 3.3 4.7 1.9 3.6 
PCK2 7.3 4.3 7.3 6.7 2.0 2.4 
PGK1 3.4 3.8 3.7 3.6 2.3 1.3 
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PGK2 3.0 7.3 3.5 1.5 7.7 3.9 
PKLR 3.2 6.1 7.3 5.6 3.2 5.4 
PRPS1L1 1.7 7.6 5.8 5.4 5.8 4.8 
RBKS 4.7 5.8 5.2 3.4 4.7 5.0 
ACO2 -3.3 -0.5 -1.2 -3.0 -2.1 -1.2 
ENO2 -3.3 -1.4 -2.5 -1.3 -3.0 -2.3 
SUCLA2 -1.7 -1.2 -2.9 -2.5 -1.2 -0.9 
UGP2 -2.4 -1.2 -1.6 -2.1 -0.8 -1.1 
Table showing the variation in expression fold change in the biopy samples compared to 
normal tissue 
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Figure A3. Glucose array scatter charts. Scatter charts showing gene fold change expression in 
biopsies compared to bomral tissue and in HK2-KO cultures compared to the respective parent 
culture.   
 
 
Table A7. Glucose array showing gene expression in paired cultures 
Gene UWLV 53 UWLV 22 UWLV 48 UWLV 156 UWLV 152 UWLV 212 
ACO1 3.2 1.9 2.1 2.3 2.6 2.5 
ACO2 3.9 2.4 3.2 2.8 3.4 3.6 
BPGM 4.4 3.2 4.5 3.3 4.1 3.7 
DLAT 4.6 4.1 3.6 3.6 3.5 3.9 
DLD 3.6 1.9 2.8 3.4 3.7 3.2 
DLST 4.3 2.9 3.5 3.6 3.9 4.5 
ENO1 2.6 2.1 3.1 3.5 1.8 2.7 
G6PC3 2.4 1.1 2.8 2.1 1.5 1.8 
G6PD 3.5 2.8 3.9 2.6 3.2 3.8 
HK2 2.8 1.4 2.9 2.6 1.4 1.7 
PDHA1 4.1 2.1 2.9 2.9 3.6 3.9 
PDK2 2.3 1.6 2.5 2.1 3.2 1.9 
PFKL 2.3 2.2 2.9 3.3 3.4 2.3 
PGLS 5.4 1.7 5.1 2.9 2.9 3.2 
PGM1 3.4 3.6 3.7 3.6 2.3 3.3 
PGM2 4.8 2.7 6.4 3.3 2.8 4.1 
PHKG2 3.8 4.3 3.1 2.6 4.0 2.7 
PYGL 4.5 4.2 3.3 4.3 1.9 3.6 
SDHB 3.2 2.4 2.8 3.3 3.3 2.3 
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TKT 5.5 3.1 1.9 5.1 2.9 2.8 
Table showing the variation in expression fold change in the culture samples compared to 
biopsy 
 
 
Figure A4. Sex vs MGMT methylation for patient OS. Females had higher rates of unmethylated 
MGMT promotors compared to male but was not significant (Chi-squared test p=0.44). 
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Figure A5. Sex vs HK2 expression for patient OS. Males had elevated HK2 over-expression 
compared to females (median 173 fold-change expression vs 130 fold-change expression), however, 
this was not significant (Mann-Whitney U test, p=0.47). 
  
Figure A6. Sex vs age for patient OS. No imbalance of age between males and females. Females 
had identical median ages to men (64) and this was not significant (Mann Whitney U test p=0.75). 
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Table A8. Patient biopsy details 
BTN
W no. 
Grad
e 
IDH1 
MGMT 
(Hospital 
diagnosis) 
Gende
r 
DOB DODiag DOD 
Total 
Days 
HK2 
Fold 
Chang
e 
MGMT status 
(MS-PCR) 
85 IV 
not 
done 
not done M 
18/04/195
9 
28/08/200
7 
16/01/200
8 
141 75.2 Unmethylated 
103 IV 
not 
done 
not done F 
03/09/193
0 
29/10/200
7 
24/02/200
8 
118 41.1 Methylated 
110 IV 
not 
done 
Allred 3+2 M 
11/05/194
8 
12/11/200
7 
22/08/200
8 
284 186.3 Methylated 
116 IV 
not 
done 
not done F 
21/10/194
1 
04/12/200
7 
17/05/200
9 
530 6.7 Methylated 
121 IV 
not 
done 
not done F 
31/07/194
6 
19/03/200
7 
04/03/200
8 
351 51.7 Unmethylated 
122 IV 
not 
done 
Allred 3+3 M 
19/02/195
5 
21/12/200
7 
22/08/201
0 
975 26.1 Methylated 
142 IV 
not 
done 
not done M 
08/06/193
8 
06/02/200
8 
31/03/200
8 
54 788.3 Unmethylated 
165 IV 
not 
done 
not done M 
28/09/193
5 
02/04/200
8 
14/05/200
8 
42 40.1 Methylated 
175 IV 
not 
done 
not done F 
22/04/195
3 
15/04/200
8 
28/07/200
9 
469 14.9 Unmethylated 
204 IV 
not 
done 
not done F 
29/04/195
4 
10/06/200
8 
15/03/200
9 
278 57.4 Unmethylated 
338 IV 
not 
done 
not done M 
29/12/193
7 
05/05/200
9 
08/06/200
9 
34 825.6 Unmethylated 
343 IV 
not 
done 
not done M 
12/09/193
9 
12/11/200
8 
07/08/200
9 
268 20.1 Methylated 
352 IV 
not 
done 
not done M 
26/05/196
0 
02/06/200
9 
14/06/200
9 
12 240.7 Unmethylated 
374 IV 
not 
done 
Allred 5+3 F 
20/11/197
5 
17/07/200
9 
20/03/201
0 
246 136.7 Unmethylated 
377 IV 
not 
done 
not done F 
08/03/196
5 
22/07/200
9 
31/07/201
0 
374 120.3 Methylated 
382 IV 
not 
done 
not done F 
07/01/193
5 
04/08/200
9 
11/09/201
1 
768 39.3 Methylated 
396 IV 
not 
done 
Allred 4+2 M 
08/12/194
0 
10/09/200
9 
17/09/201
0 
372 69.4 Methylated 
410 IV 
not 
done 
not done F 
12/04/193
1 
15/10/200
9 
03/11/200
9 
19 260.1 Unmethylated 
411 IV 
not 
done 
not done M 
27/09/194
7 
15/10/200
9 
13/03/201
0 
149 120.7 Unmethylated 
436 IV 
not 
done 
Allred 4+3 F 
07/07/197
1 
01/04/200
9 
29/03/201
0 
362 127.4 Unmethylated 
445 IV 
not 
done 
not done M 
02/07/198
0 
26/11/200
9 
19/01/201
0 
54 669.9 Methylated 
472 IV 
not 
done 
Allred 5+2 F 
08/03/196
5 
22/07/200
9 
31/07/201
0 
198 99.5 Unmethylated 
522 IV 
not 
done 
not done M 
22/06/193
6 
18/03/201
0 
05/05/201
0 
48 30.8 Methylated 
535 IV 
not 
done 
not done F 
12/01/194
8 
17/05/201
0 
17/12/201
0 
214 87.8 Methylated 
590 IV 
not 
done 
Allred 3+2 M 
13/01/196
0 
15/07/201
0 
22/01/201
2 
556 49.1 Methylated 
626 IV 
not 
done 
not done M 
22/05/193
8 
12/08/201
0 
11/06/201
1 
303 195.3 Methylated 
640 IV 
not 
done 
not done M 
22/02/195
7 
20/08/201
0 
27/04/201
1 
250 51.1 Methylated 
651 IV 
not 
done 
not done M 
29/03/194
6 
03/09/201
0 
18/08/201
1 
349 89.8 Methylated 
685 IV 
not 
done 
not done M 
09/09/194
3 
21/10/201
0 
13/04/201
1 
174 446.0 Methylated 
693 IV 
not 
done 
not done M 
14/04/193
6 
04/11/201
0 
07/11/201
1 
368 819.8 Methylated 
705 IV 
not 
done 
Allred 2+2 F 
10/05/194
7 
02/12/201
0 
02/05/201
1 
151 121.6 Methylated 
717 IV 
not 
done 
not done F 
02/06/194
4 
04/01/201
1 
22/05/201
1 
138 65.3 Methylated 
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723 IV 
not 
done 
not done M 
04/03/193
9 
14/01/201
1 
17/09/201
1 
246 77.0 Methylated 
729 IV neg not done F 
02/02/193
6 
03/02/201
1 
20/06/201
1 
137 132.7 Methylated 
733 IV 
not 
done 
not done M 
16/02/193
7 
17/02/201
1 
21/06/201
2 
504 176.4 Methylated 
743 IV neg not done F 
16/04/195
2 
24/03/201
1 
27/07/201
2 
491 286.0 Methylated 
746 IV 
not 
done 
not done F 
12/10/193
8 
07/04/201
1 
23/03/201
2 
351 867.6 Methylated 
749 IV WT 
methylate
d 
F 
26/03/196
6 
14/04/200
8 
01/02/201
2 
296 216.6 Methylated 
758 IV 
not 
done 
Allred 2+2 M 
18/07/196
1 
08/04/201
1 
28/02/201
2 
313 409.2 Methylated 
769 IV 
not 
done 
not done M 
02/04/194
1 
20/05/201
1 
30/06/201
2 
420 172.1 Methylated 
781 IV neg not done F 
23/04/193
6 
07/06/201
1 
01/09/201
1 
86 320.2 Methylated 
792 IV 
not 
done 
Allred 2+2 F 
12/10/194
3 
24/06/201
1 
27/02/201
2 
248 196.0 Unmethylated 
793 IV 
not 
done 
not done M 
19/08/193
0 
24/06/201
1 
20/09/201
1 
88 875.8 Methylated 
813 IV 
not 
done 
not done M 
03/01/192
8 
12/08/201
1 
19/05/201
2 
281 216.6 Methylated 
816 IV 
not 
done 
not done M 
02/11/195
7 
18/08/201
1 
05/12/201
1 
109 679.9 Methylated 
819 IV 
not 
done 
not done F 
24/10/193
4 
25/08/201
1 
11/03/201
2 
199 288.4 Methylated 
820 IV 
not 
done 
Allred 2+3 M 
28/02/195
0 
26/08/201
1 
02/10/201
1 
37 283.3 Methylated 
822 IV 
not 
done 
not done F 
31/08/194
9 
01/09/201
1 
24/04/201
2 
236 763.7 Methylated 
826 IV 
not 
done 
not done F 
12/11/193
2 
08/09/201
1 
29/01/201
2 
143 569.8 Methylated 
848 IV 
R132
H 
methylate
d 
M 
12/07/196
1 
11/04/200
6 
13/05/201
2 
206 122.1 Methylated 
849 IV 
not 
done 
neg M 
31/01/194
8 
21/10/201
1 
25/03/201
2 
156 205.2 Methylated 
859 IV 
not 
done 
not done F 
17/10/195
0 
11/11/201
1 
02/03/201
2 
112 897.5 Methylated 
860 IV 
not 
done 
not done M 
19/07/194
4 
16/11/201
1 
13/01/201
3 
424 26.1 Methylated 
874 IV neg Allred 3+3 M 
18/03/194
8 
16/12/201
1 
14/07/201
2 
211 176.0 Unmethylated 
876 IV 
not 
done 
Allred 2+1 M 
12/06/196
8 
21/12/201
1 
22/03/201
2 
92 358.8 Methylated 
898 IV neg Allred 3+2 M 
12/12/194
4 
02/02/201
2 
22/06/201
4 
871 43.6 Methylated 
905 IV neg Allred 3+2 M 
15/04/194
6 
16/02/201
2 
12/04/201
3 
421 286.0 Methylated 
911 IV neg Allred 3+2 M 
07/05/194
7 
01/03/201
2 
06/07/201
2 
127 172.1 Methylated 
915 IV neg Allred 4+3 M 
28/07/198
1 
14/03/201
2 
02/10/201
2 
202 104.5 Methylated 
916 IV neg not done M 
26/06/193
0 
15/03/201
2 
18/05/201
2 
64 883.3 Methylated 
919 IV neg not done F 
13/04/193
4 
29/03/201
2 
19/05/201
2 
1374 126.6 Unmethylated 
966 IV 
not 
done 
Allred 4+2 M 
09/07/195
7 
12/07/201
2 
28/09/201
4 
808 125.6 Unmethylated 
970 IV 
not 
done 
neg M 
19/07/194
4 
16/11/201
1 
13/01/201
3 
424 78.7 Methylated 
1000 IV neg neg M 
22/10/195
0 
28/08/201
2 
22/07/201
3 
298 221.2 Methylated 
1006 IV neg neg F 
23/08/196
6 
18/09/201
2 
22/03/201
4 
550 199.0 Unmethylated 
1007 IV neg Allred 3+3 F 
05/03/194
4 
05/10/201
2 
16/09/201
3 
346 159.0 Unmethylated 
1008 IV neg 
10% 
Allred 3+2 
M 
12/03/194
1 
05/10/201
2 
08/01/201
3 
88 288.4 Unmethylated 
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1013 IV neg 
10% 
Allred 2+1 
M 
14/03/194
8 
11/10/201
2 
08/01/201
3 
298 149.8 Methylated 
1015 IV neg 
10% 
Allred 3+2 
M 
12/03/194
1 
05/10/201
2 
08/01/201
3 
95 288.4 Unmethylated 
1016 IV neg Allred 3+3 F 
05/03/194
4 
05/10/201
2 
16/01/201
3 
146 109.2 Methylated 
1054 IV neg not done M 
29/08/197
0 
20/12/201
1 
04/03/201
3 
210 173.9 Unmethylated 
1091 IV neg not done M 
13/04/194
7 
07/02/201
3 
18/12/201
3 
319 115.8 Unmethylated 
1404 IV neg 
mostly 
neg Allred 
4+2 
M 
27/05/196
5 
17/07/201
2 
06/02/201
4 
569 111.4 Unmethylated 
1428 IV neg <10% M 
24/04/195
2 
19/12/201
3 
28/07/201
4 
588 7.4 Unmethylated 
1902 IV neg Allred 3+2 F 
24/04/196
1 
29/07/201
5 
15/082016 364 31.1 Unmethylated 
2229 IV neg Allred 3+3 M 
23/07/196
2 
03/03/201
6 
08/062016 84 18.4 Methylated 
Table showing biopsy details, including MGMT status, HK2 expression, sex and OS. MS-PCR MGMT 
status was determined in the laboratory. MGMT hospital diagnosis was given upon receipt of sample 
collection. 
 
Table A9. Array Gene List 
Glycolytic genes 
ACLY ATP citrate lyase PDHA1 Pyruvate dehydrogenase alpha 1 
ACO1 Aconitase 1, soluble PDHB Pyruvate dehydrogenase (lipoamide) beta3 
ACO2 Aconitase 2, mitochondrial PDK1 Pyruvate dehydrogenase kinase, isozyme 1 
AGL Amylo-alpha-1, 6-glucosidase, 4-alpha-
glucanotransferase 
PDK2 Pyruvate dehydrogenase kinase, isozyme 2 
ALDOA Aldolase A, fructose-bisphosphate PDK3 Pyruvate dehydrogenase kinase, isozyme 3 
ALDOB Aldolase B, fructose-bisphosphate PDK4 Pyruvate dehydrogenase kinase, isozyme 4 
ALDOC Aldolase C, fructose-bisphosphate 
PDP2 Pyruvate dehyrogenase phosphatase 
catalytic subunit 2 
BPGM 2,3-bisphosphoglycerate mutase 
PDPR Pyruvate dehydrogenase phosphatase 
regulatory subunit 
CS Citrate synthase PFKL Phosphofructokinase, liver 
DLAT Dihydrolipoamide S-acetyltransferase PGAM2 Phosphoglycerate mutase 2 (muscle) 
DLD Dihydrolipoamide dehydrogenase PGK1 Phosphoglycerate kinase 1 
DLST Dihydrolipoamide S-succinyltransferase (E2 
component of 2-oxo-glutarate complex) 
PGK2 Phosphoglycerate kinase 2 
ENO1 Enolase 1, (alpha) PGLS 6-phosphogluconolactonase 
ENO2 Enolase 2 (gamma, neuronal) PGM1 Phosphoglucomutase 1 
ENO3 Enolase 3 (beta, muscle) PGM2 Phosphoglucomutase 2 
FBP1 Fructose-1,6-bisphosphatase 1 PGM3 Phosphoglucomutase 3 
FBP2 Fructose-1,6-bisphosphatase 2 PHKA1 Phosphorylase kinase, alpha 1 (muscle) 
FH Fumarate hydratase PHKB Phosphorylase kinase, beta 
G6PC Glucose-6-phosphatase, catalytic subunit PHKG1 Phosphorylase kinase, gamma 1 (muscle) 
G6PC3 Glucose 6 phosphatase, catalytic, 3 PHKG2 Phosphorylase kinase, gamma 2 (testis) 
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G6PD Glucose-6-phosphate dehydrogenase PKLR Pyruvate kinase, liver and RBC 
GALM Galactose mutarotase (aldose 1-epimerase) 
PRPS1 Phosphoribosyl pyrophosphate synthetase 
1 
GBE1 Glucan (1,4-alpha-), branching enzyme 1 
PRPS1L1 Phosphoribosyl pyrophosphate 
synthetase 1-like 1 
GCK Glucokinase (hexokinase 4) 
PRPS2 Phosphoribosyl pyrophosphate synthetase 
2 
GPI Glucose-6-phosphate isomerase PYGL Phosphorylase, glycogen, liver 
GSK3A Glycogen synthase kinase 3 alpha PYGM Phosphorylase, glycogen, muscle 
GSK3B Glycogen synthase kinase 3 beta RBKS Ribokinase 
GYS1 Glycogen synthase 1 (muscle) RPE Ribulose-5-phosphate-3-epimerase 
GYS2 Glycogen synthase 2 (liver) RPIA Ribose 5-phosphate isomerase A 
H6PD Hexose-6-phosphate dehydrogenase 
(glucose 1-dehydrogenase) 
SDHA Succinate dehydrogenase complex, subunit 
A, flavoprotein (Fp) 
HK2 Hexokinase 2 
SDHB Succinate dehydrogenase complex, subunit 
B, iron sulfur (Ip) 
HK3 Hexokinase 3 (white cell) 
SDHC Succinate dehydrogenase complex, subunit 
C, integral membrane protein, 15kDa 
IDH1 Isocitrate dehydrogenase 1 (NADP+), 
soluble 
SDHD Succinate dehydrogenase complex, subunit 
D, integral membrane protein 
IDH2 Isocitrate dehydrogenase 2 (NADP+), 
mitochondrial 
SUCLA2 Succinate-CoA ligase, ADP-forming, beta 
subunit 
IDH3A Isocitrate dehydrogenase 3 (NAD+) alpha SUCLG1 Succinate-CoA ligase, alpha subunit 
IDH3B Isocitrate dehydrogenase 3 (NAD+) beta 
SUCLG2 Succinate-CoA ligase, GDP-forming, beta 
subunit 
IDH3G Isocitrate dehydrogenase 3 (NAD+) 
gamma 
TALDO1 Transaldolase 1 
MDH1 Malate dehydrogenase 1, NAD (soluble) TKT Transketolase 
MDH1B Malate dehydrogenase 1B, NAD (soluble) TPI1 Triosephosphate isomerase 1 
MDH2 Malate dehydrogenase 2, NAD 
(mitochondrial) 
UGP2 UDP-glucose pyrophosphorylase 2 
OGDH Oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) 
ACTB Actin, beta 
PC Pyruvate carboxylase B2M Beta-2-microglobulin 
PCK1 Phosphoenolpyruvate carboxykinase 1 
(soluble) 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
PCK2 Phosphoenolpyruvate carboxykinase 2 
(mitochondrial) 
HPRT1 Hypoxanthine phosphoribosyltransferase 
1 
 
mTOR genes 
AKT1 V-akt murine thymoma viral oncogene homolog 
1 
PLD1 Phospholipase D1, phosphatidylcholine-
specific 
AKT1 substrate 1 (proline-rich) PLD2 Phospholipase D2 
AKT2 V-akt murine thymoma viral oncogene homolog 
2 
PPP2CA Protein phosphatase 2, catalytic 
subunit, alpha isozyme 
AKT3 V-akt murine thymoma viral oncogene homolog 
3 (protein kinase B, gamma) 
PPP2R2B Protein phosphatase 2, regulatory 
subunit B, beta 
CAB39 Calcium binding protein 39 PPP2R4 Protein phosphatase 2A activator, 
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regulatory subunit 4 
CAB39L Calcium binding protein 39-like 
PRKAA1 Protein kinase, AMP-activated, alpha 
1 catalytic subunit 
CDC42 Cell division cycle 42 (GTP binding protein, 
25kDa) 
PRKAA2 Protein kinase, AMP-activated, alpha 
2 catalytic subunit 
CHUK Conserved helix-loop-helix ubiquitous kinase 
PRKAB1 Protein kinase, AMP-activated, beta 
1 non-catalytic subunit 
DDIT4 DNA-damage-inducible transcript 4 
PRKAB2 Protein kinase, AMP-activated, beta 
2 non-catalytic subunit 
DDIT4L DNA-damage-inducible transcript 4-like 
PRKAG1 Protein kinase, AMP-activated, 
gamma 1 non-catalytic subunit 
DEPTOR DEP domain containing MTOR-interacting 
protein 
PRKAG2 Protein kinase, AMP-activated, 
gamma 2 non-catalytic subunit 
EIF4B Eukaryotic translation initiation factor 4B 
PRKAG3 Protein kinase, AMP-activated, 
gamma 3 non-catalytic subunit 
EIF4E Eukaryotic translation initiation factor 4E PRKCA Protein kinase C, alpha 
EIF4EBP1 Eukaryotic translation initiation factor 4E 
binding protein 1 
PRKCB Protein kinase C, beta 
EIF4EBP2 Eukaryotic translation initiation factor 4E 
binding protein 2 
PRKCE Protein kinase C, epsilon 
FKBP1A FK506 binding protein 1A, 12kDa PRKCG Protein kinase C, gamma 
FKBP8 FK506 binding protein 8, 38kDa PTEN Phosphatase and tensin homolog 
GSK3B Glycogen synthase kinase 3 beta RHEB Ras homolog enriched in brain 
HIF1A Hypoxia inducible factor 1, alpha subunit RHOA Ras homolog gene family, member A 
HRAS V-Ha-ras Harvey rat sarcoma viral oncogene 
homolog 
RICTOR RPTOR independent companion of 
MTOR, complex 2 
HSPA4 Heat shock 70kDa protein 4 RPS6 Ribosomal protein S6 
IGF1 Insulin-like growth factor 1 (somatomedin C) 
RPS6KA1 Ribosomal protein S6 kinase, 90kDa, 
polypeptide 1 
IGFBP3 Insulin-like growth factor binding protein 3 
RPS6KA2 Ribosomal protein S6 kinase, 90kDa, 
polypeptide 2 
6 IKBKB Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta 
RPS6KA5 Ribosomal protein S6 kinase, 90kDa, 
polypeptide 5 
ILK Integrin-linked kinase 
RPS6KB1 Ribosomal protein S6 kinase, 70kDa, 
polypeptide 1 
INS Insulin 
RPS6KB2 Ribosomal protein S6 kinase, 70kDa, 
polypeptide 2 
INSR Insulin receptor 
RPTOR Regulatory associated protein of 
MTOR, complex 1 
IRS1 Insulin receptor substrate 1 RRAGA Ras-related GTP binding A 
MAPK1 Mitogen-activated protein kinase 1 RRAGB Ras-related GTP binding B 
MAPK3 Mitogen-activated protein kinase 3 RRAGC Ras-related GTP binding C 
MAPKAP1 Mitogen-activated protein kinase 
associated protein 1 
RRAGD Ras-related GTP binding D 
MLST8 MTOR associated protein, LST8 homolog (S. 
cerevisiae) 
SGK1 Serum/glucocorticoid regulated kinase 
1 
MTOR Mechanistic target of rapamycin 
(serine/threonine kinase) 
STK11 Serine/threonine kinase 11 
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MYO1C Myosin IC STRADB STE20-related kinase adaptor beta 
PDPK1 3-phosphoinositide dependent protein kinase-
1 
TELO2 TEL2, telomere maintenance 2, 
homolog (S. cerevisiae) 
PIK3C3 Phosphoinositide-3-kinase, class 3 TP53 Tumor protein p53 
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha 
polypeptide 
TSC1 Tuberous sclerosis 1 
PIK3CB Phosphoinositide-3-kinase, catalytic, beta 
polypeptide 
TSC2 Tuberous sclerosis 2 
PIK3CD Phosphoinositide-3-kinase, catalytic, delta 
polypeptide 
ULK1 Unc-51-like kinase 1 (C. elegans) 
PIK3CG Phosphoinositide-3-kinase, catalytic, gamma 
polypeptide 
ULK2 Unc-51-like kinase 2 (C. elegans) 
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